Some of our cancer centers are experiencing issues.  View More Important Notifications x
texas oncology more breakthroughs. more victories

Fort Worth Clinical Trials

Texas Oncology cancer centers in Fort Worth participate in a wide range of clinical trials and ground-breaking cancer research paving the way for new breakthroughs in cancer care. If you are a Texas Oncology patient in the Fort Worth area, you may be able to take part in these innovative clinical trials. Learn more and see a full list of current trials.

Our cancer researchers in the Fort Worth area are involved in several types of clinical trials:

  • Prevention trials focused on preventing cancer or recurrence. Trials might focus on the use of vitamins, different medications or a change in diet or exercise to determine if the risk of developing cancer is lowered.
  • Screening trials focused on identifying and detecting cancer in people who do not exhibit symptoms of cancer.
  • Diagnostic trials determining how to identify cancers using new tests. These trials often involve participants who show signs or symptoms of a particular cancer.
  • Treatment trials designed to answer questions about new treatments, such as drugs, surgical procedures, vaccines, or therapies involving current cancer patients.

Benefits and Risks of Participating in Clinical Trials

Discuss the benefits and risks with your physician if you're interested in participating in a clinical trial or cancer research in the Fort Worth area. Benefits include being actively involved in your healthcare, getting access to new treatments and medical care, and helping to further medical research. Risks may include unpleasant or serious side effects, treatments that are ineffective, and trials which take more time than standard treatment.

Clinical Trial Eligibility

Your eligibility for a clinical trial depends on several criteria, including your age and sex, your cancer type and stage of the cancer, previous treatments, and your overall medical history. View the list below of open clinical trials and cancer research opportunities in the Fort Worth area and talk to you doctor to determine which clinical trial is right for you.

Anal Cancer

Title: STAR Ph3 Carbo/Pac NCMGA00012 MSCC View

Description: A Phase 3 Global Multicenter Double-Blind Randomized Study of Carboplatin-Paclitaxel With INCMGA00012 or Placebo in Participants With Inoperable Locally Recurrent or Metastatic Squamous Cell Carcinoma of the Anal Canal Not Previously Treated With Systemic Chemotherapy (POD1UM-303/InterAACT 2) (INCMGA 0012-303)

Indication: Anal Cancer

Location: Texas Oncology-Arlington Cancer Center North

Phase: III

Title: STAR Ph3 Carbo/Pac NCMGA00012 MSCC View

Description: A Phase 3 Global Multicenter Double-Blind Randomized Study of Carboplatin-Paclitaxel With INCMGA00012 or Placebo in Participants With Inoperable Locally Recurrent or Metastatic Squamous Cell Carcinoma of the Anal Canal Not Previously Treated With Systemic Chemotherapy (POD1UM-303/InterAACT 2) (INCMGA 0012-303)

Indication: Anal Cancer

Location: Texas Oncology-Arlington South

Phase: III

Title: STAR Ph1/2 MRTX849 Solids KRAS G12C View

Description: A Phase 1/2 Multiple Expansion Cohort Trial of MRTX849 in Patients with Advanced Solid Tumors with KRAS G12C Mutation (849-001)

Indication: Anal Cancer

Location: Texas Oncology-Arlington Cancer Center North

Phase: I/II

Title: STAR Ph1/2 MRTX849 Solids KRAS G12C View

Description: A Phase 1/2 Multiple Expansion Cohort Trial of MRTX849 in Patients with Advanced Solid Tumors with KRAS G12C Mutation (849-001)

Indication: Anal Cancer

Location: Texas Oncology-Arlington South

Phase: I/II

Title: STAR Ph1/2 MRTX849 Solids KRAS G12C View

Description: A Phase 1/2 Multiple Expansion Cohort Trial of MRTX849 in Patients with Advanced Solid Tumors with KRAS G12C Mutation (849-001)

Indication: Anal Cancer

Location: Texas Oncology-Bedford

Phase: I/II

Title: STAR Ph3 Carbo/Pac NCMGA00012 MSCC View

Description: A Phase 3 Global Multicenter Double-Blind Randomized Study of Carboplatin-Paclitaxel With INCMGA00012 or Placebo in Participants With Inoperable Locally Recurrent or Metastatic Squamous Cell Carcinoma of the Anal Canal Not Previously Treated With Systemic Chemotherapy (POD1UM-303/InterAACT 2) (INCMGA 0012-303)

Indication: Anal Cancer

Location: Texas Oncology-Bedford

Phase: III

Title: STAR Ph3 Carbo/Pac NCMGA00012 MSCC View

Description: A Phase 3 Global Multicenter Double-Blind Randomized Study of Carboplatin-Paclitaxel With INCMGA00012 or Placebo in Participants With Inoperable Locally Recurrent or Metastatic Squamous Cell Carcinoma of the Anal Canal Not Previously Treated With Systemic Chemotherapy (POD1UM-303/InterAACT 2) (INCMGA 0012-303)

Indication: Anal Cancer

Location: Texas Oncology-Fort Worth Cancer Center

Phase: III

Title: STAR Ph1/2 MRTX849 Solids KRAS G12C View

Description: A Phase 1/2 Multiple Expansion Cohort Trial of MRTX849 in Patients with Advanced Solid Tumors with KRAS G12C Mutation (849-001)

Indication: Anal Cancer

Location: Texas Oncology-Fort Worth Cancer Center

Phase: I/II

Title: STAR Ph3 Carbo/Pac NCMGA00012 MSCC View

Description: A Phase 3 Global Multicenter Double-Blind Randomized Study of Carboplatin-Paclitaxel With INCMGA00012 or Placebo in Participants With Inoperable Locally Recurrent or Metastatic Squamous Cell Carcinoma of the Anal Canal Not Previously Treated With Systemic Chemotherapy (POD1UM-303/InterAACT 2) (INCMGA 0012-303)

Indication: Anal Cancer

Location: Texas Oncology-Grapevine

Phase: III

Title: STAR Ph1/2 MRTX849 Solids KRAS G12C View

Description: A Phase 1/2 Multiple Expansion Cohort Trial of MRTX849 in Patients with Advanced Solid Tumors with KRAS G12C Mutation (849-001)

Indication: Anal Cancer

Location: Texas Oncology-Grapevine

Phase: I/II

Biliary Cancer

Title: STAR Ph2 Basket Tucat+Tras ST HER2 Alt View

Description: A Phase 2 Basket Study of Tucatinib in Combination with Trastuzumab in Subjects with Previously Treated Locally-Advanced Unresectable or Metastatic Solid Tumors Driven by HER2 Alterations (SGNTUC-019)

Indication: Biliary Cancer

Location: Texas Oncology-Arlington Cancer Center North

Phase: II

Title: STAR Ph2 Basket Tucat+Tras ST HER2 Alt View

Description: A Phase 2 Basket Study of Tucatinib in Combination with Trastuzumab in Subjects with Previously Treated Locally-Advanced Unresectable or Metastatic Solid Tumors Driven by HER2 Alterations (SGNTUC-019)

Indication: Biliary Cancer

Location: Texas Oncology-Arlington South

Phase: II

Title: STAR Ph1/2 MRTX849 Solids KRAS G12C View

Description: A Phase 1/2 Multiple Expansion Cohort Trial of MRTX849 in Patients with Advanced Solid Tumors with KRAS G12C Mutation (849-001)

Indication: Biliary Cancer

Location: Texas Oncology-Arlington Cancer Center North

Phase: I/II

Title: STAR Ph1/2 MRTX849 Solids KRAS G12C View

Description: A Phase 1/2 Multiple Expansion Cohort Trial of MRTX849 in Patients with Advanced Solid Tumors with KRAS G12C Mutation (849-001)

Indication: Biliary Cancer

Location: Texas Oncology-Arlington South

Phase: I/II

Title: STAR Infigratinib vs Gem/Cis Cholangio View

Description: A Phase 3 Multicenter Open-Label Randomized Controlled Study of Oral Infigratinib versus Gemcitabine with Cisplatin in Subjects with Advanced/Metastatic or Inoperable Cholangiocarcinoma with FGFR2 Gene Fusions/Translocations: The PROOF Trial (QBGJ398-301)

Indication: Biliary Cancer

Location: Texas Oncology-Arlington South

Phase: III

Title: STAR Infigratinib vs Gem/Cis Cholangio View

Description: A Phase 3 Multicenter Open-Label Randomized Controlled Study of Oral Infigratinib versus Gemcitabine with Cisplatin in Subjects with Advanced/Metastatic or Inoperable Cholangiocarcinoma with FGFR2 Gene Fusions/Translocations: The PROOF Trial (QBGJ398-301)

Indication: Biliary Cancer

Location: Texas Oncology-Bedford

Phase: III

Title: STAR Ph1/2 MRTX849 Solids KRAS G12C View

Description: A Phase 1/2 Multiple Expansion Cohort Trial of MRTX849 in Patients with Advanced Solid Tumors with KRAS G12C Mutation (849-001)

Indication: Biliary Cancer

Location: Texas Oncology-Bedford

Phase: I/II

Title: STAR Ph2 Basket Tucat+Tras ST HER2 Alt View

Description: A Phase 2 Basket Study of Tucatinib in Combination with Trastuzumab in Subjects with Previously Treated Locally-Advanced Unresectable or Metastatic Solid Tumors Driven by HER2 Alterations (SGNTUC-019)

Indication: Biliary Cancer

Location: Texas Oncology-Bedford

Phase: II

Title: STAR Ph2 Basket Tucat+Tras ST HER2 Alt View

Description: A Phase 2 Basket Study of Tucatinib in Combination with Trastuzumab in Subjects with Previously Treated Locally-Advanced Unresectable or Metastatic Solid Tumors Driven by HER2 Alterations (SGNTUC-019)

Indication: Biliary Cancer

Location: Texas Oncology-Fort Worth Cancer Center

Phase: II

Title: STAR Ph1/2 MRTX849 Solids KRAS G12C View

Description: A Phase 1/2 Multiple Expansion Cohort Trial of MRTX849 in Patients with Advanced Solid Tumors with KRAS G12C Mutation (849-001)

Indication: Biliary Cancer

Location: Texas Oncology-Fort Worth Cancer Center

Phase: I/II

Title: STAR Infigratinib vs Gem/Cis Cholangio View

Description: A Phase 3 Multicenter Open-Label Randomized Controlled Study of Oral Infigratinib versus Gemcitabine with Cisplatin in Subjects with Advanced/Metastatic or Inoperable Cholangiocarcinoma with FGFR2 Gene Fusions/Translocations: The PROOF Trial (QBGJ398-301)

Indication: Biliary Cancer

Location: Texas Oncology-Fort Worth Cancer Center

Phase: III

Title: STAR Ph2 Basket Tucat+Tras ST HER2 Alt View

Description: A Phase 2 Basket Study of Tucatinib in Combination with Trastuzumab in Subjects with Previously Treated Locally-Advanced Unresectable or Metastatic Solid Tumors Driven by HER2 Alterations (SGNTUC-019)

Indication: Biliary Cancer

Location: Texas Oncology-Grapevine

Phase: II

Title: STAR Infigratinib vs Gem/Cis Cholangio View

Description: A Phase 3 Multicenter Open-Label Randomized Controlled Study of Oral Infigratinib versus Gemcitabine with Cisplatin in Subjects with Advanced/Metastatic or Inoperable Cholangiocarcinoma with FGFR2 Gene Fusions/Translocations: The PROOF Trial (QBGJ398-301)

Indication: Biliary Cancer

Location: Texas Oncology-Grapevine

Phase: III

Title: STAR Ph1/2 MRTX849 Solids KRAS G12C View

Description: A Phase 1/2 Multiple Expansion Cohort Trial of MRTX849 in Patients with Advanced Solid Tumors with KRAS G12C Mutation (849-001)

Indication: Biliary Cancer

Location: Texas Oncology-Grapevine

Phase: I/II

Bladder Cancer

Title: STAR PH 2 Enfortumab in Urothelial Pts View

Description: A study of enfortumab vedotin (ASG-22CE) as monotherapy or in combination with other anticancer therapies for the treatment of urothelial cancer (SGN22E-002)

Indication: Bladder Cancer

Location: Texas Oncology-Arlington South

Phase: I/II

Title: STAR Ph1/2 MRTX849 Solids KRAS G12C View

Description: A Phase 1/2 Multiple Expansion Cohort Trial of MRTX849 in Patients with Advanced Solid Tumors with KRAS G12C Mutation (849-001)

Indication: Bladder Cancer

Location: Texas Oncology-Arlington Cancer Center North

Phase: I/II

Title: STAR Ph1/2 MRTX849 Solids KRAS G12C View

Description: A Phase 1/2 Multiple Expansion Cohort Trial of MRTX849 in Patients with Advanced Solid Tumors with KRAS G12C Mutation (849-001)

Indication: Bladder Cancer

Location: Texas Oncology-Arlington South

Phase: I/II

Title: STAR Sitra+Nivo/Pembro+Enfor Adv/Met Uro View

Description: A Phase 2 Study of Sitravatinib in Combination with PD-(L)1 Checkpoint Inhibitor Regimens in Patients With Advanced or Metastatic Urothelial Carcinoma (516-003)

Indication: Bladder Cancer

Location: Texas Oncology-Arlington Cancer Center North

Phase: II

Title: STAR Sitra+Nivo/Pembro+Enfor Adv/Met Uro View

Description: A Phase 2 Study of Sitravatinib in Combination with PD-(L)1 Checkpoint Inhibitor Regimens in Patients With Advanced or Metastatic Urothelial Carcinoma (516-003)

Indication: Bladder Cancer

Location: Texas Oncology-Arlington South

Phase: II

Title: STAR Sitra+Nivo/Pembro+Enfor Adv/Met Uro View

Description: A Phase 2 Study of Sitravatinib in Combination with PD-(L)1 Checkpoint Inhibitor Regimens in Patients With Advanced or Metastatic Urothelial Carcinoma (516-003)

Indication: Bladder Cancer

Location: Texas Oncology-Bedford

Phase: II

Title: STAR Ph1/2 MRTX849 Solids KRAS G12C View

Description: A Phase 1/2 Multiple Expansion Cohort Trial of MRTX849 in Patients with Advanced Solid Tumors with KRAS G12C Mutation (849-001)

Indication: Bladder Cancer

Location: Texas Oncology-Bedford

Phase: I/II

Title: STAR PH 2 Enfortumab in Urothelial Pts View

Description: A study of enfortumab vedotin (ASG-22CE) as monotherapy or in combination with other anticancer therapies for the treatment of urothelial cancer (SGN22E-002)

Indication: Bladder Cancer

Location: Texas Oncology-Bedford

Phase: I/II

Title: STAR PH 2 Enfortumab in Urothelial Pts View

Description: A study of enfortumab vedotin (ASG-22CE) as monotherapy or in combination with other anticancer therapies for the treatment of urothelial cancer (SGN22E-002)

Indication: Bladder Cancer

Location: Texas Oncology-Fort Worth Cancer Center

Phase: I/II

Title: STAR Ph1/2 MRTX849 Solids KRAS G12C View

Description: A Phase 1/2 Multiple Expansion Cohort Trial of MRTX849 in Patients with Advanced Solid Tumors with KRAS G12C Mutation (849-001)

Indication: Bladder Cancer

Location: Texas Oncology-Fort Worth Cancer Center

Phase: I/II

Title: Biomarker Advcd Uro Cncer and FGFR Aber View

Description: Biomarker Study to Identify Subjects with Urothelial Cancer and Fibroblast Growth Factor Receptor Gene Aberrations (42756493BLC0002)

Indication: Bladder Cancer

Location: Texas Oncology-Fort Worth Cancer Center

Phase: IV

Title: STAR Sitra+Nivo/Pembro+Enfor Adv/Met Uro View

Description: A Phase 2 Study of Sitravatinib in Combination with PD-(L)1 Checkpoint Inhibitor Regimens in Patients With Advanced or Metastatic Urothelial Carcinoma (516-003)

Indication: Bladder Cancer

Location: Texas Oncology-Fort Worth Cancer Center

Phase: II

Title: Ph3 Pembro + BCG High-risk Bladder View

Description: A Phase 3 Randomized Comparator-controlled Clinical Trial to Study the Efficacy and Safety of Pembrolizumab (MK-3475) in Combination with Bacillus Calmette- Guerin (BCG) in Participants with High-risk Non-muscle Invasive Bladder Cancer (HR NMIBC) that is Persistent or Recurrent Following BCG Induction (KEYNOTE-676)

Indication: Bladder Cancer

Location: Texas Oncology-Fort Worth Cancer Center

Phase: III

Title: STAR PH 2 Enfortumab in Urothelial Pts View

Description: A study of enfortumab vedotin (ASG-22CE) as monotherapy or in combination with other anticancer therapies for the treatment of urothelial cancer (SGN22E-002)

Indication: Bladder Cancer

Location: Texas Oncology-Grapevine

Phase: I/II

Title: STAR Sitra+Nivo/Pembro+Enfor Adv/Met Uro View

Description: A Phase 2 Study of Sitravatinib in Combination with PD-(L)1 Checkpoint Inhibitor Regimens in Patients With Advanced or Metastatic Urothelial Carcinoma (516-003)

Indication: Bladder Cancer

Location: Texas Oncology-Grapevine

Phase: II

Title: STAR Ph1/2 MRTX849 Solids KRAS G12C View

Description: A Phase 1/2 Multiple Expansion Cohort Trial of MRTX849 in Patients with Advanced Solid Tumors with KRAS G12C Mutation (849-001)

Indication: Bladder Cancer

Location: Texas Oncology-Grapevine

Phase: I/II

Bone Mets

Title: STAR Ph1/2 MRTX849 Solids KRAS G12C View

Description: A Phase 1/2 Multiple Expansion Cohort Trial of MRTX849 in Patients with Advanced Solid Tumors with KRAS G12C Mutation (849-001)

Indication: Bone Mets

Location: Texas Oncology-Arlington Cancer Center North

Phase: I/II

Title: STAR Ph1/2 MRTX849 Solids KRAS G12C View

Description: A Phase 1/2 Multiple Expansion Cohort Trial of MRTX849 in Patients with Advanced Solid Tumors with KRAS G12C Mutation (849-001)

Indication: Bone Mets

Location: Texas Oncology-Arlington South

Phase: I/II

Title: STAR Ph1/2 MRTX849 Solids KRAS G12C View

Description: A Phase 1/2 Multiple Expansion Cohort Trial of MRTX849 in Patients with Advanced Solid Tumors with KRAS G12C Mutation (849-001)

Indication: Bone Mets

Location: Texas Oncology-Bedford

Phase: I/II

Title: STAR Ph1/2 MRTX849 Solids KRAS G12C View

Description: A Phase 1/2 Multiple Expansion Cohort Trial of MRTX849 in Patients with Advanced Solid Tumors with KRAS G12C Mutation (849-001)

Indication: Bone Mets

Location: Texas Oncology-Fort Worth Cancer Center

Phase: I/II

Title: STAR Ph1/2 MRTX849 Solids KRAS G12C View

Description: A Phase 1/2 Multiple Expansion Cohort Trial of MRTX849 in Patients with Advanced Solid Tumors with KRAS G12C Mutation (849-001)

Indication: Bone Mets

Location: Texas Oncology-Grapevine

Phase: I/II

Brain Cancer

Title: STAR Ph1/2 MRTX849 Solids KRAS G12C View

Description: A Phase 1/2 Multiple Expansion Cohort Trial of MRTX849 in Patients with Advanced Solid Tumors with KRAS G12C Mutation (849-001)

Indication: Brain Cancer

Location: Texas Oncology-Arlington Cancer Center North

Phase: I/II

Title: STAR Ph1/2 MRTX849 Solids KRAS G12C View

Description: A Phase 1/2 Multiple Expansion Cohort Trial of MRTX849 in Patients with Advanced Solid Tumors with KRAS G12C Mutation (849-001)

Indication: Brain Cancer

Location: Texas Oncology-Arlington South

Phase: I/II

Title: STAR Ph1/2 MRTX849 Solids KRAS G12C View

Description: A Phase 1/2 Multiple Expansion Cohort Trial of MRTX849 in Patients with Advanced Solid Tumors with KRAS G12C Mutation (849-001)

Indication: Brain Cancer

Location: Texas Oncology-Bedford

Phase: I/II

Title: STAR Ph1/2 MRTX849 Solids KRAS G12C View

Description: A Phase 1/2 Multiple Expansion Cohort Trial of MRTX849 in Patients with Advanced Solid Tumors with KRAS G12C Mutation (849-001)

Indication: Brain Cancer

Location: Texas Oncology-Fort Worth Cancer Center

Phase: I/II

Title: STAR Ph1/2 MRTX849 Solids KRAS G12C View

Description: A Phase 1/2 Multiple Expansion Cohort Trial of MRTX849 in Patients with Advanced Solid Tumors with KRAS G12C Mutation (849-001)

Indication: Brain Cancer

Location: Texas Oncology-Grapevine

Phase: I/II

Breast Cancer

Title: STAR Ph2 Basket Tucat+Tras ST HER2 Alt View

Description: A Phase 2 Basket Study of Tucatinib in Combination with Trastuzumab in Subjects with Previously Treated Locally-Advanced Unresectable or Metastatic Solid Tumors Driven by HER2 Alterations (SGNTUC-019)

Indication: Breast Cancer

Location: Texas Oncology-Arlington Cancer Center North

Phase: II

Title: STAR Ph2 Basket Tucat+Tras ST HER2 Alt View

Description: A Phase 2 Basket Study of Tucatinib in Combination with Trastuzumab in Subjects with Previously Treated Locally-Advanced Unresectable or Metastatic Solid Tumors Driven by HER2 Alterations (SGNTUC-019)

Indication: Breast Cancer

Location: Texas Oncology-Arlington South

Phase: II

Title: STAR Ph1/2 MRTX849 Solids KRAS G12C View

Description: A Phase 1/2 Multiple Expansion Cohort Trial of MRTX849 in Patients with Advanced Solid Tumors with KRAS G12C Mutation (849-001)

Indication: Breast Cancer

Location: Texas Oncology-Arlington Cancer Center North

Phase: I/II

Title: STAR Ph1/2 MRTX849 Solids KRAS G12C View

Description: A Phase 1/2 Multiple Expansion Cohort Trial of MRTX849 in Patients with Advanced Solid Tumors with KRAS G12C Mutation (849-001)

Indication: Breast Cancer

Location: Texas Oncology-Arlington South

Phase: I/II

Title: STAR Ph 3 Tuca/Placbo + T-DM1 HER2+ View

Description: STAR: Randomized double-blind phase 3 study of tucatinib or placebo in combination with ado-trastuzumab emtansine (T-DM1) for subjects with unresectable locally-advanced or metastatic HER2+ breast cancer (HER2CLIMB-02)(SGNTUC-016)

Indication: Breast Cancer

Location: Texas Oncology-Arlington South

Phase: III

Title: FLEX Registry: Evaluate New Gene Express View

Description: MammaPrint BluePrint and Full-genome Data Linked with Clinical Data to Evaluate New Gene EXpression Profiles: An Adaptable Registry (FLEX Registry)

Indication: Breast Cancer

Location: Texas Oncology-Bedford

Title: STAR Ph 3 Tuca/Placbo + T-DM1 HER2+ View

Description: STAR: Randomized double-blind phase 3 study of tucatinib or placebo in combination with ado-trastuzumab emtansine (T-DM1) for subjects with unresectable locally-advanced or metastatic HER2+ breast cancer (HER2CLIMB-02)(SGNTUC-016)

Indication: Breast Cancer

Location: Texas Oncology-Bedford

Phase: III

Title: Ph 3 Chemo+Atez/Placbo TNBC View

Description: A Randomized Double-Blind Phase III Clinical Trial of Neoadjuvant Chemotherapy with Atezolizumab or Placebo in Patients with Triple-Negative Breast Cancer Followed by Adjuvant Continuation of Atezolizumab or Placebo(NSABP B-59/GBG 96-GeparDouze).

Indication: Breast Cancer

Location: Texas Oncology-Bedford

Phase: III

Title: STAR Ph1/2 MRTX849 Solids KRAS G12C View

Description: A Phase 1/2 Multiple Expansion Cohort Trial of MRTX849 in Patients with Advanced Solid Tumors with KRAS G12C Mutation (849-001)

Indication: Breast Cancer

Location: Texas Oncology-Bedford

Phase: I/II

Title: STAR Ph2 Basket Tucat+Tras ST HER2 Alt View

Description: A Phase 2 Basket Study of Tucatinib in Combination with Trastuzumab in Subjects with Previously Treated Locally-Advanced Unresectable or Metastatic Solid Tumors Driven by HER2 Alterations (SGNTUC-019)

Indication: Breast Cancer

Location: Texas Oncology-Bedford

Phase: II

Title: STAR Ph2 Basket Tucat+Tras ST HER2 Alt View

Description: A Phase 2 Basket Study of Tucatinib in Combination with Trastuzumab in Subjects with Previously Treated Locally-Advanced Unresectable or Metastatic Solid Tumors Driven by HER2 Alterations (SGNTUC-019)

Indication: Breast Cancer

Location: Texas Oncology-Fort Worth Cancer Center

Phase: II

Title: STAR Ph1/2 MRTX849 Solids KRAS G12C View

Description: A Phase 1/2 Multiple Expansion Cohort Trial of MRTX849 in Patients with Advanced Solid Tumors with KRAS G12C Mutation (849-001)

Indication: Breast Cancer

Location: Texas Oncology-Fort Worth Cancer Center

Phase: I/II

Title: STAR Ph 3 Tuca/Placbo + T-DM1 HER2+ View

Description: STAR: Randomized double-blind phase 3 study of tucatinib or placebo in combination with ado-trastuzumab emtansine (T-DM1) for subjects with unresectable locally-advanced or metastatic HER2+ breast cancer (HER2CLIMB-02)(SGNTUC-016)

Indication: Breast Cancer

Location: Texas Oncology-Fort Worth Cancer Center

Phase: III

Title: STAR Ph2 Basket Tucat+Tras ST HER2 Alt View

Description: A Phase 2 Basket Study of Tucatinib in Combination with Trastuzumab in Subjects with Previously Treated Locally-Advanced Unresectable or Metastatic Solid Tumors Driven by HER2 Alterations (SGNTUC-019)

Indication: Breast Cancer

Location: Texas Oncology-Grapevine

Phase: II

Title: FLEX Registry: Evaluate New Gene Express View

Description: MammaPrint BluePrint and Full-genome Data Linked with Clinical Data to Evaluate New Gene EXpression Profiles: An Adaptable Registry (FLEX Registry)

Indication: Breast Cancer

Location: Texas Oncology-Grapevine

Title: STAR Ph 3 Tuca/Placbo + T-DM1 HER2+ View

Description: STAR: Randomized double-blind phase 3 study of tucatinib or placebo in combination with ado-trastuzumab emtansine (T-DM1) for subjects with unresectable locally-advanced or metastatic HER2+ breast cancer (HER2CLIMB-02)(SGNTUC-016)

Indication: Breast Cancer

Location: Texas Oncology-Grapevine

Phase: III

Title: Ph 3 Chemo+Atez/Placbo TNBC View

Description: A Randomized Double-Blind Phase III Clinical Trial of Neoadjuvant Chemotherapy with Atezolizumab or Placebo in Patients with Triple-Negative Breast Cancer Followed by Adjuvant Continuation of Atezolizumab or Placebo(NSABP B-59/GBG 96-GeparDouze).

Indication: Breast Cancer

Location: Texas Oncology-Grapevine

Phase: III

Title: STAR Ph1/2 MRTX849 Solids KRAS G12C View

Description: A Phase 1/2 Multiple Expansion Cohort Trial of MRTX849 in Patients with Advanced Solid Tumors with KRAS G12C Mutation (849-001)

Indication: Breast Cancer

Location: Texas Oncology-Grapevine

Phase: I/II

Title: Pragmatic Phase III Randomized Trial Of Proton Vs. Photon Therapy For Patients With Non-Metastatic Breast Cancer Receiving Comprehensive Nodal Radiation: A Radiotherapy Comparative Effectiveness (Radcomp) Consortium Trial View

Indication: Breast Cancer

Location: Texas Oncology-Bedford

Phase: III

Title: Pragmatic Phase III Randomized Trial Of Proton Vs. Photon Therapy For Patients With Non-Metastatic Breast Cancer Receiving Comprehensive Nodal Radiation: A Radiotherapy Comparative Effectiveness (Radcomp) Consortium Trial View

Indication: Breast Cancer

Location: Texas Oncology-Grapevine

Phase: III

Carcinoid

Title: STAR Ph3 Carbo/Pac NCMGA00012 MSCC View

Description: A Phase 3 Global Multicenter Double-Blind Randomized Study of Carboplatin-Paclitaxel With INCMGA00012 or Placebo in Participants With Inoperable Locally Recurrent or Metastatic Squamous Cell Carcinoma of the Anal Canal Not Previously Treated With Systemic Chemotherapy (POD1UM-303/InterAACT 2) (INCMGA 0012-303)

Indication: Carcinoid

Location: Texas Oncology-Arlington Cancer Center North

Phase: III

Title: STAR Ph3 Carbo/Pac NCMGA00012 MSCC View

Description: A Phase 3 Global Multicenter Double-Blind Randomized Study of Carboplatin-Paclitaxel With INCMGA00012 or Placebo in Participants With Inoperable Locally Recurrent or Metastatic Squamous Cell Carcinoma of the Anal Canal Not Previously Treated With Systemic Chemotherapy (POD1UM-303/InterAACT 2) (INCMGA 0012-303)

Indication: Carcinoid

Location: Texas Oncology-Arlington South

Phase: III

Title: STAR Ph3 Carbo/Pac NCMGA00012 MSCC View

Description: A Phase 3 Global Multicenter Double-Blind Randomized Study of Carboplatin-Paclitaxel With INCMGA00012 or Placebo in Participants With Inoperable Locally Recurrent or Metastatic Squamous Cell Carcinoma of the Anal Canal Not Previously Treated With Systemic Chemotherapy (POD1UM-303/InterAACT 2) (INCMGA 0012-303)

Indication: Carcinoid

Location: Texas Oncology-Bedford

Phase: III

Title: STAR Ph3 Carbo/Pac NCMGA00012 MSCC View

Description: A Phase 3 Global Multicenter Double-Blind Randomized Study of Carboplatin-Paclitaxel With INCMGA00012 or Placebo in Participants With Inoperable Locally Recurrent or Metastatic Squamous Cell Carcinoma of the Anal Canal Not Previously Treated With Systemic Chemotherapy (POD1UM-303/InterAACT 2) (INCMGA 0012-303)

Indication: Carcinoid

Location: Texas Oncology-Fort Worth Cancer Center

Phase: III

Title: STAR Ph3 Carbo/Pac NCMGA00012 MSCC View

Description: A Phase 3 Global Multicenter Double-Blind Randomized Study of Carboplatin-Paclitaxel With INCMGA00012 or Placebo in Participants With Inoperable Locally Recurrent or Metastatic Squamous Cell Carcinoma of the Anal Canal Not Previously Treated With Systemic Chemotherapy (POD1UM-303/InterAACT 2) (INCMGA 0012-303)

Indication: Carcinoid

Location: Texas Oncology-Grapevine

Phase: III

Cervical Cancer

Title: STAR Ph2 Basket Tucat+Tras ST HER2 Alt View

Description: A Phase 2 Basket Study of Tucatinib in Combination with Trastuzumab in Subjects with Previously Treated Locally-Advanced Unresectable or Metastatic Solid Tumors Driven by HER2 Alterations (SGNTUC-019)

Indication: Cervical Cancer

Location: Texas Oncology-Arlington Cancer Center North

Phase: II

Title: STAR Ph2 Basket Tucat+Tras ST HER2 Alt View

Description: A Phase 2 Basket Study of Tucatinib in Combination with Trastuzumab in Subjects with Previously Treated Locally-Advanced Unresectable or Metastatic Solid Tumors Driven by HER2 Alterations (SGNTUC-019)

Indication: Cervical Cancer

Location: Texas Oncology-Arlington South

Phase: II

Title: STAR Ph2 Ak104 Cervical Cancer View

Description: A Phase 2 multicenter single-arm open-label study to evaluate the efficacy and safety of AK104 in subjects with recurrent or metastatic cervical cancer (AK104-201-AU)

Indication: Cervical Cancer

Location: Texas Oncology-Arlington Cancer Center North

Phase: II

Title: STAR Ph2 Ak104 Cervical Cancer View

Description: A Phase 2 multicenter single-arm open-label study to evaluate the efficacy and safety of AK104 in subjects with recurrent or metastatic cervical cancer (AK104-201-AU)

Indication: Cervical Cancer

Location: Texas Oncology-Arlington South

Phase: II

Title: STAR Ph1/2 MRTX849 Solids KRAS G12C View

Description: A Phase 1/2 Multiple Expansion Cohort Trial of MRTX849 in Patients with Advanced Solid Tumors with KRAS G12C Mutation (849-001)

Indication: Cervical Cancer

Location: Texas Oncology-Arlington Cancer Center North

Phase: I/II

Title: STAR Ph1/2 MRTX849 Solids KRAS G12C View

Description: A Phase 1/2 Multiple Expansion Cohort Trial of MRTX849 in Patients with Advanced Solid Tumors with KRAS G12C Mutation (849-001)

Indication: Cervical Cancer

Location: Texas Oncology-Arlington South

Phase: I/II

Title: Ph2 Cervical 2L (RaPiDS) View

Description: A Two-arm Randomized Non-comparative Phase 2 Trial of AGEN2034(anti-PD-1) as a Monotherapy or Combination Therapy with AGEN1884(anti-CTLA4) or with Placebo in Women with Recurrent Cervical Cancer(Second Line) - RaPiDS (C-750-01/GOG-3028)

Indication: Cervical Cancer

Location: Texas Oncology-Bedford

Phase: II

Title: STAR Ph1/2 MRTX849 Solids KRAS G12C View

Description: A Phase 1/2 Multiple Expansion Cohort Trial of MRTX849 in Patients with Advanced Solid Tumors with KRAS G12C Mutation (849-001)

Indication: Cervical Cancer

Location: Texas Oncology-Bedford

Phase: I/II

Title: STAR Ph2 Basket Tucat+Tras ST HER2 Alt View

Description: A Phase 2 Basket Study of Tucatinib in Combination with Trastuzumab in Subjects with Previously Treated Locally-Advanced Unresectable or Metastatic Solid Tumors Driven by HER2 Alterations (SGNTUC-019)

Indication: Cervical Cancer

Location: Texas Oncology-Bedford

Phase: II

Title: STAR Ph2 Basket Tucat+Tras ST HER2 Alt View

Description: A Phase 2 Basket Study of Tucatinib in Combination with Trastuzumab in Subjects with Previously Treated Locally-Advanced Unresectable or Metastatic Solid Tumors Driven by HER2 Alterations (SGNTUC-019)

Indication: Cervical Cancer

Location: Texas Oncology-Fort Worth Cancer Center

Phase: II

Title: PH3 adv CC View

Description: A Randomized Phase 3 Double-Blind Study of Chemoradiotherapy With or Without Pembrolizumab for the Treatment of High-risk Locally Advanced Cervical Cancer (KEYNOTE-A18 / ENGOT-cx11)

Indication: Cervical Cancer

Location: Texas Oncology-Fort Worth Cancer Center

Phase: III

Title: STAR Ph2 Ak104 Cervical Cancer View

Description: A Phase 2 multicenter single-arm open-label study to evaluate the efficacy and safety of AK104 in subjects with recurrent or metastatic cervical cancer (AK104-201-AU)

Indication: Cervical Cancer

Location: Texas Oncology-Fort Worth Cancer Center

Phase: II

Title: STAR Ph1/2 MRTX849 Solids KRAS G12C View

Description: A Phase 1/2 Multiple Expansion Cohort Trial of MRTX849 in Patients with Advanced Solid Tumors with KRAS G12C Mutation (849-001)

Indication: Cervical Cancer

Location: Texas Oncology-Fort Worth Cancer Center

Phase: I/II

Title: Ph2 Cervical 2L (RaPiDS) View

Description: A Two-arm Randomized Non-comparative Phase 2 Trial of AGEN2034(anti-PD-1) as a Monotherapy or Combination Therapy with AGEN1884(anti-CTLA4) or with Placebo in Women with Recurrent Cervical Cancer(Second Line) - RaPiDS (C-750-01/GOG-3028)

Indication: Cervical Cancer

Location: Texas Oncology-Fort Worth Cancer Center

Phase: II

Title: STAR Ph2 Basket Tucat+Tras ST HER2 Alt View

Description: A Phase 2 Basket Study of Tucatinib in Combination with Trastuzumab in Subjects with Previously Treated Locally-Advanced Unresectable or Metastatic Solid Tumors Driven by HER2 Alterations (SGNTUC-019)

Indication: Cervical Cancer

Location: Texas Oncology-Grapevine

Phase: II

Title: Ph2 Cervical 2L (RaPiDS) View

Description: A Two-arm Randomized Non-comparative Phase 2 Trial of AGEN2034(anti-PD-1) as a Monotherapy or Combination Therapy with AGEN1884(anti-CTLA4) or with Placebo in Women with Recurrent Cervical Cancer(Second Line) - RaPiDS (C-750-01/GOG-3028)

Indication: Cervical Cancer

Location: Texas Oncology-Grapevine

Phase: II

Title: STAR Ph1/2 MRTX849 Solids KRAS G12C View

Description: A Phase 1/2 Multiple Expansion Cohort Trial of MRTX849 in Patients with Advanced Solid Tumors with KRAS G12C Mutation (849-001)

Indication: Cervical Cancer

Location: Texas Oncology-Grapevine

Phase: I/II

Colon Cancer

Title: STAR PH2 Tuca+ Tras HER2+ CC View

Description: MOUNTAINEER: A Phase 2 Open Label Study of Tucatinib Combined with Trastuzumab in Patients with HER2+ Metastatic Colorectal Cancer (ACCRU-GI-1617 SGNTUC-017)

Indication: Colon Cancer

Location: Texas Oncology-Arlington Cancer Center North

Phase: II

Title: STAR PH2 Tuca+ Tras HER2+ CC View

Description: MOUNTAINEER: A Phase 2 Open Label Study of Tucatinib Combined with Trastuzumab in Patients with HER2+ Metastatic Colorectal Cancer (ACCRU-GI-1617 SGNTUC-017)

Indication: Colon Cancer

Location: Texas Oncology-Arlington South

Phase: II

Title: STAR Ph1/2 MRTX849 Solids KRAS G12C View

Description: A Phase 1/2 Multiple Expansion Cohort Trial of MRTX849 in Patients with Advanced Solid Tumors with KRAS G12C Mutation (849-001)

Indication: Colon Cancer

Location: Texas Oncology-Arlington Cancer Center North

Phase: I/II

Title: STAR Ph1/2 MRTX849 Solids KRAS G12C View

Description: A Phase 1/2 Multiple Expansion Cohort Trial of MRTX849 in Patients with Advanced Solid Tumors with KRAS G12C Mutation (849-001)

Indication: Colon Cancer

Location: Texas Oncology-Arlington South

Phase: I/II

Title: STAR Ph1/2 MRTX849 Solids KRAS G12C View

Description: A Phase 1/2 Multiple Expansion Cohort Trial of MRTX849 in Patients with Advanced Solid Tumors with KRAS G12C Mutation (849-001)

Indication: Colon Cancer

Location: Texas Oncology-Bedford

Phase: I/II

Title: STAR PH2 Tuca+ Tras HER2+ CC View

Description: MOUNTAINEER: A Phase 2 Open Label Study of Tucatinib Combined with Trastuzumab in Patients with HER2+ Metastatic Colorectal Cancer (ACCRU-GI-1617 SGNTUC-017)

Indication: Colon Cancer

Location: Texas Oncology-Bedford

Phase: II

Title: STAR PH2 Tuca+ Tras HER2+ CC View

Description: MOUNTAINEER: A Phase 2 Open Label Study of Tucatinib Combined with Trastuzumab in Patients with HER2+ Metastatic Colorectal Cancer (ACCRU-GI-1617 SGNTUC-017)

Indication: Colon Cancer

Location: Texas Oncology-Fort Worth Cancer Center

Phase: II

Title: STAR Ph1/2 MRTX849 Solids KRAS G12C View

Description: A Phase 1/2 Multiple Expansion Cohort Trial of MRTX849 in Patients with Advanced Solid Tumors with KRAS G12C Mutation (849-001)

Indication: Colon Cancer

Location: Texas Oncology-Fort Worth Cancer Center

Phase: I/II

Title: STAR PH2 Tuca+ Tras HER2+ CC View

Description: MOUNTAINEER: A Phase 2 Open Label Study of Tucatinib Combined with Trastuzumab in Patients with HER2+ Metastatic Colorectal Cancer (ACCRU-GI-1617 SGNTUC-017)

Indication: Colon Cancer

Location: Texas Oncology-Grapevine

Phase: II

Title: STAR Ph1/2 MRTX849 Solids KRAS G12C View

Description: A Phase 1/2 Multiple Expansion Cohort Trial of MRTX849 in Patients with Advanced Solid Tumors with KRAS G12C Mutation (849-001)

Indication: Colon Cancer

Location: Texas Oncology-Grapevine

Phase: I/II

Endometrial Cancer

Title: STAR Ph1/2 MRTX849 Solids KRAS G12C View

Description: A Phase 1/2 Multiple Expansion Cohort Trial of MRTX849 in Patients with Advanced Solid Tumors with KRAS G12C Mutation (849-001)

Indication: Endometrial Cancer

Location: Texas Oncology-Arlington Cancer Center North

Phase: I/II

Title: STAR Ph1/2 MRTX849 Solids KRAS G12C View

Description: A Phase 1/2 Multiple Expansion Cohort Trial of MRTX849 in Patients with Advanced Solid Tumors with KRAS G12C Mutation (849-001)

Indication: Endometrial Cancer

Location: Texas Oncology-Arlington South

Phase: I/II

Title: STAR Ph1/2 MRTX849 Solids KRAS G12C View

Description: A Phase 1/2 Multiple Expansion Cohort Trial of MRTX849 in Patients with Advanced Solid Tumors with KRAS G12C Mutation (849-001)

Indication: Endometrial Cancer

Location: Texas Oncology-Bedford

Phase: I/II

Title: PH3 Plac Carbo Pacil Dura +/- Olap DUO-E View

Description: D9311C00001; GOG-3041; ENGOT-EN10: A Randomised Multicentre Double-blind Placebo-controlled Phase III Study of First-line Carboplatin and Paclitaxel in Combination with Durvalumab Followed by Maintenance Durvalumab with or without Olaparib in Patients with Newly Diagnosed Advanced or Recurrent Endometrial Cancer (DUO-E)

Indication: Endometrial Cancer

Location: Texas Oncology-Bedford

Phase: III

Title: INCMGA00012 Endo Cancer View

Description: An Umbrella Study of INCMGA00012 Alone and in Combination With Other Therapies in Participants With Advanced or Metastatic Endometrial Cancer Who Have Progressed on or After Platinum-Based Chemotherapy (INCMGA 0012-204/ POD1UM-204)

Indication: Endometrial Cancer

Location: Texas Oncology-Fort Worth Cancer Center

Phase: II

Title: STAR Ph1/2 MRTX849 Solids KRAS G12C View

Description: A Phase 1/2 Multiple Expansion Cohort Trial of MRTX849 in Patients with Advanced Solid Tumors with KRAS G12C Mutation (849-001)

Indication: Endometrial Cancer

Location: Texas Oncology-Fort Worth Cancer Center

Phase: I/II

Title: Ph3 TSR-042+car-pac vs plac+car-pac endo View

Description: A PHASE 3 RANDOMIZED DOUBLE-BLIND MULTICENTER STUDY OF DOSTARLIMAB (TSR-042) PLUS CARBOPLATIN-PACLITAXEL VERSUS PLACEBO PLUS CARBOPLATIN-PACLITAXEL IN PATIENTS WITH RECURRENT OR PRIMARY ADVANCED ENDOMETRIAL CANCER (RUBY) (4010-03-001 / ENGOT EN-6 / GOG-3031)

Indication: Endometrial Cancer

Location: Texas Oncology-Fort Worth Cancer Center

Phase: III

Title: PH3 Plac Carbo Pacil Dura +/- Olap DUO-E View

Description: D9311C00001; GOG-3041; ENGOT-EN10: A Randomised Multicentre Double-blind Placebo-controlled Phase III Study of First-line Carboplatin and Paclitaxel in Combination with Durvalumab Followed by Maintenance Durvalumab with or without Olaparib in Patients with Newly Diagnosed Advanced or Recurrent Endometrial Cancer (DUO-E)

Indication: Endometrial Cancer

Location: Texas Oncology-Grapevine

Phase: III

Title: STAR Ph1/2 MRTX849 Solids KRAS G12C View

Description: A Phase 1/2 Multiple Expansion Cohort Trial of MRTX849 in Patients with Advanced Solid Tumors with KRAS G12C Mutation (849-001)

Indication: Endometrial Cancer

Location: Texas Oncology-Grapevine

Phase: I/II

Esophageal Cancer

Title: STAR Ph3 Sinti vs Placebo ESCC View

Description: A Multicenter Double-Blind Randomized Phase III Clinical Trial Evaluating the Efficacy and Safety of Sintilimab vs. Placebo in Combination with Chemotherapy for First-Line Treatment of Unresectable Locally Advanced Recurrent or Metastatic Esophageal Squamous Cell Carcinoma (ORIENT-15)CIBI308A301

Indication: Esophageal Cancer

Location: Texas Oncology-Arlington South

Phase: III

Title: STAR Ph1/2 MRTX849 Solids KRAS G12C View

Description: A Phase 1/2 Multiple Expansion Cohort Trial of MRTX849 in Patients with Advanced Solid Tumors with KRAS G12C Mutation (849-001)

Indication: Esophageal Cancer

Location: Texas Oncology-Arlington Cancer Center North

Phase: I/II

Title: STAR Ph1/2 MRTX849 Solids KRAS G12C View

Description: A Phase 1/2 Multiple Expansion Cohort Trial of MRTX849 in Patients with Advanced Solid Tumors with KRAS G12C Mutation (849-001)

Indication: Esophageal Cancer

Location: Texas Oncology-Arlington South

Phase: I/II

Title: STAR Ph1/2 MRTX849 Solids KRAS G12C View

Description: A Phase 1/2 Multiple Expansion Cohort Trial of MRTX849 in Patients with Advanced Solid Tumors with KRAS G12C Mutation (849-001)

Indication: Esophageal Cancer

Location: Texas Oncology-Bedford

Phase: I/II

Title: STAR Ph3 Sinti vs Placebo ESCC View

Description: A Multicenter Double-Blind Randomized Phase III Clinical Trial Evaluating the Efficacy and Safety of Sintilimab vs. Placebo in Combination with Chemotherapy for First-Line Treatment of Unresectable Locally Advanced Recurrent or Metastatic Esophageal Squamous Cell Carcinoma (ORIENT-15)CIBI308A301

Indication: Esophageal Cancer

Location: Texas Oncology-Fort Worth Cancer Center

Phase: III

Title: STAR Ph1/2 MRTX849 Solids KRAS G12C View

Description: A Phase 1/2 Multiple Expansion Cohort Trial of MRTX849 in Patients with Advanced Solid Tumors with KRAS G12C Mutation (849-001)

Indication: Esophageal Cancer

Location: Texas Oncology-Fort Worth Cancer Center

Phase: I/II

Title: STAR Ph3 Sinti vs Placebo ESCC View

Description: A Multicenter Double-Blind Randomized Phase III Clinical Trial Evaluating the Efficacy and Safety of Sintilimab vs. Placebo in Combination with Chemotherapy for First-Line Treatment of Unresectable Locally Advanced Recurrent or Metastatic Esophageal Squamous Cell Carcinoma (ORIENT-15)CIBI308A301

Indication: Esophageal Cancer

Location: Texas Oncology-Grapevine

Phase: III

Title: STAR Ph1/2 MRTX849 Solids KRAS G12C View

Description: A Phase 1/2 Multiple Expansion Cohort Trial of MRTX849 in Patients with Advanced Solid Tumors with KRAS G12C Mutation (849-001)

Indication: Esophageal Cancer

Location: Texas Oncology-Grapevine

Phase: I/II

Essential Thrombocythemia

Title: STAR PH3 Pacritinib vs MD choice in MF View

Description: A Randomized Controlled Phase 3 Study of Pacritinib Versus Physician's Choice in Patients with Primary Myelofibrosis Post Polycythemia Vera Myelofibrosis or Post-Essential Thrombocythemia Myelofibrosis with Severe Thrombocytopenia (Platelets Counts <50000/µL) (PAC203)

Indication: Essential Thrombocythemia

Location: Texas Oncology-Arlington South

Phase: III

Title: STAR PH3 Pacritinib vs MD choice in MF View

Description: A Randomized Controlled Phase 3 Study of Pacritinib Versus Physician's Choice in Patients with Primary Myelofibrosis Post Polycythemia Vera Myelofibrosis or Post-Essential Thrombocythemia Myelofibrosis with Severe Thrombocytopenia (Platelets Counts <50000/µL) (PAC203)

Indication: Essential Thrombocythemia

Location: Texas Oncology-Bedford

Phase: III

Title: STAR PH3 Pacritinib vs MD choice in MF View

Description: A Randomized Controlled Phase 3 Study of Pacritinib Versus Physician's Choice in Patients with Primary Myelofibrosis Post Polycythemia Vera Myelofibrosis or Post-Essential Thrombocythemia Myelofibrosis with Severe Thrombocytopenia (Platelets Counts <50000/µL) (PAC203)

Indication: Essential Thrombocythemia

Location: Texas Oncology-Fort Worth Cancer Center

Phase: III

Title: STAR PH3 Pacritinib vs MD choice in MF View

Description: A Randomized Controlled Phase 3 Study of Pacritinib Versus Physician's Choice in Patients with Primary Myelofibrosis Post Polycythemia Vera Myelofibrosis or Post-Essential Thrombocythemia Myelofibrosis with Severe Thrombocytopenia (Platelets Counts <50000/µL) (PAC203)

Indication: Essential Thrombocythemia

Location: Texas Oncology-Grapevine

Phase: III

Fallopian Tube Cancer

Title: STAR Ph1/2 MRTX849 Solids KRAS G12C View

Description: A Phase 1/2 Multiple Expansion Cohort Trial of MRTX849 in Patients with Advanced Solid Tumors with KRAS G12C Mutation (849-001)

Indication: Fallopian Tube Cancer

Location: Texas Oncology-Arlington Cancer Center North

Phase: I/II

Title: STAR Ph1/2 MRTX849 Solids KRAS G12C View

Description: A Phase 1/2 Multiple Expansion Cohort Trial of MRTX849 in Patients with Advanced Solid Tumors with KRAS G12C Mutation (849-001)

Indication: Fallopian Tube Cancer

Location: Texas Oncology-Arlington South

Phase: I/II

Title: STAR Ph1/2 MRTX849 Solids KRAS G12C View

Description: A Phase 1/2 Multiple Expansion Cohort Trial of MRTX849 in Patients with Advanced Solid Tumors with KRAS G12C Mutation (849-001)

Indication: Fallopian Tube Cancer

Location: Texas Oncology-Bedford

Phase: I/II

Title: Ph3 Mirv Sora Epi Ova FTC View

Description: SORAYA: A Phase 3 Single Arm Study of Mirvetuximab Soravtansine in Advanced High-Grade Epithelial Ovarian Primary Peritoneal or Fallopian Tube Cancers with High Folate Receptor-Alpha Expression (IMGN853-0417)

Indication: Fallopian Tube Cancer

Location: Texas Oncology-Fort Worth Cancer Center

Phase: III

Title: STAR Ph1/2 MRTX849 Solids KRAS G12C View

Description: A Phase 1/2 Multiple Expansion Cohort Trial of MRTX849 in Patients with Advanced Solid Tumors with KRAS G12C Mutation (849-001)

Indication: Fallopian Tube Cancer

Location: Texas Oncology-Fort Worth Cancer Center

Phase: I/II

Title: STAR Ph1/2 MRTX849 Solids KRAS G12C View

Description: A Phase 1/2 Multiple Expansion Cohort Trial of MRTX849 in Patients with Advanced Solid Tumors with KRAS G12C Mutation (849-001)

Indication: Fallopian Tube Cancer

Location: Texas Oncology-Grapevine

Phase: I/II

Gall Bladder Cancer

Title: STAR Ph2 Basket Tucat+Tras ST HER2 Alt View

Description: A Phase 2 Basket Study of Tucatinib in Combination with Trastuzumab in Subjects with Previously Treated Locally-Advanced Unresectable or Metastatic Solid Tumors Driven by HER2 Alterations (SGNTUC-019)

Indication: Gall Bladder Cancer

Location: Texas Oncology-Arlington Cancer Center North

Phase: II

Title: STAR Ph2 Basket Tucat+Tras ST HER2 Alt View

Description: A Phase 2 Basket Study of Tucatinib in Combination with Trastuzumab in Subjects with Previously Treated Locally-Advanced Unresectable or Metastatic Solid Tumors Driven by HER2 Alterations (SGNTUC-019)

Indication: Gall Bladder Cancer

Location: Texas Oncology-Arlington South

Phase: II

Title: STAR Ph1/2 MRTX849 Solids KRAS G12C View

Description: A Phase 1/2 Multiple Expansion Cohort Trial of MRTX849 in Patients with Advanced Solid Tumors with KRAS G12C Mutation (849-001)

Indication: Gall Bladder Cancer

Location: Texas Oncology-Arlington Cancer Center North

Phase: I/II

Title: STAR Ph1/2 MRTX849 Solids KRAS G12C View

Description: A Phase 1/2 Multiple Expansion Cohort Trial of MRTX849 in Patients with Advanced Solid Tumors with KRAS G12C Mutation (849-001)

Indication: Gall Bladder Cancer

Location: Texas Oncology-Arlington South

Phase: I/II

Title: STAR Ph1/2 MRTX849 Solids KRAS G12C View

Description: A Phase 1/2 Multiple Expansion Cohort Trial of MRTX849 in Patients with Advanced Solid Tumors with KRAS G12C Mutation (849-001)

Indication: Gall Bladder Cancer

Location: Texas Oncology-Bedford

Phase: I/II

Title: STAR Ph2 Basket Tucat+Tras ST HER2 Alt View

Description: A Phase 2 Basket Study of Tucatinib in Combination with Trastuzumab in Subjects with Previously Treated Locally-Advanced Unresectable or Metastatic Solid Tumors Driven by HER2 Alterations (SGNTUC-019)

Indication: Gall Bladder Cancer

Location: Texas Oncology-Bedford

Phase: II

Title: STAR Ph2 Basket Tucat+Tras ST HER2 Alt View

Description: A Phase 2 Basket Study of Tucatinib in Combination with Trastuzumab in Subjects with Previously Treated Locally-Advanced Unresectable or Metastatic Solid Tumors Driven by HER2 Alterations (SGNTUC-019)

Indication: Gall Bladder Cancer

Location: Texas Oncology-Fort Worth Cancer Center

Phase: II

Title: STAR Ph1/2 MRTX849 Solids KRAS G12C View

Description: A Phase 1/2 Multiple Expansion Cohort Trial of MRTX849 in Patients with Advanced Solid Tumors with KRAS G12C Mutation (849-001)

Indication: Gall Bladder Cancer

Location: Texas Oncology-Fort Worth Cancer Center

Phase: I/II

Title: STAR Ph2 Basket Tucat+Tras ST HER2 Alt View

Description: A Phase 2 Basket Study of Tucatinib in Combination with Trastuzumab in Subjects with Previously Treated Locally-Advanced Unresectable or Metastatic Solid Tumors Driven by HER2 Alterations (SGNTUC-019)

Indication: Gall Bladder Cancer

Location: Texas Oncology-Grapevine

Phase: II

Title: STAR Ph1/2 MRTX849 Solids KRAS G12C View

Description: A Phase 1/2 Multiple Expansion Cohort Trial of MRTX849 in Patients with Advanced Solid Tumors with KRAS G12C Mutation (849-001)

Indication: Gall Bladder Cancer

Location: Texas Oncology-Grapevine

Phase: I/II

Gastric Cancer

Title: STAR Ph1/2 MRTX849 Solids KRAS G12C View

Description: A Phase 1/2 Multiple Expansion Cohort Trial of MRTX849 in Patients with Advanced Solid Tumors with KRAS G12C Mutation (849-001)

Indication: Gastric Cancer

Location: Texas Oncology-Arlington Cancer Center North

Phase: I/II

Title: STAR Ph1/2 MRTX849 Solids KRAS G12C View

Description: A Phase 1/2 Multiple Expansion Cohort Trial of MRTX849 in Patients with Advanced Solid Tumors with KRAS G12C Mutation (849-001)

Indication: Gastric Cancer

Location: Texas Oncology-Arlington South

Phase: I/II

Title: STAR Ph1/2 MRTX849 Solids KRAS G12C View

Description: A Phase 1/2 Multiple Expansion Cohort Trial of MRTX849 in Patients with Advanced Solid Tumors with KRAS G12C Mutation (849-001)

Indication: Gastric Cancer

Location: Texas Oncology-Bedford

Phase: I/II

Title: STAR Ph1/2 MRTX849 Solids KRAS G12C View

Description: A Phase 1/2 Multiple Expansion Cohort Trial of MRTX849 in Patients with Advanced Solid Tumors with KRAS G12C Mutation (849-001)

Indication: Gastric Cancer

Location: Texas Oncology-Fort Worth Cancer Center

Phase: I/II

Title: STAR Ph1/2 MRTX849 Solids KRAS G12C View

Description: A Phase 1/2 Multiple Expansion Cohort Trial of MRTX849 in Patients with Advanced Solid Tumors with KRAS G12C Mutation (849-001)

Indication: Gastric Cancer

Location: Texas Oncology-Grapevine

Phase: I/II

Head and Neck Cancer

Title: STAR Ph1/2 MRTX849 Solids KRAS G12C View

Description: A Phase 1/2 Multiple Expansion Cohort Trial of MRTX849 in Patients with Advanced Solid Tumors with KRAS G12C Mutation (849-001)

Indication: Head and Neck Cancer

Location: Texas Oncology-Arlington Cancer Center North

Phase: I/II

Title: STAR Ph1/2 MRTX849 Solids KRAS G12C View

Description: A Phase 1/2 Multiple Expansion Cohort Trial of MRTX849 in Patients with Advanced Solid Tumors with KRAS G12C Mutation (849-001)

Indication: Head and Neck Cancer

Location: Texas Oncology-Arlington South

Phase: I/II

Title: STAR Ph1/2 MRTX849 Solids KRAS G12C View

Description: A Phase 1/2 Multiple Expansion Cohort Trial of MRTX849 in Patients with Advanced Solid Tumors with KRAS G12C Mutation (849-001)

Indication: Head and Neck Cancer

Location: Texas Oncology-Bedford

Phase: I/II

Title: STAR Ph1/2 MRTX849 Solids KRAS G12C View

Description: A Phase 1/2 Multiple Expansion Cohort Trial of MRTX849 in Patients with Advanced Solid Tumors with KRAS G12C Mutation (849-001)

Indication: Head and Neck Cancer

Location: Texas Oncology-Fort Worth Cancer Center

Phase: I/II

Title: STAR Ph1/2 MRTX849 Solids KRAS G12C View

Description: A Phase 1/2 Multiple Expansion Cohort Trial of MRTX849 in Patients with Advanced Solid Tumors with KRAS G12C Mutation (849-001)

Indication: Head and Neck Cancer

Location: Texas Oncology-Grapevine

Phase: I/II

Hematologic

Title: PH2 Brentux+CHP In Tx Naive PTCL View

Description: A dual-cohort open-label phase 2 study of brentuximab vedotin and CHP (A+CHP) in the frontline treatment of subjects with peripheral T-cell lymphoma (PTCL) with less than 10% CD30 expression (SGN35-032)

Indication: Hematologic

Location: Texas Oncology-Fort Worth Cancer Center

Phase: II

Kaposi's Sarcoma

Title: STAR Ph1/2 MRTX849 Solids KRAS G12C View

Description: A Phase 1/2 Multiple Expansion Cohort Trial of MRTX849 in Patients with Advanced Solid Tumors with KRAS G12C Mutation (849-001)

Indication: Kaposi's Sarcoma

Location: Texas Oncology-Arlington Cancer Center North

Phase: I/II

Title: STAR Ph1/2 MRTX849 Solids KRAS G12C View

Description: A Phase 1/2 Multiple Expansion Cohort Trial of MRTX849 in Patients with Advanced Solid Tumors with KRAS G12C Mutation (849-001)

Indication: Kaposi's Sarcoma

Location: Texas Oncology-Arlington South

Phase: I/II

Title: STAR Ph1/2 MRTX849 Solids KRAS G12C View

Description: A Phase 1/2 Multiple Expansion Cohort Trial of MRTX849 in Patients with Advanced Solid Tumors with KRAS G12C Mutation (849-001)

Indication: Kaposi's Sarcoma

Location: Texas Oncology-Bedford

Phase: I/II

Title: STAR Ph1/2 MRTX849 Solids KRAS G12C View

Description: A Phase 1/2 Multiple Expansion Cohort Trial of MRTX849 in Patients with Advanced Solid Tumors with KRAS G12C Mutation (849-001)

Indication: Kaposi's Sarcoma

Location: Texas Oncology-Fort Worth Cancer Center

Phase: I/II

Title: STAR Ph1/2 MRTX849 Solids KRAS G12C View

Description: A Phase 1/2 Multiple Expansion Cohort Trial of MRTX849 in Patients with Advanced Solid Tumors with KRAS G12C Mutation (849-001)

Indication: Kaposi's Sarcoma

Location: Texas Oncology-Grapevine

Phase: I/II

Kidney Cancer

Title: STAR Ph1/2 MRTX849 Solids KRAS G12C View

Description: A Phase 1/2 Multiple Expansion Cohort Trial of MRTX849 in Patients with Advanced Solid Tumors with KRAS G12C Mutation (849-001)

Indication: Kidney Cancer

Location: Texas Oncology-Arlington Cancer Center North

Phase: I/II

Title: STAR Ph1/2 MRTX849 Solids KRAS G12C View

Description: A Phase 1/2 Multiple Expansion Cohort Trial of MRTX849 in Patients with Advanced Solid Tumors with KRAS G12C Mutation (849-001)

Indication: Kidney Cancer

Location: Texas Oncology-Arlington South

Phase: I/II

Title: STAR Ph1/2 MRTX849 Solids KRAS G12C View

Description: A Phase 1/2 Multiple Expansion Cohort Trial of MRTX849 in Patients with Advanced Solid Tumors with KRAS G12C Mutation (849-001)

Indication: Kidney Cancer

Location: Texas Oncology-Bedford

Phase: I/II

Title: STAR Ph1/2 MRTX849 Solids KRAS G12C View

Description: A Phase 1/2 Multiple Expansion Cohort Trial of MRTX849 in Patients with Advanced Solid Tumors with KRAS G12C Mutation (849-001)

Indication: Kidney Cancer

Location: Texas Oncology-Fort Worth Cancer Center

Phase: I/II

Title: STAR Ph1/2 MRTX849 Solids KRAS G12C View

Description: A Phase 1/2 Multiple Expansion Cohort Trial of MRTX849 in Patients with Advanced Solid Tumors with KRAS G12C Mutation (849-001)

Indication: Kidney Cancer

Location: Texas Oncology-Grapevine

Phase: I/II

Leukemia

Title: STAR Ublituximab+TGR-1202 Cross-over View

Description: (UTX-TGR-204) A Multi-Center Open-Label Compassionate Use Extension Study of Ublituximab (TG-1101) in Combination with Umbralisib (TGR-1202) for Patients Previously Enrolled in Protocol UTX-TGR-304

Indication: Leukemia

Location: Texas Oncology-Bedford

Phase: II

Title: PH2 Brentux+CHP In Tx Naive PTCL View

Description: A dual-cohort open-label phase 2 study of brentuximab vedotin and CHP (A+CHP) in the frontline treatment of subjects with peripheral T-cell lymphoma (PTCL) with less than 10% CD30 expression (SGN35-032)

Indication: Leukemia

Location: Texas Oncology-Fort Worth Cancer Center

Phase: II

Title: STAR Ublituximab+TGR-1202 Cross-over View

Description: (UTX-TGR-204) A Multi-Center Open-Label Compassionate Use Extension Study of Ublituximab (TG-1101) in Combination with Umbralisib (TGR-1202) for Patients Previously Enrolled in Protocol UTX-TGR-304

Indication: Leukemia

Location: Texas Oncology-Grapevine

Phase: II

Liver Cancer

Title: STAR Ph1/2 MRTX849 Solids KRAS G12C View

Description: A Phase 1/2 Multiple Expansion Cohort Trial of MRTX849 in Patients with Advanced Solid Tumors with KRAS G12C Mutation (849-001)

Indication: Liver Cancer

Location: Texas Oncology-Arlington Cancer Center North

Phase: I/II

Title: STAR Ph1/2 MRTX849 Solids KRAS G12C View

Description: A Phase 1/2 Multiple Expansion Cohort Trial of MRTX849 in Patients with Advanced Solid Tumors with KRAS G12C Mutation (849-001)

Indication: Liver Cancer

Location: Texas Oncology-Arlington South

Phase: I/II

Title: STAR Ph1/2 MRTX849 Solids KRAS G12C View

Description: A Phase 1/2 Multiple Expansion Cohort Trial of MRTX849 in Patients with Advanced Solid Tumors with KRAS G12C Mutation (849-001)

Indication: Liver Cancer

Location: Texas Oncology-Bedford

Phase: I/II

Title: STAR Ph1/2 MRTX849 Solids KRAS G12C View

Description: A Phase 1/2 Multiple Expansion Cohort Trial of MRTX849 in Patients with Advanced Solid Tumors with KRAS G12C Mutation (849-001)

Indication: Liver Cancer

Location: Texas Oncology-Fort Worth Cancer Center

Phase: I/II

Title: STAR Ph1/2 MRTX849 Solids KRAS G12C View

Description: A Phase 1/2 Multiple Expansion Cohort Trial of MRTX849 in Patients with Advanced Solid Tumors with KRAS G12C Mutation (849-001)

Indication: Liver Cancer

Location: Texas Oncology-Grapevine

Phase: I/II

Lung Cancer

Title: STAR Ph2 Basket Tucat+Tras ST HER2 Alt View

Description: A Phase 2 Basket Study of Tucatinib in Combination with Trastuzumab in Subjects with Previously Treated Locally-Advanced Unresectable or Metastatic Solid Tumors Driven by HER2 Alterations (SGNTUC-019)

Indication: Lung Cancer

Location: Texas Oncology-Arlington Cancer Center North

Phase: II

Title: STAR Ph2 Basket Tucat+Tras ST HER2 Alt View

Description: A Phase 2 Basket Study of Tucatinib in Combination with Trastuzumab in Subjects with Previously Treated Locally-Advanced Unresectable or Metastatic Solid Tumors Driven by HER2 Alterations (SGNTUC-019)

Indication: Lung Cancer

Location: Texas Oncology-Arlington South

Phase: II

Title: STAR Ph3 61186372 Osim Lazert EGFR NSCLC View

Description: A Phase 3 Randomized Study of Amivantamab and Lazertinib Combination Therapy Versus Osimertinib Versus Lazertinib as First-Line Treatment in Patients with EGFR-Mutated Locally Advanced or Metastatic Non-Small Cell Lung Cancer (73841937NSC3003)MARIPOSA

Indication: Lung Cancer

Location: Texas Oncology-Arlington Cancer Center North

Phase: III

Title: STAR Ph3 61186372 Osim Lazert EGFR NSCLC View

Description: A Phase 3 Randomized Study of Amivantamab and Lazertinib Combination Therapy Versus Osimertinib Versus Lazertinib as First-Line Treatment in Patients with EGFR-Mutated Locally Advanced or Metastatic Non-Small Cell Lung Cancer (73841937NSC3003)MARIPOSA

Indication: Lung Cancer

Location: Texas Oncology-Arlington South

Phase: III

Title: STAR PH3 JNJ-61186372 Peme EGFR NSCLC View

Description: A Randomized Open-label Phase 3 Study of Combination Amivantamab and Carboplatin-Pemetrexed Therapy Compared with Carboplatin-Pemetrexed in Patients with EGFR Exon 20ins Mutated Locally Advanced or Metastatic Non-Small Cell Lung Cancer (61186372NSC3001)

Indication: Lung Cancer

Location: Texas Oncology-Arlington Cancer Center North

Phase: III

Title: STAR PH3 JNJ-61186372 Peme EGFR NSCLC View

Description: A Randomized Open-label Phase 3 Study of Combination Amivantamab and Carboplatin-Pemetrexed Therapy Compared with Carboplatin-Pemetrexed in Patients with EGFR Exon 20ins Mutated Locally Advanced or Metastatic Non-Small Cell Lung Cancer (61186372NSC3001)

Indication: Lung Cancer

Location: Texas Oncology-Arlington South

Phase: III

Title: STAR KEAP1/NRF2 NSCLC View

Description: CX-839-014 "KEAPSAKE": A Phase 2 Randomized Multicenter Double-blind Study of the Glutaminase Inhibitor Telaglenastat with Pembrolizumab and Chemotherapy versus Placebo with Pembrolizumab and Chemotherapy in First-line Metastatic KEAP1/NRF2-mutated Nonsquamous Non-Small Cell Lung Cancer (NSCLC)

Indication: Lung Cancer

Location: Texas Oncology-Arlington South

Phase: II

Title: STAR-PH3 pral(Blu-667) RET-fusion mNSCLC View

Description: A Randomized Open-Label Phase 3 Study of Pralsetinib versus Standard of Care for First Line Treatment of RET fusion-positive Metastatic Non-Small Cell Lung Cancer (BLU-667-2303)

Indication: Lung Cancer

Location: Texas Oncology-Arlington South

Phase: III

Title: STAR Ph1/2 MRTX849 Solids KRAS G12C View

Description: A Phase 1/2 Multiple Expansion Cohort Trial of MRTX849 in Patients with Advanced Solid Tumors with KRAS G12C Mutation (849-001)

Indication: Lung Cancer

Location: Texas Oncology-Arlington Cancer Center North

Phase: I/II

Title: STAR Ph1/2 MRTX849 Solids KRAS G12C View

Description: A Phase 1/2 Multiple Expansion Cohort Trial of MRTX849 in Patients with Advanced Solid Tumors with KRAS G12C Mutation (849-001)

Indication: Lung Cancer

Location: Texas Oncology-Arlington South

Phase: I/II

Title: STAR Ph3 ALK+ mNSCLC (Brigatinib-3001) View

Description: Brigatinib-3001- A Phase 3 Randomized Open-label Study of Brigatinib (ALUNBRIG®)Versus Alectinib (ALECENSA®) in Advanced Anaplastic Lymphoma Kinase-Positive Non-Small-Cell Lung Cancer Patients Who Have Progressed on Crizotinib (XALKORI®)

Indication: Lung Cancer

Location: Texas Oncology-Arlington South

Phase: III

Title: STAR Ph1/2 BLU667 thy NSCLC Sol tum View

Description: A Phase 1/2 Study of the Highly-selective RET Inhibitor BLU-667 in Patients with Thyroid Cancer Non-Small Cell Lung Cancer (NSCLC) and Other Advanced Solid Tumors (BLU-667-1101)

Indication: Lung Cancer

Location: Texas Oncology-Arlington South

Phase: I/II

Title: STAR Ph1/2 BLU667 thy NSCLC Sol tum View

Description: A Phase 1/2 Study of the Highly-selective RET Inhibitor BLU-667 in Patients with Thyroid Cancer Non-Small Cell Lung Cancer (NSCLC) and Other Advanced Solid Tumors (BLU-667-1101)

Indication: Lung Cancer

Location: Texas Oncology-Bedford

Phase: I/II

Title: STAR Ph1/2 MRTX849 Solids KRAS G12C View

Description: A Phase 1/2 Multiple Expansion Cohort Trial of MRTX849 in Patients with Advanced Solid Tumors with KRAS G12C Mutation (849-001)

Indication: Lung Cancer

Location: Texas Oncology-Bedford

Phase: I/II

Title: PH3 AMG 510 vs Doce a/mNSCLC View

Description: 20190009: A Phase 3 Multicenter Randomized Open Label Active-controlled Study of AMG 510 Versus Docetaxel for the Treatment of Previously Treated Locally Advanced and Unresectable or Metastatic NSCLC Subjects with Mutated KRAS p.G12C

Indication: Lung Cancer

Location: Texas Oncology-Bedford

Phase: III

Title: STAR-PH3 pral(Blu-667) RET-fusion mNSCLC View

Description: A Randomized Open-Label Phase 3 Study of Pralsetinib versus Standard of Care for First Line Treatment of RET fusion-positive Metastatic Non-Small Cell Lung Cancer (BLU-667-2303)

Indication: Lung Cancer

Location: Texas Oncology-Bedford

Phase: III

Title: STAR KEAP1/NRF2 NSCLC View

Description: CX-839-014 "KEAPSAKE": A Phase 2 Randomized Multicenter Double-blind Study of the Glutaminase Inhibitor Telaglenastat with Pembrolizumab and Chemotherapy versus Placebo with Pembrolizumab and Chemotherapy in First-line Metastatic KEAP1/NRF2-mutated Nonsquamous Non-Small Cell Lung Cancer (NSCLC)

Indication: Lung Cancer

Location: Texas Oncology-Bedford

Phase: II

Title: STAR PH3 JNJ-61186372 Peme EGFR NSCLC View

Description: A Randomized Open-label Phase 3 Study of Combination Amivantamab and Carboplatin-Pemetrexed Therapy Compared with Carboplatin-Pemetrexed in Patients with EGFR Exon 20ins Mutated Locally Advanced or Metastatic Non-Small Cell Lung Cancer (61186372NSC3001)

Indication: Lung Cancer

Location: Texas Oncology-Bedford

Phase: III

Title: STAR Ph3 61186372 Osim Lazert EGFR NSCLC View

Description: A Phase 3 Randomized Study of Amivantamab and Lazertinib Combination Therapy Versus Osimertinib Versus Lazertinib as First-Line Treatment in Patients with EGFR-Mutated Locally Advanced or Metastatic Non-Small Cell Lung Cancer (73841937NSC3003)MARIPOSA

Indication: Lung Cancer

Location: Texas Oncology-Bedford

Phase: III

Title: STAR Ph3 61186372 Osim Lazert EGFR NSCLC View

Description: A Phase 3 Randomized Study of Amivantamab and Lazertinib Combination Therapy Versus Osimertinib Versus Lazertinib as First-Line Treatment in Patients with EGFR-Mutated Locally Advanced or Metastatic Non-Small Cell Lung Cancer (73841937NSC3003)MARIPOSA

Indication: Lung Cancer

Location: Texas Oncology-Bedford

Phase: III

Title: STAR Ph2 Basket Tucat+Tras ST HER2 Alt View

Description: A Phase 2 Basket Study of Tucatinib in Combination with Trastuzumab in Subjects with Previously Treated Locally-Advanced Unresectable or Metastatic Solid Tumors Driven by HER2 Alterations (SGNTUC-019)

Indication: Lung Cancer

Location: Texas Oncology-Bedford

Phase: II

Title: STAR Ph2 Basket Tucat+Tras ST HER2 Alt View

Description: A Phase 2 Basket Study of Tucatinib in Combination with Trastuzumab in Subjects with Previously Treated Locally-Advanced Unresectable or Metastatic Solid Tumors Driven by HER2 Alterations (SGNTUC-019)

Indication: Lung Cancer

Location: Texas Oncology-Fort Worth Cancer Center

Phase: II

Title: Ph2 Bren Vedo + Pembro ST prior PD-1 View

Description: A phase 2 study of brentuximab vedotin in combination with pembrolizumab in subjects with metastatic solid malignancies after progression on prior PD-1 inhibitor treatment (SGN35-033)

Indication: Lung Cancer

Location: Texas Oncology-Fort Worth Cancer Center

Phase: II

Title: STAR Ph3 61186372 Osim Lazert EGFR NSCLC View

Description: A Phase 3 Randomized Study of Amivantamab and Lazertinib Combination Therapy Versus Osimertinib Versus Lazertinib as First-Line Treatment in Patients with EGFR-Mutated Locally Advanced or Metastatic Non-Small Cell Lung Cancer (73841937NSC3003)MARIPOSA

Indication: Lung Cancer

Location: Texas Oncology-Fort Worth Cancer Center

Phase: III

Title: STAR Ph3 61186372 Osim Lazert EGFR NSCLC View

Description: A Phase 3 Randomized Study of Amivantamab and Lazertinib Combination Therapy Versus Osimertinib Versus Lazertinib as First-Line Treatment in Patients with EGFR-Mutated Locally Advanced or Metastatic Non-Small Cell Lung Cancer (73841937NSC3003)MARIPOSA

Indication: Lung Cancer

Location: Texas Oncology-Fort Worth Cancer Center

Phase: III

Title: STAR Ph3 61186372 Osim Lazert EGFR NSCLC View

Description: A Phase 3 Randomized Study of Amivantamab and Lazertinib Combination Therapy Versus Osimertinib Versus Lazertinib as First-Line Treatment in Patients with EGFR-Mutated Locally Advanced or Metastatic Non-Small Cell Lung Cancer (73841937NSC3003)MARIPOSA

Indication: Lung Cancer

Location: Texas Oncology-Fort Worth Cancer Center

Phase: III

Title: STAR PH3 JNJ-61186372 Peme EGFR NSCLC View

Description: A Randomized Open-label Phase 3 Study of Combination Amivantamab and Carboplatin-Pemetrexed Therapy Compared with Carboplatin-Pemetrexed in Patients with EGFR Exon 20ins Mutated Locally Advanced or Metastatic Non-Small Cell Lung Cancer (61186372NSC3001)

Indication: Lung Cancer

Location: Texas Oncology-Fort Worth Cancer Center

Phase: III

Title: STAR KEAP1/NRF2 NSCLC View

Description: CX-839-014 "KEAPSAKE": A Phase 2 Randomized Multicenter Double-blind Study of the Glutaminase Inhibitor Telaglenastat with Pembrolizumab and Chemotherapy versus Placebo with Pembrolizumab and Chemotherapy in First-line Metastatic KEAP1/NRF2-mutated Nonsquamous Non-Small Cell Lung Cancer (NSCLC)

Indication: Lung Cancer

Location: Texas Oncology-Fort Worth Cancer Center

Phase: II

Title: STAR-PH3 pral(Blu-667) RET-fusion mNSCLC View

Description: A Randomized Open-Label Phase 3 Study of Pralsetinib versus Standard of Care for First Line Treatment of RET fusion-positive Metastatic Non-Small Cell Lung Cancer (BLU-667-2303)

Indication: Lung Cancer

Location: Texas Oncology-Fort Worth Cancer Center

Phase: III

Title: Ph 1 PF-06821497 R/R SCLC CRPC & FL View

Description: C2321001: A PHASE I DOSE ESCALATION AND EXPANDED COHORT STUDY OF PF-06821497 IN THE TREATMENT OF ADULT PATIENTS WITH RELAPSED/REFRACTORY SMALL CELL LUNG CANCER (SCLC) CASTRATION RESISTANT PROSTATE CANCER (CRPC) AND FOLLICULAR LYMPHOMA (FL)

Indication: Lung Cancer

Location: Texas Oncology-Fort Worth Cancer Center

Phase: I

Title: STAR Ph1/2 MRTX849 Solids KRAS G12C View

Description: A Phase 1/2 Multiple Expansion Cohort Trial of MRTX849 in Patients with Advanced Solid Tumors with KRAS G12C Mutation (849-001)

Indication: Lung Cancer

Location: Texas Oncology-Fort Worth Cancer Center

Phase: I/II

Title: Ph 1b FIH XMT-1536 Solid Tumor NaPi2b View

Description: A Phase 1b/2 First-in-Human Dose Escalation and Expansion Study of XMT-1536 In Patients with Solid Tumors Likely to Express NaPi2b (MER-XMT-1536-1)

Indication: Lung Cancer

Location: Texas Oncology-Fort Worth Cancer Center

Phase: I

Title: Ph 1/1b Immunotherapy Combo in NSCLC View

Description: (AB928CSP0004) A Phase 1/1b Study to Evaluate the Safety and Tolerability of Immunotherapy Combinations in Participants with Lung Cancer

Indication: Lung Cancer

Location: Texas Oncology-Fort Worth Cancer Center

Phase: I

Title: STAR Ph3 ALK+ mNSCLC (Brigatinib-3001) View

Description: Brigatinib-3001- A Phase 3 Randomized Open-label Study of Brigatinib (ALUNBRIG®)Versus Alectinib (ALECENSA®) in Advanced Anaplastic Lymphoma Kinase-Positive Non-Small-Cell Lung Cancer Patients Who Have Progressed on Crizotinib (XALKORI®)

Indication: Lung Cancer

Location: Texas Oncology-Fort Worth Cancer Center

Phase: III

Title: STAR Ph1/2 BLU667 thy NSCLC Sol tum View

Description: A Phase 1/2 Study of the Highly-selective RET Inhibitor BLU-667 in Patients with Thyroid Cancer Non-Small Cell Lung Cancer (NSCLC) and Other Advanced Solid Tumors (BLU-667-1101)

Indication: Lung Cancer

Location: Texas Oncology-Fort Worth Cancer Center

Phase: I/II

Title: STAR Ph3 61186372 Osim Lazert EGFR NSCLC View

Description: A Phase 3 Randomized Study of Amivantamab and Lazertinib Combination Therapy Versus Osimertinib Versus Lazertinib as First-Line Treatment in Patients with EGFR-Mutated Locally Advanced or Metastatic Non-Small Cell Lung Cancer (73841937NSC3003)MARIPOSA

Indication: Lung Cancer

Location: Texas Oncology-Fort Worth Cancer Center

Phase: III

Title: STAR Ph3 61186372 Osim Lazert EGFR NSCLC View

Description: A Phase 3 Randomized Study of Amivantamab and Lazertinib Combination Therapy Versus Osimertinib Versus Lazertinib as First-Line Treatment in Patients with EGFR-Mutated Locally Advanced or Metastatic Non-Small Cell Lung Cancer (73841937NSC3003)MARIPOSA

Indication: Lung Cancer

Location: Texas Oncology-Grapevine

Phase: III

Title: STAR Ph3 61186372 Osim Lazert EGFR NSCLC View

Description: A Phase 3 Randomized Study of Amivantamab and Lazertinib Combination Therapy Versus Osimertinib Versus Lazertinib as First-Line Treatment in Patients with EGFR-Mutated Locally Advanced or Metastatic Non-Small Cell Lung Cancer (73841937NSC3003)MARIPOSA

Indication: Lung Cancer

Location: Texas Oncology-Grapevine

Phase: III

Title: STAR PH3 JNJ-61186372 Peme EGFR NSCLC View

Description: A Randomized Open-label Phase 3 Study of Combination Amivantamab and Carboplatin-Pemetrexed Therapy Compared with Carboplatin-Pemetrexed in Patients with EGFR Exon 20ins Mutated Locally Advanced or Metastatic Non-Small Cell Lung Cancer (61186372NSC3001)

Indication: Lung Cancer

Location: Texas Oncology-Grapevine

Phase: III

Title: PH3 AMG 510 vs Doce a/mNSCLC View

Description: 20190009: A Phase 3 Multicenter Randomized Open Label Active-controlled Study of AMG 510 Versus Docetaxel for the Treatment of Previously Treated Locally Advanced and Unresectable or Metastatic NSCLC Subjects with Mutated KRAS p.G12C

Indication: Lung Cancer

Location: Texas Oncology-Grapevine

Phase: III

Title: STAR-PH3 pral(Blu-667) RET-fusion mNSCLC View

Description: A Randomized Open-Label Phase 3 Study of Pralsetinib versus Standard of Care for First Line Treatment of RET fusion-positive Metastatic Non-Small Cell Lung Cancer (BLU-667-2303)

Indication: Lung Cancer

Location: Texas Oncology-Grapevine

Phase: III

Title: STAR KEAP1/NRF2 NSCLC View

Description: CX-839-014 "KEAPSAKE": A Phase 2 Randomized Multicenter Double-blind Study of the Glutaminase Inhibitor Telaglenastat with Pembrolizumab and Chemotherapy versus Placebo with Pembrolizumab and Chemotherapy in First-line Metastatic KEAP1/NRF2-mutated Nonsquamous Non-Small Cell Lung Cancer (NSCLC)

Indication: Lung Cancer

Location: Texas Oncology-Grapevine

Phase: II

Title: STAR Ph2 Basket Tucat+Tras ST HER2 Alt View

Description: A Phase 2 Basket Study of Tucatinib in Combination with Trastuzumab in Subjects with Previously Treated Locally-Advanced Unresectable or Metastatic Solid Tumors Driven by HER2 Alterations (SGNTUC-019)

Indication: Lung Cancer

Location: Texas Oncology-Grapevine

Phase: II

Title: STAR Ph1/2 BLU667 thy NSCLC Sol tum View

Description: A Phase 1/2 Study of the Highly-selective RET Inhibitor BLU-667 in Patients with Thyroid Cancer Non-Small Cell Lung Cancer (NSCLC) and Other Advanced Solid Tumors (BLU-667-1101)

Indication: Lung Cancer

Location: Texas Oncology-Grapevine

Phase: I/II

Title: STAR Ph1/2 MRTX849 Solids KRAS G12C View

Description: A Phase 1/2 Multiple Expansion Cohort Trial of MRTX849 in Patients with Advanced Solid Tumors with KRAS G12C Mutation (849-001)

Indication: Lung Cancer

Location: Texas Oncology-Grapevine

Phase: I/II

Title: LUNAR: Pivotal, Randomized, Open-label Study of Tumor Treating Fields (TTFields) Concurrent With Standard of Care Therapies for Treatment of Stage 4 Non-small Cell Lung Cancer (NSCLC) Following Platinum Failure View

Indication: Lung Cancer

Location: Texas Oncology-Arlington South

Phase: III

Lymphomas

Title: STAR BV in pts w/1L cHL or PTCL View

Description: (SGN35-015) A phase 2 open-label study of brentuximab vedotin in front-line therapy of Hodgkin lymphoma (HL) and CD30-expressing peripheral T-cell lymphoma (PTCL) in older patients or patients with significant comorbidities ineligible for standard chemotherapy

Indication: Lymphomas

Location: Texas Oncology-Arlington Cancer Center North

Phase: II

Title: STAR BV in pts w/1L cHL or PTCL View

Description: (SGN35-015) A phase 2 open-label study of brentuximab vedotin in front-line therapy of Hodgkin lymphoma (HL) and CD30-expressing peripheral T-cell lymphoma (PTCL) in older patients or patients with significant comorbidities ineligible for standard chemotherapy

Indication: Lymphomas

Location: Texas Oncology-Arlington South

Phase: II

Title: STAR BV in pts w/1L cHL or PTCL View

Description: (SGN35-015) A phase 2 open-label study of brentuximab vedotin in front-line therapy of Hodgkin lymphoma (HL) and CD30-expressing peripheral T-cell lymphoma (PTCL) in older patients or patients with significant comorbidities ineligible for standard chemotherapy

Indication: Lymphomas

Location: Texas Oncology-Bedford

Phase: II

Title: EAP BGB-3111 B-Cell Malig View

Description: A Single-Arm Expanded Access Study of Zanubrutinib (BGB-3111) in Patients with B-cell Malignancies (BGB-3111-216)

Indication: Lymphomas

Location: Texas Oncology-Bedford

Title: PH3 R-CHOP +/- Acalab Tx Naive DLBCL View

Description: A Phase 3 Randomized Double-Blind Placebo-Controlled Study of Acalabrutinib in Combination with Rituximab Cyclophosphamide Doxorubicin Vincristine and Prednisone (R-CHOP) in Subjects < or = 65 Years with Previously Untreated Non-Germinal Center Diffuse Large B-Cell Lymphoma (ACE-LY-312/ D8227C00001)

Indication: Lymphomas

Location: Texas Oncology-Fort Worth Cancer Center

Phase: III

Title: PH2 Brentux+CHP In Tx Naive PTCL View

Description: A dual-cohort open-label phase 2 study of brentuximab vedotin and CHP (A+CHP) in the frontline treatment of subjects with peripheral T-cell lymphoma (PTCL) with less than 10% CD30 expression (SGN35-032)

Indication: Lymphomas

Location: Texas Oncology-Fort Worth Cancer Center

Phase: II

Title: Ph 1 PF-06821497 R/R SCLC CRPC & FL View

Description: C2321001: A PHASE I DOSE ESCALATION AND EXPANDED COHORT STUDY OF PF-06821497 IN THE TREATMENT OF ADULT PATIENTS WITH RELAPSED/REFRACTORY SMALL CELL LUNG CANCER (SCLC) CASTRATION RESISTANT PROSTATE CANCER (CRPC) AND FOLLICULAR LYMPHOMA (FL)

Indication: Lymphomas

Location: Texas Oncology-Fort Worth Cancer Center

Phase: I

Title: STAR BV in pts w/1L cHL or PTCL View

Description: (SGN35-015) A phase 2 open-label study of brentuximab vedotin in front-line therapy of Hodgkin lymphoma (HL) and CD30-expressing peripheral T-cell lymphoma (PTCL) in older patients or patients with significant comorbidities ineligible for standard chemotherapy

Indication: Lymphomas

Location: Texas Oncology-Fort Worth Cancer Center

Phase: II

Title: STAR Ph2 A+AVD +G-CSF or AOAD in CHL View

Description: SGN35-027: Multiple Part Clinical Trial of Brentuximab Vedotin in Classical Hodgkin Lymphoma Subjects

Indication: Lymphomas

Location: Texas Oncology-Fort Worth Cancer Center

Phase: II

Title: STAR BV in pts w/1L cHL or PTCL View

Description: (SGN35-015) A phase 2 open-label study of brentuximab vedotin in front-line therapy of Hodgkin lymphoma (HL) and CD30-expressing peripheral T-cell lymphoma (PTCL) in older patients or patients with significant comorbidities ineligible for standard chemotherapy

Indication: Lymphomas

Location: Texas Oncology-Grapevine

Phase: II

Title: EAP BGB-3111 B-Cell Malig View

Description: A Single-Arm Expanded Access Study of Zanubrutinib (BGB-3111) in Patients with B-cell Malignancies (BGB-3111-216)

Indication: Lymphomas

Location: Texas Oncology-Grapevine

Title: A phase 2, multicenter, single-arm study of retreatment with brentuximab vedotin in subjects with relapsed or refractory classical Hodgkin lymphoma (cHL) or CD30-expressing peripheral T cell lymphoma (PTCL) View

Indication: Lymphomas

Location: Texas Oncology-Fort Worth Cancer Center

Phase: II

Title: A Phase 2/3, Multicenter, Randomized, Study of Rituximab-Gemcitabine-Dexamethasone-Platinum (R_GDP) With or Without Selinexor in Patients with Relapsed/Refractory Diffuse Large B-Cell Lymphoma (DLBCL) View

Indication: Lymphomas

Location: Texas Oncology-Fort Worth Cancer Center

Phase: II/III

Malignant Adenoma

Title: STAR Ph1/2 MRTX849 Solids KRAS G12C View

Description: A Phase 1/2 Multiple Expansion Cohort Trial of MRTX849 in Patients with Advanced Solid Tumors with KRAS G12C Mutation (849-001)

Indication: Malignant Adenoma

Location: Texas Oncology-Arlington Cancer Center North

Phase: I/II

Title: STAR Ph1/2 MRTX849 Solids KRAS G12C View

Description: A Phase 1/2 Multiple Expansion Cohort Trial of MRTX849 in Patients with Advanced Solid Tumors with KRAS G12C Mutation (849-001)

Indication: Malignant Adenoma

Location: Texas Oncology-Arlington South

Phase: I/II

Title: STAR Ph1/2 MRTX849 Solids KRAS G12C View

Description: A Phase 1/2 Multiple Expansion Cohort Trial of MRTX849 in Patients with Advanced Solid Tumors with KRAS G12C Mutation (849-001)

Indication: Malignant Adenoma

Location: Texas Oncology-Bedford

Phase: I/II

Title: STAR Ph1/2 MRTX849 Solids KRAS G12C View

Description: A Phase 1/2 Multiple Expansion Cohort Trial of MRTX849 in Patients with Advanced Solid Tumors with KRAS G12C Mutation (849-001)

Indication: Malignant Adenoma

Location: Texas Oncology-Fort Worth Cancer Center

Phase: I/II

Title: STAR Ph1/2 MRTX849 Solids KRAS G12C View

Description: A Phase 1/2 Multiple Expansion Cohort Trial of MRTX849 in Patients with Advanced Solid Tumors with KRAS G12C Mutation (849-001)

Indication: Malignant Adenoma

Location: Texas Oncology-Grapevine

Phase: I/II

Melanoma

Title: Ph2 Bren Vedo + Pembro ST prior PD-1 View

Description: A phase 2 study of brentuximab vedotin in combination with pembrolizumab in subjects with metastatic solid malignancies after progression on prior PD-1 inhibitor treatment (SGN35-033)

Indication: Melanoma

Location: Texas Oncology-Fort Worth Cancer Center

Phase: II

Myelodysplastic Syndrome

Title: Ph 1/2 ASTX727 Lower Risk MDS View

Description: A Randomized Open-Label Phase 1-2 Study of ASTX727 Low Dose (ASTX727 LD)Extended Schedule in Subjects with Lower Risk (IPSS Low or Intermediate-1)Myelodysplastic Syndromes (MDS) (ASTX727-03)

Indication: Myelodysplastic Syndrome

Location: Texas Oncology-Fort Worth Cancer Center

Phase: I/II

Myelofibrosis

Title: STAR Ph3 Navi Ruxo Myelofibrosis View

Description: M16-191: A Randomized Double-Blind Placebo-Controlled Phase 3 Study of Navitoclax in Combination with Ruxolitinib versus Ruxolitinib in Subjects with Myelofibrosis (TRANSFORM-1)

Indication: Myelofibrosis

Location: Texas Oncology-Arlington Cancer Center North

Phase: III

Title: STAR Ph3 Navi Ruxo Myelofibrosis View

Description: M16-191: A Randomized Double-Blind Placebo-Controlled Phase 3 Study of Navitoclax in Combination with Ruxolitinib versus Ruxolitinib in Subjects with Myelofibrosis (TRANSFORM-1)

Indication: Myelofibrosis

Location: Texas Oncology-Arlington South

Phase: III

Title: STAR PH3 Pacritinib vs MD choice in MF View

Description: A Randomized Controlled Phase 3 Study of Pacritinib Versus Physician's Choice in Patients with Primary Myelofibrosis Post Polycythemia Vera Myelofibrosis or Post-Essential Thrombocythemia Myelofibrosis with Severe Thrombocytopenia (Platelets Counts <50000/µL) (PAC203)

Indication: Myelofibrosis

Location: Texas Oncology-Arlington South

Phase: III

Title: STAR PH3 Pacritinib vs MD choice in MF View

Description: A Randomized Controlled Phase 3 Study of Pacritinib Versus Physician's Choice in Patients with Primary Myelofibrosis Post Polycythemia Vera Myelofibrosis or Post-Essential Thrombocythemia Myelofibrosis with Severe Thrombocytopenia (Platelets Counts <50000/µL) (PAC203)

Indication: Myelofibrosis

Location: Texas Oncology-Bedford

Phase: III

Title: STAR Ph3 Navi Ruxo Myelofibrosis View

Description: M16-191: A Randomized Double-Blind Placebo-Controlled Phase 3 Study of Navitoclax in Combination with Ruxolitinib versus Ruxolitinib in Subjects with Myelofibrosis (TRANSFORM-1)

Indication: Myelofibrosis

Location: Texas Oncology-Fort Worth Cancer Center

Phase: III

Title: STAR PH3 Pacritinib vs MD choice in MF View

Description: A Randomized Controlled Phase 3 Study of Pacritinib Versus Physician's Choice in Patients with Primary Myelofibrosis Post Polycythemia Vera Myelofibrosis or Post-Essential Thrombocythemia Myelofibrosis with Severe Thrombocytopenia (Platelets Counts <50000/µL) (PAC203)

Indication: Myelofibrosis

Location: Texas Oncology-Fort Worth Cancer Center

Phase: III

Title: STAR Ph3 Navi Ruxo Myelofibrosis View

Description: M16-191: A Randomized Double-Blind Placebo-Controlled Phase 3 Study of Navitoclax in Combination with Ruxolitinib versus Ruxolitinib in Subjects with Myelofibrosis (TRANSFORM-1)

Indication: Myelofibrosis

Location: Texas Oncology-Grapevine

Phase: III

Title: STAR PH3 Pacritinib vs MD choice in MF View

Description: A Randomized Controlled Phase 3 Study of Pacritinib Versus Physician's Choice in Patients with Primary Myelofibrosis Post Polycythemia Vera Myelofibrosis or Post-Essential Thrombocythemia Myelofibrosis with Severe Thrombocytopenia (Platelets Counts <50000/µL) (PAC203)

Indication: Myelofibrosis

Location: Texas Oncology-Grapevine

Phase: III

Title: A PHASE 3B, MULTICENTER, SINGLE-ARM, OPENLABEL EFFICACY AND SAFETY STUDY OF FEDRATINIB IN SUBJECTS WITH DIPSSINTERMEDIATE OR HIGH-RISK PRIMARY MYELOFIBROSIS, POST POLYCYTHEMIA VERA MYELOFIBROSIS, OR POST-ESSENTIAL THROMBOCYTHEMIA MYELOFIBROSIS AND PREVIOUSLY TREATED WITH RUXOLITINIB INCLUDING A SUB-STUDY WITH CONCOMITANTLUSPATERCEPT FOR SUBJECTS WITH ANEMIA(The "FREEDOM" Trial) View

Indication: Myelofibrosis

Location: Texas Oncology-Fort Worth Cancer Center

Phase: III

Myelomas

Title: PH2 MM Carf Poma & dexa (KPd) View

Description: An Open-label Phase 2 Study Treating Subjects With First or Second Relapse of Multiple Myeloma with Carfilzomib Pomalidomide and Dexamethasone (KPd) (20180117)

Indication: Myelomas

Location: Texas Oncology-Fort Worth Cancer Center

Phase: II

Ovarian Cancer

Title: STAR Ph1/2 MRTX849 Solids KRAS G12C View

Description: A Phase 1/2 Multiple Expansion Cohort Trial of MRTX849 in Patients with Advanced Solid Tumors with KRAS G12C Mutation (849-001)

Indication: Ovarian Cancer

Location: Texas Oncology-Arlington Cancer Center North

Phase: I/II

Title: STAR Ph1/2 MRTX849 Solids KRAS G12C View

Description: A Phase 1/2 Multiple Expansion Cohort Trial of MRTX849 in Patients with Advanced Solid Tumors with KRAS G12C Mutation (849-001)

Indication: Ovarian Cancer

Location: Texas Oncology-Arlington South

Phase: I/II

Title: STAR Ph1/2 MRTX849 Solids KRAS G12C View

Description: A Phase 1/2 Multiple Expansion Cohort Trial of MRTX849 in Patients with Advanced Solid Tumors with KRAS G12C Mutation (849-001)

Indication: Ovarian Cancer

Location: Texas Oncology-Bedford

Phase: I/II

Title: Ph 3 Chemo +/- Pembro/Olap EOC View

Description: A Randomized Phase 3 Double-Blind Study of Chemotherapy With or Without Pembrolizumab Followed by Maintenance With Olaparib or Placebo for the First-Line Treatment of BRCA non-mutated Advanced Epithelial Ovarian Cancer (EOC) (MK-7339-001/ENGOT-ov43/GOG-3036)

Indication: Ovarian Cancer

Location: Texas Oncology-Bedford

Phase: III

Title: Ph3 Mirv Sora Epi Ova FTC View

Description: SORAYA: A Phase 3 Single Arm Study of Mirvetuximab Soravtansine in Advanced High-Grade Epithelial Ovarian Primary Peritoneal or Fallopian Tube Cancers with High Folate Receptor-Alpha Expression (IMGN853-0417)

Indication: Ovarian Cancer

Location: Texas Oncology-Fort Worth Cancer Center

Phase: III

Title: STAR Ph1/2 MRTX849 Solids KRAS G12C View

Description: A Phase 1/2 Multiple Expansion Cohort Trial of MRTX849 in Patients with Advanced Solid Tumors with KRAS G12C Mutation (849-001)

Indication: Ovarian Cancer

Location: Texas Oncology-Fort Worth Cancer Center

Phase: I/II

Title: Ph 1b FIH XMT-1536 Solid Tumor NaPi2b View

Description: A Phase 1b/2 First-in-Human Dose Escalation and Expansion Study of XMT-1536 In Patients with Solid Tumors Likely to Express NaPi2b (MER-XMT-1536-1)

Indication: Ovarian Cancer

Location: Texas Oncology-Fort Worth Cancer Center

Phase: I

Title: TTFlds cncmnt w/ PTX recurrent ovn cnr View

Description: ENGOT-ov50 / INNOVATE-3: Pivotal Randomized Open-Label Study ofTumor Treating Fields (TTFields 200kHz) Concomitant with WeeklyPaclitaxel for the Treatment of Recurrent Ovarian Cancer

Indication: Ovarian Cancer

Location: Texas Oncology-Fort Worth Cancer Center

Phase: III

Title: Ph 3 Chemo +/- Pembro/Olap EOC View

Description: A Randomized Phase 3 Double-Blind Study of Chemotherapy With or Without Pembrolizumab Followed by Maintenance With Olaparib or Placebo for the First-Line Treatment of BRCA non-mutated Advanced Epithelial Ovarian Cancer (EOC) (MK-7339-001/ENGOT-ov43/GOG-3036)

Indication: Ovarian Cancer

Location: Texas Oncology-Grapevine

Phase: III

Title: STAR Ph1/2 MRTX849 Solids KRAS G12C View

Description: A Phase 1/2 Multiple Expansion Cohort Trial of MRTX849 in Patients with Advanced Solid Tumors with KRAS G12C Mutation (849-001)

Indication: Ovarian Cancer

Location: Texas Oncology-Grapevine

Phase: I/II

Pancreatic Cancer

Title: STAR Ph1/2 MRTX849 Solids KRAS G12C View

Description: A Phase 1/2 Multiple Expansion Cohort Trial of MRTX849 in Patients with Advanced Solid Tumors with KRAS G12C Mutation (849-001)

Indication: Pancreatic Cancer

Location: Texas Oncology-Arlington Cancer Center North

Phase: I/II

Title: STAR Ph1/2 MRTX849 Solids KRAS G12C View

Description: A Phase 1/2 Multiple Expansion Cohort Trial of MRTX849 in Patients with Advanced Solid Tumors with KRAS G12C Mutation (849-001)

Indication: Pancreatic Cancer

Location: Texas Oncology-Arlington South

Phase: I/II

Title: PANOVA-3: 1L Gemcit + nab-pac pancreatic View

Description: PANOVA-3: Pivotal randomized open-label study of Tumor Treating Fields (TTFields 150kHz) concomitant with gemcitabine and nab-paclitaxel for front-line treatment of locally-advanced pancreatic adenocarcinoma (EF-27)

Indication: Pancreatic Cancer

Location: Texas Oncology-Bedford

Phase: III

Title: STAR Ph1/2 MRTX849 Solids KRAS G12C View

Description: A Phase 1/2 Multiple Expansion Cohort Trial of MRTX849 in Patients with Advanced Solid Tumors with KRAS G12C Mutation (849-001)

Indication: Pancreatic Cancer

Location: Texas Oncology-Bedford

Phase: I/II

Title: STAR Ph1/2 MRTX849 Solids KRAS G12C View

Description: A Phase 1/2 Multiple Expansion Cohort Trial of MRTX849 in Patients with Advanced Solid Tumors with KRAS G12C Mutation (849-001)

Indication: Pancreatic Cancer

Location: Texas Oncology-Fort Worth Cancer Center

Phase: I/II

Title: PANOVA-3: 1L Gemcit + nab-pac pancreatic View

Description: PANOVA-3: Pivotal randomized open-label study of Tumor Treating Fields (TTFields 150kHz) concomitant with gemcitabine and nab-paclitaxel for front-line treatment of locally-advanced pancreatic adenocarcinoma (EF-27)

Indication: Pancreatic Cancer

Location: Texas Oncology-Grapevine

Phase: III

Title: STAR Ph1/2 MRTX849 Solids KRAS G12C View

Description: A Phase 1/2 Multiple Expansion Cohort Trial of MRTX849 in Patients with Advanced Solid Tumors with KRAS G12C Mutation (849-001)

Indication: Pancreatic Cancer

Location: Texas Oncology-Grapevine

Phase: I/II

Penile Cancer

Title: STAR Ph1/2 MRTX849 Solids KRAS G12C View

Description: A Phase 1/2 Multiple Expansion Cohort Trial of MRTX849 in Patients with Advanced Solid Tumors with KRAS G12C Mutation (849-001)

Indication: Penile Cancer

Location: Texas Oncology-Arlington Cancer Center North

Phase: I/II

Title: STAR Ph1/2 MRTX849 Solids KRAS G12C View

Description: A Phase 1/2 Multiple Expansion Cohort Trial of MRTX849 in Patients with Advanced Solid Tumors with KRAS G12C Mutation (849-001)

Indication: Penile Cancer

Location: Texas Oncology-Arlington South

Phase: I/II

Title: STAR Ph1/2 MRTX849 Solids KRAS G12C View

Description: A Phase 1/2 Multiple Expansion Cohort Trial of MRTX849 in Patients with Advanced Solid Tumors with KRAS G12C Mutation (849-001)

Indication: Penile Cancer

Location: Texas Oncology-Bedford

Phase: I/II

Title: STAR Ph1/2 MRTX849 Solids KRAS G12C View

Description: A Phase 1/2 Multiple Expansion Cohort Trial of MRTX849 in Patients with Advanced Solid Tumors with KRAS G12C Mutation (849-001)

Indication: Penile Cancer

Location: Texas Oncology-Fort Worth Cancer Center

Phase: I/II

Title: STAR Ph1/2 MRTX849 Solids KRAS G12C View

Description: A Phase 1/2 Multiple Expansion Cohort Trial of MRTX849 in Patients with Advanced Solid Tumors with KRAS G12C Mutation (849-001)

Indication: Penile Cancer

Location: Texas Oncology-Grapevine

Phase: I/II

Peritoneal Cancer

Title: STAR Ph1/2 MRTX849 Solids KRAS G12C View

Description: A Phase 1/2 Multiple Expansion Cohort Trial of MRTX849 in Patients with Advanced Solid Tumors with KRAS G12C Mutation (849-001)

Indication: Peritoneal Cancer

Location: Texas Oncology-Arlington Cancer Center North

Phase: I/II

Title: STAR Ph1/2 MRTX849 Solids KRAS G12C View

Description: A Phase 1/2 Multiple Expansion Cohort Trial of MRTX849 in Patients with Advanced Solid Tumors with KRAS G12C Mutation (849-001)

Indication: Peritoneal Cancer

Location: Texas Oncology-Arlington South

Phase: I/II

Title: STAR Ph1/2 MRTX849 Solids KRAS G12C View

Description: A Phase 1/2 Multiple Expansion Cohort Trial of MRTX849 in Patients with Advanced Solid Tumors with KRAS G12C Mutation (849-001)

Indication: Peritoneal Cancer

Location: Texas Oncology-Bedford

Phase: I/II

Title: Ph3 Mirv Sora Epi Ova FTC View

Description: SORAYA: A Phase 3 Single Arm Study of Mirvetuximab Soravtansine in Advanced High-Grade Epithelial Ovarian Primary Peritoneal or Fallopian Tube Cancers with High Folate Receptor-Alpha Expression (IMGN853-0417)

Indication: Peritoneal Cancer

Location: Texas Oncology-Fort Worth Cancer Center

Phase: III

Title: STAR Ph1/2 MRTX849 Solids KRAS G12C View

Description: A Phase 1/2 Multiple Expansion Cohort Trial of MRTX849 in Patients with Advanced Solid Tumors with KRAS G12C Mutation (849-001)

Indication: Peritoneal Cancer

Location: Texas Oncology-Fort Worth Cancer Center

Phase: I/II

Title: STAR Ph1/2 MRTX849 Solids KRAS G12C View

Description: A Phase 1/2 Multiple Expansion Cohort Trial of MRTX849 in Patients with Advanced Solid Tumors with KRAS G12C Mutation (849-001)

Indication: Peritoneal Cancer

Location: Texas Oncology-Grapevine

Phase: I/II

Prostate Cancer

Title: STAR PH3 Nirap Abira HRR mCSPC View

Description: A Phase 3 Randomized Placebo-controlled Double-blind Study of Niraparib in Combination with Abiraterone Acetate and Prednisone Versus Abiraterone Acetate and Prednisone for the Treatment of Participants with Deleterious Germline or Somatic Homologous Recombination Repair (HRR) Gene-Mutated Metastatic Castration-Sensitive Prostate Cancer (mCSPC)(67652000PCR3002)

Indication: Prostate Cancer

Location: Texas Oncology-Arlington Cancer Center North

Phase: III

Title: STAR PH3 Nirap Abira HRR mCSPC View

Description: A Phase 3 Randomized Placebo-controlled Double-blind Study of Niraparib in Combination with Abiraterone Acetate and Prednisone Versus Abiraterone Acetate and Prednisone for the Treatment of Participants with Deleterious Germline or Somatic Homologous Recombination Repair (HRR) Gene-Mutated Metastatic Castration-Sensitive Prostate Cancer (mCSPC)(67652000PCR3002)

Indication: Prostate Cancer

Location: Texas Oncology-Arlington South

Phase: III

Title: STAR Ph1/2 MRTX849 Solids KRAS G12C View

Description: A Phase 1/2 Multiple Expansion Cohort Trial of MRTX849 in Patients with Advanced Solid Tumors with KRAS G12C Mutation (849-001)

Indication: Prostate Cancer

Location: Texas Oncology-Arlington Cancer Center North

Phase: I/II

Title: STAR Ph1/2 MRTX849 Solids KRAS G12C View

Description: A Phase 1/2 Multiple Expansion Cohort Trial of MRTX849 in Patients with Advanced Solid Tumors with KRAS G12C Mutation (849-001)

Indication: Prostate Cancer

Location: Texas Oncology-Arlington South

Phase: I/II

Title: STAR Ph3 Nirap+Abirat+Pred mCRPC View

Description: A Phase 3 Randomized Placebo-controlled Double-blind Study of Niraparib in Combination with Abiraterone Acetate and Prednisone Versus Abiraterone Acetate and Prednisone for Treatment of Subjects with Metastatic Prostate Cancer(64091742PCR3001)

Indication: Prostate Cancer

Location: Texas Oncology-Arlington South

Phase: III

Title: STAR Rucaparib v PhysC mCRPC (TRITON3) View

Description: TRITON3: A Multicenter Randomized Open-label Phase 3 Study of Rucaparib versus Physician's Choice of Therapy for Patients withMetastatic Castration-resistant Prostate Cancer Associated withHomologous Recombination Deficiency (CO-338-063)

Indication: Prostate Cancer

Location: Texas Oncology-Arlington South

Phase: III

Title: STAR Rucaparib v PhysC mCRPC (TRITON3) View

Description: TRITON3: A Multicenter Randomized Open-label Phase 3 Study of Rucaparib versus Physician's Choice of Therapy for Patients withMetastatic Castration-resistant Prostate Cancer Associated withHomologous Recombination Deficiency (CO-338-063)

Indication: Prostate Cancer

Location: Texas Oncology-Bedford

Phase: III

Title: STAR Ph3 Nirap+Abirat+Pred mCRPC View

Description: A Phase 3 Randomized Placebo-controlled Double-blind Study of Niraparib in Combination with Abiraterone Acetate and Prednisone Versus Abiraterone Acetate and Prednisone for Treatment of Subjects with Metastatic Prostate Cancer(64091742PCR3001)

Indication: Prostate Cancer

Location: Texas Oncology-Bedford

Phase: III

Title: STAR Ph1/2 MRTX849 Solids KRAS G12C View

Description: A Phase 1/2 Multiple Expansion Cohort Trial of MRTX849 in Patients with Advanced Solid Tumors with KRAS G12C Mutation (849-001)

Indication: Prostate Cancer

Location: Texas Oncology-Bedford

Phase: I/II

Title: STAR PH3 Nirap Abira HRR mCSPC View

Description: A Phase 3 Randomized Placebo-controlled Double-blind Study of Niraparib in Combination with Abiraterone Acetate and Prednisone Versus Abiraterone Acetate and Prednisone for the Treatment of Participants with Deleterious Germline or Somatic Homologous Recombination Repair (HRR) Gene-Mutated Metastatic Castration-Sensitive Prostate Cancer (mCSPC)(67652000PCR3002)

Indication: Prostate Cancer

Location: Texas Oncology-Bedford

Phase: III

Title: STAR PH3 Nirap Abira HRR mCSPC View

Description: A Phase 3 Randomized Placebo-controlled Double-blind Study of Niraparib in Combination with Abiraterone Acetate and Prednisone Versus Abiraterone Acetate and Prednisone for the Treatment of Participants with Deleterious Germline or Somatic Homologous Recombination Repair (HRR) Gene-Mutated Metastatic Castration-Sensitive Prostate Cancer (mCSPC)(67652000PCR3002)

Indication: Prostate Cancer

Location: Texas Oncology-Fort Worth Cancer Center

Phase: III

Title: Biomarker DNA Defect Men Prostate View

Description: Biomarker Study to Determine Frequency of DNA-repair Defects in Men with Metastatic Prostate Cancer (64091742PCR0002)

Indication: Prostate Cancer

Location: Texas Oncology-Fort Worth Cancer Center

Title: Ph 1 PF-06821497 R/R SCLC CRPC & FL View

Description: C2321001: A PHASE I DOSE ESCALATION AND EXPANDED COHORT STUDY OF PF-06821497 IN THE TREATMENT OF ADULT PATIENTS WITH RELAPSED/REFRACTORY SMALL CELL LUNG CANCER (SCLC) CASTRATION RESISTANT PROSTATE CANCER (CRPC) AND FOLLICULAR LYMPHOMA (FL)

Indication: Prostate Cancer

Location: Texas Oncology-Fort Worth Cancer Center

Phase: I

Title: STAR Ph1/2 MRTX849 Solids KRAS G12C View

Description: A Phase 1/2 Multiple Expansion Cohort Trial of MRTX849 in Patients with Advanced Solid Tumors with KRAS G12C Mutation (849-001)

Indication: Prostate Cancer

Location: Texas Oncology-Fort Worth Cancer Center

Phase: I/II

Title: STAR Ph3 Nirap+Abirat+Pred mCRPC View

Description: A Phase 3 Randomized Placebo-controlled Double-blind Study of Niraparib in Combination with Abiraterone Acetate and Prednisone Versus Abiraterone Acetate and Prednisone for Treatment of Subjects with Metastatic Prostate Cancer(64091742PCR3001)

Indication: Prostate Cancer

Location: Texas Oncology-Fort Worth Cancer Center

Phase: III

Title: STAR Rucaparib v PhysC mCRPC (TRITON3) View

Description: TRITON3: A Multicenter Randomized Open-label Phase 3 Study of Rucaparib versus Physician's Choice of Therapy for Patients withMetastatic Castration-resistant Prostate Cancer Associated withHomologous Recombination Deficiency (CO-338-063)

Indication: Prostate Cancer

Location: Texas Oncology-Fort Worth Cancer Center

Phase: III

Title: STAR PH3 Nirap Abira HRR mCSPC View

Description: A Phase 3 Randomized Placebo-controlled Double-blind Study of Niraparib in Combination with Abiraterone Acetate and Prednisone Versus Abiraterone Acetate and Prednisone for the Treatment of Participants with Deleterious Germline or Somatic Homologous Recombination Repair (HRR) Gene-Mutated Metastatic Castration-Sensitive Prostate Cancer (mCSPC)(67652000PCR3002)

Indication: Prostate Cancer

Location: Texas Oncology-Grapevine

Phase: III

Title: STAR Rucaparib v PhysC mCRPC (TRITON3) View

Description: TRITON3: A Multicenter Randomized Open-label Phase 3 Study of Rucaparib versus Physician's Choice of Therapy for Patients withMetastatic Castration-resistant Prostate Cancer Associated withHomologous Recombination Deficiency (CO-338-063)

Indication: Prostate Cancer

Location: Texas Oncology-Grapevine

Phase: III

Title: STAR Ph3 Nirap+Abirat+Pred mCRPC View

Description: A Phase 3 Randomized Placebo-controlled Double-blind Study of Niraparib in Combination with Abiraterone Acetate and Prednisone Versus Abiraterone Acetate and Prednisone for Treatment of Subjects with Metastatic Prostate Cancer(64091742PCR3001)

Indication: Prostate Cancer

Location: Texas Oncology-Grapevine

Phase: III

Title: STAR Ph1/2 MRTX849 Solids KRAS G12C View

Description: A Phase 1/2 Multiple Expansion Cohort Trial of MRTX849 in Patients with Advanced Solid Tumors with KRAS G12C Mutation (849-001)

Indication: Prostate Cancer

Location: Texas Oncology-Grapevine

Phase: I/II

Rectal Cancer

Title: STAR PH2 Tuca+ Tras HER2+ CC View

Description: MOUNTAINEER: A Phase 2 Open Label Study of Tucatinib Combined with Trastuzumab in Patients with HER2+ Metastatic Colorectal Cancer (ACCRU-GI-1617 SGNTUC-017)

Indication: Rectal Cancer

Location: Texas Oncology-Arlington Cancer Center North

Phase: II

Title: STAR PH2 Tuca+ Tras HER2+ CC View

Description: MOUNTAINEER: A Phase 2 Open Label Study of Tucatinib Combined with Trastuzumab in Patients with HER2+ Metastatic Colorectal Cancer (ACCRU-GI-1617 SGNTUC-017)

Indication: Rectal Cancer

Location: Texas Oncology-Arlington South

Phase: II

Title: STAR Ph1/2 MRTX849 Solids KRAS G12C View

Description: A Phase 1/2 Multiple Expansion Cohort Trial of MRTX849 in Patients with Advanced Solid Tumors with KRAS G12C Mutation (849-001)

Indication: Rectal Cancer

Location: Texas Oncology-Arlington Cancer Center North

Phase: I/II

Title: STAR Ph1/2 MRTX849 Solids KRAS G12C View

Description: A Phase 1/2 Multiple Expansion Cohort Trial of MRTX849 in Patients with Advanced Solid Tumors with KRAS G12C Mutation (849-001)

Indication: Rectal Cancer

Location: Texas Oncology-Arlington South

Phase: I/II

Title: STAR Ph1/2 MRTX849 Solids KRAS G12C View

Description: A Phase 1/2 Multiple Expansion Cohort Trial of MRTX849 in Patients with Advanced Solid Tumors with KRAS G12C Mutation (849-001)

Indication: Rectal Cancer

Location: Texas Oncology-Bedford

Phase: I/II

Title: STAR PH2 Tuca+ Tras HER2+ CC View

Description: MOUNTAINEER: A Phase 2 Open Label Study of Tucatinib Combined with Trastuzumab in Patients with HER2+ Metastatic Colorectal Cancer (ACCRU-GI-1617 SGNTUC-017)

Indication: Rectal Cancer

Location: Texas Oncology-Bedford

Phase: II

Title: STAR PH2 Tuca+ Tras HER2+ CC View

Description: MOUNTAINEER: A Phase 2 Open Label Study of Tucatinib Combined with Trastuzumab in Patients with HER2+ Metastatic Colorectal Cancer (ACCRU-GI-1617 SGNTUC-017)

Indication: Rectal Cancer

Location: Texas Oncology-Fort Worth Cancer Center

Phase: II

Title: STAR Ph1/2 MRTX849 Solids KRAS G12C View

Description: A Phase 1/2 Multiple Expansion Cohort Trial of MRTX849 in Patients with Advanced Solid Tumors with KRAS G12C Mutation (849-001)

Indication: Rectal Cancer

Location: Texas Oncology-Fort Worth Cancer Center

Phase: I/II

Title: STAR PH2 Tuca+ Tras HER2+ CC View

Description: MOUNTAINEER: A Phase 2 Open Label Study of Tucatinib Combined with Trastuzumab in Patients with HER2+ Metastatic Colorectal Cancer (ACCRU-GI-1617 SGNTUC-017)

Indication: Rectal Cancer

Location: Texas Oncology-Grapevine

Phase: II

Title: STAR Ph1/2 MRTX849 Solids KRAS G12C View

Description: A Phase 1/2 Multiple Expansion Cohort Trial of MRTX849 in Patients with Advanced Solid Tumors with KRAS G12C Mutation (849-001)

Indication: Rectal Cancer

Location: Texas Oncology-Grapevine

Phase: I/II

Renal Cancer

Title: STAR Ph1/2 MRTX849 Solids KRAS G12C View

Description: A Phase 1/2 Multiple Expansion Cohort Trial of MRTX849 in Patients with Advanced Solid Tumors with KRAS G12C Mutation (849-001)

Indication: Renal Cancer

Location: Texas Oncology-Arlington Cancer Center North

Phase: I/II

Title: STAR Ph1/2 MRTX849 Solids KRAS G12C View

Description: A Phase 1/2 Multiple Expansion Cohort Trial of MRTX849 in Patients with Advanced Solid Tumors with KRAS G12C Mutation (849-001)

Indication: Renal Cancer

Location: Texas Oncology-Arlington South

Phase: I/II

Title: STAR Ph1/2 MRTX849 Solids KRAS G12C View

Description: A Phase 1/2 Multiple Expansion Cohort Trial of MRTX849 in Patients with Advanced Solid Tumors with KRAS G12C Mutation (849-001)

Indication: Renal Cancer

Location: Texas Oncology-Bedford

Phase: I/II

Title: STAR Ph1/2 MRTX849 Solids KRAS G12C View

Description: A Phase 1/2 Multiple Expansion Cohort Trial of MRTX849 in Patients with Advanced Solid Tumors with KRAS G12C Mutation (849-001)

Indication: Renal Cancer

Location: Texas Oncology-Fort Worth Cancer Center

Phase: I/II

Title: STAR Ph1/2 MRTX849 Solids KRAS G12C View

Description: A Phase 1/2 Multiple Expansion Cohort Trial of MRTX849 in Patients with Advanced Solid Tumors with KRAS G12C Mutation (849-001)

Indication: Renal Cancer

Location: Texas Oncology-Grapevine

Phase: I/II

Sarcoma

Title: STAR Ph1/2 MRTX849 Solids KRAS G12C View

Description: A Phase 1/2 Multiple Expansion Cohort Trial of MRTX849 in Patients with Advanced Solid Tumors with KRAS G12C Mutation (849-001)

Indication: Sarcoma

Location: Texas Oncology-Arlington Cancer Center North

Phase: I/II

Title: STAR Ph1/2 MRTX849 Solids KRAS G12C View

Description: A Phase 1/2 Multiple Expansion Cohort Trial of MRTX849 in Patients with Advanced Solid Tumors with KRAS G12C Mutation (849-001)

Indication: Sarcoma

Location: Texas Oncology-Arlington South

Phase: I/II

Title: STAR Ph1/2 MRTX849 Solids KRAS G12C View

Description: A Phase 1/2 Multiple Expansion Cohort Trial of MRTX849 in Patients with Advanced Solid Tumors with KRAS G12C Mutation (849-001)

Indication: Sarcoma

Location: Texas Oncology-Bedford

Phase: I/II

Title: STAR Ph1/2 MRTX849 Solids KRAS G12C View

Description: A Phase 1/2 Multiple Expansion Cohort Trial of MRTX849 in Patients with Advanced Solid Tumors with KRAS G12C Mutation (849-001)

Indication: Sarcoma

Location: Texas Oncology-Fort Worth Cancer Center

Phase: I/II

Title: STAR Ph1/2 MRTX849 Solids KRAS G12C View

Description: A Phase 1/2 Multiple Expansion Cohort Trial of MRTX849 in Patients with Advanced Solid Tumors with KRAS G12C Mutation (849-001)

Indication: Sarcoma

Location: Texas Oncology-Grapevine

Phase: I/II

Skin Cancer

Title: STAR Ph1 CX-4945 Basal Cell Carcinoma View

Description: A Phase I Multi-Center Open-Label Treatment Duration Increment Expansion Safety and Pharmacodynamic Study of CX-4945 Administered Orally Twice Daily to Patients with Advanced Basal Cell Carcinoma (CX-4945-07)

Indication: Skin Cancer

Location: Texas Oncology-Arlington South

Phase: I

Title: STAR Ph1 CX-4945 Basal Cell Carcinoma View

Description: A Phase I Multi-Center Open-Label Treatment Duration Increment Expansion Safety and Pharmacodynamic Study of CX-4945 Administered Orally Twice Daily to Patients with Advanced Basal Cell Carcinoma (CX-4945-07)

Indication: Skin Cancer

Location: Texas Oncology-Bedford

Phase: I

Title: STAR Ph1 CX-4945 Basal Cell Carcinoma View

Description: A Phase I Multi-Center Open-Label Treatment Duration Increment Expansion Safety and Pharmacodynamic Study of CX-4945 Administered Orally Twice Daily to Patients with Advanced Basal Cell Carcinoma (CX-4945-07)

Indication: Skin Cancer

Location: Texas Oncology-Fort Worth Cancer Center

Phase: I

Title: STAR Ph1 CX-4945 Basal Cell Carcinoma View

Description: A Phase I Multi-Center Open-Label Treatment Duration Increment Expansion Safety and Pharmacodynamic Study of CX-4945 Administered Orally Twice Daily to Patients with Advanced Basal Cell Carcinoma (CX-4945-07)

Indication: Skin Cancer

Location: Texas Oncology-Grapevine

Phase: I

Solid Tumors

Title: STAR Ph2 Seribantumab NRG1 Fusion+ ST View

Description: CRESTONE: A Phase 2 Study of Seribantumab in Adult Patients with Neuregulin-1 (NRG1) Fusion Positive Locally Advanced or Metastatic Solid Tumors (ELVCAP-001-01)

Indication: Solid Tumors

Location: Texas Oncology-Arlington Cancer Center North

Phase: II

Title: STAR Ph2 Seribantumab NRG1 Fusion+ ST View

Description: CRESTONE: A Phase 2 Study of Seribantumab in Adult Patients with Neuregulin-1 (NRG1) Fusion Positive Locally Advanced or Metastatic Solid Tumors (ELVCAP-001-01)

Indication: Solid Tumors

Location: Texas Oncology-Arlington South

Phase: II

Title: STAR Ph2 Basket Tucat+Tras ST HER2 Alt View

Description: A Phase 2 Basket Study of Tucatinib in Combination with Trastuzumab in Subjects with Previously Treated Locally-Advanced Unresectable or Metastatic Solid Tumors Driven by HER2 Alterations (SGNTUC-019)

Indication: Solid Tumors

Location: Texas Oncology-Arlington Cancer Center North

Phase: II

Title: STAR Ph2 Basket Tucat+Tras ST HER2 Alt View

Description: A Phase 2 Basket Study of Tucatinib in Combination with Trastuzumab in Subjects with Previously Treated Locally-Advanced Unresectable or Metastatic Solid Tumors Driven by HER2 Alterations (SGNTUC-019)

Indication: Solid Tumors

Location: Texas Oncology-Arlington South

Phase: II

Title: STAR Ph2 Erdafitinib FGFR Solid Tumors View

Description: A Phase 2 Study of Erdafitinib in Subjects With Advanced Solid Tumors and FGFR Gene Alterations (42756493CAN2002)

Indication: Solid Tumors

Location: Texas Oncology-Arlington South

Phase: II

Title: STAR Ph1/2 MRTX849 Solids KRAS G12C View

Description: A Phase 1/2 Multiple Expansion Cohort Trial of MRTX849 in Patients with Advanced Solid Tumors with KRAS G12C Mutation (849-001)

Indication: Solid Tumors

Location: Texas Oncology-Arlington Cancer Center North

Phase: I/II

Title: STAR Ph1/2 MRTX849 Solids KRAS G12C View

Description: A Phase 1/2 Multiple Expansion Cohort Trial of MRTX849 in Patients with Advanced Solid Tumors with KRAS G12C Mutation (849-001)

Indication: Solid Tumors

Location: Texas Oncology-Arlington South

Phase: I/II

Title: STAR Ph2 Pemigatinib Solids FGFR View

Description: (INCB 54828-207) A Phase 2 Open-Label Single-Arm Multicenter Study to Evaluate the Efficacy and Safety of Pemigatinib in Participants With Previously Treated Locally Advanced/Metastatic or Surgically Unresectable Solid Tumor Malignancies Harboring Activating FGFR Mutations or Translocations (FIGHT-207)

Indication: Solid Tumors

Location: Texas Oncology-Arlington South

Phase: II

Title: STAR Ph1/2 BLU667 thy NSCLC Sol tum View

Description: A Phase 1/2 Study of the Highly-selective RET Inhibitor BLU-667 in Patients with Thyroid Cancer Non-Small Cell Lung Cancer (NSCLC) and Other Advanced Solid Tumors (BLU-667-1101)

Indication: Solid Tumors

Location: Texas Oncology-Arlington South

Phase: I/II

Title: STAR Ph1/2 BLU667 thy NSCLC Sol tum View

Description: A Phase 1/2 Study of the Highly-selective RET Inhibitor BLU-667 in Patients with Thyroid Cancer Non-Small Cell Lung Cancer (NSCLC) and Other Advanced Solid Tumors (BLU-667-1101)

Indication: Solid Tumors

Location: Texas Oncology-Bedford

Phase: I/II

Title: STAR Ph2 Pemigatinib Solids FGFR View

Description: (INCB 54828-207) A Phase 2 Open-Label Single-Arm Multicenter Study to Evaluate the Efficacy and Safety of Pemigatinib in Participants With Previously Treated Locally Advanced/Metastatic or Surgically Unresectable Solid Tumor Malignancies Harboring Activating FGFR Mutations or Translocations (FIGHT-207)

Indication: Solid Tumors

Location: Texas Oncology-Bedford

Phase: II

Title: STAR Ph1/2 MRTX849 Solids KRAS G12C View

Description: A Phase 1/2 Multiple Expansion Cohort Trial of MRTX849 in Patients with Advanced Solid Tumors with KRAS G12C Mutation (849-001)

Indication: Solid Tumors

Location: Texas Oncology-Bedford

Phase: I/II

Title: STAR Ph2 Erdafitinib FGFR Solid Tumors View

Description: A Phase 2 Study of Erdafitinib in Subjects With Advanced Solid Tumors and FGFR Gene Alterations (42756493CAN2002)

Indication: Solid Tumors

Location: Texas Oncology-Bedford

Phase: II

Title: STAR Ph2 Seribantumab NRG1 Fusion+ ST View

Description: CRESTONE: A Phase 2 Study of Seribantumab in Adult Patients with Neuregulin-1 (NRG1) Fusion Positive Locally Advanced or Metastatic Solid Tumors (ELVCAP-001-01)

Indication: Solid Tumors

Location: Texas Oncology-Bedford

Phase: II

Title: STAR Ph2 Basket Tucat+Tras ST HER2 Alt View

Description: A Phase 2 Basket Study of Tucatinib in Combination with Trastuzumab in Subjects with Previously Treated Locally-Advanced Unresectable or Metastatic Solid Tumors Driven by HER2 Alterations (SGNTUC-019)

Indication: Solid Tumors

Location: Texas Oncology-Bedford

Phase: II

Title: STAR Ph2 Basket Tucat+Tras ST HER2 Alt View

Description: A Phase 2 Basket Study of Tucatinib in Combination with Trastuzumab in Subjects with Previously Treated Locally-Advanced Unresectable or Metastatic Solid Tumors Driven by HER2 Alterations (SGNTUC-019)

Indication: Solid Tumors

Location: Texas Oncology-Fort Worth Cancer Center

Phase: II

Title: Ph2 Bren Vedo + Pembro ST prior PD-1 View

Description: A phase 2 study of brentuximab vedotin in combination with pembrolizumab in subjects with metastatic solid malignancies after progression on prior PD-1 inhibitor treatment (SGN35-033)

Indication: Solid Tumors

Location: Texas Oncology-Fort Worth Cancer Center

Phase: II

Title: STAR Ph2 Seribantumab NRG1 Fusion+ ST View

Description: CRESTONE: A Phase 2 Study of Seribantumab in Adult Patients with Neuregulin-1 (NRG1) Fusion Positive Locally Advanced or Metastatic Solid Tumors (ELVCAP-001-01)

Indication: Solid Tumors

Location: Texas Oncology-Fort Worth Cancer Center

Phase: II

Title: STAR Ph2 Erdafitinib FGFR Solid Tumors View

Description: A Phase 2 Study of Erdafitinib in Subjects With Advanced Solid Tumors and FGFR Gene Alterations (42756493CAN2002)

Indication: Solid Tumors

Location: Texas Oncology-Fort Worth Cancer Center

Phase: II

Title: Ph 1 PF-06821497 R/R SCLC CRPC & FL View

Description: C2321001: A PHASE I DOSE ESCALATION AND EXPANDED COHORT STUDY OF PF-06821497 IN THE TREATMENT OF ADULT PATIENTS WITH RELAPSED/REFRACTORY SMALL CELL LUNG CANCER (SCLC) CASTRATION RESISTANT PROSTATE CANCER (CRPC) AND FOLLICULAR LYMPHOMA (FL)

Indication: Solid Tumors

Location: Texas Oncology-Fort Worth Cancer Center

Phase: I

Title: STAR Ph1/2 MRTX849 Solids KRAS G12C View

Description: A Phase 1/2 Multiple Expansion Cohort Trial of MRTX849 in Patients with Advanced Solid Tumors with KRAS G12C Mutation (849-001)

Indication: Solid Tumors

Location: Texas Oncology-Fort Worth Cancer Center

Phase: I/II

Title: STAR Ph2 Pemigatinib Solids FGFR View

Description: (INCB 54828-207) A Phase 2 Open-Label Single-Arm Multicenter Study to Evaluate the Efficacy and Safety of Pemigatinib in Participants With Previously Treated Locally Advanced/Metastatic or Surgically Unresectable Solid Tumor Malignancies Harboring Activating FGFR Mutations or Translocations (FIGHT-207)

Indication: Solid Tumors

Location: Texas Oncology-Fort Worth Cancer Center

Phase: II

Title: STAR Ph1/2 BLU667 thy NSCLC Sol tum View

Description: A Phase 1/2 Study of the Highly-selective RET Inhibitor BLU-667 in Patients with Thyroid Cancer Non-Small Cell Lung Cancer (NSCLC) and Other Advanced Solid Tumors (BLU-667-1101)

Indication: Solid Tumors

Location: Texas Oncology-Fort Worth Cancer Center

Phase: I/II

Title: STAR Ph2 Seribantumab NRG1 Fusion+ ST View

Description: CRESTONE: A Phase 2 Study of Seribantumab in Adult Patients with Neuregulin-1 (NRG1) Fusion Positive Locally Advanced or Metastatic Solid Tumors (ELVCAP-001-01)

Indication: Solid Tumors

Location: Texas Oncology-Grapevine

Phase: II

Title: STAR Ph2 Erdafitinib FGFR Solid Tumors View

Description: A Phase 2 Study of Erdafitinib in Subjects With Advanced Solid Tumors and FGFR Gene Alterations (42756493CAN2002)

Indication: Solid Tumors

Location: Texas Oncology-Grapevine

Phase: II

Title: STAR Ph2 Basket Tucat+Tras ST HER2 Alt View

Description: A Phase 2 Basket Study of Tucatinib in Combination with Trastuzumab in Subjects with Previously Treated Locally-Advanced Unresectable or Metastatic Solid Tumors Driven by HER2 Alterations (SGNTUC-019)

Indication: Solid Tumors

Location: Texas Oncology-Grapevine

Phase: II

Title: STAR Ph1/2 BLU667 thy NSCLC Sol tum View

Description: A Phase 1/2 Study of the Highly-selective RET Inhibitor BLU-667 in Patients with Thyroid Cancer Non-Small Cell Lung Cancer (NSCLC) and Other Advanced Solid Tumors (BLU-667-1101)

Indication: Solid Tumors

Location: Texas Oncology-Grapevine

Phase: I/II

Title: STAR Ph2 Pemigatinib Solids FGFR View

Description: (INCB 54828-207) A Phase 2 Open-Label Single-Arm Multicenter Study to Evaluate the Efficacy and Safety of Pemigatinib in Participants With Previously Treated Locally Advanced/Metastatic or Surgically Unresectable Solid Tumor Malignancies Harboring Activating FGFR Mutations or Translocations (FIGHT-207)

Indication: Solid Tumors

Location: Texas Oncology-Grapevine

Phase: II

Title: STAR Ph1/2 MRTX849 Solids KRAS G12C View

Description: A Phase 1/2 Multiple Expansion Cohort Trial of MRTX849 in Patients with Advanced Solid Tumors with KRAS G12C Mutation (849-001)

Indication: Solid Tumors

Location: Texas Oncology-Grapevine

Phase: I/II

Testicular Cancer

Title: STAR Ph1/2 MRTX849 Solids KRAS G12C View

Description: A Phase 1/2 Multiple Expansion Cohort Trial of MRTX849 in Patients with Advanced Solid Tumors with KRAS G12C Mutation (849-001)

Indication: Testicular Cancer

Location: Texas Oncology-Arlington Cancer Center North

Phase: I/II

Title: STAR Ph1/2 MRTX849 Solids KRAS G12C View

Description: A Phase 1/2 Multiple Expansion Cohort Trial of MRTX849 in Patients with Advanced Solid Tumors with KRAS G12C Mutation (849-001)

Indication: Testicular Cancer

Location: Texas Oncology-Arlington South

Phase: I/II

Title: STAR Ph1/2 MRTX849 Solids KRAS G12C View

Description: A Phase 1/2 Multiple Expansion Cohort Trial of MRTX849 in Patients with Advanced Solid Tumors with KRAS G12C Mutation (849-001)

Indication: Testicular Cancer

Location: Texas Oncology-Bedford

Phase: I/II

Title: STAR Ph1/2 MRTX849 Solids KRAS G12C View

Description: A Phase 1/2 Multiple Expansion Cohort Trial of MRTX849 in Patients with Advanced Solid Tumors with KRAS G12C Mutation (849-001)

Indication: Testicular Cancer

Location: Texas Oncology-Fort Worth Cancer Center

Phase: I/II

Title: STAR Ph1/2 MRTX849 Solids KRAS G12C View

Description: A Phase 1/2 Multiple Expansion Cohort Trial of MRTX849 in Patients with Advanced Solid Tumors with KRAS G12C Mutation (849-001)

Indication: Testicular Cancer

Location: Texas Oncology-Grapevine

Phase: I/II

Thyroid Cancer

Title: STAR Ph1/2 MRTX849 Solids KRAS G12C View

Description: A Phase 1/2 Multiple Expansion Cohort Trial of MRTX849 in Patients with Advanced Solid Tumors with KRAS G12C Mutation (849-001)

Indication: Thyroid Cancer

Location: Texas Oncology-Arlington Cancer Center North

Phase: I/II

Title: STAR Ph1/2 MRTX849 Solids KRAS G12C View

Description: A Phase 1/2 Multiple Expansion Cohort Trial of MRTX849 in Patients with Advanced Solid Tumors with KRAS G12C Mutation (849-001)

Indication: Thyroid Cancer

Location: Texas Oncology-Arlington South

Phase: I/II

Title: STAR Ph1/2 BLU667 thy NSCLC Sol tum View

Description: A Phase 1/2 Study of the Highly-selective RET Inhibitor BLU-667 in Patients with Thyroid Cancer Non-Small Cell Lung Cancer (NSCLC) and Other Advanced Solid Tumors (BLU-667-1101)

Indication: Thyroid Cancer

Location: Texas Oncology-Arlington South

Phase: I/II

Title: STAR Ph1/2 BLU667 thy NSCLC Sol tum View

Description: A Phase 1/2 Study of the Highly-selective RET Inhibitor BLU-667 in Patients with Thyroid Cancer Non-Small Cell Lung Cancer (NSCLC) and Other Advanced Solid Tumors (BLU-667-1101)

Indication: Thyroid Cancer

Location: Texas Oncology-Bedford

Phase: I/II

Title: STAR Ph1/2 MRTX849 Solids KRAS G12C View

Description: A Phase 1/2 Multiple Expansion Cohort Trial of MRTX849 in Patients with Advanced Solid Tumors with KRAS G12C Mutation (849-001)

Indication: Thyroid Cancer

Location: Texas Oncology-Bedford

Phase: I/II

Title: STAR Ph1/2 MRTX849 Solids KRAS G12C View

Description: A Phase 1/2 Multiple Expansion Cohort Trial of MRTX849 in Patients with Advanced Solid Tumors with KRAS G12C Mutation (849-001)

Indication: Thyroid Cancer

Location: Texas Oncology-Fort Worth Cancer Center

Phase: I/II

Title: STAR Ph1/2 BLU667 thy NSCLC Sol tum View

Description: A Phase 1/2 Study of the Highly-selective RET Inhibitor BLU-667 in Patients with Thyroid Cancer Non-Small Cell Lung Cancer (NSCLC) and Other Advanced Solid Tumors (BLU-667-1101)

Indication: Thyroid Cancer

Location: Texas Oncology-Fort Worth Cancer Center

Phase: I/II

Title: STAR Ph1/2 BLU667 thy NSCLC Sol tum View

Description: A Phase 1/2 Study of the Highly-selective RET Inhibitor BLU-667 in Patients with Thyroid Cancer Non-Small Cell Lung Cancer (NSCLC) and Other Advanced Solid Tumors (BLU-667-1101)

Indication: Thyroid Cancer

Location: Texas Oncology-Grapevine

Phase: I/II

Title: STAR Ph1/2 MRTX849 Solids KRAS G12C View

Description: A Phase 1/2 Multiple Expansion Cohort Trial of MRTX849 in Patients with Advanced Solid Tumors with KRAS G12C Mutation (849-001)

Indication: Thyroid Cancer

Location: Texas Oncology-Grapevine

Phase: I/II

Urothelial Cancer

Title: STAR Ph2 Basket Tucat+Tras ST HER2 Alt View

Description: A Phase 2 Basket Study of Tucatinib in Combination with Trastuzumab in Subjects with Previously Treated Locally-Advanced Unresectable or Metastatic Solid Tumors Driven by HER2 Alterations (SGNTUC-019)

Indication: Urothelial Cancer

Location: Texas Oncology-Arlington Cancer Center North

Phase: II

Title: STAR Ph2 Basket Tucat+Tras ST HER2 Alt View

Description: A Phase 2 Basket Study of Tucatinib in Combination with Trastuzumab in Subjects with Previously Treated Locally-Advanced Unresectable or Metastatic Solid Tumors Driven by HER2 Alterations (SGNTUC-019)

Indication: Urothelial Cancer

Location: Texas Oncology-Arlington South

Phase: II

Title: STAR PH 2 Enfortumab in Urothelial Pts View

Description: A study of enfortumab vedotin (ASG-22CE) as monotherapy or in combination with other anticancer therapies for the treatment of urothelial cancer (SGN22E-002)

Indication: Urothelial Cancer

Location: Texas Oncology-Arlington South

Phase: I/II

Title: STAR Ph1/2 MRTX849 Solids KRAS G12C View

Description: A Phase 1/2 Multiple Expansion Cohort Trial of MRTX849 in Patients with Advanced Solid Tumors with KRAS G12C Mutation (849-001)

Indication: Urothelial Cancer

Location: Texas Oncology-Arlington Cancer Center North

Phase: I/II

Title: STAR Ph1/2 MRTX849 Solids KRAS G12C View

Description: A Phase 1/2 Multiple Expansion Cohort Trial of MRTX849 in Patients with Advanced Solid Tumors with KRAS G12C Mutation (849-001)

Indication: Urothelial Cancer

Location: Texas Oncology-Arlington South

Phase: I/II

Title: STAR Sitra+Nivo/Pembro+Enfor Adv/Met Uro View

Description: A Phase 2 Study of Sitravatinib in Combination with PD-(L)1 Checkpoint Inhibitor Regimens in Patients With Advanced or Metastatic Urothelial Carcinoma (516-003)

Indication: Urothelial Cancer

Location: Texas Oncology-Arlington Cancer Center North

Phase: II

Title: STAR Sitra+Nivo/Pembro+Enfor Adv/Met Uro View

Description: A Phase 2 Study of Sitravatinib in Combination with PD-(L)1 Checkpoint Inhibitor Regimens in Patients With Advanced or Metastatic Urothelial Carcinoma (516-003)

Indication: Urothelial Cancer

Location: Texas Oncology-Arlington South

Phase: II

Title: STAR Ph3 FGFR erdafitinib urothelial View

Description: (42756493BLC3001) A Phase 3 Study of Erdafitinib Compared with Vinflunine or Docetaxel or Pembrolizumab in Subjects with Advanced Urothelial Cancer and Selected FGFR Gene Aberrations (THOR)

Indication: Urothelial Cancer

Location: Texas Oncology-Arlington South

Phase: III

Title: STAR Ph3 FGFR erdafitinib urothelial View

Description: (42756493BLC3001) A Phase 3 Study of Erdafitinib Compared with Vinflunine or Docetaxel or Pembrolizumab in Subjects with Advanced Urothelial Cancer and Selected FGFR Gene Aberrations (THOR)

Indication: Urothelial Cancer

Location: Texas Oncology-Bedford

Phase: III

Title: STAR Sitra+Nivo/Pembro+Enfor Adv/Met Uro View

Description: A Phase 2 Study of Sitravatinib in Combination with PD-(L)1 Checkpoint Inhibitor Regimens in Patients With Advanced or Metastatic Urothelial Carcinoma (516-003)

Indication: Urothelial Cancer

Location: Texas Oncology-Bedford

Phase: II

Title: STAR Ph1/2 MRTX849 Solids KRAS G12C View

Description: A Phase 1/2 Multiple Expansion Cohort Trial of MRTX849 in Patients with Advanced Solid Tumors with KRAS G12C Mutation (849-001)

Indication: Urothelial Cancer

Location: Texas Oncology-Bedford

Phase: I/II

Title: STAR PH 2 Enfortumab in Urothelial Pts View

Description: A study of enfortumab vedotin (ASG-22CE) as monotherapy or in combination with other anticancer therapies for the treatment of urothelial cancer (SGN22E-002)

Indication: Urothelial Cancer

Location: Texas Oncology-Bedford

Phase: I/II

Title: STAR Ph2 Basket Tucat+Tras ST HER2 Alt View

Description: A Phase 2 Basket Study of Tucatinib in Combination with Trastuzumab in Subjects with Previously Treated Locally-Advanced Unresectable or Metastatic Solid Tumors Driven by HER2 Alterations (SGNTUC-019)

Indication: Urothelial Cancer

Location: Texas Oncology-Bedford

Phase: II

Title: STAR Ph2 Basket Tucat+Tras ST HER2 Alt View

Description: A Phase 2 Basket Study of Tucatinib in Combination with Trastuzumab in Subjects with Previously Treated Locally-Advanced Unresectable or Metastatic Solid Tumors Driven by HER2 Alterations (SGNTUC-019)

Indication: Urothelial Cancer

Location: Texas Oncology-Fort Worth Cancer Center

Phase: II

Title: STAR PH 2 Enfortumab in Urothelial Pts View

Description: A study of enfortumab vedotin (ASG-22CE) as monotherapy or in combination with other anticancer therapies for the treatment of urothelial cancer (SGN22E-002)

Indication: Urothelial Cancer

Location: Texas Oncology-Fort Worth Cancer Center

Phase: I/II

Title: STAR Ph 3 Infigratinib UC w/ FGFR3 Alt View

Description: QBGJ398-302: Phase 3 Multicenter Double-Blind Randomized Placebo-Controlled Trial of Infigratinib for the Adjuvant Treatment of Subjects with Invasive Urothelial Carcinoma with Susceptible FGFR3 Genetic Alterations (PROOF302)

Indication: Urothelial Cancer

Location: Texas Oncology-Fort Worth Cancer Center

Phase: III

Title: STAR Ph1/2 MRTX849 Solids KRAS G12C View

Description: A Phase 1/2 Multiple Expansion Cohort Trial of MRTX849 in Patients with Advanced Solid Tumors with KRAS G12C Mutation (849-001)

Indication: Urothelial Cancer

Location: Texas Oncology-Fort Worth Cancer Center

Phase: I/II

Title: Biomarker Advcd Uro Cncer and FGFR Aber View

Description: Biomarker Study to Identify Subjects with Urothelial Cancer and Fibroblast Growth Factor Receptor Gene Aberrations (42756493BLC0002)

Indication: Urothelial Cancer

Location: Texas Oncology-Fort Worth Cancer Center

Phase: IV

Title: STAR Sitra+Nivo/Pembro+Enfor Adv/Met Uro View

Description: A Phase 2 Study of Sitravatinib in Combination with PD-(L)1 Checkpoint Inhibitor Regimens in Patients With Advanced or Metastatic Urothelial Carcinoma (516-003)

Indication: Urothelial Cancer

Location: Texas Oncology-Fort Worth Cancer Center

Phase: II

Title: STAR Ph3 FGFR erdafitinib urothelial View

Description: (42756493BLC3001) A Phase 3 Study of Erdafitinib Compared with Vinflunine or Docetaxel or Pembrolizumab in Subjects with Advanced Urothelial Cancer and Selected FGFR Gene Aberrations (THOR)

Indication: Urothelial Cancer

Location: Texas Oncology-Fort Worth Cancer Center

Phase: III

Title: STAR PH 2 Enfortumab in Urothelial Pts View

Description: A study of enfortumab vedotin (ASG-22CE) as monotherapy or in combination with other anticancer therapies for the treatment of urothelial cancer (SGN22E-002)

Indication: Urothelial Cancer

Location: Texas Oncology-Grapevine

Phase: I/II

Title: STAR Ph2 Basket Tucat+Tras ST HER2 Alt View

Description: A Phase 2 Basket Study of Tucatinib in Combination with Trastuzumab in Subjects with Previously Treated Locally-Advanced Unresectable or Metastatic Solid Tumors Driven by HER2 Alterations (SGNTUC-019)

Indication: Urothelial Cancer

Location: Texas Oncology-Grapevine

Phase: II

Title: STAR Ph3 FGFR erdafitinib urothelial View

Description: (42756493BLC3001) A Phase 3 Study of Erdafitinib Compared with Vinflunine or Docetaxel or Pembrolizumab in Subjects with Advanced Urothelial Cancer and Selected FGFR Gene Aberrations (THOR)

Indication: Urothelial Cancer

Location: Texas Oncology-Grapevine

Phase: III

Title: STAR Sitra+Nivo/Pembro+Enfor Adv/Met Uro View

Description: A Phase 2 Study of Sitravatinib in Combination with PD-(L)1 Checkpoint Inhibitor Regimens in Patients With Advanced or Metastatic Urothelial Carcinoma (516-003)

Indication: Urothelial Cancer

Location: Texas Oncology-Grapevine

Phase: II

Title: STAR Ph1/2 MRTX849 Solids KRAS G12C View

Description: A Phase 1/2 Multiple Expansion Cohort Trial of MRTX849 in Patients with Advanced Solid Tumors with KRAS G12C Mutation (849-001)

Indication: Urothelial Cancer

Location: Texas Oncology-Grapevine

Phase: I/II

Uterine Cancer

Title: STAR Ph2 Basket Tucat+Tras ST HER2 Alt View

Description: A Phase 2 Basket Study of Tucatinib in Combination with Trastuzumab in Subjects with Previously Treated Locally-Advanced Unresectable or Metastatic Solid Tumors Driven by HER2 Alterations (SGNTUC-019)

Indication: Uterine Cancer

Location: Texas Oncology-Arlington Cancer Center North

Phase: II

Title: STAR Ph2 Basket Tucat+Tras ST HER2 Alt View

Description: A Phase 2 Basket Study of Tucatinib in Combination with Trastuzumab in Subjects with Previously Treated Locally-Advanced Unresectable or Metastatic Solid Tumors Driven by HER2 Alterations (SGNTUC-019)

Indication: Uterine Cancer

Location: Texas Oncology-Arlington South

Phase: II

Title: STAR Ph1/2 MRTX849 Solids KRAS G12C View

Description: A Phase 1/2 Multiple Expansion Cohort Trial of MRTX849 in Patients with Advanced Solid Tumors with KRAS G12C Mutation (849-001)

Indication: Uterine Cancer

Location: Texas Oncology-Arlington Cancer Center North

Phase: I/II

Title: STAR Ph1/2 MRTX849 Solids KRAS G12C View

Description: A Phase 1/2 Multiple Expansion Cohort Trial of MRTX849 in Patients with Advanced Solid Tumors with KRAS G12C Mutation (849-001)

Indication: Uterine Cancer

Location: Texas Oncology-Arlington South

Phase: I/II

Title: STAR Ph1/2 MRTX849 Solids KRAS G12C View

Description: A Phase 1/2 Multiple Expansion Cohort Trial of MRTX849 in Patients with Advanced Solid Tumors with KRAS G12C Mutation (849-001)

Indication: Uterine Cancer

Location: Texas Oncology-Bedford

Phase: I/II

Title: STAR Ph2 Basket Tucat+Tras ST HER2 Alt View

Description: A Phase 2 Basket Study of Tucatinib in Combination with Trastuzumab in Subjects with Previously Treated Locally-Advanced Unresectable or Metastatic Solid Tumors Driven by HER2 Alterations (SGNTUC-019)

Indication: Uterine Cancer

Location: Texas Oncology-Bedford

Phase: II

Title: STAR Ph2 Basket Tucat+Tras ST HER2 Alt View

Description: A Phase 2 Basket Study of Tucatinib in Combination with Trastuzumab in Subjects with Previously Treated Locally-Advanced Unresectable or Metastatic Solid Tumors Driven by HER2 Alterations (SGNTUC-019)

Indication: Uterine Cancer

Location: Texas Oncology-Fort Worth Cancer Center

Phase: II

Title: STAR Ph1/2 MRTX849 Solids KRAS G12C View

Description: A Phase 1/2 Multiple Expansion Cohort Trial of MRTX849 in Patients with Advanced Solid Tumors with KRAS G12C Mutation (849-001)

Indication: Uterine Cancer

Location: Texas Oncology-Fort Worth Cancer Center

Phase: I/II

Title: STAR Ph2 Basket Tucat+Tras ST HER2 Alt View

Description: A Phase 2 Basket Study of Tucatinib in Combination with Trastuzumab in Subjects with Previously Treated Locally-Advanced Unresectable or Metastatic Solid Tumors Driven by HER2 Alterations (SGNTUC-019)

Indication: Uterine Cancer

Location: Texas Oncology-Grapevine

Phase: II

Title: STAR Ph1/2 MRTX849 Solids KRAS G12C View

Description: A Phase 1/2 Multiple Expansion Cohort Trial of MRTX849 in Patients with Advanced Solid Tumors with KRAS G12C Mutation (849-001)

Indication: Uterine Cancer

Location: Texas Oncology-Grapevine

Phase: I/II

Vaginal Cancer

Title: STAR Ph1/2 MRTX849 Solids KRAS G12C View

Description: A Phase 1/2 Multiple Expansion Cohort Trial of MRTX849 in Patients with Advanced Solid Tumors with KRAS G12C Mutation (849-001)

Indication: Vaginal Cancer

Location: Texas Oncology-Arlington Cancer Center North

Phase: I/II

Title: STAR Ph1/2 MRTX849 Solids KRAS G12C View

Description: A Phase 1/2 Multiple Expansion Cohort Trial of MRTX849 in Patients with Advanced Solid Tumors with KRAS G12C Mutation (849-001)

Indication: Vaginal Cancer

Location: Texas Oncology-Arlington South

Phase: I/II

Title: STAR Ph1/2 MRTX849 Solids KRAS G12C View

Description: A Phase 1/2 Multiple Expansion Cohort Trial of MRTX849 in Patients with Advanced Solid Tumors with KRAS G12C Mutation (849-001)

Indication: Vaginal Cancer

Location: Texas Oncology-Bedford

Phase: I/II

Title: STAR Ph1/2 MRTX849 Solids KRAS G12C View

Description: A Phase 1/2 Multiple Expansion Cohort Trial of MRTX849 in Patients with Advanced Solid Tumors with KRAS G12C Mutation (849-001)

Indication: Vaginal Cancer

Location: Texas Oncology-Fort Worth Cancer Center

Phase: I/II

Title: STAR Ph1/2 MRTX849 Solids KRAS G12C View

Description: A Phase 1/2 Multiple Expansion Cohort Trial of MRTX849 in Patients with Advanced Solid Tumors with KRAS G12C Mutation (849-001)

Indication: Vaginal Cancer

Location: Texas Oncology-Grapevine

Phase: I/II

Vulvar Cancer

Title: STAR Ph1/2 MRTX849 Solids KRAS G12C View

Description: A Phase 1/2 Multiple Expansion Cohort Trial of MRTX849 in Patients with Advanced Solid Tumors with KRAS G12C Mutation (849-001)

Indication: Vulvar Cancer

Location: Texas Oncology-Arlington Cancer Center North

Phase: I/II

Title: STAR Ph1/2 MRTX849 Solids KRAS G12C View

Description: A Phase 1/2 Multiple Expansion Cohort Trial of MRTX849 in Patients with Advanced Solid Tumors with KRAS G12C Mutation (849-001)

Indication: Vulvar Cancer

Location: Texas Oncology-Arlington South

Phase: I/II

Title: STAR Ph1/2 MRTX849 Solids KRAS G12C View

Description: A Phase 1/2 Multiple Expansion Cohort Trial of MRTX849 in Patients with Advanced Solid Tumors with KRAS G12C Mutation (849-001)

Indication: Vulvar Cancer

Location: Texas Oncology-Bedford

Phase: I/II

Title: STAR Ph1/2 MRTX849 Solids KRAS G12C View

Description: A Phase 1/2 Multiple Expansion Cohort Trial of MRTX849 in Patients with Advanced Solid Tumors with KRAS G12C Mutation (849-001)

Indication: Vulvar Cancer

Location: Texas Oncology-Fort Worth Cancer Center

Phase: I/II

Title: STAR Ph1/2 MRTX849 Solids KRAS G12C View

Description: A Phase 1/2 Multiple Expansion Cohort Trial of MRTX849 in Patients with Advanced Solid Tumors with KRAS G12C Mutation (849-001)

Indication: Vulvar Cancer

Location: Texas Oncology-Grapevine

Phase: I/II

Texas Oncology-Arlington Cancer Center North

Title: STAR Ph2 Seribantumab NRG1 Fusion+ ST View

Description: CRESTONE: A Phase 2 Study of Seribantumab in Adult Patients with Neuregulin-1 (NRG1) Fusion Positive Locally Advanced or Metastatic Solid Tumors (ELVCAP-001-01)

Indication: Solid Tumors

Location: Texas Oncology-Arlington Cancer Center North

Phase: II

Title: STAR Ph2 Basket Tucat+Tras ST HER2 Alt View

Description: A Phase 2 Basket Study of Tucatinib in Combination with Trastuzumab in Subjects with Previously Treated Locally-Advanced Unresectable or Metastatic Solid Tumors Driven by HER2 Alterations (SGNTUC-019)

Indication: Biliary Cancer

Location: Texas Oncology-Arlington Cancer Center North

Phase: II

Title: STAR Ph2 Basket Tucat+Tras ST HER2 Alt View

Description: A Phase 2 Basket Study of Tucatinib in Combination with Trastuzumab in Subjects with Previously Treated Locally-Advanced Unresectable or Metastatic Solid Tumors Driven by HER2 Alterations (SGNTUC-019)

Indication: Breast Cancer

Location: Texas Oncology-Arlington Cancer Center North

Phase: II

Title: STAR Ph2 Basket Tucat+Tras ST HER2 Alt View

Description: A Phase 2 Basket Study of Tucatinib in Combination with Trastuzumab in Subjects with Previously Treated Locally-Advanced Unresectable or Metastatic Solid Tumors Driven by HER2 Alterations (SGNTUC-019)

Indication: Cervical Cancer

Location: Texas Oncology-Arlington Cancer Center North

Phase: II

Title: STAR Ph2 Basket Tucat+Tras ST HER2 Alt View

Description: A Phase 2 Basket Study of Tucatinib in Combination with Trastuzumab in Subjects with Previously Treated Locally-Advanced Unresectable or Metastatic Solid Tumors Driven by HER2 Alterations (SGNTUC-019)

Indication: Gall Bladder Cancer

Location: Texas Oncology-Arlington Cancer Center North

Phase: II

Title: STAR Ph2 Basket Tucat+Tras ST HER2 Alt View

Description: A Phase 2 Basket Study of Tucatinib in Combination with Trastuzumab in Subjects with Previously Treated Locally-Advanced Unresectable or Metastatic Solid Tumors Driven by HER2 Alterations (SGNTUC-019)

Indication: Lung Cancer

Location: Texas Oncology-Arlington Cancer Center North

Phase: II

Title: STAR Ph2 Basket Tucat+Tras ST HER2 Alt View

Description: A Phase 2 Basket Study of Tucatinib in Combination with Trastuzumab in Subjects with Previously Treated Locally-Advanced Unresectable or Metastatic Solid Tumors Driven by HER2 Alterations (SGNTUC-019)

Indication: Solid Tumors

Location: Texas Oncology-Arlington Cancer Center North

Phase: II

Title: STAR Ph2 Basket Tucat+Tras ST HER2 Alt View

Description: A Phase 2 Basket Study of Tucatinib in Combination with Trastuzumab in Subjects with Previously Treated Locally-Advanced Unresectable or Metastatic Solid Tumors Driven by HER2 Alterations (SGNTUC-019)

Indication: Urothelial Cancer

Location: Texas Oncology-Arlington Cancer Center North

Phase: II

Title: STAR Ph2 Basket Tucat+Tras ST HER2 Alt View

Description: A Phase 2 Basket Study of Tucatinib in Combination with Trastuzumab in Subjects with Previously Treated Locally-Advanced Unresectable or Metastatic Solid Tumors Driven by HER2 Alterations (SGNTUC-019)

Indication: Uterine Cancer

Location: Texas Oncology-Arlington Cancer Center North

Phase: II

Title: STAR Ph3 61186372 Osim Lazert EGFR NSCLC View

Description: A Phase 3 Randomized Study of Amivantamab and Lazertinib Combination Therapy Versus Osimertinib Versus Lazertinib as First-Line Treatment in Patients with EGFR-Mutated Locally Advanced or Metastatic Non-Small Cell Lung Cancer (73841937NSC3003)MARIPOSA

Indication: Lung Cancer

Location: Texas Oncology-Arlington Cancer Center North

Phase: III

Title: STAR PH3 JNJ-61186372 Peme EGFR NSCLC View

Description: A Randomized Open-label Phase 3 Study of Combination Amivantamab and Carboplatin-Pemetrexed Therapy Compared with Carboplatin-Pemetrexed in Patients with EGFR Exon 20ins Mutated Locally Advanced or Metastatic Non-Small Cell Lung Cancer (61186372NSC3001)

Indication: Lung Cancer

Location: Texas Oncology-Arlington Cancer Center North

Phase: III

Title: STAR PH3 Nirap Abira HRR mCSPC View

Description: A Phase 3 Randomized Placebo-controlled Double-blind Study of Niraparib in Combination with Abiraterone Acetate and Prednisone Versus Abiraterone Acetate and Prednisone for the Treatment of Participants with Deleterious Germline or Somatic Homologous Recombination Repair (HRR) Gene-Mutated Metastatic Castration-Sensitive Prostate Cancer (mCSPC)(67652000PCR3002)

Indication: Prostate Cancer

Location: Texas Oncology-Arlington Cancer Center North

Phase: III

Title: STAR Ph2 Ak104 Cervical Cancer View

Description: A Phase 2 multicenter single-arm open-label study to evaluate the efficacy and safety of AK104 in subjects with recurrent or metastatic cervical cancer (AK104-201-AU)

Indication: Cervical Cancer

Location: Texas Oncology-Arlington Cancer Center North

Phase: II

Title: STAR PH2 Tuca+ Tras HER2+ CC View

Description: MOUNTAINEER: A Phase 2 Open Label Study of Tucatinib Combined with Trastuzumab in Patients with HER2+ Metastatic Colorectal Cancer (ACCRU-GI-1617 SGNTUC-017)

Indication: Colon Cancer

Location: Texas Oncology-Arlington Cancer Center North

Phase: II

Title: STAR PH2 Tuca+ Tras HER2+ CC View

Description: MOUNTAINEER: A Phase 2 Open Label Study of Tucatinib Combined with Trastuzumab in Patients with HER2+ Metastatic Colorectal Cancer (ACCRU-GI-1617 SGNTUC-017)

Indication: Rectal Cancer

Location: Texas Oncology-Arlington Cancer Center North

Phase: II

Title: STAR Ph3 Carbo/Pac NCMGA00012 MSCC View

Description: A Phase 3 Global Multicenter Double-Blind Randomized Study of Carboplatin-Paclitaxel With INCMGA00012 or Placebo in Participants With Inoperable Locally Recurrent or Metastatic Squamous Cell Carcinoma of the Anal Canal Not Previously Treated With Systemic Chemotherapy (POD1UM-303/InterAACT 2) (INCMGA 0012-303)

Indication: Anal Cancer

Location: Texas Oncology-Arlington Cancer Center North

Phase: III

Title: STAR Ph3 Carbo/Pac NCMGA00012 MSCC View

Description: A Phase 3 Global Multicenter Double-Blind Randomized Study of Carboplatin-Paclitaxel With INCMGA00012 or Placebo in Participants With Inoperable Locally Recurrent or Metastatic Squamous Cell Carcinoma of the Anal Canal Not Previously Treated With Systemic Chemotherapy (POD1UM-303/InterAACT 2) (INCMGA 0012-303)

Indication: Carcinoid

Location: Texas Oncology-Arlington Cancer Center North

Phase: III

Title: STAR Ph3 Navi Ruxo Myelofibrosis View

Description: M16-191: A Randomized Double-Blind Placebo-Controlled Phase 3 Study of Navitoclax in Combination with Ruxolitinib versus Ruxolitinib in Subjects with Myelofibrosis (TRANSFORM-1)

Indication: Myelofibrosis

Location: Texas Oncology-Arlington Cancer Center North

Phase: III

Title: STAR Ph1/2 MRTX849 Solids KRAS G12C View

Description: A Phase 1/2 Multiple Expansion Cohort Trial of MRTX849 in Patients with Advanced Solid Tumors with KRAS G12C Mutation (849-001)

Indication: Anal Cancer

Location: Texas Oncology-Arlington Cancer Center North

Phase: I/II

Title: STAR Ph1/2 MRTX849 Solids KRAS G12C View

Description: A Phase 1/2 Multiple Expansion Cohort Trial of MRTX849 in Patients with Advanced Solid Tumors with KRAS G12C Mutation (849-001)

Indication: Biliary Cancer

Location: Texas Oncology-Arlington Cancer Center North

Phase: I/II

Title: STAR Ph1/2 MRTX849 Solids KRAS G12C View

Description: A Phase 1/2 Multiple Expansion Cohort Trial of MRTX849 in Patients with Advanced Solid Tumors with KRAS G12C Mutation (849-001)

Indication: Bladder Cancer

Location: Texas Oncology-Arlington Cancer Center North

Phase: I/II

Title: STAR Ph1/2 MRTX849 Solids KRAS G12C View

Description: A Phase 1/2 Multiple Expansion Cohort Trial of MRTX849 in Patients with Advanced Solid Tumors with KRAS G12C Mutation (849-001)

Indication: Bone Mets

Location: Texas Oncology-Arlington Cancer Center North

Phase: I/II

Title: STAR Ph1/2 MRTX849 Solids KRAS G12C View

Description: A Phase 1/2 Multiple Expansion Cohort Trial of MRTX849 in Patients with Advanced Solid Tumors with KRAS G12C Mutation (849-001)

Indication: Brain Cancer

Location: Texas Oncology-Arlington Cancer Center North

Phase: I/II

Title: STAR Ph1/2 MRTX849 Solids KRAS G12C View

Description: A Phase 1/2 Multiple Expansion Cohort Trial of MRTX849 in Patients with Advanced Solid Tumors with KRAS G12C Mutation (849-001)

Indication: Breast Cancer

Location: Texas Oncology-Arlington Cancer Center North

Phase: I/II

Title: STAR Ph1/2 MRTX849 Solids KRAS G12C View

Description: A Phase 1/2 Multiple Expansion Cohort Trial of MRTX849 in Patients with Advanced Solid Tumors with KRAS G12C Mutation (849-001)

Indication: Urothelial Cancer

Location: Texas Oncology-Arlington Cancer Center North

Phase: I/II

Title: STAR Ph1/2 MRTX849 Solids KRAS G12C View

Description: A Phase 1/2 Multiple Expansion Cohort Trial of MRTX849 in Patients with Advanced Solid Tumors with KRAS G12C Mutation (849-001)

Indication: Uterine Cancer

Location: Texas Oncology-Arlington Cancer Center North

Phase: I/II

Title: STAR Ph1/2 MRTX849 Solids KRAS G12C View

Description: A Phase 1/2 Multiple Expansion Cohort Trial of MRTX849 in Patients with Advanced Solid Tumors with KRAS G12C Mutation (849-001)

Indication: Vaginal Cancer

Location: Texas Oncology-Arlington Cancer Center North

Phase: I/II

Title: STAR Ph1/2 MRTX849 Solids KRAS G12C View

Description: A Phase 1/2 Multiple Expansion Cohort Trial of MRTX849 in Patients with Advanced Solid Tumors with KRAS G12C Mutation (849-001)

Indication: Vulvar Cancer

Location: Texas Oncology-Arlington Cancer Center North

Phase: I/II

Title: STAR Ph1/2 MRTX849 Solids KRAS G12C View

Description: A Phase 1/2 Multiple Expansion Cohort Trial of MRTX849 in Patients with Advanced Solid Tumors with KRAS G12C Mutation (849-001)

Indication: Rectal Cancer

Location: Texas Oncology-Arlington Cancer Center North

Phase: I/II

Title: STAR Ph1/2 MRTX849 Solids KRAS G12C View

Description: A Phase 1/2 Multiple Expansion Cohort Trial of MRTX849 in Patients with Advanced Solid Tumors with KRAS G12C Mutation (849-001)

Indication: Renal Cancer

Location: Texas Oncology-Arlington Cancer Center North

Phase: I/II

Title: STAR Ph1/2 MRTX849 Solids KRAS G12C View

Description: A Phase 1/2 Multiple Expansion Cohort Trial of MRTX849 in Patients with Advanced Solid Tumors with KRAS G12C Mutation (849-001)

Indication: Sarcoma

Location: Texas Oncology-Arlington Cancer Center North

Phase: I/II

Title: STAR Ph1/2 MRTX849 Solids KRAS G12C View

Description: A Phase 1/2 Multiple Expansion Cohort Trial of MRTX849 in Patients with Advanced Solid Tumors with KRAS G12C Mutation (849-001)

Indication: Solid Tumors

Location: Texas Oncology-Arlington Cancer Center North

Phase: I/II

Title: STAR Ph1/2 MRTX849 Solids KRAS G12C View

Description: A Phase 1/2 Multiple Expansion Cohort Trial of MRTX849 in Patients with Advanced Solid Tumors with KRAS G12C Mutation (849-001)

Indication: Testicular Cancer

Location: Texas Oncology-Arlington Cancer Center North

Phase: I/II

Title: STAR Ph1/2 MRTX849 Solids KRAS G12C View

Description: A Phase 1/2 Multiple Expansion Cohort Trial of MRTX849 in Patients with Advanced Solid Tumors with KRAS G12C Mutation (849-001)

Indication: Thyroid Cancer

Location: Texas Oncology-Arlington Cancer Center North

Phase: I/II

Title: STAR Ph1/2 MRTX849 Solids KRAS G12C View

Description: A Phase 1/2 Multiple Expansion Cohort Trial of MRTX849 in Patients with Advanced Solid Tumors with KRAS G12C Mutation (849-001)

Indication: Malignant Adenoma

Location: Texas Oncology-Arlington Cancer Center North

Phase: I/II

Title: STAR Ph1/2 MRTX849 Solids KRAS G12C View

Description: A Phase 1/2 Multiple Expansion Cohort Trial of MRTX849 in Patients with Advanced Solid Tumors with KRAS G12C Mutation (849-001)

Indication: Ovarian Cancer

Location: Texas Oncology-Arlington Cancer Center North

Phase: I/II

Title: STAR Ph1/2 MRTX849 Solids KRAS G12C View

Description: A Phase 1/2 Multiple Expansion Cohort Trial of MRTX849 in Patients with Advanced Solid Tumors with KRAS G12C Mutation (849-001)

Indication: Pancreatic Cancer

Location: Texas Oncology-Arlington Cancer Center North

Phase: I/II

Title: STAR Ph1/2 MRTX849 Solids KRAS G12C View

Description: A Phase 1/2 Multiple Expansion Cohort Trial of MRTX849 in Patients with Advanced Solid Tumors with KRAS G12C Mutation (849-001)

Indication: Penile Cancer

Location: Texas Oncology-Arlington Cancer Center North

Phase: I/II

Title: STAR Ph1/2 MRTX849 Solids KRAS G12C View

Description: A Phase 1/2 Multiple Expansion Cohort Trial of MRTX849 in Patients with Advanced Solid Tumors with KRAS G12C Mutation (849-001)

Indication: Peritoneal Cancer

Location: Texas Oncology-Arlington Cancer Center North

Phase: I/II

Title: STAR Ph1/2 MRTX849 Solids KRAS G12C View

Description: A Phase 1/2 Multiple Expansion Cohort Trial of MRTX849 in Patients with Advanced Solid Tumors with KRAS G12C Mutation (849-001)

Indication: Prostate Cancer

Location: Texas Oncology-Arlington Cancer Center North

Phase: I/II

Title: STAR Ph1/2 MRTX849 Solids KRAS G12C View

Description: A Phase 1/2 Multiple Expansion Cohort Trial of MRTX849 in Patients with Advanced Solid Tumors with KRAS G12C Mutation (849-001)

Indication: Gastric Cancer

Location: Texas Oncology-Arlington Cancer Center North

Phase: I/II

Title: STAR Ph1/2 MRTX849 Solids KRAS G12C View

Description: A Phase 1/2 Multiple Expansion Cohort Trial of MRTX849 in Patients with Advanced Solid Tumors with KRAS G12C Mutation (849-001)

Indication: Head and Neck Cancer

Location: Texas Oncology-Arlington Cancer Center North

Phase: I/II

Title: STAR Ph1/2 MRTX849 Solids KRAS G12C View

Description: A Phase 1/2 Multiple Expansion Cohort Trial of MRTX849 in Patients with Advanced Solid Tumors with KRAS G12C Mutation (849-001)

Indication: Kaposi's Sarcoma

Location: Texas Oncology-Arlington Cancer Center North

Phase: I/II

Title: STAR Ph1/2 MRTX849 Solids KRAS G12C View

Description: A Phase 1/2 Multiple Expansion Cohort Trial of MRTX849 in Patients with Advanced Solid Tumors with KRAS G12C Mutation (849-001)

Indication: Kidney Cancer

Location: Texas Oncology-Arlington Cancer Center North

Phase: I/II

Title: STAR Ph1/2 MRTX849 Solids KRAS G12C View

Description: A Phase 1/2 Multiple Expansion Cohort Trial of MRTX849 in Patients with Advanced Solid Tumors with KRAS G12C Mutation (849-001)

Indication: Liver Cancer

Location: Texas Oncology-Arlington Cancer Center North

Phase: I/II

Title: STAR Ph1/2 MRTX849 Solids KRAS G12C View

Description: A Phase 1/2 Multiple Expansion Cohort Trial of MRTX849 in Patients with Advanced Solid Tumors with KRAS G12C Mutation (849-001)

Indication: Lung Cancer

Location: Texas Oncology-Arlington Cancer Center North

Phase: I/II

Title: STAR Ph1/2 MRTX849 Solids KRAS G12C View

Description: A Phase 1/2 Multiple Expansion Cohort Trial of MRTX849 in Patients with Advanced Solid Tumors with KRAS G12C Mutation (849-001)

Indication: Cervical Cancer

Location: Texas Oncology-Arlington Cancer Center North

Phase: I/II

Title: STAR Ph1/2 MRTX849 Solids KRAS G12C View

Description: A Phase 1/2 Multiple Expansion Cohort Trial of MRTX849 in Patients with Advanced Solid Tumors with KRAS G12C Mutation (849-001)

Indication: Colon Cancer

Location: Texas Oncology-Arlington Cancer Center North

Phase: I/II

Title: STAR Ph1/2 MRTX849 Solids KRAS G12C View

Description: A Phase 1/2 Multiple Expansion Cohort Trial of MRTX849 in Patients with Advanced Solid Tumors with KRAS G12C Mutation (849-001)

Indication: Endometrial Cancer

Location: Texas Oncology-Arlington Cancer Center North

Phase: I/II

Title: STAR Ph1/2 MRTX849 Solids KRAS G12C View

Description: A Phase 1/2 Multiple Expansion Cohort Trial of MRTX849 in Patients with Advanced Solid Tumors with KRAS G12C Mutation (849-001)

Indication: Esophageal Cancer

Location: Texas Oncology-Arlington Cancer Center North

Phase: I/II

Title: STAR Ph1/2 MRTX849 Solids KRAS G12C View

Description: A Phase 1/2 Multiple Expansion Cohort Trial of MRTX849 in Patients with Advanced Solid Tumors with KRAS G12C Mutation (849-001)

Indication: Fallopian Tube Cancer

Location: Texas Oncology-Arlington Cancer Center North

Phase: I/II

Title: STAR Ph1/2 MRTX849 Solids KRAS G12C View

Description: A Phase 1/2 Multiple Expansion Cohort Trial of MRTX849 in Patients with Advanced Solid Tumors with KRAS G12C Mutation (849-001)

Indication: Gall Bladder Cancer

Location: Texas Oncology-Arlington Cancer Center North

Phase: I/II

Title: STAR Sitra+Nivo/Pembro+Enfor Adv/Met Uro View

Description: A Phase 2 Study of Sitravatinib in Combination with PD-(L)1 Checkpoint Inhibitor Regimens in Patients With Advanced or Metastatic Urothelial Carcinoma (516-003)

Indication: Bladder Cancer

Location: Texas Oncology-Arlington Cancer Center North

Phase: II

Title: STAR Sitra+Nivo/Pembro+Enfor Adv/Met Uro View

Description: A Phase 2 Study of Sitravatinib in Combination with PD-(L)1 Checkpoint Inhibitor Regimens in Patients With Advanced or Metastatic Urothelial Carcinoma (516-003)

Indication: Urothelial Cancer

Location: Texas Oncology-Arlington Cancer Center North

Phase: II

Title: STAR BV in pts w/1L cHL or PTCL View

Description: (SGN35-015) A phase 2 open-label study of brentuximab vedotin in front-line therapy of Hodgkin lymphoma (HL) and CD30-expressing peripheral T-cell lymphoma (PTCL) in older patients or patients with significant comorbidities ineligible for standard chemotherapy

Indication: Lymphomas

Location: Texas Oncology-Arlington Cancer Center North

Phase: II

Texas Oncology-Arlington South

Title: STAR Ph2 Seribantumab NRG1 Fusion+ ST View

Description: CRESTONE: A Phase 2 Study of Seribantumab in Adult Patients with Neuregulin-1 (NRG1) Fusion Positive Locally Advanced or Metastatic Solid Tumors (ELVCAP-001-01)

Indication: Solid Tumors

Location: Texas Oncology-Arlington South

Phase: II

Title: STAR Ph2 Basket Tucat+Tras ST HER2 Alt View

Description: A Phase 2 Basket Study of Tucatinib in Combination with Trastuzumab in Subjects with Previously Treated Locally-Advanced Unresectable or Metastatic Solid Tumors Driven by HER2 Alterations (SGNTUC-019)

Indication: Biliary Cancer

Location: Texas Oncology-Arlington South

Phase: II

Title: STAR Ph2 Basket Tucat+Tras ST HER2 Alt View

Description: A Phase 2 Basket Study of Tucatinib in Combination with Trastuzumab in Subjects with Previously Treated Locally-Advanced Unresectable or Metastatic Solid Tumors Driven by HER2 Alterations (SGNTUC-019)

Indication: Breast Cancer

Location: Texas Oncology-Arlington South

Phase: II

Title: STAR Ph2 Basket Tucat+Tras ST HER2 Alt View

Description: A Phase 2 Basket Study of Tucatinib in Combination with Trastuzumab in Subjects with Previously Treated Locally-Advanced Unresectable or Metastatic Solid Tumors Driven by HER2 Alterations (SGNTUC-019)

Indication: Cervical Cancer

Location: Texas Oncology-Arlington South

Phase: II

Title: STAR Ph2 Basket Tucat+Tras ST HER2 Alt View

Description: A Phase 2 Basket Study of Tucatinib in Combination with Trastuzumab in Subjects with Previously Treated Locally-Advanced Unresectable or Metastatic Solid Tumors Driven by HER2 Alterations (SGNTUC-019)

Indication: Gall Bladder Cancer

Location: Texas Oncology-Arlington South

Phase: II

Title: STAR Ph2 Basket Tucat+Tras ST HER2 Alt View

Description: A Phase 2 Basket Study of Tucatinib in Combination with Trastuzumab in Subjects with Previously Treated Locally-Advanced Unresectable or Metastatic Solid Tumors Driven by HER2 Alterations (SGNTUC-019)

Indication: Lung Cancer

Location: Texas Oncology-Arlington South

Phase: II

Title: STAR Ph2 Basket Tucat+Tras ST HER2 Alt View

Description: A Phase 2 Basket Study of Tucatinib in Combination with Trastuzumab in Subjects with Previously Treated Locally-Advanced Unresectable or Metastatic Solid Tumors Driven by HER2 Alterations (SGNTUC-019)

Indication: Solid Tumors

Location: Texas Oncology-Arlington South

Phase: II

Title: STAR Ph2 Basket Tucat+Tras ST HER2 Alt View

Description: A Phase 2 Basket Study of Tucatinib in Combination with Trastuzumab in Subjects with Previously Treated Locally-Advanced Unresectable or Metastatic Solid Tumors Driven by HER2 Alterations (SGNTUC-019)

Indication: Urothelial Cancer

Location: Texas Oncology-Arlington South

Phase: II

Title: STAR Ph2 Basket Tucat+Tras ST HER2 Alt View

Description: A Phase 2 Basket Study of Tucatinib in Combination with Trastuzumab in Subjects with Previously Treated Locally-Advanced Unresectable or Metastatic Solid Tumors Driven by HER2 Alterations (SGNTUC-019)

Indication: Uterine Cancer

Location: Texas Oncology-Arlington South

Phase: II

Title: STAR Ph3 61186372 Osim Lazert EGFR NSCLC View

Description: A Phase 3 Randomized Study of Amivantamab and Lazertinib Combination Therapy Versus Osimertinib Versus Lazertinib as First-Line Treatment in Patients with EGFR-Mutated Locally Advanced or Metastatic Non-Small Cell Lung Cancer (73841937NSC3003)MARIPOSA

Indication: Lung Cancer

Location: Texas Oncology-Arlington South

Phase: III

Title: STAR PH3 JNJ-61186372 Peme EGFR NSCLC View

Description: A Randomized Open-label Phase 3 Study of Combination Amivantamab and Carboplatin-Pemetrexed Therapy Compared with Carboplatin-Pemetrexed in Patients with EGFR Exon 20ins Mutated Locally Advanced or Metastatic Non-Small Cell Lung Cancer (61186372NSC3001)

Indication: Lung Cancer

Location: Texas Oncology-Arlington South

Phase: III

Title: STAR PH3 Nirap Abira HRR mCSPC View

Description: A Phase 3 Randomized Placebo-controlled Double-blind Study of Niraparib in Combination with Abiraterone Acetate and Prednisone Versus Abiraterone Acetate and Prednisone for the Treatment of Participants with Deleterious Germline or Somatic Homologous Recombination Repair (HRR) Gene-Mutated Metastatic Castration-Sensitive Prostate Cancer (mCSPC)(67652000PCR3002)

Indication: Prostate Cancer

Location: Texas Oncology-Arlington South

Phase: III

Title: STAR Ph2 Ak104 Cervical Cancer View

Description: A Phase 2 multicenter single-arm open-label study to evaluate the efficacy and safety of AK104 in subjects with recurrent or metastatic cervical cancer (AK104-201-AU)

Indication: Cervical Cancer

Location: Texas Oncology-Arlington South

Phase: II

Title: STAR PH2 Tuca+ Tras HER2+ CC View

Description: MOUNTAINEER: A Phase 2 Open Label Study of Tucatinib Combined with Trastuzumab in Patients with HER2+ Metastatic Colorectal Cancer (ACCRU-GI-1617 SGNTUC-017)

Indication: Colon Cancer

Location: Texas Oncology-Arlington South

Phase: II

Title: STAR PH2 Tuca+ Tras HER2+ CC View

Description: MOUNTAINEER: A Phase 2 Open Label Study of Tucatinib Combined with Trastuzumab in Patients with HER2+ Metastatic Colorectal Cancer (ACCRU-GI-1617 SGNTUC-017)

Indication: Rectal Cancer

Location: Texas Oncology-Arlington South

Phase: II

Title: STAR Ph3 Carbo/Pac NCMGA00012 MSCC View

Description: A Phase 3 Global Multicenter Double-Blind Randomized Study of Carboplatin-Paclitaxel With INCMGA00012 or Placebo in Participants With Inoperable Locally Recurrent or Metastatic Squamous Cell Carcinoma of the Anal Canal Not Previously Treated With Systemic Chemotherapy (POD1UM-303/InterAACT 2) (INCMGA 0012-303)

Indication: Anal Cancer

Location: Texas Oncology-Arlington South

Phase: III

Title: STAR Ph3 Carbo/Pac NCMGA00012 MSCC View

Description: A Phase 3 Global Multicenter Double-Blind Randomized Study of Carboplatin-Paclitaxel With INCMGA00012 or Placebo in Participants With Inoperable Locally Recurrent or Metastatic Squamous Cell Carcinoma of the Anal Canal Not Previously Treated With Systemic Chemotherapy (POD1UM-303/InterAACT 2) (INCMGA 0012-303)

Indication: Carcinoid

Location: Texas Oncology-Arlington South

Phase: III

Title: STAR Ph3 Sinti vs Placebo ESCC View

Description: A Multicenter Double-Blind Randomized Phase III Clinical Trial Evaluating the Efficacy and Safety of Sintilimab vs. Placebo in Combination with Chemotherapy for First-Line Treatment of Unresectable Locally Advanced Recurrent or Metastatic Esophageal Squamous Cell Carcinoma (ORIENT-15)CIBI308A301

Indication: Esophageal Cancer

Location: Texas Oncology-Arlington South

Phase: III

Title: STAR Ph3 Navi Ruxo Myelofibrosis View

Description: M16-191: A Randomized Double-Blind Placebo-Controlled Phase 3 Study of Navitoclax in Combination with Ruxolitinib versus Ruxolitinib in Subjects with Myelofibrosis (TRANSFORM-1)

Indication: Myelofibrosis

Location: Texas Oncology-Arlington South

Phase: III

Title: STAR PH 2 Enfortumab in Urothelial Pts View

Description: A study of enfortumab vedotin (ASG-22CE) as monotherapy or in combination with other anticancer therapies for the treatment of urothelial cancer (SGN22E-002)

Indication: Bladder Cancer

Location: Texas Oncology-Arlington South

Phase: I/II

Title: STAR PH 2 Enfortumab in Urothelial Pts View

Description: A study of enfortumab vedotin (ASG-22CE) as monotherapy or in combination with other anticancer therapies for the treatment of urothelial cancer (SGN22E-002)

Indication: Urothelial Cancer

Location: Texas Oncology-Arlington South

Phase: I/II

Title: STAR KEAP1/NRF2 NSCLC View

Description: CX-839-014 "KEAPSAKE": A Phase 2 Randomized Multicenter Double-blind Study of the Glutaminase Inhibitor Telaglenastat with Pembrolizumab and Chemotherapy versus Placebo with Pembrolizumab and Chemotherapy in First-line Metastatic KEAP1/NRF2-mutated Nonsquamous Non-Small Cell Lung Cancer (NSCLC)

Indication: Lung Cancer

Location: Texas Oncology-Arlington South

Phase: II

Title: STAR-PH3 pral(Blu-667) RET-fusion mNSCLC View

Description: A Randomized Open-Label Phase 3 Study of Pralsetinib versus Standard of Care for First Line Treatment of RET fusion-positive Metastatic Non-Small Cell Lung Cancer (BLU-667-2303)

Indication: Lung Cancer

Location: Texas Oncology-Arlington South

Phase: III

Title: STAR PH3 Pacritinib vs MD choice in MF View

Description: A Randomized Controlled Phase 3 Study of Pacritinib Versus Physician's Choice in Patients with Primary Myelofibrosis Post Polycythemia Vera Myelofibrosis or Post-Essential Thrombocythemia Myelofibrosis with Severe Thrombocytopenia (Platelets Counts <50000/µL) (PAC203)

Indication: Essential Thrombocythemia

Location: Texas Oncology-Arlington South

Phase: III

Title: STAR PH3 Pacritinib vs MD choice in MF View

Description: A Randomized Controlled Phase 3 Study of Pacritinib Versus Physician's Choice in Patients with Primary Myelofibrosis Post Polycythemia Vera Myelofibrosis or Post-Essential Thrombocythemia Myelofibrosis with Severe Thrombocytopenia (Platelets Counts <50000/µL) (PAC203)

Indication: Myelofibrosis

Location: Texas Oncology-Arlington South

Phase: III

Title: STAR Ph2 Erdafitinib FGFR Solid Tumors View

Description: A Phase 2 Study of Erdafitinib in Subjects With Advanced Solid Tumors and FGFR Gene Alterations (42756493CAN2002)

Indication: Solid Tumors

Location: Texas Oncology-Arlington South

Phase: II

Title: STAR Ph1/2 MRTX849 Solids KRAS G12C View

Description: A Phase 1/2 Multiple Expansion Cohort Trial of MRTX849 in Patients with Advanced Solid Tumors with KRAS G12C Mutation (849-001)

Indication: Anal Cancer

Location: Texas Oncology-Arlington South

Phase: I/II

Title: STAR Ph1/2 MRTX849 Solids KRAS G12C View

Description: A Phase 1/2 Multiple Expansion Cohort Trial of MRTX849 in Patients with Advanced Solid Tumors with KRAS G12C Mutation (849-001)

Indication: Biliary Cancer

Location: Texas Oncology-Arlington South

Phase: I/II

Title: STAR Ph1/2 MRTX849 Solids KRAS G12C View

Description: A Phase 1/2 Multiple Expansion Cohort Trial of MRTX849 in Patients with Advanced Solid Tumors with KRAS G12C Mutation (849-001)

Indication: Bladder Cancer

Location: Texas Oncology-Arlington South

Phase: I/II

Title: STAR Ph1/2 MRTX849 Solids KRAS G12C View

Description: A Phase 1/2 Multiple Expansion Cohort Trial of MRTX849 in Patients with Advanced Solid Tumors with KRAS G12C Mutation (849-001)

Indication: Bone Mets

Location: Texas Oncology-Arlington South

Phase: I/II

Title: STAR Ph1/2 MRTX849 Solids KRAS G12C View

Description: A Phase 1/2 Multiple Expansion Cohort Trial of MRTX849 in Patients with Advanced Solid Tumors with KRAS G12C Mutation (849-001)

Indication: Brain Cancer

Location: Texas Oncology-Arlington South

Phase: I/II

Title: STAR Ph1/2 MRTX849 Solids KRAS G12C View

Description: A Phase 1/2 Multiple Expansion Cohort Trial of MRTX849 in Patients with Advanced Solid Tumors with KRAS G12C Mutation (849-001)

Indication: Breast Cancer

Location: Texas Oncology-Arlington South

Phase: I/II

Title: STAR Ph1/2 MRTX849 Solids KRAS G12C View

Description: A Phase 1/2 Multiple Expansion Cohort Trial of MRTX849 in Patients with Advanced Solid Tumors with KRAS G12C Mutation (849-001)

Indication: Urothelial Cancer

Location: Texas Oncology-Arlington South

Phase: I/II

Title: STAR Ph1/2 MRTX849 Solids KRAS G12C View

Description: A Phase 1/2 Multiple Expansion Cohort Trial of MRTX849 in Patients with Advanced Solid Tumors with KRAS G12C Mutation (849-001)

Indication: Uterine Cancer

Location: Texas Oncology-Arlington South

Phase: I/II

Title: STAR Ph1/2 MRTX849 Solids KRAS G12C View

Description: A Phase 1/2 Multiple Expansion Cohort Trial of MRTX849 in Patients with Advanced Solid Tumors with KRAS G12C Mutation (849-001)

Indication: Vaginal Cancer

Location: Texas Oncology-Arlington South

Phase: I/II

Title: STAR Ph1/2 MRTX849 Solids KRAS G12C View

Description: A Phase 1/2 Multiple Expansion Cohort Trial of MRTX849 in Patients with Advanced Solid Tumors with KRAS G12C Mutation (849-001)

Indication: Vulvar Cancer

Location: Texas Oncology-Arlington South

Phase: I/II

Title: STAR Ph1/2 MRTX849 Solids KRAS G12C View

Description: A Phase 1/2 Multiple Expansion Cohort Trial of MRTX849 in Patients with Advanced Solid Tumors with KRAS G12C Mutation (849-001)

Indication: Rectal Cancer

Location: Texas Oncology-Arlington South

Phase: I/II

Title: STAR Ph1/2 MRTX849 Solids KRAS G12C View

Description: A Phase 1/2 Multiple Expansion Cohort Trial of MRTX849 in Patients with Advanced Solid Tumors with KRAS G12C Mutation (849-001)

Indication: Renal Cancer

Location: Texas Oncology-Arlington South

Phase: I/II

Title: STAR Ph1/2 MRTX849 Solids KRAS G12C View

Description: A Phase 1/2 Multiple Expansion Cohort Trial of MRTX849 in Patients with Advanced Solid Tumors with KRAS G12C Mutation (849-001)

Indication: Sarcoma

Location: Texas Oncology-Arlington South

Phase: I/II

Title: STAR Ph1/2 MRTX849 Solids KRAS G12C View

Description: A Phase 1/2 Multiple Expansion Cohort Trial of MRTX849 in Patients with Advanced Solid Tumors with KRAS G12C Mutation (849-001)

Indication: Solid Tumors

Location: Texas Oncology-Arlington South

Phase: I/II

Title: STAR Ph1/2 MRTX849 Solids KRAS G12C View

Description: A Phase 1/2 Multiple Expansion Cohort Trial of MRTX849 in Patients with Advanced Solid Tumors with KRAS G12C Mutation (849-001)

Indication: Testicular Cancer

Location: Texas Oncology-Arlington South

Phase: I/II

Title: STAR Ph1/2 MRTX849 Solids KRAS G12C View

Description: A Phase 1/2 Multiple Expansion Cohort Trial of MRTX849 in Patients with Advanced Solid Tumors with KRAS G12C Mutation (849-001)

Indication: Thyroid Cancer

Location: Texas Oncology-Arlington South

Phase: I/II

Title: STAR Ph1/2 MRTX849 Solids KRAS G12C View

Description: A Phase 1/2 Multiple Expansion Cohort Trial of MRTX849 in Patients with Advanced Solid Tumors with KRAS G12C Mutation (849-001)

Indication: Malignant Adenoma

Location: Texas Oncology-Arlington South

Phase: I/II

Title: STAR Ph1/2 MRTX849 Solids KRAS G12C View

Description: A Phase 1/2 Multiple Expansion Cohort Trial of MRTX849 in Patients with Advanced Solid Tumors with KRAS G12C Mutation (849-001)

Indication: Ovarian Cancer

Location: Texas Oncology-Arlington South

Phase: I/II

Title: STAR Ph1/2 MRTX849 Solids KRAS G12C View

Description: A Phase 1/2 Multiple Expansion Cohort Trial of MRTX849 in Patients with Advanced Solid Tumors with KRAS G12C Mutation (849-001)

Indication: Pancreatic Cancer

Location: Texas Oncology-Arlington South

Phase: I/II

Title: STAR Ph1/2 MRTX849 Solids KRAS G12C View

Description: A Phase 1/2 Multiple Expansion Cohort Trial of MRTX849 in Patients with Advanced Solid Tumors with KRAS G12C Mutation (849-001)

Indication: Penile Cancer

Location: Texas Oncology-Arlington South

Phase: I/II

Title: STAR Ph1/2 MRTX849 Solids KRAS G12C View

Description: A Phase 1/2 Multiple Expansion Cohort Trial of MRTX849 in Patients with Advanced Solid Tumors with KRAS G12C Mutation (849-001)

Indication: Peritoneal Cancer

Location: Texas Oncology-Arlington South

Phase: I/II

Title: STAR Ph1/2 MRTX849 Solids KRAS G12C View

Description: A Phase 1/2 Multiple Expansion Cohort Trial of MRTX849 in Patients with Advanced Solid Tumors with KRAS G12C Mutation (849-001)

Indication: Prostate Cancer

Location: Texas Oncology-Arlington South

Phase: I/II

Title: STAR Ph1/2 MRTX849 Solids KRAS G12C View

Description: A Phase 1/2 Multiple Expansion Cohort Trial of MRTX849 in Patients with Advanced Solid Tumors with KRAS G12C Mutation (849-001)

Indication: Gastric Cancer

Location: Texas Oncology-Arlington South

Phase: I/II

Title: STAR Ph1/2 MRTX849 Solids KRAS G12C View

Description: A Phase 1/2 Multiple Expansion Cohort Trial of MRTX849 in Patients with Advanced Solid Tumors with KRAS G12C Mutation (849-001)

Indication: Head and Neck Cancer

Location: Texas Oncology-Arlington South

Phase: I/II

Title: STAR Ph1/2 MRTX849 Solids KRAS G12C View

Description: A Phase 1/2 Multiple Expansion Cohort Trial of MRTX849 in Patients with Advanced Solid Tumors with KRAS G12C Mutation (849-001)

Indication: Kaposi's Sarcoma

Location: Texas Oncology-Arlington South

Phase: I/II

Title: STAR Ph1/2 MRTX849 Solids KRAS G12C View

Description: A Phase 1/2 Multiple Expansion Cohort Trial of MRTX849 in Patients with Advanced Solid Tumors with KRAS G12C Mutation (849-001)

Indication: Kidney Cancer

Location: Texas Oncology-Arlington South

Phase: I/II

Title: STAR Ph1/2 MRTX849 Solids KRAS G12C View

Description: A Phase 1/2 Multiple Expansion Cohort Trial of MRTX849 in Patients with Advanced Solid Tumors with KRAS G12C Mutation (849-001)

Indication: Liver Cancer

Location: Texas Oncology-Arlington South

Phase: I/II

Title: STAR Ph1/2 MRTX849 Solids KRAS G12C View

Description: A Phase 1/2 Multiple Expansion Cohort Trial of MRTX849 in Patients with Advanced Solid Tumors with KRAS G12C Mutation (849-001)

Indication: Lung Cancer

Location: Texas Oncology-Arlington South

Phase: I/II

Title: STAR Ph1/2 MRTX849 Solids KRAS G12C View

Description: A Phase 1/2 Multiple Expansion Cohort Trial of MRTX849 in Patients with Advanced Solid Tumors with KRAS G12C Mutation (849-001)

Indication: Cervical Cancer

Location: Texas Oncology-Arlington South

Phase: I/II

Title: STAR Ph1/2 MRTX849 Solids KRAS G12C View

Description: A Phase 1/2 Multiple Expansion Cohort Trial of MRTX849 in Patients with Advanced Solid Tumors with KRAS G12C Mutation (849-001)

Indication: Colon Cancer

Location: Texas Oncology-Arlington South

Phase: I/II

Title: STAR Ph1/2 MRTX849 Solids KRAS G12C View

Description: A Phase 1/2 Multiple Expansion Cohort Trial of MRTX849 in Patients with Advanced Solid Tumors with KRAS G12C Mutation (849-001)

Indication: Endometrial Cancer

Location: Texas Oncology-Arlington South

Phase: I/II

Title: STAR Ph1/2 MRTX849 Solids KRAS G12C View

Description: A Phase 1/2 Multiple Expansion Cohort Trial of MRTX849 in Patients with Advanced Solid Tumors with KRAS G12C Mutation (849-001)

Indication: Esophageal Cancer

Location: Texas Oncology-Arlington South

Phase: I/II

Title: STAR Ph1/2 MRTX849 Solids KRAS G12C View

Description: A Phase 1/2 Multiple Expansion Cohort Trial of MRTX849 in Patients with Advanced Solid Tumors with KRAS G12C Mutation (849-001)

Indication: Fallopian Tube Cancer

Location: Texas Oncology-Arlington South

Phase: I/II

Title: STAR Ph1/2 MRTX849 Solids KRAS G12C View

Description: A Phase 1/2 Multiple Expansion Cohort Trial of MRTX849 in Patients with Advanced Solid Tumors with KRAS G12C Mutation (849-001)

Indication: Gall Bladder Cancer

Location: Texas Oncology-Arlington South

Phase: I/II

Title: STAR Ph 3 Tuca/Placbo + T-DM1 HER2+ View

Description: STAR: Randomized double-blind phase 3 study of tucatinib or placebo in combination with ado-trastuzumab emtansine (T-DM1) for subjects with unresectable locally-advanced or metastatic HER2+ breast cancer (HER2CLIMB-02)(SGNTUC-016)

Indication: Breast Cancer

Location: Texas Oncology-Arlington South

Phase: III

Title: STAR Ph2 Pemigatinib Solids FGFR View

Description: (INCB 54828-207) A Phase 2 Open-Label Single-Arm Multicenter Study to Evaluate the Efficacy and Safety of Pemigatinib in Participants With Previously Treated Locally Advanced/Metastatic or Surgically Unresectable Solid Tumor Malignancies Harboring Activating FGFR Mutations or Translocations (FIGHT-207)

Indication: Solid Tumors

Location: Texas Oncology-Arlington South

Phase: II

Title: STAR Infigratinib vs Gem/Cis Cholangio View

Description: A Phase 3 Multicenter Open-Label Randomized Controlled Study of Oral Infigratinib versus Gemcitabine with Cisplatin in Subjects with Advanced/Metastatic or Inoperable Cholangiocarcinoma with FGFR2 Gene Fusions/Translocations: The PROOF Trial (QBGJ398-301)

Indication: Biliary Cancer

Location: Texas Oncology-Arlington South

Phase: III

Title: STAR Ph3 ALK+ mNSCLC (Brigatinib-3001) View

Description: Brigatinib-3001- A Phase 3 Randomized Open-label Study of Brigatinib (ALUNBRIG®)Versus Alectinib (ALECENSA®) in Advanced Anaplastic Lymphoma Kinase-Positive Non-Small-Cell Lung Cancer Patients Who Have Progressed on Crizotinib (XALKORI®)

Indication: Lung Cancer

Location: Texas Oncology-Arlington South

Phase: III

Title: STAR Ph3 Nirap+Abirat+Pred mCRPC View

Description: A Phase 3 Randomized Placebo-controlled Double-blind Study of Niraparib in Combination with Abiraterone Acetate and Prednisone Versus Abiraterone Acetate and Prednisone for Treatment of Subjects with Metastatic Prostate Cancer(64091742PCR3001)

Indication: Prostate Cancer

Location: Texas Oncology-Arlington South

Phase: III

Title: STAR Ph1/2 BLU667 thy NSCLC Sol tum View

Description: A Phase 1/2 Study of the Highly-selective RET Inhibitor BLU-667 in Patients with Thyroid Cancer Non-Small Cell Lung Cancer (NSCLC) and Other Advanced Solid Tumors (BLU-667-1101)

Indication: Lung Cancer

Location: Texas Oncology-Arlington South

Phase: I/II

Title: STAR Ph1/2 BLU667 thy NSCLC Sol tum View

Description: A Phase 1/2 Study of the Highly-selective RET Inhibitor BLU-667 in Patients with Thyroid Cancer Non-Small Cell Lung Cancer (NSCLC) and Other Advanced Solid Tumors (BLU-667-1101)

Indication: Solid Tumors

Location: Texas Oncology-Arlington South

Phase: I/II

Title: STAR Ph1/2 BLU667 thy NSCLC Sol tum View

Description: A Phase 1/2 Study of the Highly-selective RET Inhibitor BLU-667 in Patients with Thyroid Cancer Non-Small Cell Lung Cancer (NSCLC) and Other Advanced Solid Tumors (BLU-667-1101)

Indication: Thyroid Cancer

Location: Texas Oncology-Arlington South

Phase: I/II

Title: STAR Sitra+Nivo/Pembro+Enfor Adv/Met Uro View

Description: A Phase 2 Study of Sitravatinib in Combination with PD-(L)1 Checkpoint Inhibitor Regimens in Patients With Advanced or Metastatic Urothelial Carcinoma (516-003)

Indication: Bladder Cancer

Location: Texas Oncology-Arlington South

Phase: II

Title: STAR Sitra+Nivo/Pembro+Enfor Adv/Met Uro View

Description: A Phase 2 Study of Sitravatinib in Combination with PD-(L)1 Checkpoint Inhibitor Regimens in Patients With Advanced or Metastatic Urothelial Carcinoma (516-003)

Indication: Urothelial Cancer

Location: Texas Oncology-Arlington South

Phase: II

Title: STAR Ph1 CX-4945 Basal Cell Carcinoma View

Description: A Phase I Multi-Center Open-Label Treatment Duration Increment Expansion Safety and Pharmacodynamic Study of CX-4945 Administered Orally Twice Daily to Patients with Advanced Basal Cell Carcinoma (CX-4945-07)

Indication: Skin Cancer

Location: Texas Oncology-Arlington South

Phase: I

Title: STAR Ph3 FGFR erdafitinib urothelial View

Description: (42756493BLC3001) A Phase 3 Study of Erdafitinib Compared with Vinflunine or Docetaxel or Pembrolizumab in Subjects with Advanced Urothelial Cancer and Selected FGFR Gene Aberrations (THOR)

Indication: Urothelial Cancer

Location: Texas Oncology-Arlington South

Phase: III

Title: STAR Rucaparib v PhysC mCRPC (TRITON3) View

Description: TRITON3: A Multicenter Randomized Open-label Phase 3 Study of Rucaparib versus Physician's Choice of Therapy for Patients withMetastatic Castration-resistant Prostate Cancer Associated withHomologous Recombination Deficiency (CO-338-063)

Indication: Prostate Cancer

Location: Texas Oncology-Arlington South

Phase: III

Title: STAR BV in pts w/1L cHL or PTCL View

Description: (SGN35-015) A phase 2 open-label study of brentuximab vedotin in front-line therapy of Hodgkin lymphoma (HL) and CD30-expressing peripheral T-cell lymphoma (PTCL) in older patients or patients with significant comorbidities ineligible for standard chemotherapy

Indication: Lymphomas

Location: Texas Oncology-Arlington South

Phase: II

Title: LUNAR: Pivotal, Randomized, Open-label Study of Tumor Treating Fields (TTFields) Concurrent With Standard of Care Therapies for Treatment of Stage 4 Non-small Cell Lung Cancer (NSCLC) Following Platinum Failure View

Indication: Lung Cancer

Location: Texas Oncology-Arlington South

Phase: III

Texas Oncology-Bedford

Title: STAR BV in pts w/1L cHL or PTCL View

Description: (SGN35-015) A phase 2 open-label study of brentuximab vedotin in front-line therapy of Hodgkin lymphoma (HL) and CD30-expressing peripheral T-cell lymphoma (PTCL) in older patients or patients with significant comorbidities ineligible for standard chemotherapy

Indication: Lymphomas

Location: Texas Oncology-Bedford

Phase: II

Title: STAR Ublituximab+TGR-1202 Cross-over View

Description: (UTX-TGR-204) A Multi-Center Open-Label Compassionate Use Extension Study of Ublituximab (TG-1101) in Combination with Umbralisib (TGR-1202) for Patients Previously Enrolled in Protocol UTX-TGR-304

Indication: Leukemia

Location: Texas Oncology-Bedford

Phase: II

Title: STAR Rucaparib v PhysC mCRPC (TRITON3) View

Description: TRITON3: A Multicenter Randomized Open-label Phase 3 Study of Rucaparib versus Physician's Choice of Therapy for Patients withMetastatic Castration-resistant Prostate Cancer Associated withHomologous Recombination Deficiency (CO-338-063)

Indication: Prostate Cancer

Location: Texas Oncology-Bedford

Phase: III

Title: FLEX Registry: Evaluate New Gene Express View

Description: MammaPrint BluePrint and Full-genome Data Linked with Clinical Data to Evaluate New Gene EXpression Profiles: An Adaptable Registry (FLEX Registry)

Indication: Breast Cancer

Location: Texas Oncology-Bedford

Title: STAR Ph3 FGFR erdafitinib urothelial View

Description: (42756493BLC3001) A Phase 3 Study of Erdafitinib Compared with Vinflunine or Docetaxel or Pembrolizumab in Subjects with Advanced Urothelial Cancer and Selected FGFR Gene Aberrations (THOR)

Indication: Urothelial Cancer

Location: Texas Oncology-Bedford

Phase: III

Title: PANOVA-3: 1L Gemcit + nab-pac pancreatic View

Description: PANOVA-3: Pivotal randomized open-label study of Tumor Treating Fields (TTFields 150kHz) concomitant with gemcitabine and nab-paclitaxel for front-line treatment of locally-advanced pancreatic adenocarcinoma (EF-27)

Indication: Pancreatic Cancer

Location: Texas Oncology-Bedford

Phase: III

Title: STAR Ph1 CX-4945 Basal Cell Carcinoma View

Description: A Phase I Multi-Center Open-Label Treatment Duration Increment Expansion Safety and Pharmacodynamic Study of CX-4945 Administered Orally Twice Daily to Patients with Advanced Basal Cell Carcinoma (CX-4945-07)

Indication: Skin Cancer

Location: Texas Oncology-Bedford

Phase: I

Title: STAR Ph1/2 BLU667 thy NSCLC Sol tum View

Description: A Phase 1/2 Study of the Highly-selective RET Inhibitor BLU-667 in Patients with Thyroid Cancer Non-Small Cell Lung Cancer (NSCLC) and Other Advanced Solid Tumors (BLU-667-1101)

Indication: Lung Cancer

Location: Texas Oncology-Bedford

Phase: I/II

Title: STAR Ph1/2 BLU667 thy NSCLC Sol tum View

Description: A Phase 1/2 Study of the Highly-selective RET Inhibitor BLU-667 in Patients with Thyroid Cancer Non-Small Cell Lung Cancer (NSCLC) and Other Advanced Solid Tumors (BLU-667-1101)

Indication: Solid Tumors

Location: Texas Oncology-Bedford

Phase: I/II

Title: STAR Ph1/2 BLU667 thy NSCLC Sol tum View

Description: A Phase 1/2 Study of the Highly-selective RET Inhibitor BLU-667 in Patients with Thyroid Cancer Non-Small Cell Lung Cancer (NSCLC) and Other Advanced Solid Tumors (BLU-667-1101)

Indication: Thyroid Cancer

Location: Texas Oncology-Bedford

Phase: I/II

Title: STAR Sitra+Nivo/Pembro+Enfor Adv/Met Uro View

Description: A Phase 2 Study of Sitravatinib in Combination with PD-(L)1 Checkpoint Inhibitor Regimens in Patients With Advanced or Metastatic Urothelial Carcinoma (516-003)

Indication: Bladder Cancer

Location: Texas Oncology-Bedford

Phase: II

Title: STAR Sitra+Nivo/Pembro+Enfor Adv/Met Uro View

Description: A Phase 2 Study of Sitravatinib in Combination with PD-(L)1 Checkpoint Inhibitor Regimens in Patients With Advanced or Metastatic Urothelial Carcinoma (516-003)

Indication: Urothelial Cancer

Location: Texas Oncology-Bedford

Phase: II

Title: STAR Ph3 Nirap+Abirat+Pred mCRPC View

Description: A Phase 3 Randomized Placebo-controlled Double-blind Study of Niraparib in Combination with Abiraterone Acetate and Prednisone Versus Abiraterone Acetate and Prednisone for Treatment of Subjects with Metastatic Prostate Cancer(64091742PCR3001)

Indication: Prostate Cancer

Location: Texas Oncology-Bedford

Phase: III

Title: STAR Infigratinib vs Gem/Cis Cholangio View

Description: A Phase 3 Multicenter Open-Label Randomized Controlled Study of Oral Infigratinib versus Gemcitabine with Cisplatin in Subjects with Advanced/Metastatic or Inoperable Cholangiocarcinoma with FGFR2 Gene Fusions/Translocations: The PROOF Trial (QBGJ398-301)

Indication: Biliary Cancer

Location: Texas Oncology-Bedford

Phase: III

Title: Ph2 Cervical 2L (RaPiDS) View

Description: A Two-arm Randomized Non-comparative Phase 2 Trial of AGEN2034(anti-PD-1) as a Monotherapy or Combination Therapy with AGEN1884(anti-CTLA4) or with Placebo in Women with Recurrent Cervical Cancer(Second Line) - RaPiDS (C-750-01/GOG-3028)

Indication: Cervical Cancer

Location: Texas Oncology-Bedford

Phase: II

Title: STAR Ph2 Pemigatinib Solids FGFR View

Description: (INCB 54828-207) A Phase 2 Open-Label Single-Arm Multicenter Study to Evaluate the Efficacy and Safety of Pemigatinib in Participants With Previously Treated Locally Advanced/Metastatic or Surgically Unresectable Solid Tumor Malignancies Harboring Activating FGFR Mutations or Translocations (FIGHT-207)

Indication: Solid Tumors

Location: Texas Oncology-Bedford

Phase: II

Title: EAP BGB-3111 B-Cell Malig View

Description: A Single-Arm Expanded Access Study of Zanubrutinib (BGB-3111) in Patients with B-cell Malignancies (BGB-3111-216)

Indication: Lymphomas

Location: Texas Oncology-Bedford

Title: STAR Ph 3 Tuca/Placbo + T-DM1 HER2+ View

Description: STAR: Randomized double-blind phase 3 study of tucatinib or placebo in combination with ado-trastuzumab emtansine (T-DM1) for subjects with unresectable locally-advanced or metastatic HER2+ breast cancer (HER2CLIMB-02)(SGNTUC-016)

Indication: Breast Cancer

Location: Texas Oncology-Bedford

Phase: III

Title: Ph 3 Chemo+Atez/Placbo TNBC View

Description: A Randomized Double-Blind Phase III Clinical Trial of Neoadjuvant Chemotherapy with Atezolizumab or Placebo in Patients with Triple-Negative Breast Cancer Followed by Adjuvant Continuation of Atezolizumab or Placebo(NSABP B-59/GBG 96-GeparDouze).

Indication: Breast Cancer

Location: Texas Oncology-Bedford

Phase: III

Title: STAR Ph1/2 MRTX849 Solids KRAS G12C View

Description: A Phase 1/2 Multiple Expansion Cohort Trial of MRTX849 in Patients with Advanced Solid Tumors with KRAS G12C Mutation (849-001)

Indication: Anal Cancer

Location: Texas Oncology-Bedford

Phase: I/II

Title: STAR Ph1/2 MRTX849 Solids KRAS G12C View

Description: A Phase 1/2 Multiple Expansion Cohort Trial of MRTX849 in Patients with Advanced Solid Tumors with KRAS G12C Mutation (849-001)

Indication: Biliary Cancer

Location: Texas Oncology-Bedford

Phase: I/II

Title: STAR Ph1/2 MRTX849 Solids KRAS G12C View

Description: A Phase 1/2 Multiple Expansion Cohort Trial of MRTX849 in Patients with Advanced Solid Tumors with KRAS G12C Mutation (849-001)

Indication: Bladder Cancer

Location: Texas Oncology-Bedford

Phase: I/II

Title: STAR Ph1/2 MRTX849 Solids KRAS G12C View

Description: A Phase 1/2 Multiple Expansion Cohort Trial of MRTX849 in Patients with Advanced Solid Tumors with KRAS G12C Mutation (849-001)

Indication: Bone Mets

Location: Texas Oncology-Bedford

Phase: I/II

Title: STAR Ph1/2 MRTX849 Solids KRAS G12C View

Description: A Phase 1/2 Multiple Expansion Cohort Trial of MRTX849 in Patients with Advanced Solid Tumors with KRAS G12C Mutation (849-001)

Indication: Brain Cancer

Location: Texas Oncology-Bedford

Phase: I/II

Title: STAR Ph1/2 MRTX849 Solids KRAS G12C View

Description: A Phase 1/2 Multiple Expansion Cohort Trial of MRTX849 in Patients with Advanced Solid Tumors with KRAS G12C Mutation (849-001)

Indication: Breast Cancer

Location: Texas Oncology-Bedford

Phase: I/II

Title: STAR Ph1/2 MRTX849 Solids KRAS G12C View

Description: A Phase 1/2 Multiple Expansion Cohort Trial of MRTX849 in Patients with Advanced Solid Tumors with KRAS G12C Mutation (849-001)

Indication: Urothelial Cancer

Location: Texas Oncology-Bedford

Phase: I/II

Title: STAR Ph1/2 MRTX849 Solids KRAS G12C View

Description: A Phase 1/2 Multiple Expansion Cohort Trial of MRTX849 in Patients with Advanced Solid Tumors with KRAS G12C Mutation (849-001)

Indication: Uterine Cancer

Location: Texas Oncology-Bedford

Phase: I/II

Title: STAR Ph1/2 MRTX849 Solids KRAS G12C View

Description: A Phase 1/2 Multiple Expansion Cohort Trial of MRTX849 in Patients with Advanced Solid Tumors with KRAS G12C Mutation (849-001)

Indication: Vaginal Cancer

Location: Texas Oncology-Bedford

Phase: I/II

Title: STAR Ph1/2 MRTX849 Solids KRAS G12C View

Description: A Phase 1/2 Multiple Expansion Cohort Trial of MRTX849 in Patients with Advanced Solid Tumors with KRAS G12C Mutation (849-001)

Indication: Vulvar Cancer

Location: Texas Oncology-Bedford

Phase: I/II

Title: STAR Ph1/2 MRTX849 Solids KRAS G12C View

Description: A Phase 1/2 Multiple Expansion Cohort Trial of MRTX849 in Patients with Advanced Solid Tumors with KRAS G12C Mutation (849-001)

Indication: Rectal Cancer

Location: Texas Oncology-Bedford

Phase: I/II

Title: STAR Ph1/2 MRTX849 Solids KRAS G12C View

Description: A Phase 1/2 Multiple Expansion Cohort Trial of MRTX849 in Patients with Advanced Solid Tumors with KRAS G12C Mutation (849-001)

Indication: Renal Cancer

Location: Texas Oncology-Bedford

Phase: I/II

Title: STAR Ph1/2 MRTX849 Solids KRAS G12C View

Description: A Phase 1/2 Multiple Expansion Cohort Trial of MRTX849 in Patients with Advanced Solid Tumors with KRAS G12C Mutation (849-001)

Indication: Sarcoma

Location: Texas Oncology-Bedford

Phase: I/II

Title: STAR Ph1/2 MRTX849 Solids KRAS G12C View

Description: A Phase 1/2 Multiple Expansion Cohort Trial of MRTX849 in Patients with Advanced Solid Tumors with KRAS G12C Mutation (849-001)

Indication: Solid Tumors

Location: Texas Oncology-Bedford

Phase: I/II

Title: STAR Ph1/2 MRTX849 Solids KRAS G12C View

Description: A Phase 1/2 Multiple Expansion Cohort Trial of MRTX849 in Patients with Advanced Solid Tumors with KRAS G12C Mutation (849-001)

Indication: Testicular Cancer

Location: Texas Oncology-Bedford

Phase: I/II

Title: STAR Ph1/2 MRTX849 Solids KRAS G12C View

Description: A Phase 1/2 Multiple Expansion Cohort Trial of MRTX849 in Patients with Advanced Solid Tumors with KRAS G12C Mutation (849-001)

Indication: Thyroid Cancer

Location: Texas Oncology-Bedford

Phase: I/II

Title: STAR Ph1/2 MRTX849 Solids KRAS G12C View

Description: A Phase 1/2 Multiple Expansion Cohort Trial of MRTX849 in Patients with Advanced Solid Tumors with KRAS G12C Mutation (849-001)

Indication: Malignant Adenoma

Location: Texas Oncology-Bedford

Phase: I/II

Title: STAR Ph1/2 MRTX849 Solids KRAS G12C View

Description: A Phase 1/2 Multiple Expansion Cohort Trial of MRTX849 in Patients with Advanced Solid Tumors with KRAS G12C Mutation (849-001)

Indication: Ovarian Cancer

Location: Texas Oncology-Bedford

Phase: I/II

Title: STAR Ph1/2 MRTX849 Solids KRAS G12C View

Description: A Phase 1/2 Multiple Expansion Cohort Trial of MRTX849 in Patients with Advanced Solid Tumors with KRAS G12C Mutation (849-001)

Indication: Pancreatic Cancer

Location: Texas Oncology-Bedford

Phase: I/II

Title: STAR Ph1/2 MRTX849 Solids KRAS G12C View

Description: A Phase 1/2 Multiple Expansion Cohort Trial of MRTX849 in Patients with Advanced Solid Tumors with KRAS G12C Mutation (849-001)

Indication: Penile Cancer

Location: Texas Oncology-Bedford

Phase: I/II

Title: STAR Ph1/2 MRTX849 Solids KRAS G12C View

Description: A Phase 1/2 Multiple Expansion Cohort Trial of MRTX849 in Patients with Advanced Solid Tumors with KRAS G12C Mutation (849-001)

Indication: Peritoneal Cancer

Location: Texas Oncology-Bedford

Phase: I/II

Title: STAR Ph1/2 MRTX849 Solids KRAS G12C View

Description: A Phase 1/2 Multiple Expansion Cohort Trial of MRTX849 in Patients with Advanced Solid Tumors with KRAS G12C Mutation (849-001)

Indication: Prostate Cancer

Location: Texas Oncology-Bedford

Phase: I/II

Title: STAR Ph1/2 MRTX849 Solids KRAS G12C View

Description: A Phase 1/2 Multiple Expansion Cohort Trial of MRTX849 in Patients with Advanced Solid Tumors with KRAS G12C Mutation (849-001)

Indication: Gastric Cancer

Location: Texas Oncology-Bedford

Phase: I/II

Title: STAR Ph1/2 MRTX849 Solids KRAS G12C View

Description: A Phase 1/2 Multiple Expansion Cohort Trial of MRTX849 in Patients with Advanced Solid Tumors with KRAS G12C Mutation (849-001)

Indication: Head and Neck Cancer

Location: Texas Oncology-Bedford

Phase: I/II

Title: STAR Ph1/2 MRTX849 Solids KRAS G12C View

Description: A Phase 1/2 Multiple Expansion Cohort Trial of MRTX849 in Patients with Advanced Solid Tumors with KRAS G12C Mutation (849-001)

Indication: Kaposi's Sarcoma

Location: Texas Oncology-Bedford

Phase: I/II

Title: STAR Ph1/2 MRTX849 Solids KRAS G12C View

Description: A Phase 1/2 Multiple Expansion Cohort Trial of MRTX849 in Patients with Advanced Solid Tumors with KRAS G12C Mutation (849-001)

Indication: Kidney Cancer

Location: Texas Oncology-Bedford

Phase: I/II

Title: STAR Ph1/2 MRTX849 Solids KRAS G12C View

Description: A Phase 1/2 Multiple Expansion Cohort Trial of MRTX849 in Patients with Advanced Solid Tumors with KRAS G12C Mutation (849-001)

Indication: Liver Cancer

Location: Texas Oncology-Bedford

Phase: I/II

Title: STAR Ph1/2 MRTX849 Solids KRAS G12C View

Description: A Phase 1/2 Multiple Expansion Cohort Trial of MRTX849 in Patients with Advanced Solid Tumors with KRAS G12C Mutation (849-001)

Indication: Lung Cancer

Location: Texas Oncology-Bedford

Phase: I/II

Title: STAR Ph1/2 MRTX849 Solids KRAS G12C View

Description: A Phase 1/2 Multiple Expansion Cohort Trial of MRTX849 in Patients with Advanced Solid Tumors with KRAS G12C Mutation (849-001)

Indication: Cervical Cancer

Location: Texas Oncology-Bedford

Phase: I/II

Title: STAR Ph1/2 MRTX849 Solids KRAS G12C View

Description: A Phase 1/2 Multiple Expansion Cohort Trial of MRTX849 in Patients with Advanced Solid Tumors with KRAS G12C Mutation (849-001)

Indication: Colon Cancer

Location: Texas Oncology-Bedford

Phase: I/II

Title: STAR Ph1/2 MRTX849 Solids KRAS G12C View

Description: A Phase 1/2 Multiple Expansion Cohort Trial of MRTX849 in Patients with Advanced Solid Tumors with KRAS G12C Mutation (849-001)

Indication: Endometrial Cancer

Location: Texas Oncology-Bedford

Phase: I/II

Title: STAR Ph1/2 MRTX849 Solids KRAS G12C View

Description: A Phase 1/2 Multiple Expansion Cohort Trial of MRTX849 in Patients with Advanced Solid Tumors with KRAS G12C Mutation (849-001)

Indication: Esophageal Cancer

Location: Texas Oncology-Bedford

Phase: I/II

Title: STAR Ph1/2 MRTX849 Solids KRAS G12C View

Description: A Phase 1/2 Multiple Expansion Cohort Trial of MRTX849 in Patients with Advanced Solid Tumors with KRAS G12C Mutation (849-001)

Indication: Fallopian Tube Cancer

Location: Texas Oncology-Bedford

Phase: I/II

Title: STAR Ph1/2 MRTX849 Solids KRAS G12C View

Description: A Phase 1/2 Multiple Expansion Cohort Trial of MRTX849 in Patients with Advanced Solid Tumors with KRAS G12C Mutation (849-001)

Indication: Gall Bladder Cancer

Location: Texas Oncology-Bedford

Phase: I/II

Title: STAR Ph2 Erdafitinib FGFR Solid Tumors View

Description: A Phase 2 Study of Erdafitinib in Subjects With Advanced Solid Tumors and FGFR Gene Alterations (42756493CAN2002)

Indication: Solid Tumors

Location: Texas Oncology-Bedford

Phase: II

Title: PH3 AMG 510 vs Doce a/mNSCLC View

Description: 20190009: A Phase 3 Multicenter Randomized Open Label Active-controlled Study of AMG 510 Versus Docetaxel for the Treatment of Previously Treated Locally Advanced and Unresectable or Metastatic NSCLC Subjects with Mutated KRAS p.G12C

Indication: Lung Cancer

Location: Texas Oncology-Bedford

Phase: III

Title: STAR-PH3 pral(Blu-667) RET-fusion mNSCLC View

Description: A Randomized Open-Label Phase 3 Study of Pralsetinib versus Standard of Care for First Line Treatment of RET fusion-positive Metastatic Non-Small Cell Lung Cancer (BLU-667-2303)

Indication: Lung Cancer

Location: Texas Oncology-Bedford

Phase: III

Title: Ph 3 Chemo +/- Pembro/Olap EOC View

Description: A Randomized Phase 3 Double-Blind Study of Chemotherapy With or Without Pembrolizumab Followed by Maintenance With Olaparib or Placebo for the First-Line Treatment of BRCA non-mutated Advanced Epithelial Ovarian Cancer (EOC) (MK-7339-001/ENGOT-ov43/GOG-3036)

Indication: Ovarian Cancer

Location: Texas Oncology-Bedford

Phase: III

Title: STAR PH3 Pacritinib vs MD choice in MF View

Description: A Randomized Controlled Phase 3 Study of Pacritinib Versus Physician's Choice in Patients with Primary Myelofibrosis Post Polycythemia Vera Myelofibrosis or Post-Essential Thrombocythemia Myelofibrosis with Severe Thrombocytopenia (Platelets Counts <50000/µL) (PAC203)

Indication: Essential Thrombocythemia

Location: Texas Oncology-Bedford

Phase: III

Title: STAR PH3 Pacritinib vs MD choice in MF View

Description: A Randomized Controlled Phase 3 Study of Pacritinib Versus Physician's Choice in Patients with Primary Myelofibrosis Post Polycythemia Vera Myelofibrosis or Post-Essential Thrombocythemia Myelofibrosis with Severe Thrombocytopenia (Platelets Counts <50000/µL) (PAC203)

Indication: Myelofibrosis

Location: Texas Oncology-Bedford

Phase: III

Title: STAR KEAP1/NRF2 NSCLC View

Description: CX-839-014 "KEAPSAKE": A Phase 2 Randomized Multicenter Double-blind Study of the Glutaminase Inhibitor Telaglenastat with Pembrolizumab and Chemotherapy versus Placebo with Pembrolizumab and Chemotherapy in First-line Metastatic KEAP1/NRF2-mutated Nonsquamous Non-Small Cell Lung Cancer (NSCLC)

Indication: Lung Cancer

Location: Texas Oncology-Bedford

Phase: II

Title: PH3 Plac Carbo Pacil Dura +/- Olap DUO-E View

Description: D9311C00001; GOG-3041; ENGOT-EN10: A Randomised Multicentre Double-blind Placebo-controlled Phase III Study of First-line Carboplatin and Paclitaxel in Combination with Durvalumab Followed by Maintenance Durvalumab with or without Olaparib in Patients with Newly Diagnosed Advanced or Recurrent Endometrial Cancer (DUO-E)

Indication: Endometrial Cancer

Location: Texas Oncology-Bedford

Phase: III

Title: STAR PH 2 Enfortumab in Urothelial Pts View

Description: A study of enfortumab vedotin (ASG-22CE) as monotherapy or in combination with other anticancer therapies for the treatment of urothelial cancer (SGN22E-002)

Indication: Bladder Cancer

Location: Texas Oncology-Bedford

Phase: I/II

Title: STAR PH 2 Enfortumab in Urothelial Pts View

Description: A study of enfortumab vedotin (ASG-22CE) as monotherapy or in combination with other anticancer therapies for the treatment of urothelial cancer (SGN22E-002)

Indication: Urothelial Cancer

Location: Texas Oncology-Bedford

Phase: I/II

Title: STAR Ph3 Carbo/Pac NCMGA00012 MSCC View

Description: A Phase 3 Global Multicenter Double-Blind Randomized Study of Carboplatin-Paclitaxel With INCMGA00012 or Placebo in Participants With Inoperable Locally Recurrent or Metastatic Squamous Cell Carcinoma of the Anal Canal Not Previously Treated With Systemic Chemotherapy (POD1UM-303/InterAACT 2) (INCMGA 0012-303)

Indication: Anal Cancer

Location: Texas Oncology-Bedford

Phase: III

Title: STAR Ph3 Carbo/Pac NCMGA00012 MSCC View

Description: A Phase 3 Global Multicenter Double-Blind Randomized Study of Carboplatin-Paclitaxel With INCMGA00012 or Placebo in Participants With Inoperable Locally Recurrent or Metastatic Squamous Cell Carcinoma of the Anal Canal Not Previously Treated With Systemic Chemotherapy (POD1UM-303/InterAACT 2) (INCMGA 0012-303)

Indication: Carcinoid

Location: Texas Oncology-Bedford

Phase: III

Title: STAR PH2 Tuca+ Tras HER2+ CC View

Description: MOUNTAINEER: A Phase 2 Open Label Study of Tucatinib Combined with Trastuzumab in Patients with HER2+ Metastatic Colorectal Cancer (ACCRU-GI-1617 SGNTUC-017)

Indication: Colon Cancer

Location: Texas Oncology-Bedford

Phase: II

Title: STAR PH2 Tuca+ Tras HER2+ CC View

Description: MOUNTAINEER: A Phase 2 Open Label Study of Tucatinib Combined with Trastuzumab in Patients with HER2+ Metastatic Colorectal Cancer (ACCRU-GI-1617 SGNTUC-017)

Indication: Rectal Cancer

Location: Texas Oncology-Bedford

Phase: II

Title: STAR Ph2 Seribantumab NRG1 Fusion+ ST View

Description: CRESTONE: A Phase 2 Study of Seribantumab in Adult Patients with Neuregulin-1 (NRG1) Fusion Positive Locally Advanced or Metastatic Solid Tumors (ELVCAP-001-01)

Indication: Solid Tumors

Location: Texas Oncology-Bedford

Phase: II

Title: STAR PH3 Nirap Abira HRR mCSPC View

Description: A Phase 3 Randomized Placebo-controlled Double-blind Study of Niraparib in Combination with Abiraterone Acetate and Prednisone Versus Abiraterone Acetate and Prednisone for the Treatment of Participants with Deleterious Germline or Somatic Homologous Recombination Repair (HRR) Gene-Mutated Metastatic Castration-Sensitive Prostate Cancer (mCSPC)(67652000PCR3002)

Indication: Prostate Cancer

Location: Texas Oncology-Bedford

Phase: III

Title: STAR PH3 JNJ-61186372 Peme EGFR NSCLC View

Description: A Randomized Open-label Phase 3 Study of Combination Amivantamab and Carboplatin-Pemetrexed Therapy Compared with Carboplatin-Pemetrexed in Patients with EGFR Exon 20ins Mutated Locally Advanced or Metastatic Non-Small Cell Lung Cancer (61186372NSC3001)

Indication: Lung Cancer

Location: Texas Oncology-Bedford

Phase: III

Title: STAR Ph3 61186372 Osim Lazert EGFR NSCLC View

Description: A Phase 3 Randomized Study of Amivantamab and Lazertinib Combination Therapy Versus Osimertinib Versus Lazertinib as First-Line Treatment in Patients with EGFR-Mutated Locally Advanced or Metastatic Non-Small Cell Lung Cancer (73841937NSC3003)MARIPOSA

Indication: Lung Cancer

Location: Texas Oncology-Bedford

Phase: III

Title: STAR Ph3 61186372 Osim Lazert EGFR NSCLC View

Description: A Phase 3 Randomized Study of Amivantamab and Lazertinib Combination Therapy Versus Osimertinib Versus Lazertinib as First-Line Treatment in Patients with EGFR-Mutated Locally Advanced or Metastatic Non-Small Cell Lung Cancer (73841937NSC3003)MARIPOSA

Indication: Lung Cancer

Location: Texas Oncology-Bedford

Phase: III

Title: STAR Ph2 Basket Tucat+Tras ST HER2 Alt View

Description: A Phase 2 Basket Study of Tucatinib in Combination with Trastuzumab in Subjects with Previously Treated Locally-Advanced Unresectable or Metastatic Solid Tumors Driven by HER2 Alterations (SGNTUC-019)

Indication: Biliary Cancer

Location: Texas Oncology-Bedford

Phase: II

Title: STAR Ph2 Basket Tucat+Tras ST HER2 Alt View

Description: A Phase 2 Basket Study of Tucatinib in Combination with Trastuzumab in Subjects with Previously Treated Locally-Advanced Unresectable or Metastatic Solid Tumors Driven by HER2 Alterations (SGNTUC-019)

Indication: Breast Cancer

Location: Texas Oncology-Bedford

Phase: II

Title: STAR Ph2 Basket Tucat+Tras ST HER2 Alt View

Description: A Phase 2 Basket Study of Tucatinib in Combination with Trastuzumab in Subjects with Previously Treated Locally-Advanced Unresectable or Metastatic Solid Tumors Driven by HER2 Alterations (SGNTUC-019)

Indication: Cervical Cancer

Location: Texas Oncology-Bedford

Phase: II

Title: STAR Ph2 Basket Tucat+Tras ST HER2 Alt View

Description: A Phase 2 Basket Study of Tucatinib in Combination with Trastuzumab in Subjects with Previously Treated Locally-Advanced Unresectable or Metastatic Solid Tumors Driven by HER2 Alterations (SGNTUC-019)

Indication: Gall Bladder Cancer

Location: Texas Oncology-Bedford

Phase: II

Title: STAR Ph2 Basket Tucat+Tras ST HER2 Alt View

Description: A Phase 2 Basket Study of Tucatinib in Combination with Trastuzumab in Subjects with Previously Treated Locally-Advanced Unresectable or Metastatic Solid Tumors Driven by HER2 Alterations (SGNTUC-019)

Indication: Lung Cancer

Location: Texas Oncology-Bedford

Phase: II

Title: STAR Ph2 Basket Tucat+Tras ST HER2 Alt View

Description: A Phase 2 Basket Study of Tucatinib in Combination with Trastuzumab in Subjects with Previously Treated Locally-Advanced Unresectable or Metastatic Solid Tumors Driven by HER2 Alterations (SGNTUC-019)

Indication: Solid Tumors

Location: Texas Oncology-Bedford

Phase: II

Title: STAR Ph2 Basket Tucat+Tras ST HER2 Alt View

Description: A Phase 2 Basket Study of Tucatinib in Combination with Trastuzumab in Subjects with Previously Treated Locally-Advanced Unresectable or Metastatic Solid Tumors Driven by HER2 Alterations (SGNTUC-019)

Indication: Urothelial Cancer

Location: Texas Oncology-Bedford

Phase: II

Title: STAR Ph2 Basket Tucat+Tras ST HER2 Alt View

Description: A Phase 2 Basket Study of Tucatinib in Combination with Trastuzumab in Subjects with Previously Treated Locally-Advanced Unresectable or Metastatic Solid Tumors Driven by HER2 Alterations (SGNTUC-019)

Indication: Uterine Cancer

Location: Texas Oncology-Bedford

Phase: II

Title: Pragmatic Phase III Randomized Trial Of Proton Vs. Photon Therapy For Patients With Non-Metastatic Breast Cancer Receiving Comprehensive Nodal Radiation: A Radiotherapy Comparative Effectiveness (Radcomp) Consortium Trial View

Indication: Breast Cancer

Location: Texas Oncology-Bedford

Phase: III

Texas Oncology-Fort Worth Cancer Center

Title: STAR Ph2 Basket Tucat+Tras ST HER2 Alt View

Description: A Phase 2 Basket Study of Tucatinib in Combination with Trastuzumab in Subjects with Previously Treated Locally-Advanced Unresectable or Metastatic Solid Tumors Driven by HER2 Alterations (SGNTUC-019)

Indication: Biliary Cancer

Location: Texas Oncology-Fort Worth Cancer Center

Phase: II

Title: STAR Ph2 Basket Tucat+Tras ST HER2 Alt View

Description: A Phase 2 Basket Study of Tucatinib in Combination with Trastuzumab in Subjects with Previously Treated Locally-Advanced Unresectable or Metastatic Solid Tumors Driven by HER2 Alterations (SGNTUC-019)

Indication: Breast Cancer

Location: Texas Oncology-Fort Worth Cancer Center

Phase: II

Title: STAR Ph2 Basket Tucat+Tras ST HER2 Alt View

Description: A Phase 2 Basket Study of Tucatinib in Combination with Trastuzumab in Subjects with Previously Treated Locally-Advanced Unresectable or Metastatic Solid Tumors Driven by HER2 Alterations (SGNTUC-019)

Indication: Cervical Cancer

Location: Texas Oncology-Fort Worth Cancer Center

Phase: II

Title: STAR Ph2 Basket Tucat+Tras ST HER2 Alt View

Description: A Phase 2 Basket Study of Tucatinib in Combination with Trastuzumab in Subjects with Previously Treated Locally-Advanced Unresectable or Metastatic Solid Tumors Driven by HER2 Alterations (SGNTUC-019)

Indication: Gall Bladder Cancer

Location: Texas Oncology-Fort Worth Cancer Center

Phase: II

Title: STAR Ph2 Basket Tucat+Tras ST HER2 Alt View

Description: A Phase 2 Basket Study of Tucatinib in Combination with Trastuzumab in Subjects with Previously Treated Locally-Advanced Unresectable or Metastatic Solid Tumors Driven by HER2 Alterations (SGNTUC-019)

Indication: Lung Cancer

Location: Texas Oncology-Fort Worth Cancer Center

Phase: II

Title: STAR Ph2 Basket Tucat+Tras ST HER2 Alt View

Description: A Phase 2 Basket Study of Tucatinib in Combination with Trastuzumab in Subjects with Previously Treated Locally-Advanced Unresectable or Metastatic Solid Tumors Driven by HER2 Alterations (SGNTUC-019)

Indication: Solid Tumors

Location: Texas Oncology-Fort Worth Cancer Center

Phase: II

Title: STAR Ph2 Basket Tucat+Tras ST HER2 Alt View

Description: A Phase 2 Basket Study of Tucatinib in Combination with Trastuzumab in Subjects with Previously Treated Locally-Advanced Unresectable or Metastatic Solid Tumors Driven by HER2 Alterations (SGNTUC-019)

Indication: Urothelial Cancer

Location: Texas Oncology-Fort Worth Cancer Center

Phase: II

Title: STAR Ph2 Basket Tucat+Tras ST HER2 Alt View

Description: A Phase 2 Basket Study of Tucatinib in Combination with Trastuzumab in Subjects with Previously Treated Locally-Advanced Unresectable or Metastatic Solid Tumors Driven by HER2 Alterations (SGNTUC-019)

Indication: Uterine Cancer

Location: Texas Oncology-Fort Worth Cancer Center

Phase: II

Title: Ph2 Bren Vedo + Pembro ST prior PD-1 View

Description: A phase 2 study of brentuximab vedotin in combination with pembrolizumab in subjects with metastatic solid malignancies after progression on prior PD-1 inhibitor treatment (SGN35-033)

Indication: Lung Cancer

Location: Texas Oncology-Fort Worth Cancer Center

Phase: II

Title: Ph2 Bren Vedo + Pembro ST prior PD-1 View

Description: A phase 2 study of brentuximab vedotin in combination with pembrolizumab in subjects with metastatic solid malignancies after progression on prior PD-1 inhibitor treatment (SGN35-033)

Indication: Melanoma

Location: Texas Oncology-Fort Worth Cancer Center

Phase: II

Title: Ph2 Bren Vedo + Pembro ST prior PD-1 View

Description: A phase 2 study of brentuximab vedotin in combination with pembrolizumab in subjects with metastatic solid malignancies after progression on prior PD-1 inhibitor treatment (SGN35-033)

Indication: Solid Tumors

Location: Texas Oncology-Fort Worth Cancer Center

Phase: II

Title: STAR Ph3 61186372 Osim Lazert EGFR NSCLC View

Description: A Phase 3 Randomized Study of Amivantamab and Lazertinib Combination Therapy Versus Osimertinib Versus Lazertinib as First-Line Treatment in Patients with EGFR-Mutated Locally Advanced or Metastatic Non-Small Cell Lung Cancer (73841937NSC3003)MARIPOSA

Indication: Lung Cancer

Location: Texas Oncology-Fort Worth Cancer Center

Phase: III

Title: STAR Ph3 61186372 Osim Lazert EGFR NSCLC View

Description: A Phase 3 Randomized Study of Amivantamab and Lazertinib Combination Therapy Versus Osimertinib Versus Lazertinib as First-Line Treatment in Patients with EGFR-Mutated Locally Advanced or Metastatic Non-Small Cell Lung Cancer (73841937NSC3003)MARIPOSA

Indication: Lung Cancer

Location: Texas Oncology-Fort Worth Cancer Center

Phase: III

Title: STAR Ph3 61186372 Osim Lazert EGFR NSCLC View

Description: A Phase 3 Randomized Study of Amivantamab and Lazertinib Combination Therapy Versus Osimertinib Versus Lazertinib as First-Line Treatment in Patients with EGFR-Mutated Locally Advanced or Metastatic Non-Small Cell Lung Cancer (73841937NSC3003)MARIPOSA

Indication: Lung Cancer

Location: Texas Oncology-Fort Worth Cancer Center

Phase: III

Title: STAR PH3 JNJ-61186372 Peme EGFR NSCLC View

Description: A Randomized Open-label Phase 3 Study of Combination Amivantamab and Carboplatin-Pemetrexed Therapy Compared with Carboplatin-Pemetrexed in Patients with EGFR Exon 20ins Mutated Locally Advanced or Metastatic Non-Small Cell Lung Cancer (61186372NSC3001)

Indication: Lung Cancer

Location: Texas Oncology-Fort Worth Cancer Center

Phase: III

Title: STAR PH3 Nirap Abira HRR mCSPC View

Description: A Phase 3 Randomized Placebo-controlled Double-blind Study of Niraparib in Combination with Abiraterone Acetate and Prednisone Versus Abiraterone Acetate and Prednisone for the Treatment of Participants with Deleterious Germline or Somatic Homologous Recombination Repair (HRR) Gene-Mutated Metastatic Castration-Sensitive Prostate Cancer (mCSPC)(67652000PCR3002)

Indication: Prostate Cancer

Location: Texas Oncology-Fort Worth Cancer Center

Phase: III

Title: PH3 R-CHOP +/- Acalab Tx Naive DLBCL View

Description: A Phase 3 Randomized Double-Blind Placebo-Controlled Study of Acalabrutinib in Combination with Rituximab Cyclophosphamide Doxorubicin Vincristine and Prednisone (R-CHOP) in Subjects < or = 65 Years with Previously Untreated Non-Germinal Center Diffuse Large B-Cell Lymphoma (ACE-LY-312/ D8227C00001)

Indication: Lymphomas

Location: Texas Oncology-Fort Worth Cancer Center

Phase: III

Title: PH3 adv CC View

Description: A Randomized Phase 3 Double-Blind Study of Chemoradiotherapy With or Without Pembrolizumab for the Treatment of High-risk Locally Advanced Cervical Cancer (KEYNOTE-A18 / ENGOT-cx11)

Indication: Cervical Cancer

Location: Texas Oncology-Fort Worth Cancer Center

Phase: III

Title: STAR Ph2 Seribantumab NRG1 Fusion+ ST View

Description: CRESTONE: A Phase 2 Study of Seribantumab in Adult Patients with Neuregulin-1 (NRG1) Fusion Positive Locally Advanced or Metastatic Solid Tumors (ELVCAP-001-01)

Indication: Solid Tumors

Location: Texas Oncology-Fort Worth Cancer Center

Phase: II

Title: STAR Ph2 Ak104 Cervical Cancer View

Description: A Phase 2 multicenter single-arm open-label study to evaluate the efficacy and safety of AK104 in subjects with recurrent or metastatic cervical cancer (AK104-201-AU)

Indication: Cervical Cancer

Location: Texas Oncology-Fort Worth Cancer Center

Phase: II

Title: STAR PH2 Tuca+ Tras HER2+ CC View

Description: MOUNTAINEER: A Phase 2 Open Label Study of Tucatinib Combined with Trastuzumab in Patients with HER2+ Metastatic Colorectal Cancer (ACCRU-GI-1617 SGNTUC-017)

Indication: Colon Cancer

Location: Texas Oncology-Fort Worth Cancer Center

Phase: II

Title: STAR PH2 Tuca+ Tras HER2+ CC View

Description: MOUNTAINEER: A Phase 2 Open Label Study of Tucatinib Combined with Trastuzumab in Patients with HER2+ Metastatic Colorectal Cancer (ACCRU-GI-1617 SGNTUC-017)

Indication: Rectal Cancer

Location: Texas Oncology-Fort Worth Cancer Center

Phase: II

Title: PH2 Brentux+CHP In Tx Naive PTCL View

Description: A dual-cohort open-label phase 2 study of brentuximab vedotin and CHP (A+CHP) in the frontline treatment of subjects with peripheral T-cell lymphoma (PTCL) with less than 10% CD30 expression (SGN35-032)

Indication: Hematologic

Location: Texas Oncology-Fort Worth Cancer Center

Phase: II

Title: PH2 Brentux+CHP In Tx Naive PTCL View

Description: A dual-cohort open-label phase 2 study of brentuximab vedotin and CHP (A+CHP) in the frontline treatment of subjects with peripheral T-cell lymphoma (PTCL) with less than 10% CD30 expression (SGN35-032)

Indication: Leukemia

Location: Texas Oncology-Fort Worth Cancer Center

Phase: II

Title: PH2 Brentux+CHP In Tx Naive PTCL View

Description: A dual-cohort open-label phase 2 study of brentuximab vedotin and CHP (A+CHP) in the frontline treatment of subjects with peripheral T-cell lymphoma (PTCL) with less than 10% CD30 expression (SGN35-032)

Indication: Lymphomas

Location: Texas Oncology-Fort Worth Cancer Center

Phase: II

Title: STAR Ph3 Carbo/Pac NCMGA00012 MSCC View

Description: A Phase 3 Global Multicenter Double-Blind Randomized Study of Carboplatin-Paclitaxel With INCMGA00012 or Placebo in Participants With Inoperable Locally Recurrent or Metastatic Squamous Cell Carcinoma of the Anal Canal Not Previously Treated With Systemic Chemotherapy (POD1UM-303/InterAACT 2) (INCMGA 0012-303)

Indication: Anal Cancer

Location: Texas Oncology-Fort Worth Cancer Center

Phase: III

Title: STAR Ph3 Carbo/Pac NCMGA00012 MSCC View

Description: A Phase 3 Global Multicenter Double-Blind Randomized Study of Carboplatin-Paclitaxel With INCMGA00012 or Placebo in Participants With Inoperable Locally Recurrent or Metastatic Squamous Cell Carcinoma of the Anal Canal Not Previously Treated With Systemic Chemotherapy (POD1UM-303/InterAACT 2) (INCMGA 0012-303)

Indication: Carcinoid

Location: Texas Oncology-Fort Worth Cancer Center

Phase: III

Title: STAR Ph3 Navi Ruxo Myelofibrosis View

Description: M16-191: A Randomized Double-Blind Placebo-Controlled Phase 3 Study of Navitoclax in Combination with Ruxolitinib versus Ruxolitinib in Subjects with Myelofibrosis (TRANSFORM-1)

Indication: Myelofibrosis

Location: Texas Oncology-Fort Worth Cancer Center

Phase: III

Title: STAR KEAP1/NRF2 NSCLC View

Description: CX-839-014 "KEAPSAKE": A Phase 2 Randomized Multicenter Double-blind Study of the Glutaminase Inhibitor Telaglenastat with Pembrolizumab and Chemotherapy versus Placebo with Pembrolizumab and Chemotherapy in First-line Metastatic KEAP1/NRF2-mutated Nonsquamous Non-Small Cell Lung Cancer (NSCLC)

Indication: Lung Cancer

Location: Texas Oncology-Fort Worth Cancer Center

Phase: II

Title: Ph3 Mirv Sora Epi Ova FTC View

Description: SORAYA: A Phase 3 Single Arm Study of Mirvetuximab Soravtansine in Advanced High-Grade Epithelial Ovarian Primary Peritoneal or Fallopian Tube Cancers with High Folate Receptor-Alpha Expression (IMGN853-0417)

Indication: Fallopian Tube Cancer

Location: Texas Oncology-Fort Worth Cancer Center

Phase: III

Title: Ph3 Mirv Sora Epi Ova FTC View

Description: SORAYA: A Phase 3 Single Arm Study of Mirvetuximab Soravtansine in Advanced High-Grade Epithelial Ovarian Primary Peritoneal or Fallopian Tube Cancers with High Folate Receptor-Alpha Expression (IMGN853-0417)

Indication: Ovarian Cancer

Location: Texas Oncology-Fort Worth Cancer Center

Phase: III

Title: Ph3 Mirv Sora Epi Ova FTC View

Description: SORAYA: A Phase 3 Single Arm Study of Mirvetuximab Soravtansine in Advanced High-Grade Epithelial Ovarian Primary Peritoneal or Fallopian Tube Cancers with High Folate Receptor-Alpha Expression (IMGN853-0417)

Indication: Peritoneal Cancer

Location: Texas Oncology-Fort Worth Cancer Center

Phase: III

Title: STAR Ph3 Sinti vs Placebo ESCC View

Description: A Multicenter Double-Blind Randomized Phase III Clinical Trial Evaluating the Efficacy and Safety of Sintilimab vs. Placebo in Combination with Chemotherapy for First-Line Treatment of Unresectable Locally Advanced Recurrent or Metastatic Esophageal Squamous Cell Carcinoma (ORIENT-15)CIBI308A301

Indication: Esophageal Cancer

Location: Texas Oncology-Fort Worth Cancer Center

Phase: III

Title: INCMGA00012 Endo Cancer View

Description: An Umbrella Study of INCMGA00012 Alone and in Combination With Other Therapies in Participants With Advanced or Metastatic Endometrial Cancer Who Have Progressed on or After Platinum-Based Chemotherapy (INCMGA 0012-204/ POD1UM-204)

Indication: Endometrial Cancer

Location: Texas Oncology-Fort Worth Cancer Center

Phase: II

Title: STAR PH 2 Enfortumab in Urothelial Pts View

Description: A study of enfortumab vedotin (ASG-22CE) as monotherapy or in combination with other anticancer therapies for the treatment of urothelial cancer (SGN22E-002)

Indication: Bladder Cancer

Location: Texas Oncology-Fort Worth Cancer Center

Phase: I/II

Title: STAR PH 2 Enfortumab in Urothelial Pts View

Description: A study of enfortumab vedotin (ASG-22CE) as monotherapy or in combination with other anticancer therapies for the treatment of urothelial cancer (SGN22E-002)

Indication: Urothelial Cancer

Location: Texas Oncology-Fort Worth Cancer Center

Phase: I/II

Title: STAR-PH3 pral(Blu-667) RET-fusion mNSCLC View

Description: A Randomized Open-Label Phase 3 Study of Pralsetinib versus Standard of Care for First Line Treatment of RET fusion-positive Metastatic Non-Small Cell Lung Cancer (BLU-667-2303)

Indication: Lung Cancer

Location: Texas Oncology-Fort Worth Cancer Center

Phase: III

Title: PH2 MM Carf Poma & dexa (KPd) View

Description: An Open-label Phase 2 Study Treating Subjects With First or Second Relapse of Multiple Myeloma with Carfilzomib Pomalidomide and Dexamethasone (KPd) (20180117)

Indication: Myelomas

Location: Texas Oncology-Fort Worth Cancer Center

Phase: II

Title: STAR PH3 Pacritinib vs MD choice in MF View

Description: A Randomized Controlled Phase 3 Study of Pacritinib Versus Physician's Choice in Patients with Primary Myelofibrosis Post Polycythemia Vera Myelofibrosis or Post-Essential Thrombocythemia Myelofibrosis with Severe Thrombocytopenia (Platelets Counts <50000/µL) (PAC203)

Indication: Essential Thrombocythemia

Location: Texas Oncology-Fort Worth Cancer Center

Phase: III

Title: STAR PH3 Pacritinib vs MD choice in MF View

Description: A Randomized Controlled Phase 3 Study of Pacritinib Versus Physician's Choice in Patients with Primary Myelofibrosis Post Polycythemia Vera Myelofibrosis or Post-Essential Thrombocythemia Myelofibrosis with Severe Thrombocytopenia (Platelets Counts <50000/µL) (PAC203)

Indication: Myelofibrosis

Location: Texas Oncology-Fort Worth Cancer Center

Phase: III

Title: Biomarker DNA Defect Men Prostate View

Description: Biomarker Study to Determine Frequency of DNA-repair Defects in Men with Metastatic Prostate Cancer (64091742PCR0002)

Indication: Prostate Cancer

Location: Texas Oncology-Fort Worth Cancer Center

Title: STAR Ph2 Erdafitinib FGFR Solid Tumors View

Description: A Phase 2 Study of Erdafitinib in Subjects With Advanced Solid Tumors and FGFR Gene Alterations (42756493CAN2002)

Indication: Solid Tumors

Location: Texas Oncology-Fort Worth Cancer Center

Phase: II

Title: STAR Ph 3 Infigratinib UC w/ FGFR3 Alt View

Description: QBGJ398-302: Phase 3 Multicenter Double-Blind Randomized Placebo-Controlled Trial of Infigratinib for the Adjuvant Treatment of Subjects with Invasive Urothelial Carcinoma with Susceptible FGFR3 Genetic Alterations (PROOF302)

Indication: Urothelial Cancer

Location: Texas Oncology-Fort Worth Cancer Center

Phase: III

Title: Ph 1 PF-06821497 R/R SCLC CRPC & FL View

Description: C2321001: A PHASE I DOSE ESCALATION AND EXPANDED COHORT STUDY OF PF-06821497 IN THE TREATMENT OF ADULT PATIENTS WITH RELAPSED/REFRACTORY SMALL CELL LUNG CANCER (SCLC) CASTRATION RESISTANT PROSTATE CANCER (CRPC) AND FOLLICULAR LYMPHOMA (FL)

Indication: Lung Cancer

Location: Texas Oncology-Fort Worth Cancer Center

Phase: I

Title: Ph 1 PF-06821497 R/R SCLC CRPC & FL View

Description: C2321001: A PHASE I DOSE ESCALATION AND EXPANDED COHORT STUDY OF PF-06821497 IN THE TREATMENT OF ADULT PATIENTS WITH RELAPSED/REFRACTORY SMALL CELL LUNG CANCER (SCLC) CASTRATION RESISTANT PROSTATE CANCER (CRPC) AND FOLLICULAR LYMPHOMA (FL)

Indication: Lymphomas

Location: Texas Oncology-Fort Worth Cancer Center

Phase: I

Title: Ph 1 PF-06821497 R/R SCLC CRPC & FL View

Description: C2321001: A PHASE I DOSE ESCALATION AND EXPANDED COHORT STUDY OF PF-06821497 IN THE TREATMENT OF ADULT PATIENTS WITH RELAPSED/REFRACTORY SMALL CELL LUNG CANCER (SCLC) CASTRATION RESISTANT PROSTATE CANCER (CRPC) AND FOLLICULAR LYMPHOMA (FL)

Indication: Prostate Cancer

Location: Texas Oncology-Fort Worth Cancer Center

Phase: I

Title: Ph 1 PF-06821497 R/R SCLC CRPC & FL View

Description: C2321001: A PHASE I DOSE ESCALATION AND EXPANDED COHORT STUDY OF PF-06821497 IN THE TREATMENT OF ADULT PATIENTS WITH RELAPSED/REFRACTORY SMALL CELL LUNG CANCER (SCLC) CASTRATION RESISTANT PROSTATE CANCER (CRPC) AND FOLLICULAR LYMPHOMA (FL)

Indication: Solid Tumors

Location: Texas Oncology-Fort Worth Cancer Center

Phase: I

Title: STAR Ph1/2 MRTX849 Solids KRAS G12C View

Description: A Phase 1/2 Multiple Expansion Cohort Trial of MRTX849 in Patients with Advanced Solid Tumors with KRAS G12C Mutation (849-001)

Indication: Anal Cancer

Location: Texas Oncology-Fort Worth Cancer Center

Phase: I/II

Title: STAR Ph1/2 MRTX849 Solids KRAS G12C View

Description: A Phase 1/2 Multiple Expansion Cohort Trial of MRTX849 in Patients with Advanced Solid Tumors with KRAS G12C Mutation (849-001)

Indication: Biliary Cancer

Location: Texas Oncology-Fort Worth Cancer Center

Phase: I/II

Title: STAR Ph1/2 MRTX849 Solids KRAS G12C View

Description: A Phase 1/2 Multiple Expansion Cohort Trial of MRTX849 in Patients with Advanced Solid Tumors with KRAS G12C Mutation (849-001)

Indication: Bladder Cancer

Location: Texas Oncology-Fort Worth Cancer Center

Phase: I/II

Title: STAR Ph1/2 MRTX849 Solids KRAS G12C View

Description: A Phase 1/2 Multiple Expansion Cohort Trial of MRTX849 in Patients with Advanced Solid Tumors with KRAS G12C Mutation (849-001)

Indication: Bone Mets

Location: Texas Oncology-Fort Worth Cancer Center

Phase: I/II

Title: STAR Ph1/2 MRTX849 Solids KRAS G12C View

Description: A Phase 1/2 Multiple Expansion Cohort Trial of MRTX849 in Patients with Advanced Solid Tumors with KRAS G12C Mutation (849-001)

Indication: Brain Cancer

Location: Texas Oncology-Fort Worth Cancer Center

Phase: I/II

Title: STAR Ph1/2 MRTX849 Solids KRAS G12C View

Description: A Phase 1/2 Multiple Expansion Cohort Trial of MRTX849 in Patients with Advanced Solid Tumors with KRAS G12C Mutation (849-001)

Indication: Breast Cancer

Location: Texas Oncology-Fort Worth Cancer Center

Phase: I/II

Title: STAR Ph1/2 MRTX849 Solids KRAS G12C View

Description: A Phase 1/2 Multiple Expansion Cohort Trial of MRTX849 in Patients with Advanced Solid Tumors with KRAS G12C Mutation (849-001)

Indication: Urothelial Cancer

Location: Texas Oncology-Fort Worth Cancer Center

Phase: I/II

Title: STAR Ph1/2 MRTX849 Solids KRAS G12C View

Description: A Phase 1/2 Multiple Expansion Cohort Trial of MRTX849 in Patients with Advanced Solid Tumors with KRAS G12C Mutation (849-001)

Indication: Uterine Cancer

Location: Texas Oncology-Fort Worth Cancer Center

Phase: I/II

Title: STAR Ph1/2 MRTX849 Solids KRAS G12C View

Description: A Phase 1/2 Multiple Expansion Cohort Trial of MRTX849 in Patients with Advanced Solid Tumors with KRAS G12C Mutation (849-001)

Indication: Vaginal Cancer

Location: Texas Oncology-Fort Worth Cancer Center

Phase: I/II

Title: STAR Ph1/2 MRTX849 Solids KRAS G12C View

Description: A Phase 1/2 Multiple Expansion Cohort Trial of MRTX849 in Patients with Advanced Solid Tumors with KRAS G12C Mutation (849-001)

Indication: Vulvar Cancer

Location: Texas Oncology-Fort Worth Cancer Center

Phase: I/II

Title: STAR Ph1/2 MRTX849 Solids KRAS G12C View

Description: A Phase 1/2 Multiple Expansion Cohort Trial of MRTX849 in Patients with Advanced Solid Tumors with KRAS G12C Mutation (849-001)

Indication: Rectal Cancer

Location: Texas Oncology-Fort Worth Cancer Center

Phase: I/II

Title: STAR Ph1/2 MRTX849 Solids KRAS G12C View

Description: A Phase 1/2 Multiple Expansion Cohort Trial of MRTX849 in Patients with Advanced Solid Tumors with KRAS G12C Mutation (849-001)

Indication: Renal Cancer

Location: Texas Oncology-Fort Worth Cancer Center

Phase: I/II

Title: STAR Ph1/2 MRTX849 Solids KRAS G12C View

Description: A Phase 1/2 Multiple Expansion Cohort Trial of MRTX849 in Patients with Advanced Solid Tumors with KRAS G12C Mutation (849-001)

Indication: Sarcoma

Location: Texas Oncology-Fort Worth Cancer Center

Phase: I/II

Title: STAR Ph1/2 MRTX849 Solids KRAS G12C View

Description: A Phase 1/2 Multiple Expansion Cohort Trial of MRTX849 in Patients with Advanced Solid Tumors with KRAS G12C Mutation (849-001)

Indication: Solid Tumors

Location: Texas Oncology-Fort Worth Cancer Center

Phase: I/II

Title: STAR Ph1/2 MRTX849 Solids KRAS G12C View

Description: A Phase 1/2 Multiple Expansion Cohort Trial of MRTX849 in Patients with Advanced Solid Tumors with KRAS G12C Mutation (849-001)

Indication: Testicular Cancer

Location: Texas Oncology-Fort Worth Cancer Center

Phase: I/II

Title: STAR Ph1/2 MRTX849 Solids KRAS G12C View

Description: A Phase 1/2 Multiple Expansion Cohort Trial of MRTX849 in Patients with Advanced Solid Tumors with KRAS G12C Mutation (849-001)

Indication: Thyroid Cancer

Location: Texas Oncology-Fort Worth Cancer Center

Phase: I/II

Title: STAR Ph1/2 MRTX849 Solids KRAS G12C View

Description: A Phase 1/2 Multiple Expansion Cohort Trial of MRTX849 in Patients with Advanced Solid Tumors with KRAS G12C Mutation (849-001)

Indication: Malignant Adenoma

Location: Texas Oncology-Fort Worth Cancer Center

Phase: I/II

Title: STAR Ph1/2 MRTX849 Solids KRAS G12C View

Description: A Phase 1/2 Multiple Expansion Cohort Trial of MRTX849 in Patients with Advanced Solid Tumors with KRAS G12C Mutation (849-001)

Indication: Ovarian Cancer

Location: Texas Oncology-Fort Worth Cancer Center

Phase: I/II

Title: STAR Ph1/2 MRTX849 Solids KRAS G12C View

Description: A Phase 1/2 Multiple Expansion Cohort Trial of MRTX849 in Patients with Advanced Solid Tumors with KRAS G12C Mutation (849-001)

Indication: Pancreatic Cancer

Location: Texas Oncology-Fort Worth Cancer Center

Phase: I/II

Title: STAR Ph1/2 MRTX849 Solids KRAS G12C View

Description: A Phase 1/2 Multiple Expansion Cohort Trial of MRTX849 in Patients with Advanced Solid Tumors with KRAS G12C Mutation (849-001)

Indication: Penile Cancer

Location: Texas Oncology-Fort Worth Cancer Center

Phase: I/II

Title: STAR Ph1/2 MRTX849 Solids KRAS G12C View

Description: A Phase 1/2 Multiple Expansion Cohort Trial of MRTX849 in Patients with Advanced Solid Tumors with KRAS G12C Mutation (849-001)

Indication: Peritoneal Cancer

Location: Texas Oncology-Fort Worth Cancer Center

Phase: I/II

Title: STAR Ph1/2 MRTX849 Solids KRAS G12C View

Description: A Phase 1/2 Multiple Expansion Cohort Trial of MRTX849 in Patients with Advanced Solid Tumors with KRAS G12C Mutation (849-001)

Indication: Prostate Cancer

Location: Texas Oncology-Fort Worth Cancer Center

Phase: I/II

Title: STAR Ph1/2 MRTX849 Solids KRAS G12C View

Description: A Phase 1/2 Multiple Expansion Cohort Trial of MRTX849 in Patients with Advanced Solid Tumors with KRAS G12C Mutation (849-001)

Indication: Gastric Cancer

Location: Texas Oncology-Fort Worth Cancer Center

Phase: I/II

Title: STAR Ph1/2 MRTX849 Solids KRAS G12C View

Description: A Phase 1/2 Multiple Expansion Cohort Trial of MRTX849 in Patients with Advanced Solid Tumors with KRAS G12C Mutation (849-001)

Indication: Head and Neck Cancer

Location: Texas Oncology-Fort Worth Cancer Center

Phase: I/II

Title: STAR Ph1/2 MRTX849 Solids KRAS G12C View

Description: A Phase 1/2 Multiple Expansion Cohort Trial of MRTX849 in Patients with Advanced Solid Tumors with KRAS G12C Mutation (849-001)

Indication: Kaposi's Sarcoma

Location: Texas Oncology-Fort Worth Cancer Center

Phase: I/II

Title: STAR Ph1/2 MRTX849 Solids KRAS G12C View

Description: A Phase 1/2 Multiple Expansion Cohort Trial of MRTX849 in Patients with Advanced Solid Tumors with KRAS G12C Mutation (849-001)

Indication: Kidney Cancer

Location: Texas Oncology-Fort Worth Cancer Center

Phase: I/II

Title: STAR Ph1/2 MRTX849 Solids KRAS G12C View

Description: A Phase 1/2 Multiple Expansion Cohort Trial of MRTX849 in Patients with Advanced Solid Tumors with KRAS G12C Mutation (849-001)

Indication: Liver Cancer

Location: Texas Oncology-Fort Worth Cancer Center

Phase: I/II

Title: STAR Ph1/2 MRTX849 Solids KRAS G12C View

Description: A Phase 1/2 Multiple Expansion Cohort Trial of MRTX849 in Patients with Advanced Solid Tumors with KRAS G12C Mutation (849-001)

Indication: Lung Cancer

Location: Texas Oncology-Fort Worth Cancer Center

Phase: I/II

Title: STAR Ph1/2 MRTX849 Solids KRAS G12C View

Description: A Phase 1/2 Multiple Expansion Cohort Trial of MRTX849 in Patients with Advanced Solid Tumors with KRAS G12C Mutation (849-001)

Indication: Cervical Cancer

Location: Texas Oncology-Fort Worth Cancer Center

Phase: I/II

Title: STAR Ph1/2 MRTX849 Solids KRAS G12C View

Description: A Phase 1/2 Multiple Expansion Cohort Trial of MRTX849 in Patients with Advanced Solid Tumors with KRAS G12C Mutation (849-001)

Indication: Colon Cancer

Location: Texas Oncology-Fort Worth Cancer Center

Phase: I/II

Title: STAR Ph1/2 MRTX849 Solids KRAS G12C View

Description: A Phase 1/2 Multiple Expansion Cohort Trial of MRTX849 in Patients with Advanced Solid Tumors with KRAS G12C Mutation (849-001)

Indication: Endometrial Cancer

Location: Texas Oncology-Fort Worth Cancer Center

Phase: I/II

Title: STAR Ph1/2 MRTX849 Solids KRAS G12C View

Description: A Phase 1/2 Multiple Expansion Cohort Trial of MRTX849 in Patients with Advanced Solid Tumors with KRAS G12C Mutation (849-001)

Indication: Esophageal Cancer

Location: Texas Oncology-Fort Worth Cancer Center

Phase: I/II

Title: STAR Ph1/2 MRTX849 Solids KRAS G12C View

Description: A Phase 1/2 Multiple Expansion Cohort Trial of MRTX849 in Patients with Advanced Solid Tumors with KRAS G12C Mutation (849-001)

Indication: Fallopian Tube Cancer

Location: Texas Oncology-Fort Worth Cancer Center

Phase: I/II

Title: STAR Ph1/2 MRTX849 Solids KRAS G12C View

Description: A Phase 1/2 Multiple Expansion Cohort Trial of MRTX849 in Patients with Advanced Solid Tumors with KRAS G12C Mutation (849-001)

Indication: Gall Bladder Cancer

Location: Texas Oncology-Fort Worth Cancer Center

Phase: I/II

Title: Ph3 TSR-042+car-pac vs plac+car-pac endo View

Description: A PHASE 3 RANDOMIZED DOUBLE-BLIND MULTICENTER STUDY OF DOSTARLIMAB (TSR-042) PLUS CARBOPLATIN-PACLITAXEL VERSUS PLACEBO PLUS CARBOPLATIN-PACLITAXEL IN PATIENTS WITH RECURRENT OR PRIMARY ADVANCED ENDOMETRIAL CANCER (RUBY) (4010-03-001 / ENGOT EN-6 / GOG-3031)

Indication: Endometrial Cancer

Location: Texas Oncology-Fort Worth Cancer Center

Phase: III

Title: STAR Ph 3 Tuca/Placbo + T-DM1 HER2+ View

Description: STAR: Randomized double-blind phase 3 study of tucatinib or placebo in combination with ado-trastuzumab emtansine (T-DM1) for subjects with unresectable locally-advanced or metastatic HER2+ breast cancer (HER2CLIMB-02)(SGNTUC-016)

Indication: Breast Cancer

Location: Texas Oncology-Fort Worth Cancer Center

Phase: III

Title: STAR Ph2 Pemigatinib Solids FGFR View

Description: (INCB 54828-207) A Phase 2 Open-Label Single-Arm Multicenter Study to Evaluate the Efficacy and Safety of Pemigatinib in Participants With Previously Treated Locally Advanced/Metastatic or Surgically Unresectable Solid Tumor Malignancies Harboring Activating FGFR Mutations or Translocations (FIGHT-207)

Indication: Solid Tumors

Location: Texas Oncology-Fort Worth Cancer Center

Phase: II

Title: Ph 1b FIH XMT-1536 Solid Tumor NaPi2b View

Description: A Phase 1b/2 First-in-Human Dose Escalation and Expansion Study of XMT-1536 In Patients with Solid Tumors Likely to Express NaPi2b (MER-XMT-1536-1)

Indication: Lung Cancer

Location: Texas Oncology-Fort Worth Cancer Center

Phase: I

Title: Ph 1b FIH XMT-1536 Solid Tumor NaPi2b View

Description: A Phase 1b/2 First-in-Human Dose Escalation and Expansion Study of XMT-1536 In Patients with Solid Tumors Likely to Express NaPi2b (MER-XMT-1536-1)

Indication: Ovarian Cancer

Location: Texas Oncology-Fort Worth Cancer Center

Phase: I

Title: Biomarker Advcd Uro Cncer and FGFR Aber View

Description: Biomarker Study to Identify Subjects with Urothelial Cancer and Fibroblast Growth Factor Receptor Gene Aberrations (42756493BLC0002)

Indication: Bladder Cancer

Location: Texas Oncology-Fort Worth Cancer Center

Phase: IV

Title: Biomarker Advcd Uro Cncer and FGFR Aber View

Description: Biomarker Study to Identify Subjects with Urothelial Cancer and Fibroblast Growth Factor Receptor Gene Aberrations (42756493BLC0002)

Indication: Urothelial Cancer

Location: Texas Oncology-Fort Worth Cancer Center

Phase: IV

Title: Ph2 Cervical 2L (RaPiDS) View

Description: A Two-arm Randomized Non-comparative Phase 2 Trial of AGEN2034(anti-PD-1) as a Monotherapy or Combination Therapy with AGEN1884(anti-CTLA4) or with Placebo in Women with Recurrent Cervical Cancer(Second Line) - RaPiDS (C-750-01/GOG-3028)

Indication: Cervical Cancer

Location: Texas Oncology-Fort Worth Cancer Center

Phase: II

Title: Ph 1/1b Immunotherapy Combo in NSCLC View

Description: (AB928CSP0004) A Phase 1/1b Study to Evaluate the Safety and Tolerability of Immunotherapy Combinations in Participants with Lung Cancer

Indication: Lung Cancer

Location: Texas Oncology-Fort Worth Cancer Center

Phase: I

Title: TTFlds cncmnt w/ PTX recurrent ovn cnr View

Description: ENGOT-ov50 / INNOVATE-3: Pivotal Randomized Open-Label Study ofTumor Treating Fields (TTFields 200kHz) Concomitant with WeeklyPaclitaxel for the Treatment of Recurrent Ovarian Cancer

Indication: Ovarian Cancer

Location: Texas Oncology-Fort Worth Cancer Center

Phase: III

Title: STAR Infigratinib vs Gem/Cis Cholangio View

Description: A Phase 3 Multicenter Open-Label Randomized Controlled Study of Oral Infigratinib versus Gemcitabine with Cisplatin in Subjects with Advanced/Metastatic or Inoperable Cholangiocarcinoma with FGFR2 Gene Fusions/Translocations: The PROOF Trial (QBGJ398-301)

Indication: Biliary Cancer

Location: Texas Oncology-Fort Worth Cancer Center

Phase: III

Title: Ph 1/2 ASTX727 Lower Risk MDS View

Description: A Randomized Open-Label Phase 1-2 Study of ASTX727 Low Dose (ASTX727 LD)Extended Schedule in Subjects with Lower Risk (IPSS Low or Intermediate-1)Myelodysplastic Syndromes (MDS) (ASTX727-03)

Indication: Myelodysplastic Syndrome

Location: Texas Oncology-Fort Worth Cancer Center

Phase: I/II

Title: STAR Sitra+Nivo/Pembro+Enfor Adv/Met Uro View

Description: A Phase 2 Study of Sitravatinib in Combination with PD-(L)1 Checkpoint Inhibitor Regimens in Patients With Advanced or Metastatic Urothelial Carcinoma (516-003)

Indication: Bladder Cancer

Location: Texas Oncology-Fort Worth Cancer Center

Phase: II

Title: STAR Sitra+Nivo/Pembro+Enfor Adv/Met Uro View

Description: A Phase 2 Study of Sitravatinib in Combination with PD-(L)1 Checkpoint Inhibitor Regimens in Patients With Advanced or Metastatic Urothelial Carcinoma (516-003)

Indication: Urothelial Cancer

Location: Texas Oncology-Fort Worth Cancer Center

Phase: II

Title: STAR Ph3 ALK+ mNSCLC (Brigatinib-3001) View

Description: Brigatinib-3001- A Phase 3 Randomized Open-label Study of Brigatinib (ALUNBRIG®)Versus Alectinib (ALECENSA®) in Advanced Anaplastic Lymphoma Kinase-Positive Non-Small-Cell Lung Cancer Patients Who Have Progressed on Crizotinib (XALKORI®)

Indication: Lung Cancer

Location: Texas Oncology-Fort Worth Cancer Center

Phase: III

Title: STAR Ph3 Nirap+Abirat+Pred mCRPC View

Description: A Phase 3 Randomized Placebo-controlled Double-blind Study of Niraparib in Combination with Abiraterone Acetate and Prednisone Versus Abiraterone Acetate and Prednisone for Treatment of Subjects with Metastatic Prostate Cancer(64091742PCR3001)

Indication: Prostate Cancer

Location: Texas Oncology-Fort Worth Cancer Center

Phase: III

Title: STAR Ph1/2 BLU667 thy NSCLC Sol tum View

Description: A Phase 1/2 Study of the Highly-selective RET Inhibitor BLU-667 in Patients with Thyroid Cancer Non-Small Cell Lung Cancer (NSCLC) and Other Advanced Solid Tumors (BLU-667-1101)

Indication: Lung Cancer

Location: Texas Oncology-Fort Worth Cancer Center

Phase: I/II

Title: STAR Ph1/2 BLU667 thy NSCLC Sol tum View

Description: A Phase 1/2 Study of the Highly-selective RET Inhibitor BLU-667 in Patients with Thyroid Cancer Non-Small Cell Lung Cancer (NSCLC) and Other Advanced Solid Tumors (BLU-667-1101)

Indication: Solid Tumors

Location: Texas Oncology-Fort Worth Cancer Center

Phase: I/II

Title: STAR Ph1/2 BLU667 thy NSCLC Sol tum View

Description: A Phase 1/2 Study of the Highly-selective RET Inhibitor BLU-667 in Patients with Thyroid Cancer Non-Small Cell Lung Cancer (NSCLC) and Other Advanced Solid Tumors (BLU-667-1101)

Indication: Thyroid Cancer

Location: Texas Oncology-Fort Worth Cancer Center

Phase: I/II

Title: STAR Rucaparib v PhysC mCRPC (TRITON3) View

Description: TRITON3: A Multicenter Randomized Open-label Phase 3 Study of Rucaparib versus Physician's Choice of Therapy for Patients withMetastatic Castration-resistant Prostate Cancer Associated withHomologous Recombination Deficiency (CO-338-063)

Indication: Prostate Cancer

Location: Texas Oncology-Fort Worth Cancer Center

Phase: III

Title: STAR BV in pts w/1L cHL or PTCL View

Description: (SGN35-015) A phase 2 open-label study of brentuximab vedotin in front-line therapy of Hodgkin lymphoma (HL) and CD30-expressing peripheral T-cell lymphoma (PTCL) in older patients or patients with significant comorbidities ineligible for standard chemotherapy

Indication: Lymphomas

Location: Texas Oncology-Fort Worth Cancer Center

Phase: II

Title: STAR Ph3 FGFR erdafitinib urothelial View

Description: (42756493BLC3001) A Phase 3 Study of Erdafitinib Compared with Vinflunine or Docetaxel or Pembrolizumab in Subjects with Advanced Urothelial Cancer and Selected FGFR Gene Aberrations (THOR)

Indication: Urothelial Cancer

Location: Texas Oncology-Fort Worth Cancer Center

Phase: III

Title: STAR Ph2 A+AVD +G-CSF or AOAD in CHL View

Description: SGN35-027: Multiple Part Clinical Trial of Brentuximab Vedotin in Classical Hodgkin Lymphoma Subjects

Indication: Lymphomas

Location: Texas Oncology-Fort Worth Cancer Center

Phase: II

Title: STAR Ph1 CX-4945 Basal Cell Carcinoma View

Description: A Phase I Multi-Center Open-Label Treatment Duration Increment Expansion Safety and Pharmacodynamic Study of CX-4945 Administered Orally Twice Daily to Patients with Advanced Basal Cell Carcinoma (CX-4945-07)

Indication: Skin Cancer

Location: Texas Oncology-Fort Worth Cancer Center

Phase: I

Title: Ph3 Pembro + BCG High-risk Bladder View

Description: A Phase 3 Randomized Comparator-controlled Clinical Trial to Study the Efficacy and Safety of Pembrolizumab (MK-3475) in Combination with Bacillus Calmette- Guerin (BCG) in Participants with High-risk Non-muscle Invasive Bladder Cancer (HR NMIBC) that is Persistent or Recurrent Following BCG Induction (KEYNOTE-676)

Indication: Bladder Cancer

Location: Texas Oncology-Fort Worth Cancer Center

Phase: III

Title: STAR Ph3 61186372 Osim Lazert EGFR NSCLC View

Description: A Phase 3 Randomized Study of Amivantamab and Lazertinib Combination Therapy Versus Osimertinib Versus Lazertinib as First-Line Treatment in Patients with EGFR-Mutated Locally Advanced or Metastatic Non-Small Cell Lung Cancer (73841937NSC3003)MARIPOSA

Indication: Lung Cancer

Location: Texas Oncology-Fort Worth Cancer Center

Phase: III

Title: A PHASE 3B, MULTICENTER, SINGLE-ARM, OPENLABEL EFFICACY AND SAFETY STUDY OF FEDRATINIB IN SUBJECTS WITH DIPSSINTERMEDIATE OR HIGH-RISK PRIMARY MYELOFIBROSIS, POST POLYCYTHEMIA VERA MYELOFIBROSIS, OR POST-ESSENTIAL THROMBOCYTHEMIA MYELOFIBROSIS AND PREVIOUSLY TREATED WITH RUXOLITINIB INCLUDING A SUB-STUDY WITH CONCOMITANTLUSPATERCEPT FOR SUBJECTS WITH ANEMIA(The "FREEDOM" Trial) View

Indication: Myelofibrosis

Location: Texas Oncology-Fort Worth Cancer Center

Phase: III

Title: A phase 2, multicenter, single-arm study of retreatment with brentuximab vedotin in subjects with relapsed or refractory classical Hodgkin lymphoma (cHL) or CD30-expressing peripheral T cell lymphoma (PTCL) View

Indication: Lymphomas

Location: Texas Oncology-Fort Worth Cancer Center

Phase: II

Title: A Phase 2/3, Multicenter, Randomized, Study of Rituximab-Gemcitabine-Dexamethasone-Platinum (R_GDP) With or Without Selinexor in Patients with Relapsed/Refractory Diffuse Large B-Cell Lymphoma (DLBCL) View

Indication: Lymphomas

Location: Texas Oncology-Fort Worth Cancer Center

Phase: II/III

Texas Oncology-Grapevine

Title: STAR Ph3 61186372 Osim Lazert EGFR NSCLC View

Description: A Phase 3 Randomized Study of Amivantamab and Lazertinib Combination Therapy Versus Osimertinib Versus Lazertinib as First-Line Treatment in Patients with EGFR-Mutated Locally Advanced or Metastatic Non-Small Cell Lung Cancer (73841937NSC3003)MARIPOSA

Indication: Lung Cancer

Location: Texas Oncology-Grapevine

Phase: III

Title: STAR Ph3 61186372 Osim Lazert EGFR NSCLC View

Description: A Phase 3 Randomized Study of Amivantamab and Lazertinib Combination Therapy Versus Osimertinib Versus Lazertinib as First-Line Treatment in Patients with EGFR-Mutated Locally Advanced or Metastatic Non-Small Cell Lung Cancer (73841937NSC3003)MARIPOSA

Indication: Lung Cancer

Location: Texas Oncology-Grapevine

Phase: III

Title: STAR PH3 JNJ-61186372 Peme EGFR NSCLC View

Description: A Randomized Open-label Phase 3 Study of Combination Amivantamab and Carboplatin-Pemetrexed Therapy Compared with Carboplatin-Pemetrexed in Patients with EGFR Exon 20ins Mutated Locally Advanced or Metastatic Non-Small Cell Lung Cancer (61186372NSC3001)

Indication: Lung Cancer

Location: Texas Oncology-Grapevine

Phase: III

Title: STAR Ph2 Seribantumab NRG1 Fusion+ ST View

Description: CRESTONE: A Phase 2 Study of Seribantumab in Adult Patients with Neuregulin-1 (NRG1) Fusion Positive Locally Advanced or Metastatic Solid Tumors (ELVCAP-001-01)

Indication: Solid Tumors

Location: Texas Oncology-Grapevine

Phase: II

Title: STAR PH3 Nirap Abira HRR mCSPC View

Description: A Phase 3 Randomized Placebo-controlled Double-blind Study of Niraparib in Combination with Abiraterone Acetate and Prednisone Versus Abiraterone Acetate and Prednisone for the Treatment of Participants with Deleterious Germline or Somatic Homologous Recombination Repair (HRR) Gene-Mutated Metastatic Castration-Sensitive Prostate Cancer (mCSPC)(67652000PCR3002)

Indication: Prostate Cancer

Location: Texas Oncology-Grapevine

Phase: III

Title: STAR Ph3 Navi Ruxo Myelofibrosis View

Description: M16-191: A Randomized Double-Blind Placebo-Controlled Phase 3 Study of Navitoclax in Combination with Ruxolitinib versus Ruxolitinib in Subjects with Myelofibrosis (TRANSFORM-1)

Indication: Myelofibrosis

Location: Texas Oncology-Grapevine

Phase: III

Title: STAR Ph3 Carbo/Pac NCMGA00012 MSCC View

Description: A Phase 3 Global Multicenter Double-Blind Randomized Study of Carboplatin-Paclitaxel With INCMGA00012 or Placebo in Participants With Inoperable Locally Recurrent or Metastatic Squamous Cell Carcinoma of the Anal Canal Not Previously Treated With Systemic Chemotherapy (POD1UM-303/InterAACT 2) (INCMGA 0012-303)

Indication: Anal Cancer

Location: Texas Oncology-Grapevine

Phase: III

Title: STAR Ph3 Carbo/Pac NCMGA00012 MSCC View

Description: A Phase 3 Global Multicenter Double-Blind Randomized Study of Carboplatin-Paclitaxel With INCMGA00012 or Placebo in Participants With Inoperable Locally Recurrent or Metastatic Squamous Cell Carcinoma of the Anal Canal Not Previously Treated With Systemic Chemotherapy (POD1UM-303/InterAACT 2) (INCMGA 0012-303)

Indication: Carcinoid

Location: Texas Oncology-Grapevine

Phase: III

Title: STAR PH2 Tuca+ Tras HER2+ CC View

Description: MOUNTAINEER: A Phase 2 Open Label Study of Tucatinib Combined with Trastuzumab in Patients with HER2+ Metastatic Colorectal Cancer (ACCRU-GI-1617 SGNTUC-017)

Indication: Colon Cancer

Location: Texas Oncology-Grapevine

Phase: II

Title: STAR PH2 Tuca+ Tras HER2+ CC View

Description: MOUNTAINEER: A Phase 2 Open Label Study of Tucatinib Combined with Trastuzumab in Patients with HER2+ Metastatic Colorectal Cancer (ACCRU-GI-1617 SGNTUC-017)

Indication: Rectal Cancer

Location: Texas Oncology-Grapevine

Phase: II

Title: STAR Ph2 Erdafitinib FGFR Solid Tumors View

Description: A Phase 2 Study of Erdafitinib in Subjects With Advanced Solid Tumors and FGFR Gene Alterations (42756493CAN2002)

Indication: Solid Tumors

Location: Texas Oncology-Grapevine

Phase: II

Title: PH3 AMG 510 vs Doce a/mNSCLC View

Description: 20190009: A Phase 3 Multicenter Randomized Open Label Active-controlled Study of AMG 510 Versus Docetaxel for the Treatment of Previously Treated Locally Advanced and Unresectable or Metastatic NSCLC Subjects with Mutated KRAS p.G12C

Indication: Lung Cancer

Location: Texas Oncology-Grapevine

Phase: III

Title: STAR PH3 Pacritinib vs MD choice in MF View

Description: A Randomized Controlled Phase 3 Study of Pacritinib Versus Physician's Choice in Patients with Primary Myelofibrosis Post Polycythemia Vera Myelofibrosis or Post-Essential Thrombocythemia Myelofibrosis with Severe Thrombocytopenia (Platelets Counts <50000/µL) (PAC203)

Indication: Essential Thrombocythemia

Location: Texas Oncology-Grapevine

Phase: III

Title: STAR PH3 Pacritinib vs MD choice in MF View

Description: A Randomized Controlled Phase 3 Study of Pacritinib Versus Physician's Choice in Patients with Primary Myelofibrosis Post Polycythemia Vera Myelofibrosis or Post-Essential Thrombocythemia Myelofibrosis with Severe Thrombocytopenia (Platelets Counts <50000/µL) (PAC203)

Indication: Myelofibrosis

Location: Texas Oncology-Grapevine

Phase: III

Title: Ph 3 Chemo +/- Pembro/Olap EOC View

Description: A Randomized Phase 3 Double-Blind Study of Chemotherapy With or Without Pembrolizumab Followed by Maintenance With Olaparib or Placebo for the First-Line Treatment of BRCA non-mutated Advanced Epithelial Ovarian Cancer (EOC) (MK-7339-001/ENGOT-ov43/GOG-3036)

Indication: Ovarian Cancer

Location: Texas Oncology-Grapevine

Phase: III

Title: STAR-PH3 pral(Blu-667) RET-fusion mNSCLC View

Description: A Randomized Open-Label Phase 3 Study of Pralsetinib versus Standard of Care for First Line Treatment of RET fusion-positive Metastatic Non-Small Cell Lung Cancer (BLU-667-2303)

Indication: Lung Cancer

Location: Texas Oncology-Grapevine

Phase: III

Title: STAR PH 2 Enfortumab in Urothelial Pts View

Description: A study of enfortumab vedotin (ASG-22CE) as monotherapy or in combination with other anticancer therapies for the treatment of urothelial cancer (SGN22E-002)

Indication: Bladder Cancer

Location: Texas Oncology-Grapevine

Phase: I/II

Title: STAR PH 2 Enfortumab in Urothelial Pts View

Description: A study of enfortumab vedotin (ASG-22CE) as monotherapy or in combination with other anticancer therapies for the treatment of urothelial cancer (SGN22E-002)

Indication: Urothelial Cancer

Location: Texas Oncology-Grapevine

Phase: I/II

Title: STAR Ph3 Sinti vs Placebo ESCC View

Description: A Multicenter Double-Blind Randomized Phase III Clinical Trial Evaluating the Efficacy and Safety of Sintilimab vs. Placebo in Combination with Chemotherapy for First-Line Treatment of Unresectable Locally Advanced Recurrent or Metastatic Esophageal Squamous Cell Carcinoma (ORIENT-15)CIBI308A301

Indication: Esophageal Cancer

Location: Texas Oncology-Grapevine

Phase: III

Title: STAR KEAP1/NRF2 NSCLC View

Description: CX-839-014 "KEAPSAKE": A Phase 2 Randomized Multicenter Double-blind Study of the Glutaminase Inhibitor Telaglenastat with Pembrolizumab and Chemotherapy versus Placebo with Pembrolizumab and Chemotherapy in First-line Metastatic KEAP1/NRF2-mutated Nonsquamous Non-Small Cell Lung Cancer (NSCLC)

Indication: Lung Cancer

Location: Texas Oncology-Grapevine

Phase: II

Title: PH3 Plac Carbo Pacil Dura +/- Olap DUO-E View

Description: D9311C00001; GOG-3041; ENGOT-EN10: A Randomised Multicentre Double-blind Placebo-controlled Phase III Study of First-line Carboplatin and Paclitaxel in Combination with Durvalumab Followed by Maintenance Durvalumab with or without Olaparib in Patients with Newly Diagnosed Advanced or Recurrent Endometrial Cancer (DUO-E)

Indication: Endometrial Cancer

Location: Texas Oncology-Grapevine

Phase: III

Title: STAR Ph2 Basket Tucat+Tras ST HER2 Alt View

Description: A Phase 2 Basket Study of Tucatinib in Combination with Trastuzumab in Subjects with Previously Treated Locally-Advanced Unresectable or Metastatic Solid Tumors Driven by HER2 Alterations (SGNTUC-019)

Indication: Biliary Cancer

Location: Texas Oncology-Grapevine

Phase: II

Title: STAR Ph2 Basket Tucat+Tras ST HER2 Alt View

Description: A Phase 2 Basket Study of Tucatinib in Combination with Trastuzumab in Subjects with Previously Treated Locally-Advanced Unresectable or Metastatic Solid Tumors Driven by HER2 Alterations (SGNTUC-019)

Indication: Breast Cancer

Location: Texas Oncology-Grapevine

Phase: II

Title: STAR Ph2 Basket Tucat+Tras ST HER2 Alt View

Description: A Phase 2 Basket Study of Tucatinib in Combination with Trastuzumab in Subjects with Previously Treated Locally-Advanced Unresectable or Metastatic Solid Tumors Driven by HER2 Alterations (SGNTUC-019)

Indication: Cervical Cancer

Location: Texas Oncology-Grapevine

Phase: II

Title: STAR Ph2 Basket Tucat+Tras ST HER2 Alt View

Description: A Phase 2 Basket Study of Tucatinib in Combination with Trastuzumab in Subjects with Previously Treated Locally-Advanced Unresectable or Metastatic Solid Tumors Driven by HER2 Alterations (SGNTUC-019)

Indication: Gall Bladder Cancer

Location: Texas Oncology-Grapevine

Phase: II

Title: STAR Ph2 Basket Tucat+Tras ST HER2 Alt View

Description: A Phase 2 Basket Study of Tucatinib in Combination with Trastuzumab in Subjects with Previously Treated Locally-Advanced Unresectable or Metastatic Solid Tumors Driven by HER2 Alterations (SGNTUC-019)

Indication: Lung Cancer

Location: Texas Oncology-Grapevine

Phase: II

Title: STAR Ph2 Basket Tucat+Tras ST HER2 Alt View

Description: A Phase 2 Basket Study of Tucatinib in Combination with Trastuzumab in Subjects with Previously Treated Locally-Advanced Unresectable or Metastatic Solid Tumors Driven by HER2 Alterations (SGNTUC-019)

Indication: Solid Tumors

Location: Texas Oncology-Grapevine

Phase: II

Title: STAR Ph2 Basket Tucat+Tras ST HER2 Alt View

Description: A Phase 2 Basket Study of Tucatinib in Combination with Trastuzumab in Subjects with Previously Treated Locally-Advanced Unresectable or Metastatic Solid Tumors Driven by HER2 Alterations (SGNTUC-019)

Indication: Urothelial Cancer

Location: Texas Oncology-Grapevine

Phase: II

Title: STAR Ph2 Basket Tucat+Tras ST HER2 Alt View

Description: A Phase 2 Basket Study of Tucatinib in Combination with Trastuzumab in Subjects with Previously Treated Locally-Advanced Unresectable or Metastatic Solid Tumors Driven by HER2 Alterations (SGNTUC-019)

Indication: Uterine Cancer

Location: Texas Oncology-Grapevine

Phase: II

Title: STAR Ph1 CX-4945 Basal Cell Carcinoma View

Description: A Phase I Multi-Center Open-Label Treatment Duration Increment Expansion Safety and Pharmacodynamic Study of CX-4945 Administered Orally Twice Daily to Patients with Advanced Basal Cell Carcinoma (CX-4945-07)

Indication: Skin Cancer

Location: Texas Oncology-Grapevine

Phase: I

Title: PANOVA-3: 1L Gemcit + nab-pac pancreatic View

Description: PANOVA-3: Pivotal randomized open-label study of Tumor Treating Fields (TTFields 150kHz) concomitant with gemcitabine and nab-paclitaxel for front-line treatment of locally-advanced pancreatic adenocarcinoma (EF-27)

Indication: Pancreatic Cancer

Location: Texas Oncology-Grapevine

Phase: III

Title: STAR Ph3 FGFR erdafitinib urothelial View

Description: (42756493BLC3001) A Phase 3 Study of Erdafitinib Compared with Vinflunine or Docetaxel or Pembrolizumab in Subjects with Advanced Urothelial Cancer and Selected FGFR Gene Aberrations (THOR)

Indication: Urothelial Cancer

Location: Texas Oncology-Grapevine

Phase: III

Title: STAR BV in pts w/1L cHL or PTCL View

Description: (SGN35-015) A phase 2 open-label study of brentuximab vedotin in front-line therapy of Hodgkin lymphoma (HL) and CD30-expressing peripheral T-cell lymphoma (PTCL) in older patients or patients with significant comorbidities ineligible for standard chemotherapy

Indication: Lymphomas

Location: Texas Oncology-Grapevine

Phase: II

Title: STAR Ublituximab+TGR-1202 Cross-over View

Description: (UTX-TGR-204) A Multi-Center Open-Label Compassionate Use Extension Study of Ublituximab (TG-1101) in Combination with Umbralisib (TGR-1202) for Patients Previously Enrolled in Protocol UTX-TGR-304

Indication: Leukemia

Location: Texas Oncology-Grapevine

Phase: II

Title: STAR Rucaparib v PhysC mCRPC (TRITON3) View

Description: TRITON3: A Multicenter Randomized Open-label Phase 3 Study of Rucaparib versus Physician's Choice of Therapy for Patients withMetastatic Castration-resistant Prostate Cancer Associated withHomologous Recombination Deficiency (CO-338-063)

Indication: Prostate Cancer

Location: Texas Oncology-Grapevine

Phase: III

Title: FLEX Registry: Evaluate New Gene Express View

Description: MammaPrint BluePrint and Full-genome Data Linked with Clinical Data to Evaluate New Gene EXpression Profiles: An Adaptable Registry (FLEX Registry)

Indication: Breast Cancer

Location: Texas Oncology-Grapevine

Title: STAR Ph1/2 BLU667 thy NSCLC Sol tum View

Description: A Phase 1/2 Study of the Highly-selective RET Inhibitor BLU-667 in Patients with Thyroid Cancer Non-Small Cell Lung Cancer (NSCLC) and Other Advanced Solid Tumors (BLU-667-1101)

Indication: Lung Cancer

Location: Texas Oncology-Grapevine

Phase: I/II

Title: STAR Ph1/2 BLU667 thy NSCLC Sol tum View

Description: A Phase 1/2 Study of the Highly-selective RET Inhibitor BLU-667 in Patients with Thyroid Cancer Non-Small Cell Lung Cancer (NSCLC) and Other Advanced Solid Tumors (BLU-667-1101)

Indication: Solid Tumors

Location: Texas Oncology-Grapevine

Phase: I/II

Title: STAR Ph1/2 BLU667 thy NSCLC Sol tum View

Description: A Phase 1/2 Study of the Highly-selective RET Inhibitor BLU-667 in Patients with Thyroid Cancer Non-Small Cell Lung Cancer (NSCLC) and Other Advanced Solid Tumors (BLU-667-1101)

Indication: Thyroid Cancer

Location: Texas Oncology-Grapevine

Phase: I/II

Title: STAR Ph3 Nirap+Abirat+Pred mCRPC View

Description: A Phase 3 Randomized Placebo-controlled Double-blind Study of Niraparib in Combination with Abiraterone Acetate and Prednisone Versus Abiraterone Acetate and Prednisone for Treatment of Subjects with Metastatic Prostate Cancer(64091742PCR3001)

Indication: Prostate Cancer

Location: Texas Oncology-Grapevine

Phase: III

Title: STAR Sitra+Nivo/Pembro+Enfor Adv/Met Uro View

Description: A Phase 2 Study of Sitravatinib in Combination with PD-(L)1 Checkpoint Inhibitor Regimens in Patients With Advanced or Metastatic Urothelial Carcinoma (516-003)

Indication: Bladder Cancer

Location: Texas Oncology-Grapevine

Phase: II

Title: STAR Sitra+Nivo/Pembro+Enfor Adv/Met Uro View

Description: A Phase 2 Study of Sitravatinib in Combination with PD-(L)1 Checkpoint Inhibitor Regimens in Patients With Advanced or Metastatic Urothelial Carcinoma (516-003)

Indication: Urothelial Cancer

Location: Texas Oncology-Grapevine

Phase: II

Title: STAR Infigratinib vs Gem/Cis Cholangio View

Description: A Phase 3 Multicenter Open-Label Randomized Controlled Study of Oral Infigratinib versus Gemcitabine with Cisplatin in Subjects with Advanced/Metastatic or Inoperable Cholangiocarcinoma with FGFR2 Gene Fusions/Translocations: The PROOF Trial (QBGJ398-301)

Indication: Biliary Cancer

Location: Texas Oncology-Grapevine

Phase: III

Title: Ph2 Cervical 2L (RaPiDS) View

Description: A Two-arm Randomized Non-comparative Phase 2 Trial of AGEN2034(anti-PD-1) as a Monotherapy or Combination Therapy with AGEN1884(anti-CTLA4) or with Placebo in Women with Recurrent Cervical Cancer(Second Line) - RaPiDS (C-750-01/GOG-3028)

Indication: Cervical Cancer

Location: Texas Oncology-Grapevine

Phase: II

Title: EAP BGB-3111 B-Cell Malig View

Description: A Single-Arm Expanded Access Study of Zanubrutinib (BGB-3111) in Patients with B-cell Malignancies (BGB-3111-216)

Indication: Lymphomas

Location: Texas Oncology-Grapevine

Title: STAR Ph2 Pemigatinib Solids FGFR View

Description: (INCB 54828-207) A Phase 2 Open-Label Single-Arm Multicenter Study to Evaluate the Efficacy and Safety of Pemigatinib in Participants With Previously Treated Locally Advanced/Metastatic or Surgically Unresectable Solid Tumor Malignancies Harboring Activating FGFR Mutations or Translocations (FIGHT-207)

Indication: Solid Tumors

Location: Texas Oncology-Grapevine

Phase: II

Title: STAR Ph 3 Tuca/Placbo + T-DM1 HER2+ View

Description: STAR: Randomized double-blind phase 3 study of tucatinib or placebo in combination with ado-trastuzumab emtansine (T-DM1) for subjects with unresectable locally-advanced or metastatic HER2+ breast cancer (HER2CLIMB-02)(SGNTUC-016)

Indication: Breast Cancer

Location: Texas Oncology-Grapevine

Phase: III

Title: Ph 3 Chemo+Atez/Placbo TNBC View

Description: A Randomized Double-Blind Phase III Clinical Trial of Neoadjuvant Chemotherapy with Atezolizumab or Placebo in Patients with Triple-Negative Breast Cancer Followed by Adjuvant Continuation of Atezolizumab or Placebo(NSABP B-59/GBG 96-GeparDouze).

Indication: Breast Cancer

Location: Texas Oncology-Grapevine

Phase: III

Title: STAR Ph1/2 MRTX849 Solids KRAS G12C View

Description: A Phase 1/2 Multiple Expansion Cohort Trial of MRTX849 in Patients with Advanced Solid Tumors with KRAS G12C Mutation (849-001)

Indication: Anal Cancer

Location: Texas Oncology-Grapevine

Phase: I/II

Title: STAR Ph1/2 MRTX849 Solids KRAS G12C View

Description: A Phase 1/2 Multiple Expansion Cohort Trial of MRTX849 in Patients with Advanced Solid Tumors with KRAS G12C Mutation (849-001)

Indication: Biliary Cancer

Location: Texas Oncology-Grapevine

Phase: I/II

Title: STAR Ph1/2 MRTX849 Solids KRAS G12C View

Description: A Phase 1/2 Multiple Expansion Cohort Trial of MRTX849 in Patients with Advanced Solid Tumors with KRAS G12C Mutation (849-001)

Indication: Bladder Cancer

Location: Texas Oncology-Grapevine

Phase: I/II

Title: STAR Ph1/2 MRTX849 Solids KRAS G12C View

Description: A Phase 1/2 Multiple Expansion Cohort Trial of MRTX849 in Patients with Advanced Solid Tumors with KRAS G12C Mutation (849-001)

Indication: Bone Mets

Location: Texas Oncology-Grapevine

Phase: I/II

Title: STAR Ph1/2 MRTX849 Solids KRAS G12C View

Description: A Phase 1/2 Multiple Expansion Cohort Trial of MRTX849 in Patients with Advanced Solid Tumors with KRAS G12C Mutation (849-001)

Indication: Brain Cancer

Location: Texas Oncology-Grapevine

Phase: I/II

Title: STAR Ph1/2 MRTX849 Solids KRAS G12C View

Description: A Phase 1/2 Multiple Expansion Cohort Trial of MRTX849 in Patients with Advanced Solid Tumors with KRAS G12C Mutation (849-001)

Indication: Breast Cancer

Location: Texas Oncology-Grapevine

Phase: I/II

Title: STAR Ph1/2 MRTX849 Solids KRAS G12C View

Description: A Phase 1/2 Multiple Expansion Cohort Trial of MRTX849 in Patients with Advanced Solid Tumors with KRAS G12C Mutation (849-001)

Indication: Urothelial Cancer

Location: Texas Oncology-Grapevine

Phase: I/II

Title: STAR Ph1/2 MRTX849 Solids KRAS G12C View

Description: A Phase 1/2 Multiple Expansion Cohort Trial of MRTX849 in Patients with Advanced Solid Tumors with KRAS G12C Mutation (849-001)

Indication: Uterine Cancer

Location: Texas Oncology-Grapevine

Phase: I/II

Title: STAR Ph1/2 MRTX849 Solids KRAS G12C View

Description: A Phase 1/2 Multiple Expansion Cohort Trial of MRTX849 in Patients with Advanced Solid Tumors with KRAS G12C Mutation (849-001)

Indication: Vaginal Cancer

Location: Texas Oncology-Grapevine

Phase: I/II

Title: STAR Ph1/2 MRTX849 Solids KRAS G12C View

Description: A Phase 1/2 Multiple Expansion Cohort Trial of MRTX849 in Patients with Advanced Solid Tumors with KRAS G12C Mutation (849-001)

Indication: Vulvar Cancer

Location: Texas Oncology-Grapevine

Phase: I/II

Title: STAR Ph1/2 MRTX849 Solids KRAS G12C View

Description: A Phase 1/2 Multiple Expansion Cohort Trial of MRTX849 in Patients with Advanced Solid Tumors with KRAS G12C Mutation (849-001)

Indication: Rectal Cancer

Location: Texas Oncology-Grapevine

Phase: I/II

Title: STAR Ph1/2 MRTX849 Solids KRAS G12C View

Description: A Phase 1/2 Multiple Expansion Cohort Trial of MRTX849 in Patients with Advanced Solid Tumors with KRAS G12C Mutation (849-001)

Indication: Renal Cancer

Location: Texas Oncology-Grapevine

Phase: I/II

Title: STAR Ph1/2 MRTX849 Solids KRAS G12C View

Description: A Phase 1/2 Multiple Expansion Cohort Trial of MRTX849 in Patients with Advanced Solid Tumors with KRAS G12C Mutation (849-001)

Indication: Sarcoma

Location: Texas Oncology-Grapevine

Phase: I/II

Title: STAR Ph1/2 MRTX849 Solids KRAS G12C View

Description: A Phase 1/2 Multiple Expansion Cohort Trial of MRTX849 in Patients with Advanced Solid Tumors with KRAS G12C Mutation (849-001)

Indication: Solid Tumors

Location: Texas Oncology-Grapevine

Phase: I/II

Title: STAR Ph1/2 MRTX849 Solids KRAS G12C View

Description: A Phase 1/2 Multiple Expansion Cohort Trial of MRTX849 in Patients with Advanced Solid Tumors with KRAS G12C Mutation (849-001)

Indication: Testicular Cancer

Location: Texas Oncology-Grapevine

Phase: I/II

Title: STAR Ph1/2 MRTX849 Solids KRAS G12C View

Description: A Phase 1/2 Multiple Expansion Cohort Trial of MRTX849 in Patients with Advanced Solid Tumors with KRAS G12C Mutation (849-001)

Indication: Thyroid Cancer

Location: Texas Oncology-Grapevine

Phase: I/II

Title: STAR Ph1/2 MRTX849 Solids KRAS G12C View

Description: A Phase 1/2 Multiple Expansion Cohort Trial of MRTX849 in Patients with Advanced Solid Tumors with KRAS G12C Mutation (849-001)

Indication: Malignant Adenoma

Location: Texas Oncology-Grapevine

Phase: I/II

Title: STAR Ph1/2 MRTX849 Solids KRAS G12C View

Description: A Phase 1/2 Multiple Expansion Cohort Trial of MRTX849 in Patients with Advanced Solid Tumors with KRAS G12C Mutation (849-001)

Indication: Ovarian Cancer

Location: Texas Oncology-Grapevine

Phase: I/II

Title: STAR Ph1/2 MRTX849 Solids KRAS G12C View

Description: A Phase 1/2 Multiple Expansion Cohort Trial of MRTX849 in Patients with Advanced Solid Tumors with KRAS G12C Mutation (849-001)

Indication: Pancreatic Cancer

Location: Texas Oncology-Grapevine

Phase: I/II

Title: STAR Ph1/2 MRTX849 Solids KRAS G12C View

Description: A Phase 1/2 Multiple Expansion Cohort Trial of MRTX849 in Patients with Advanced Solid Tumors with KRAS G12C Mutation (849-001)

Indication: Penile Cancer

Location: Texas Oncology-Grapevine

Phase: I/II

Title: STAR Ph1/2 MRTX849 Solids KRAS G12C View

Description: A Phase 1/2 Multiple Expansion Cohort Trial of MRTX849 in Patients with Advanced Solid Tumors with KRAS G12C Mutation (849-001)

Indication: Peritoneal Cancer

Location: Texas Oncology-Grapevine

Phase: I/II

Title: STAR Ph1/2 MRTX849 Solids KRAS G12C View

Description: A Phase 1/2 Multiple Expansion Cohort Trial of MRTX849 in Patients with Advanced Solid Tumors with KRAS G12C Mutation (849-001)

Indication: Prostate Cancer

Location: Texas Oncology-Grapevine

Phase: I/II

Title: STAR Ph1/2 MRTX849 Solids KRAS G12C View

Description: A Phase 1/2 Multiple Expansion Cohort Trial of MRTX849 in Patients with Advanced Solid Tumors with KRAS G12C Mutation (849-001)

Indication: Gastric Cancer

Location: Texas Oncology-Grapevine

Phase: I/II

Title: STAR Ph1/2 MRTX849 Solids KRAS G12C View

Description: A Phase 1/2 Multiple Expansion Cohort Trial of MRTX849 in Patients with Advanced Solid Tumors with KRAS G12C Mutation (849-001)

Indication: Head and Neck Cancer

Location: Texas Oncology-Grapevine

Phase: I/II

Title: STAR Ph1/2 MRTX849 Solids KRAS G12C View

Description: A Phase 1/2 Multiple Expansion Cohort Trial of MRTX849 in Patients with Advanced Solid Tumors with KRAS G12C Mutation (849-001)

Indication: Kaposi's Sarcoma

Location: Texas Oncology-Grapevine

Phase: I/II

Title: STAR Ph1/2 MRTX849 Solids KRAS G12C View

Description: A Phase 1/2 Multiple Expansion Cohort Trial of MRTX849 in Patients with Advanced Solid Tumors with KRAS G12C Mutation (849-001)

Indication: Kidney Cancer

Location: Texas Oncology-Grapevine

Phase: I/II

Title: STAR Ph1/2 MRTX849 Solids KRAS G12C View

Description: A Phase 1/2 Multiple Expansion Cohort Trial of MRTX849 in Patients with Advanced Solid Tumors with KRAS G12C Mutation (849-001)

Indication: Liver Cancer

Location: Texas Oncology-Grapevine

Phase: I/II

Title: STAR Ph1/2 MRTX849 Solids KRAS G12C View

Description: A Phase 1/2 Multiple Expansion Cohort Trial of MRTX849 in Patients with Advanced Solid Tumors with KRAS G12C Mutation (849-001)

Indication: Lung Cancer

Location: Texas Oncology-Grapevine

Phase: I/II

Title: STAR Ph1/2 MRTX849 Solids KRAS G12C View

Description: A Phase 1/2 Multiple Expansion Cohort Trial of MRTX849 in Patients with Advanced Solid Tumors with KRAS G12C Mutation (849-001)

Indication: Cervical Cancer

Location: Texas Oncology-Grapevine

Phase: I/II

Title: STAR Ph1/2 MRTX849 Solids KRAS G12C View

Description: A Phase 1/2 Multiple Expansion Cohort Trial of MRTX849 in Patients with Advanced Solid Tumors with KRAS G12C Mutation (849-001)

Indication: Colon Cancer

Location: Texas Oncology-Grapevine

Phase: I/II

Title: STAR Ph1/2 MRTX849 Solids KRAS G12C View

Description: A Phase 1/2 Multiple Expansion Cohort Trial of MRTX849 in Patients with Advanced Solid Tumors with KRAS G12C Mutation (849-001)

Indication: Endometrial Cancer

Location: Texas Oncology-Grapevine

Phase: I/II

Title: STAR Ph1/2 MRTX849 Solids KRAS G12C View

Description: A Phase 1/2 Multiple Expansion Cohort Trial of MRTX849 in Patients with Advanced Solid Tumors with KRAS G12C Mutation (849-001)

Indication: Esophageal Cancer

Location: Texas Oncology-Grapevine

Phase: I/II

Title: STAR Ph1/2 MRTX849 Solids KRAS G12C View

Description: A Phase 1/2 Multiple Expansion Cohort Trial of MRTX849 in Patients with Advanced Solid Tumors with KRAS G12C Mutation (849-001)

Indication: Fallopian Tube Cancer

Location: Texas Oncology-Grapevine

Phase: I/II

Title: STAR Ph1/2 MRTX849 Solids KRAS G12C View

Description: A Phase 1/2 Multiple Expansion Cohort Trial of MRTX849 in Patients with Advanced Solid Tumors with KRAS G12C Mutation (849-001)

Indication: Gall Bladder Cancer

Location: Texas Oncology-Grapevine

Phase: I/II

Title: Pragmatic Phase III Randomized Trial Of Proton Vs. Photon Therapy For Patients With Non-Metastatic Breast Cancer Receiving Comprehensive Nodal Radiation: A Radiotherapy Comparative Effectiveness (Radcomp) Consortium Trial View

Indication: Breast Cancer

Location: Texas Oncology-Grapevine

Phase: III

No Phase

Title: FLEX Registry: Evaluate New Gene Express View

Description: MammaPrint BluePrint and Full-genome Data Linked with Clinical Data to Evaluate New Gene EXpression Profiles: An Adaptable Registry (FLEX Registry)

Indication: Breast Cancer

Location: Texas Oncology-Bedford

Title: EAP BGB-3111 B-Cell Malig View

Description: A Single-Arm Expanded Access Study of Zanubrutinib (BGB-3111) in Patients with B-cell Malignancies (BGB-3111-216)

Indication: Lymphomas

Location: Texas Oncology-Bedford

Title: Biomarker DNA Defect Men Prostate View

Description: Biomarker Study to Determine Frequency of DNA-repair Defects in Men with Metastatic Prostate Cancer (64091742PCR0002)

Indication: Prostate Cancer

Location: Texas Oncology-Fort Worth Cancer Center

Title: FLEX Registry: Evaluate New Gene Express View

Description: MammaPrint BluePrint and Full-genome Data Linked with Clinical Data to Evaluate New Gene EXpression Profiles: An Adaptable Registry (FLEX Registry)

Indication: Breast Cancer

Location: Texas Oncology-Grapevine

Title: EAP BGB-3111 B-Cell Malig View

Description: A Single-Arm Expanded Access Study of Zanubrutinib (BGB-3111) in Patients with B-cell Malignancies (BGB-3111-216)

Indication: Lymphomas

Location: Texas Oncology-Grapevine

Phase I

Title: STAR Ph1 CX-4945 Basal Cell Carcinoma View

Description: A Phase I Multi-Center Open-Label Treatment Duration Increment Expansion Safety and Pharmacodynamic Study of CX-4945 Administered Orally Twice Daily to Patients with Advanced Basal Cell Carcinoma (CX-4945-07)

Indication: Skin Cancer

Location: Texas Oncology-Arlington South

Phase: I

Title: STAR Ph1 CX-4945 Basal Cell Carcinoma View

Description: A Phase I Multi-Center Open-Label Treatment Duration Increment Expansion Safety and Pharmacodynamic Study of CX-4945 Administered Orally Twice Daily to Patients with Advanced Basal Cell Carcinoma (CX-4945-07)

Indication: Skin Cancer

Location: Texas Oncology-Bedford

Phase: I

Title: Ph 1 PF-06821497 R/R SCLC CRPC & FL View

Description: C2321001: A PHASE I DOSE ESCALATION AND EXPANDED COHORT STUDY OF PF-06821497 IN THE TREATMENT OF ADULT PATIENTS WITH RELAPSED/REFRACTORY SMALL CELL LUNG CANCER (SCLC) CASTRATION RESISTANT PROSTATE CANCER (CRPC) AND FOLLICULAR LYMPHOMA (FL)

Indication: Lung Cancer

Location: Texas Oncology-Fort Worth Cancer Center

Phase: I

Title: Ph 1 PF-06821497 R/R SCLC CRPC & FL View

Description: C2321001: A PHASE I DOSE ESCALATION AND EXPANDED COHORT STUDY OF PF-06821497 IN THE TREATMENT OF ADULT PATIENTS WITH RELAPSED/REFRACTORY SMALL CELL LUNG CANCER (SCLC) CASTRATION RESISTANT PROSTATE CANCER (CRPC) AND FOLLICULAR LYMPHOMA (FL)

Indication: Lymphomas

Location: Texas Oncology-Fort Worth Cancer Center

Phase: I

Title: Ph 1 PF-06821497 R/R SCLC CRPC & FL View

Description: C2321001: A PHASE I DOSE ESCALATION AND EXPANDED COHORT STUDY OF PF-06821497 IN THE TREATMENT OF ADULT PATIENTS WITH RELAPSED/REFRACTORY SMALL CELL LUNG CANCER (SCLC) CASTRATION RESISTANT PROSTATE CANCER (CRPC) AND FOLLICULAR LYMPHOMA (FL)

Indication: Prostate Cancer

Location: Texas Oncology-Fort Worth Cancer Center

Phase: I

Title: Ph 1 PF-06821497 R/R SCLC CRPC & FL View

Description: C2321001: A PHASE I DOSE ESCALATION AND EXPANDED COHORT STUDY OF PF-06821497 IN THE TREATMENT OF ADULT PATIENTS WITH RELAPSED/REFRACTORY SMALL CELL LUNG CANCER (SCLC) CASTRATION RESISTANT PROSTATE CANCER (CRPC) AND FOLLICULAR LYMPHOMA (FL)

Indication: Solid Tumors

Location: Texas Oncology-Fort Worth Cancer Center

Phase: I

Title: Ph 1b FIH XMT-1536 Solid Tumor NaPi2b View

Description: A Phase 1b/2 First-in-Human Dose Escalation and Expansion Study of XMT-1536 In Patients with Solid Tumors Likely to Express NaPi2b (MER-XMT-1536-1)

Indication: Lung Cancer

Location: Texas Oncology-Fort Worth Cancer Center

Phase: I

Title: Ph 1b FIH XMT-1536 Solid Tumor NaPi2b View

Description: A Phase 1b/2 First-in-Human Dose Escalation and Expansion Study of XMT-1536 In Patients with Solid Tumors Likely to Express NaPi2b (MER-XMT-1536-1)

Indication: Ovarian Cancer

Location: Texas Oncology-Fort Worth Cancer Center

Phase: I

Title: Ph 1/1b Immunotherapy Combo in NSCLC View

Description: (AB928CSP0004) A Phase 1/1b Study to Evaluate the Safety and Tolerability of Immunotherapy Combinations in Participants with Lung Cancer

Indication: Lung Cancer

Location: Texas Oncology-Fort Worth Cancer Center

Phase: I

Title: STAR Ph1 CX-4945 Basal Cell Carcinoma View

Description: A Phase I Multi-Center Open-Label Treatment Duration Increment Expansion Safety and Pharmacodynamic Study of CX-4945 Administered Orally Twice Daily to Patients with Advanced Basal Cell Carcinoma (CX-4945-07)

Indication: Skin Cancer

Location: Texas Oncology-Fort Worth Cancer Center

Phase: I

Title: STAR Ph1 CX-4945 Basal Cell Carcinoma View

Description: A Phase I Multi-Center Open-Label Treatment Duration Increment Expansion Safety and Pharmacodynamic Study of CX-4945 Administered Orally Twice Daily to Patients with Advanced Basal Cell Carcinoma (CX-4945-07)

Indication: Skin Cancer

Location: Texas Oncology-Grapevine

Phase: I

Phase I/II

Title: STAR PH 2 Enfortumab in Urothelial Pts View

Description: A study of enfortumab vedotin (ASG-22CE) as monotherapy or in combination with other anticancer therapies for the treatment of urothelial cancer (SGN22E-002)

Indication: Bladder Cancer

Location: Texas Oncology-Arlington South

Phase: I/II

Title: STAR PH 2 Enfortumab in Urothelial Pts View

Description: A study of enfortumab vedotin (ASG-22CE) as monotherapy or in combination with other anticancer therapies for the treatment of urothelial cancer (SGN22E-002)

Indication: Urothelial Cancer

Location: Texas Oncology-Arlington South

Phase: I/II

Title: STAR Ph1/2 MRTX849 Solids KRAS G12C View

Description: A Phase 1/2 Multiple Expansion Cohort Trial of MRTX849 in Patients with Advanced Solid Tumors with KRAS G12C Mutation (849-001)

Indication: Anal Cancer

Location: Texas Oncology-Arlington Cancer Center North

Phase: I/II

Title: STAR Ph1/2 MRTX849 Solids KRAS G12C View

Description: A Phase 1/2 Multiple Expansion Cohort Trial of MRTX849 in Patients with Advanced Solid Tumors with KRAS G12C Mutation (849-001)

Indication: Biliary Cancer

Location: Texas Oncology-Arlington Cancer Center North

Phase: I/II

Title: STAR Ph1/2 MRTX849 Solids KRAS G12C View

Description: A Phase 1/2 Multiple Expansion Cohort Trial of MRTX849 in Patients with Advanced Solid Tumors with KRAS G12C Mutation (849-001)

Indication: Bladder Cancer

Location: Texas Oncology-Arlington Cancer Center North

Phase: I/II

Title: STAR Ph1/2 MRTX849 Solids KRAS G12C View

Description: A Phase 1/2 Multiple Expansion Cohort Trial of MRTX849 in Patients with Advanced Solid Tumors with KRAS G12C Mutation (849-001)

Indication: Bone Mets

Location: Texas Oncology-Arlington Cancer Center North

Phase: I/II

Title: STAR Ph1/2 MRTX849 Solids KRAS G12C View

Description: A Phase 1/2 Multiple Expansion Cohort Trial of MRTX849 in Patients with Advanced Solid Tumors with KRAS G12C Mutation (849-001)

Indication: Brain Cancer

Location: Texas Oncology-Arlington Cancer Center North

Phase: I/II

Title: STAR Ph1/2 MRTX849 Solids KRAS G12C View

Description: A Phase 1/2 Multiple Expansion Cohort Trial of MRTX849 in Patients with Advanced Solid Tumors with KRAS G12C Mutation (849-001)

Indication: Breast Cancer

Location: Texas Oncology-Arlington Cancer Center North

Phase: I/II

Title: STAR Ph1/2 MRTX849 Solids KRAS G12C View

Description: A Phase 1/2 Multiple Expansion Cohort Trial of MRTX849 in Patients with Advanced Solid Tumors with KRAS G12C Mutation (849-001)

Indication: Urothelial Cancer

Location: Texas Oncology-Arlington Cancer Center North

Phase: I/II

Title: STAR Ph1/2 MRTX849 Solids KRAS G12C View

Description: A Phase 1/2 Multiple Expansion Cohort Trial of MRTX849 in Patients with Advanced Solid Tumors with KRAS G12C Mutation (849-001)

Indication: Uterine Cancer

Location: Texas Oncology-Arlington Cancer Center North

Phase: I/II

Title: STAR Ph1/2 MRTX849 Solids KRAS G12C View

Description: A Phase 1/2 Multiple Expansion Cohort Trial of MRTX849 in Patients with Advanced Solid Tumors with KRAS G12C Mutation (849-001)

Indication: Vaginal Cancer

Location: Texas Oncology-Arlington Cancer Center North

Phase: I/II

Title: STAR Ph1/2 MRTX849 Solids KRAS G12C View

Description: A Phase 1/2 Multiple Expansion Cohort Trial of MRTX849 in Patients with Advanced Solid Tumors with KRAS G12C Mutation (849-001)

Indication: Vulvar Cancer

Location: Texas Oncology-Arlington Cancer Center North

Phase: I/II

Title: STAR Ph1/2 MRTX849 Solids KRAS G12C View

Description: A Phase 1/2 Multiple Expansion Cohort Trial of MRTX849 in Patients with Advanced Solid Tumors with KRAS G12C Mutation (849-001)

Indication: Rectal Cancer

Location: Texas Oncology-Arlington Cancer Center North

Phase: I/II

Title: STAR Ph1/2 MRTX849 Solids KRAS G12C View

Description: A Phase 1/2 Multiple Expansion Cohort Trial of MRTX849 in Patients with Advanced Solid Tumors with KRAS G12C Mutation (849-001)

Indication: Renal Cancer

Location: Texas Oncology-Arlington Cancer Center North

Phase: I/II

Title: STAR Ph1/2 MRTX849 Solids KRAS G12C View

Description: A Phase 1/2 Multiple Expansion Cohort Trial of MRTX849 in Patients with Advanced Solid Tumors with KRAS G12C Mutation (849-001)

Indication: Sarcoma

Location: Texas Oncology-Arlington Cancer Center North

Phase: I/II

Title: STAR Ph1/2 MRTX849 Solids KRAS G12C View

Description: A Phase 1/2 Multiple Expansion Cohort Trial of MRTX849 in Patients with Advanced Solid Tumors with KRAS G12C Mutation (849-001)

Indication: Solid Tumors

Location: Texas Oncology-Arlington Cancer Center North

Phase: I/II

Title: STAR Ph1/2 MRTX849 Solids KRAS G12C View

Description: A Phase 1/2 Multiple Expansion Cohort Trial of MRTX849 in Patients with Advanced Solid Tumors with KRAS G12C Mutation (849-001)

Indication: Testicular Cancer

Location: Texas Oncology-Arlington Cancer Center North

Phase: I/II

Title: STAR Ph1/2 MRTX849 Solids KRAS G12C View

Description: A Phase 1/2 Multiple Expansion Cohort Trial of MRTX849 in Patients with Advanced Solid Tumors with KRAS G12C Mutation (849-001)

Indication: Thyroid Cancer

Location: Texas Oncology-Arlington Cancer Center North

Phase: I/II

Title: STAR Ph1/2 MRTX849 Solids KRAS G12C View

Description: A Phase 1/2 Multiple Expansion Cohort Trial of MRTX849 in Patients with Advanced Solid Tumors with KRAS G12C Mutation (849-001)

Indication: Malignant Adenoma

Location: Texas Oncology-Arlington Cancer Center North

Phase: I/II

Title: STAR Ph1/2 MRTX849 Solids KRAS G12C View

Description: A Phase 1/2 Multiple Expansion Cohort Trial of MRTX849 in Patients with Advanced Solid Tumors with KRAS G12C Mutation (849-001)

Indication: Ovarian Cancer

Location: Texas Oncology-Arlington Cancer Center North

Phase: I/II

Title: STAR Ph1/2 MRTX849 Solids KRAS G12C View

Description: A Phase 1/2 Multiple Expansion Cohort Trial of MRTX849 in Patients with Advanced Solid Tumors with KRAS G12C Mutation (849-001)

Indication: Pancreatic Cancer

Location: Texas Oncology-Arlington Cancer Center North

Phase: I/II

Title: STAR Ph1/2 MRTX849 Solids KRAS G12C View

Description: A Phase 1/2 Multiple Expansion Cohort Trial of MRTX849 in Patients with Advanced Solid Tumors with KRAS G12C Mutation (849-001)

Indication: Penile Cancer

Location: Texas Oncology-Arlington Cancer Center North

Phase: I/II

Title: STAR Ph1/2 MRTX849 Solids KRAS G12C View

Description: A Phase 1/2 Multiple Expansion Cohort Trial of MRTX849 in Patients with Advanced Solid Tumors with KRAS G12C Mutation (849-001)

Indication: Peritoneal Cancer

Location: Texas Oncology-Arlington Cancer Center North

Phase: I/II

Title: STAR Ph1/2 MRTX849 Solids KRAS G12C View

Description: A Phase 1/2 Multiple Expansion Cohort Trial of MRTX849 in Patients with Advanced Solid Tumors with KRAS G12C Mutation (849-001)

Indication: Prostate Cancer

Location: Texas Oncology-Arlington Cancer Center North

Phase: I/II

Title: STAR Ph1/2 MRTX849 Solids KRAS G12C View

Description: A Phase 1/2 Multiple Expansion Cohort Trial of MRTX849 in Patients with Advanced Solid Tumors with KRAS G12C Mutation (849-001)

Indication: Gastric Cancer

Location: Texas Oncology-Arlington Cancer Center North

Phase: I/II

Title: STAR Ph1/2 MRTX849 Solids KRAS G12C View

Description: A Phase 1/2 Multiple Expansion Cohort Trial of MRTX849 in Patients with Advanced Solid Tumors with KRAS G12C Mutation (849-001)

Indication: Head and Neck Cancer

Location: Texas Oncology-Arlington Cancer Center North

Phase: I/II

Title: STAR Ph1/2 MRTX849 Solids KRAS G12C View

Description: A Phase 1/2 Multiple Expansion Cohort Trial of MRTX849 in Patients with Advanced Solid Tumors with KRAS G12C Mutation (849-001)

Indication: Kaposi's Sarcoma

Location: Texas Oncology-Arlington Cancer Center North

Phase: I/II

Title: STAR Ph1/2 MRTX849 Solids KRAS G12C View

Description: A Phase 1/2 Multiple Expansion Cohort Trial of MRTX849 in Patients with Advanced Solid Tumors with KRAS G12C Mutation (849-001)

Indication: Kidney Cancer

Location: Texas Oncology-Arlington Cancer Center North

Phase: I/II

Title: STAR Ph1/2 MRTX849 Solids KRAS G12C View

Description: A Phase 1/2 Multiple Expansion Cohort Trial of MRTX849 in Patients with Advanced Solid Tumors with KRAS G12C Mutation (849-001)

Indication: Liver Cancer

Location: Texas Oncology-Arlington Cancer Center North

Phase: I/II

Title: STAR Ph1/2 MRTX849 Solids KRAS G12C View

Description: A Phase 1/2 Multiple Expansion Cohort Trial of MRTX849 in Patients with Advanced Solid Tumors with KRAS G12C Mutation (849-001)

Indication: Lung Cancer

Location: Texas Oncology-Arlington Cancer Center North

Phase: I/II

Title: STAR Ph1/2 MRTX849 Solids KRAS G12C View

Description: A Phase 1/2 Multiple Expansion Cohort Trial of MRTX849 in Patients with Advanced Solid Tumors with KRAS G12C Mutation (849-001)

Indication: Cervical Cancer

Location: Texas Oncology-Arlington Cancer Center North

Phase: I/II

Title: STAR Ph1/2 MRTX849 Solids KRAS G12C View

Description: A Phase 1/2 Multiple Expansion Cohort Trial of MRTX849 in Patients with Advanced Solid Tumors with KRAS G12C Mutation (849-001)

Indication: Colon Cancer

Location: Texas Oncology-Arlington Cancer Center North

Phase: I/II

Title: STAR Ph1/2 MRTX849 Solids KRAS G12C View

Description: A Phase 1/2 Multiple Expansion Cohort Trial of MRTX849 in Patients with Advanced Solid Tumors with KRAS G12C Mutation (849-001)

Indication: Endometrial Cancer

Location: Texas Oncology-Arlington Cancer Center North

Phase: I/II

Title: STAR Ph1/2 MRTX849 Solids KRAS G12C View

Description: A Phase 1/2 Multiple Expansion Cohort Trial of MRTX849 in Patients with Advanced Solid Tumors with KRAS G12C Mutation (849-001)

Indication: Esophageal Cancer

Location: Texas Oncology-Arlington Cancer Center North

Phase: I/II

Title: STAR Ph1/2 MRTX849 Solids KRAS G12C View

Description: A Phase 1/2 Multiple Expansion Cohort Trial of MRTX849 in Patients with Advanced Solid Tumors with KRAS G12C Mutation (849-001)

Indication: Fallopian Tube Cancer

Location: Texas Oncology-Arlington Cancer Center North

Phase: I/II

Title: STAR Ph1/2 MRTX849 Solids KRAS G12C View

Description: A Phase 1/2 Multiple Expansion Cohort Trial of MRTX849 in Patients with Advanced Solid Tumors with KRAS G12C Mutation (849-001)

Indication: Gall Bladder Cancer

Location: Texas Oncology-Arlington Cancer Center North

Phase: I/II

Title: STAR Ph1/2 MRTX849 Solids KRAS G12C View

Description: A Phase 1/2 Multiple Expansion Cohort Trial of MRTX849 in Patients with Advanced Solid Tumors with KRAS G12C Mutation (849-001)

Indication: Anal Cancer

Location: Texas Oncology-Arlington South

Phase: I/II

Title: STAR Ph1/2 MRTX849 Solids KRAS G12C View

Description: A Phase 1/2 Multiple Expansion Cohort Trial of MRTX849 in Patients with Advanced Solid Tumors with KRAS G12C Mutation (849-001)

Indication: Biliary Cancer

Location: Texas Oncology-Arlington South

Phase: I/II

Title: STAR Ph1/2 MRTX849 Solids KRAS G12C View

Description: A Phase 1/2 Multiple Expansion Cohort Trial of MRTX849 in Patients with Advanced Solid Tumors with KRAS G12C Mutation (849-001)

Indication: Bladder Cancer

Location: Texas Oncology-Arlington South

Phase: I/II

Title: STAR Ph1/2 MRTX849 Solids KRAS G12C View

Description: A Phase 1/2 Multiple Expansion Cohort Trial of MRTX849 in Patients with Advanced Solid Tumors with KRAS G12C Mutation (849-001)

Indication: Bone Mets

Location: Texas Oncology-Arlington South

Phase: I/II

Title: STAR Ph1/2 MRTX849 Solids KRAS G12C View

Description: A Phase 1/2 Multiple Expansion Cohort Trial of MRTX849 in Patients with Advanced Solid Tumors with KRAS G12C Mutation (849-001)

Indication: Brain Cancer

Location: Texas Oncology-Arlington South

Phase: I/II

Title: STAR Ph1/2 MRTX849 Solids KRAS G12C View

Description: A Phase 1/2 Multiple Expansion Cohort Trial of MRTX849 in Patients with Advanced Solid Tumors with KRAS G12C Mutation (849-001)

Indication: Breast Cancer

Location: Texas Oncology-Arlington South

Phase: I/II

Title: STAR Ph1/2 MRTX849 Solids KRAS G12C View

Description: A Phase 1/2 Multiple Expansion Cohort Trial of MRTX849 in Patients with Advanced Solid Tumors with KRAS G12C Mutation (849-001)

Indication: Urothelial Cancer

Location: Texas Oncology-Arlington South

Phase: I/II

Title: STAR Ph1/2 MRTX849 Solids KRAS G12C View

Description: A Phase 1/2 Multiple Expansion Cohort Trial of MRTX849 in Patients with Advanced Solid Tumors with KRAS G12C Mutation (849-001)

Indication: Uterine Cancer

Location: Texas Oncology-Arlington South

Phase: I/II

Title: STAR Ph1/2 MRTX849 Solids KRAS G12C View

Description: A Phase 1/2 Multiple Expansion Cohort Trial of MRTX849 in Patients with Advanced Solid Tumors with KRAS G12C Mutation (849-001)

Indication: Vaginal Cancer

Location: Texas Oncology-Arlington South

Phase: I/II

Title: STAR Ph1/2 MRTX849 Solids KRAS G12C View

Description: A Phase 1/2 Multiple Expansion Cohort Trial of MRTX849 in Patients with Advanced Solid Tumors with KRAS G12C Mutation (849-001)

Indication: Vulvar Cancer

Location: Texas Oncology-Arlington South

Phase: I/II

Title: STAR Ph1/2 MRTX849 Solids KRAS G12C View

Description: A Phase 1/2 Multiple Expansion Cohort Trial of MRTX849 in Patients with Advanced Solid Tumors with KRAS G12C Mutation (849-001)

Indication: Rectal Cancer

Location: Texas Oncology-Arlington South

Phase: I/II

Title: STAR Ph1/2 MRTX849 Solids KRAS G12C View

Description: A Phase 1/2 Multiple Expansion Cohort Trial of MRTX849 in Patients with Advanced Solid Tumors with KRAS G12C Mutation (849-001)

Indication: Renal Cancer

Location: Texas Oncology-Arlington South

Phase: I/II

Title: STAR Ph1/2 MRTX849 Solids KRAS G12C View

Description: A Phase 1/2 Multiple Expansion Cohort Trial of MRTX849 in Patients with Advanced Solid Tumors with KRAS G12C Mutation (849-001)

Indication: Sarcoma

Location: Texas Oncology-Arlington South

Phase: I/II

Title: STAR Ph1/2 MRTX849 Solids KRAS G12C View

Description: A Phase 1/2 Multiple Expansion Cohort Trial of MRTX849 in Patients with Advanced Solid Tumors with KRAS G12C Mutation (849-001)

Indication: Solid Tumors

Location: Texas Oncology-Arlington South

Phase: I/II

Title: STAR Ph1/2 MRTX849 Solids KRAS G12C View

Description: A Phase 1/2 Multiple Expansion Cohort Trial of MRTX849 in Patients with Advanced Solid Tumors with KRAS G12C Mutation (849-001)

Indication: Testicular Cancer

Location: Texas Oncology-Arlington South

Phase: I/II

Title: STAR Ph1/2 MRTX849 Solids KRAS G12C View

Description: A Phase 1/2 Multiple Expansion Cohort Trial of MRTX849 in Patients with Advanced Solid Tumors with KRAS G12C Mutation (849-001)

Indication: Thyroid Cancer

Location: Texas Oncology-Arlington South

Phase: I/II

Title: STAR Ph1/2 MRTX849 Solids KRAS G12C View

Description: A Phase 1/2 Multiple Expansion Cohort Trial of MRTX849 in Patients with Advanced Solid Tumors with KRAS G12C Mutation (849-001)

Indication: Malignant Adenoma

Location: Texas Oncology-Arlington South

Phase: I/II

Title: STAR Ph1/2 MRTX849 Solids KRAS G12C View

Description: A Phase 1/2 Multiple Expansion Cohort Trial of MRTX849 in Patients with Advanced Solid Tumors with KRAS G12C Mutation (849-001)

Indication: Ovarian Cancer

Location: Texas Oncology-Arlington South

Phase: I/II

Title: STAR Ph1/2 MRTX849 Solids KRAS G12C View

Description: A Phase 1/2 Multiple Expansion Cohort Trial of MRTX849 in Patients with Advanced Solid Tumors with KRAS G12C Mutation (849-001)

Indication: Pancreatic Cancer

Location: Texas Oncology-Arlington South

Phase: I/II

Title: STAR Ph1/2 MRTX849 Solids KRAS G12C View

Description: A Phase 1/2 Multiple Expansion Cohort Trial of MRTX849 in Patients with Advanced Solid Tumors with KRAS G12C Mutation (849-001)

Indication: Penile Cancer

Location: Texas Oncology-Arlington South

Phase: I/II

Title: STAR Ph1/2 MRTX849 Solids KRAS G12C View

Description: A Phase 1/2 Multiple Expansion Cohort Trial of MRTX849 in Patients with Advanced Solid Tumors with KRAS G12C Mutation (849-001)

Indication: Peritoneal Cancer

Location: Texas Oncology-Arlington South

Phase: I/II

Title: STAR Ph1/2 MRTX849 Solids KRAS G12C View

Description: A Phase 1/2 Multiple Expansion Cohort Trial of MRTX849 in Patients with Advanced Solid Tumors with KRAS G12C Mutation (849-001)

Indication: Prostate Cancer

Location: Texas Oncology-Arlington South

Phase: I/II

Title: STAR Ph1/2 MRTX849 Solids KRAS G12C View

Description: A Phase 1/2 Multiple Expansion Cohort Trial of MRTX849 in Patients with Advanced Solid Tumors with KRAS G12C Mutation (849-001)

Indication: Gastric Cancer

Location: Texas Oncology-Arlington South

Phase: I/II

Title: STAR Ph1/2 MRTX849 Solids KRAS G12C View

Description: A Phase 1/2 Multiple Expansion Cohort Trial of MRTX849 in Patients with Advanced Solid Tumors with KRAS G12C Mutation (849-001)

Indication: Head and Neck Cancer

Location: Texas Oncology-Arlington South

Phase: I/II

Title: STAR Ph1/2 MRTX849 Solids KRAS G12C View

Description: A Phase 1/2 Multiple Expansion Cohort Trial of MRTX849 in Patients with Advanced Solid Tumors with KRAS G12C Mutation (849-001)

Indication: Kaposi's Sarcoma

Location: Texas Oncology-Arlington South

Phase: I/II

Title: STAR Ph1/2 MRTX849 Solids KRAS G12C View

Description: A Phase 1/2 Multiple Expansion Cohort Trial of MRTX849 in Patients with Advanced Solid Tumors with KRAS G12C Mutation (849-001)

Indication: Kidney Cancer

Location: Texas Oncology-Arlington South

Phase: I/II

Title: STAR Ph1/2 MRTX849 Solids KRAS G12C View

Description: A Phase 1/2 Multiple Expansion Cohort Trial of MRTX849 in Patients with Advanced Solid Tumors with KRAS G12C Mutation (849-001)

Indication: Liver Cancer

Location: Texas Oncology-Arlington South

Phase: I/II

Title: STAR Ph1/2 MRTX849 Solids KRAS G12C View

Description: A Phase 1/2 Multiple Expansion Cohort Trial of MRTX849 in Patients with Advanced Solid Tumors with KRAS G12C Mutation (849-001)

Indication: Lung Cancer

Location: Texas Oncology-Arlington South

Phase: I/II

Title: STAR Ph1/2 MRTX849 Solids KRAS G12C View

Description: A Phase 1/2 Multiple Expansion Cohort Trial of MRTX849 in Patients with Advanced Solid Tumors with KRAS G12C Mutation (849-001)

Indication: Cervical Cancer

Location: Texas Oncology-Arlington South

Phase: I/II

Title: STAR Ph1/2 MRTX849 Solids KRAS G12C View

Description: A Phase 1/2 Multiple Expansion Cohort Trial of MRTX849 in Patients with Advanced Solid Tumors with KRAS G12C Mutation (849-001)

Indication: Colon Cancer

Location: Texas Oncology-Arlington South

Phase: I/II

Title: STAR Ph1/2 MRTX849 Solids KRAS G12C View

Description: A Phase 1/2 Multiple Expansion Cohort Trial of MRTX849 in Patients with Advanced Solid Tumors with KRAS G12C Mutation (849-001)

Indication: Endometrial Cancer

Location: Texas Oncology-Arlington South

Phase: I/II

Title: STAR Ph1/2 MRTX849 Solids KRAS G12C View

Description: A Phase 1/2 Multiple Expansion Cohort Trial of MRTX849 in Patients with Advanced Solid Tumors with KRAS G12C Mutation (849-001)

Indication: Esophageal Cancer

Location: Texas Oncology-Arlington South

Phase: I/II

Title: STAR Ph1/2 MRTX849 Solids KRAS G12C View

Description: A Phase 1/2 Multiple Expansion Cohort Trial of MRTX849 in Patients with Advanced Solid Tumors with KRAS G12C Mutation (849-001)

Indication: Fallopian Tube Cancer

Location: Texas Oncology-Arlington South

Phase: I/II

Title: STAR Ph1/2 MRTX849 Solids KRAS G12C View

Description: A Phase 1/2 Multiple Expansion Cohort Trial of MRTX849 in Patients with Advanced Solid Tumors with KRAS G12C Mutation (849-001)

Indication: Gall Bladder Cancer

Location: Texas Oncology-Arlington South

Phase: I/II

Title: STAR Ph1/2 BLU667 thy NSCLC Sol tum View

Description: A Phase 1/2 Study of the Highly-selective RET Inhibitor BLU-667 in Patients with Thyroid Cancer Non-Small Cell Lung Cancer (NSCLC) and Other Advanced Solid Tumors (BLU-667-1101)

Indication: Lung Cancer

Location: Texas Oncology-Arlington South

Phase: I/II

Title: STAR Ph1/2 BLU667 thy NSCLC Sol tum View

Description: A Phase 1/2 Study of the Highly-selective RET Inhibitor BLU-667 in Patients with Thyroid Cancer Non-Small Cell Lung Cancer (NSCLC) and Other Advanced Solid Tumors (BLU-667-1101)

Indication: Solid Tumors

Location: Texas Oncology-Arlington South

Phase: I/II

Title: STAR Ph1/2 BLU667 thy NSCLC Sol tum View

Description: A Phase 1/2 Study of the Highly-selective RET Inhibitor BLU-667 in Patients with Thyroid Cancer Non-Small Cell Lung Cancer (NSCLC) and Other Advanced Solid Tumors (BLU-667-1101)

Indication: Thyroid Cancer

Location: Texas Oncology-Arlington South

Phase: I/II

Title: STAR Ph1/2 BLU667 thy NSCLC Sol tum View

Description: A Phase 1/2 Study of the Highly-selective RET Inhibitor BLU-667 in Patients with Thyroid Cancer Non-Small Cell Lung Cancer (NSCLC) and Other Advanced Solid Tumors (BLU-667-1101)

Indication: Lung Cancer

Location: Texas Oncology-Bedford

Phase: I/II

Title: STAR Ph1/2 BLU667 thy NSCLC Sol tum View

Description: A Phase 1/2 Study of the Highly-selective RET Inhibitor BLU-667 in Patients with Thyroid Cancer Non-Small Cell Lung Cancer (NSCLC) and Other Advanced Solid Tumors (BLU-667-1101)

Indication: Solid Tumors

Location: Texas Oncology-Bedford

Phase: I/II

Title: STAR Ph1/2 BLU667 thy NSCLC Sol tum View

Description: A Phase 1/2 Study of the Highly-selective RET Inhibitor BLU-667 in Patients with Thyroid Cancer Non-Small Cell Lung Cancer (NSCLC) and Other Advanced Solid Tumors (BLU-667-1101)

Indication: Thyroid Cancer

Location: Texas Oncology-Bedford

Phase: I/II

Title: STAR Ph1/2 MRTX849 Solids KRAS G12C View

Description: A Phase 1/2 Multiple Expansion Cohort Trial of MRTX849 in Patients with Advanced Solid Tumors with KRAS G12C Mutation (849-001)

Indication: Anal Cancer

Location: Texas Oncology-Bedford

Phase: I/II

Title: STAR Ph1/2 MRTX849 Solids KRAS G12C View

Description: A Phase 1/2 Multiple Expansion Cohort Trial of MRTX849 in Patients with Advanced Solid Tumors with KRAS G12C Mutation (849-001)

Indication: Biliary Cancer

Location: Texas Oncology-Bedford

Phase: I/II

Title: STAR Ph1/2 MRTX849 Solids KRAS G12C View

Description: A Phase 1/2 Multiple Expansion Cohort Trial of MRTX849 in Patients with Advanced Solid Tumors with KRAS G12C Mutation (849-001)

Indication: Bladder Cancer

Location: Texas Oncology-Bedford

Phase: I/II

Title: STAR Ph1/2 MRTX849 Solids KRAS G12C View

Description: A Phase 1/2 Multiple Expansion Cohort Trial of MRTX849 in Patients with Advanced Solid Tumors with KRAS G12C Mutation (849-001)

Indication: Bone Mets

Location: Texas Oncology-Bedford

Phase: I/II

Title: STAR Ph1/2 MRTX849 Solids KRAS G12C View

Description: A Phase 1/2 Multiple Expansion Cohort Trial of MRTX849 in Patients with Advanced Solid Tumors with KRAS G12C Mutation (849-001)

Indication: Brain Cancer

Location: Texas Oncology-Bedford

Phase: I/II

Title: STAR Ph1/2 MRTX849 Solids KRAS G12C View

Description: A Phase 1/2 Multiple Expansion Cohort Trial of MRTX849 in Patients with Advanced Solid Tumors with KRAS G12C Mutation (849-001)

Indication: Breast Cancer

Location: Texas Oncology-Bedford

Phase: I/II

Title: STAR Ph1/2 MRTX849 Solids KRAS G12C View

Description: A Phase 1/2 Multiple Expansion Cohort Trial of MRTX849 in Patients with Advanced Solid Tumors with KRAS G12C Mutation (849-001)

Indication: Urothelial Cancer

Location: Texas Oncology-Bedford

Phase: I/II

Title: STAR Ph1/2 MRTX849 Solids KRAS G12C View

Description: A Phase 1/2 Multiple Expansion Cohort Trial of MRTX849 in Patients with Advanced Solid Tumors with KRAS G12C Mutation (849-001)

Indication: Uterine Cancer

Location: Texas Oncology-Bedford

Phase: I/II

Title: STAR Ph1/2 MRTX849 Solids KRAS G12C View

Description: A Phase 1/2 Multiple Expansion Cohort Trial of MRTX849 in Patients with Advanced Solid Tumors with KRAS G12C Mutation (849-001)

Indication: Vaginal Cancer

Location: Texas Oncology-Bedford

Phase: I/II

Title: STAR Ph1/2 MRTX849 Solids KRAS G12C View

Description: A Phase 1/2 Multiple Expansion Cohort Trial of MRTX849 in Patients with Advanced Solid Tumors with KRAS G12C Mutation (849-001)

Indication: Vulvar Cancer

Location: Texas Oncology-Bedford

Phase: I/II

Title: STAR Ph1/2 MRTX849 Solids KRAS G12C View

Description: A Phase 1/2 Multiple Expansion Cohort Trial of MRTX849 in Patients with Advanced Solid Tumors with KRAS G12C Mutation (849-001)

Indication: Rectal Cancer

Location: Texas Oncology-Bedford

Phase: I/II

Title: STAR Ph1/2 MRTX849 Solids KRAS G12C View

Description: A Phase 1/2 Multiple Expansion Cohort Trial of MRTX849 in Patients with Advanced Solid Tumors with KRAS G12C Mutation (849-001)

Indication: Renal Cancer

Location: Texas Oncology-Bedford

Phase: I/II

Title: STAR Ph1/2 MRTX849 Solids KRAS G12C View

Description: A Phase 1/2 Multiple Expansion Cohort Trial of MRTX849 in Patients with Advanced Solid Tumors with KRAS G12C Mutation (849-001)

Indication: Sarcoma

Location: Texas Oncology-Bedford

Phase: I/II

Title: STAR Ph1/2 MRTX849 Solids KRAS G12C View

Description: A Phase 1/2 Multiple Expansion Cohort Trial of MRTX849 in Patients with Advanced Solid Tumors with KRAS G12C Mutation (849-001)

Indication: Solid Tumors

Location: Texas Oncology-Bedford

Phase: I/II

Title: STAR Ph1/2 MRTX849 Solids KRAS G12C View

Description: A Phase 1/2 Multiple Expansion Cohort Trial of MRTX849 in Patients with Advanced Solid Tumors with KRAS G12C Mutation (849-001)

Indication: Testicular Cancer

Location: Texas Oncology-Bedford

Phase: I/II

Title: STAR Ph1/2 MRTX849 Solids KRAS G12C View

Description: A Phase 1/2 Multiple Expansion Cohort Trial of MRTX849 in Patients with Advanced Solid Tumors with KRAS G12C Mutation (849-001)

Indication: Thyroid Cancer

Location: Texas Oncology-Bedford

Phase: I/II

Title: STAR Ph1/2 MRTX849 Solids KRAS G12C View

Description: A Phase 1/2 Multiple Expansion Cohort Trial of MRTX849 in Patients with Advanced Solid Tumors with KRAS G12C Mutation (849-001)

Indication: Malignant Adenoma

Location: Texas Oncology-Bedford

Phase: I/II

Title: STAR Ph1/2 MRTX849 Solids KRAS G12C View

Description: A Phase 1/2 Multiple Expansion Cohort Trial of MRTX849 in Patients with Advanced Solid Tumors with KRAS G12C Mutation (849-001)

Indication: Ovarian Cancer

Location: Texas Oncology-Bedford

Phase: I/II

Title: STAR Ph1/2 MRTX849 Solids KRAS G12C View

Description: A Phase 1/2 Multiple Expansion Cohort Trial of MRTX849 in Patients with Advanced Solid Tumors with KRAS G12C Mutation (849-001)

Indication: Pancreatic Cancer

Location: Texas Oncology-Bedford

Phase: I/II

Title: STAR Ph1/2 MRTX849 Solids KRAS G12C View

Description: A Phase 1/2 Multiple Expansion Cohort Trial of MRTX849 in Patients with Advanced Solid Tumors with KRAS G12C Mutation (849-001)

Indication: Penile Cancer

Location: Texas Oncology-Bedford

Phase: I/II

Title: STAR Ph1/2 MRTX849 Solids KRAS G12C View

Description: A Phase 1/2 Multiple Expansion Cohort Trial of MRTX849 in Patients with Advanced Solid Tumors with KRAS G12C Mutation (849-001)

Indication: Peritoneal Cancer

Location: Texas Oncology-Bedford

Phase: I/II

Title: STAR Ph1/2 MRTX849 Solids KRAS G12C View

Description: A Phase 1/2 Multiple Expansion Cohort Trial of MRTX849 in Patients with Advanced Solid Tumors with KRAS G12C Mutation (849-001)

Indication: Prostate Cancer

Location: Texas Oncology-Bedford

Phase: I/II

Title: STAR Ph1/2 MRTX849 Solids KRAS G12C View

Description: A Phase 1/2 Multiple Expansion Cohort Trial of MRTX849 in Patients with Advanced Solid Tumors with KRAS G12C Mutation (849-001)

Indication: Gastric Cancer

Location: Texas Oncology-Bedford

Phase: I/II

Title: STAR Ph1/2 MRTX849 Solids KRAS G12C View

Description: A Phase 1/2 Multiple Expansion Cohort Trial of MRTX849 in Patients with Advanced Solid Tumors with KRAS G12C Mutation (849-001)

Indication: Head and Neck Cancer

Location: Texas Oncology-Bedford

Phase: I/II

Title: STAR Ph1/2 MRTX849 Solids KRAS G12C View

Description: A Phase 1/2 Multiple Expansion Cohort Trial of MRTX849 in Patients with Advanced Solid Tumors with KRAS G12C Mutation (849-001)

Indication: Kaposi's Sarcoma

Location: Texas Oncology-Bedford

Phase: I/II

Title: STAR Ph1/2 MRTX849 Solids KRAS G12C View

Description: A Phase 1/2 Multiple Expansion Cohort Trial of MRTX849 in Patients with Advanced Solid Tumors with KRAS G12C Mutation (849-001)

Indication: Kidney Cancer

Location: Texas Oncology-Bedford

Phase: I/II

Title: STAR Ph1/2 MRTX849 Solids KRAS G12C View

Description: A Phase 1/2 Multiple Expansion Cohort Trial of MRTX849 in Patients with Advanced Solid Tumors with KRAS G12C Mutation (849-001)

Indication: Liver Cancer

Location: Texas Oncology-Bedford

Phase: I/II

Title: STAR Ph1/2 MRTX849 Solids KRAS G12C View

Description: A Phase 1/2 Multiple Expansion Cohort Trial of MRTX849 in Patients with Advanced Solid Tumors with KRAS G12C Mutation (849-001)

Indication: Lung Cancer

Location: Texas Oncology-Bedford

Phase: I/II

Title: STAR Ph1/2 MRTX849 Solids KRAS G12C View

Description: A Phase 1/2 Multiple Expansion Cohort Trial of MRTX849 in Patients with Advanced Solid Tumors with KRAS G12C Mutation (849-001)

Indication: Cervical Cancer

Location: Texas Oncology-Bedford

Phase: I/II

Title: STAR Ph1/2 MRTX849 Solids KRAS G12C View

Description: A Phase 1/2 Multiple Expansion Cohort Trial of MRTX849 in Patients with Advanced Solid Tumors with KRAS G12C Mutation (849-001)

Indication: Colon Cancer

Location: Texas Oncology-Bedford

Phase: I/II

Title: STAR Ph1/2 MRTX849 Solids KRAS G12C View

Description: A Phase 1/2 Multiple Expansion Cohort Trial of MRTX849 in Patients with Advanced Solid Tumors with KRAS G12C Mutation (849-001)

Indication: Endometrial Cancer

Location: Texas Oncology-Bedford

Phase: I/II

Title: STAR Ph1/2 MRTX849 Solids KRAS G12C View

Description: A Phase 1/2 Multiple Expansion Cohort Trial of MRTX849 in Patients with Advanced Solid Tumors with KRAS G12C Mutation (849-001)

Indication: Esophageal Cancer

Location: Texas Oncology-Bedford

Phase: I/II

Title: STAR Ph1/2 MRTX849 Solids KRAS G12C View

Description: A Phase 1/2 Multiple Expansion Cohort Trial of MRTX849 in Patients with Advanced Solid Tumors with KRAS G12C Mutation (849-001)

Indication: Fallopian Tube Cancer

Location: Texas Oncology-Bedford

Phase: I/II

Title: STAR Ph1/2 MRTX849 Solids KRAS G12C View

Description: A Phase 1/2 Multiple Expansion Cohort Trial of MRTX849 in Patients with Advanced Solid Tumors with KRAS G12C Mutation (849-001)

Indication: Gall Bladder Cancer

Location: Texas Oncology-Bedford

Phase: I/II

Title: STAR PH 2 Enfortumab in Urothelial Pts View

Description: A study of enfortumab vedotin (ASG-22CE) as monotherapy or in combination with other anticancer therapies for the treatment of urothelial cancer (SGN22E-002)

Indication: Bladder Cancer

Location: Texas Oncology-Bedford

Phase: I/II

Title: STAR PH 2 Enfortumab in Urothelial Pts View

Description: A study of enfortumab vedotin (ASG-22CE) as monotherapy or in combination with other anticancer therapies for the treatment of urothelial cancer (SGN22E-002)

Indication: Urothelial Cancer

Location: Texas Oncology-Bedford

Phase: I/II

Title: STAR PH 2 Enfortumab in Urothelial Pts View

Description: A study of enfortumab vedotin (ASG-22CE) as monotherapy or in combination with other anticancer therapies for the treatment of urothelial cancer (SGN22E-002)

Indication: Bladder Cancer

Location: Texas Oncology-Fort Worth Cancer Center

Phase: I/II

Title: STAR PH 2 Enfortumab in Urothelial Pts View

Description: A study of enfortumab vedotin (ASG-22CE) as monotherapy or in combination with other anticancer therapies for the treatment of urothelial cancer (SGN22E-002)

Indication: Urothelial Cancer

Location: Texas Oncology-Fort Worth Cancer Center

Phase: I/II

Title: STAR Ph1/2 MRTX849 Solids KRAS G12C View

Description: A Phase 1/2 Multiple Expansion Cohort Trial of MRTX849 in Patients with Advanced Solid Tumors with KRAS G12C Mutation (849-001)

Indication: Anal Cancer

Location: Texas Oncology-Fort Worth Cancer Center

Phase: I/II

Title: STAR Ph1/2 MRTX849 Solids KRAS G12C View

Description: A Phase 1/2 Multiple Expansion Cohort Trial of MRTX849 in Patients with Advanced Solid Tumors with KRAS G12C Mutation (849-001)

Indication: Biliary Cancer

Location: Texas Oncology-Fort Worth Cancer Center

Phase: I/II

Title: STAR Ph1/2 MRTX849 Solids KRAS G12C View

Description: A Phase 1/2 Multiple Expansion Cohort Trial of MRTX849 in Patients with Advanced Solid Tumors with KRAS G12C Mutation (849-001)

Indication: Bladder Cancer

Location: Texas Oncology-Fort Worth Cancer Center

Phase: I/II

Title: STAR Ph1/2 MRTX849 Solids KRAS G12C View

Description: A Phase 1/2 Multiple Expansion Cohort Trial of MRTX849 in Patients with Advanced Solid Tumors with KRAS G12C Mutation (849-001)

Indication: Bone Mets

Location: Texas Oncology-Fort Worth Cancer Center

Phase: I/II

Title: STAR Ph1/2 MRTX849 Solids KRAS G12C View

Description: A Phase 1/2 Multiple Expansion Cohort Trial of MRTX849 in Patients with Advanced Solid Tumors with KRAS G12C Mutation (849-001)

Indication: Brain Cancer

Location: Texas Oncology-Fort Worth Cancer Center

Phase: I/II

Title: STAR Ph1/2 MRTX849 Solids KRAS G12C View

Description: A Phase 1/2 Multiple Expansion Cohort Trial of MRTX849 in Patients with Advanced Solid Tumors with KRAS G12C Mutation (849-001)

Indication: Breast Cancer

Location: Texas Oncology-Fort Worth Cancer Center

Phase: I/II

Title: STAR Ph1/2 MRTX849 Solids KRAS G12C View

Description: A Phase 1/2 Multiple Expansion Cohort Trial of MRTX849 in Patients with Advanced Solid Tumors with KRAS G12C Mutation (849-001)

Indication: Urothelial Cancer

Location: Texas Oncology-Fort Worth Cancer Center

Phase: I/II

Title: STAR Ph1/2 MRTX849 Solids KRAS G12C View

Description: A Phase 1/2 Multiple Expansion Cohort Trial of MRTX849 in Patients with Advanced Solid Tumors with KRAS G12C Mutation (849-001)

Indication: Uterine Cancer

Location: Texas Oncology-Fort Worth Cancer Center

Phase: I/II

Title: STAR Ph1/2 MRTX849 Solids KRAS G12C View

Description: A Phase 1/2 Multiple Expansion Cohort Trial of MRTX849 in Patients with Advanced Solid Tumors with KRAS G12C Mutation (849-001)

Indication: Vaginal Cancer

Location: Texas Oncology-Fort Worth Cancer Center

Phase: I/II

Title: STAR Ph1/2 MRTX849 Solids KRAS G12C View

Description: A Phase 1/2 Multiple Expansion Cohort Trial of MRTX849 in Patients with Advanced Solid Tumors with KRAS G12C Mutation (849-001)

Indication: Vulvar Cancer

Location: Texas Oncology-Fort Worth Cancer Center

Phase: I/II

Title: STAR Ph1/2 MRTX849 Solids KRAS G12C View

Description: A Phase 1/2 Multiple Expansion Cohort Trial of MRTX849 in Patients with Advanced Solid Tumors with KRAS G12C Mutation (849-001)

Indication: Rectal Cancer

Location: Texas Oncology-Fort Worth Cancer Center

Phase: I/II

Title: STAR Ph1/2 MRTX849 Solids KRAS G12C View

Description: A Phase 1/2 Multiple Expansion Cohort Trial of MRTX849 in Patients with Advanced Solid Tumors with KRAS G12C Mutation (849-001)

Indication: Renal Cancer

Location: Texas Oncology-Fort Worth Cancer Center

Phase: I/II

Title: STAR Ph1/2 MRTX849 Solids KRAS G12C View

Description: A Phase 1/2 Multiple Expansion Cohort Trial of MRTX849 in Patients with Advanced Solid Tumors with KRAS G12C Mutation (849-001)

Indication: Sarcoma

Location: Texas Oncology-Fort Worth Cancer Center

Phase: I/II

Title: STAR Ph1/2 MRTX849 Solids KRAS G12C View

Description: A Phase 1/2 Multiple Expansion Cohort Trial of MRTX849 in Patients with Advanced Solid Tumors with KRAS G12C Mutation (849-001)

Indication: Solid Tumors

Location: Texas Oncology-Fort Worth Cancer Center

Phase: I/II

Title: STAR Ph1/2 MRTX849 Solids KRAS G12C View

Description: A Phase 1/2 Multiple Expansion Cohort Trial of MRTX849 in Patients with Advanced Solid Tumors with KRAS G12C Mutation (849-001)

Indication: Testicular Cancer

Location: Texas Oncology-Fort Worth Cancer Center

Phase: I/II

Title: STAR Ph1/2 MRTX849 Solids KRAS G12C View

Description: A Phase 1/2 Multiple Expansion Cohort Trial of MRTX849 in Patients with Advanced Solid Tumors with KRAS G12C Mutation (849-001)

Indication: Thyroid Cancer

Location: Texas Oncology-Fort Worth Cancer Center

Phase: I/II

Title: STAR Ph1/2 MRTX849 Solids KRAS G12C View

Description: A Phase 1/2 Multiple Expansion Cohort Trial of MRTX849 in Patients with Advanced Solid Tumors with KRAS G12C Mutation (849-001)

Indication: Malignant Adenoma

Location: Texas Oncology-Fort Worth Cancer Center

Phase: I/II

Title: STAR Ph1/2 MRTX849 Solids KRAS G12C View

Description: A Phase 1/2 Multiple Expansion Cohort Trial of MRTX849 in Patients with Advanced Solid Tumors with KRAS G12C Mutation (849-001)

Indication: Ovarian Cancer

Location: Texas Oncology-Fort Worth Cancer Center

Phase: I/II

Title: STAR Ph1/2 MRTX849 Solids KRAS G12C View

Description: A Phase 1/2 Multiple Expansion Cohort Trial of MRTX849 in Patients with Advanced Solid Tumors with KRAS G12C Mutation (849-001)

Indication: Pancreatic Cancer

Location: Texas Oncology-Fort Worth Cancer Center

Phase: I/II

Title: STAR Ph1/2 MRTX849 Solids KRAS G12C View

Description: A Phase 1/2 Multiple Expansion Cohort Trial of MRTX849 in Patients with Advanced Solid Tumors with KRAS G12C Mutation (849-001)

Indication: Penile Cancer

Location: Texas Oncology-Fort Worth Cancer Center

Phase: I/II

Title: STAR Ph1/2 MRTX849 Solids KRAS G12C View

Description: A Phase 1/2 Multiple Expansion Cohort Trial of MRTX849 in Patients with Advanced Solid Tumors with KRAS G12C Mutation (849-001)

Indication: Peritoneal Cancer

Location: Texas Oncology-Fort Worth Cancer Center

Phase: I/II

Title: STAR Ph1/2 MRTX849 Solids KRAS G12C View

Description: A Phase 1/2 Multiple Expansion Cohort Trial of MRTX849 in Patients with Advanced Solid Tumors with KRAS G12C Mutation (849-001)

Indication: Prostate Cancer

Location: Texas Oncology-Fort Worth Cancer Center

Phase: I/II

Title: STAR Ph1/2 MRTX849 Solids KRAS G12C View

Description: A Phase 1/2 Multiple Expansion Cohort Trial of MRTX849 in Patients with Advanced Solid Tumors with KRAS G12C Mutation (849-001)

Indication: Gastric Cancer

Location: Texas Oncology-Fort Worth Cancer Center

Phase: I/II

Title: STAR Ph1/2 MRTX849 Solids KRAS G12C View

Description: A Phase 1/2 Multiple Expansion Cohort Trial of MRTX849 in Patients with Advanced Solid Tumors with KRAS G12C Mutation (849-001)

Indication: Head and Neck Cancer

Location: Texas Oncology-Fort Worth Cancer Center

Phase: I/II

Title: STAR Ph1/2 MRTX849 Solids KRAS G12C View

Description: A Phase 1/2 Multiple Expansion Cohort Trial of MRTX849 in Patients with Advanced Solid Tumors with KRAS G12C Mutation (849-001)

Indication: Kaposi's Sarcoma

Location: Texas Oncology-Fort Worth Cancer Center

Phase: I/II

Title: STAR Ph1/2 MRTX849 Solids KRAS G12C View

Description: A Phase 1/2 Multiple Expansion Cohort Trial of MRTX849 in Patients with Advanced Solid Tumors with KRAS G12C Mutation (849-001)

Indication: Kidney Cancer

Location: Texas Oncology-Fort Worth Cancer Center

Phase: I/II

Title: STAR Ph1/2 MRTX849 Solids KRAS G12C View

Description: A Phase 1/2 Multiple Expansion Cohort Trial of MRTX849 in Patients with Advanced Solid Tumors with KRAS G12C Mutation (849-001)

Indication: Liver Cancer

Location: Texas Oncology-Fort Worth Cancer Center

Phase: I/II

Title: STAR Ph1/2 MRTX849 Solids KRAS G12C View

Description: A Phase 1/2 Multiple Expansion Cohort Trial of MRTX849 in Patients with Advanced Solid Tumors with KRAS G12C Mutation (849-001)

Indication: Lung Cancer

Location: Texas Oncology-Fort Worth Cancer Center

Phase: I/II

Title: STAR Ph1/2 MRTX849 Solids KRAS G12C View

Description: A Phase 1/2 Multiple Expansion Cohort Trial of MRTX849 in Patients with Advanced Solid Tumors with KRAS G12C Mutation (849-001)

Indication: Cervical Cancer

Location: Texas Oncology-Fort Worth Cancer Center

Phase: I/II

Title: STAR Ph1/2 MRTX849 Solids KRAS G12C View

Description: A Phase 1/2 Multiple Expansion Cohort Trial of MRTX849 in Patients with Advanced Solid Tumors with KRAS G12C Mutation (849-001)

Indication: Colon Cancer

Location: Texas Oncology-Fort Worth Cancer Center

Phase: I/II

Title: STAR Ph1/2 MRTX849 Solids KRAS G12C View

Description: A Phase 1/2 Multiple Expansion Cohort Trial of MRTX849 in Patients with Advanced Solid Tumors with KRAS G12C Mutation (849-001)

Indication: Endometrial Cancer

Location: Texas Oncology-Fort Worth Cancer Center

Phase: I/II

Title: STAR Ph1/2 MRTX849 Solids KRAS G12C View

Description: A Phase 1/2 Multiple Expansion Cohort Trial of MRTX849 in Patients with Advanced Solid Tumors with KRAS G12C Mutation (849-001)

Indication: Esophageal Cancer

Location: Texas Oncology-Fort Worth Cancer Center

Phase: I/II

Title: STAR Ph1/2 MRTX849 Solids KRAS G12C View

Description: A Phase 1/2 Multiple Expansion Cohort Trial of MRTX849 in Patients with Advanced Solid Tumors with KRAS G12C Mutation (849-001)

Indication: Fallopian Tube Cancer

Location: Texas Oncology-Fort Worth Cancer Center

Phase: I/II

Title: STAR Ph1/2 MRTX849 Solids KRAS G12C View

Description: A Phase 1/2 Multiple Expansion Cohort Trial of MRTX849 in Patients with Advanced Solid Tumors with KRAS G12C Mutation (849-001)

Indication: Gall Bladder Cancer

Location: Texas Oncology-Fort Worth Cancer Center

Phase: I/II

Title: Ph 1/2 ASTX727 Lower Risk MDS View

Description: A Randomized Open-Label Phase 1-2 Study of ASTX727 Low Dose (ASTX727 LD)Extended Schedule in Subjects with Lower Risk (IPSS Low or Intermediate-1)Myelodysplastic Syndromes (MDS) (ASTX727-03)

Indication: Myelodysplastic Syndrome

Location: Texas Oncology-Fort Worth Cancer Center

Phase: I/II

Title: STAR Ph1/2 BLU667 thy NSCLC Sol tum View

Description: A Phase 1/2 Study of the Highly-selective RET Inhibitor BLU-667 in Patients with Thyroid Cancer Non-Small Cell Lung Cancer (NSCLC) and Other Advanced Solid Tumors (BLU-667-1101)

Indication: Lung Cancer

Location: Texas Oncology-Fort Worth Cancer Center

Phase: I/II

Title: STAR Ph1/2 BLU667 thy NSCLC Sol tum View

Description: A Phase 1/2 Study of the Highly-selective RET Inhibitor BLU-667 in Patients with Thyroid Cancer Non-Small Cell Lung Cancer (NSCLC) and Other Advanced Solid Tumors (BLU-667-1101)

Indication: Solid Tumors

Location: Texas Oncology-Fort Worth Cancer Center

Phase: I/II

Title: STAR Ph1/2 BLU667 thy NSCLC Sol tum View

Description: A Phase 1/2 Study of the Highly-selective RET Inhibitor BLU-667 in Patients with Thyroid Cancer Non-Small Cell Lung Cancer (NSCLC) and Other Advanced Solid Tumors (BLU-667-1101)

Indication: Thyroid Cancer

Location: Texas Oncology-Fort Worth Cancer Center

Phase: I/II

Title: STAR PH 2 Enfortumab in Urothelial Pts View

Description: A study of enfortumab vedotin (ASG-22CE) as monotherapy or in combination with other anticancer therapies for the treatment of urothelial cancer (SGN22E-002)

Indication: Bladder Cancer

Location: Texas Oncology-Grapevine

Phase: I/II

Title: STAR PH 2 Enfortumab in Urothelial Pts View

Description: A study of enfortumab vedotin (ASG-22CE) as monotherapy or in combination with other anticancer therapies for the treatment of urothelial cancer (SGN22E-002)

Indication: Urothelial Cancer

Location: Texas Oncology-Grapevine

Phase: I/II

Title: STAR Ph1/2 BLU667 thy NSCLC Sol tum View

Description: A Phase 1/2 Study of the Highly-selective RET Inhibitor BLU-667 in Patients with Thyroid Cancer Non-Small Cell Lung Cancer (NSCLC) and Other Advanced Solid Tumors (BLU-667-1101)

Indication: Lung Cancer

Location: Texas Oncology-Grapevine

Phase: I/II

Title: STAR Ph1/2 BLU667 thy NSCLC Sol tum View

Description: A Phase 1/2 Study of the Highly-selective RET Inhibitor BLU-667 in Patients with Thyroid Cancer Non-Small Cell Lung Cancer (NSCLC) and Other Advanced Solid Tumors (BLU-667-1101)

Indication: Solid Tumors

Location: Texas Oncology-Grapevine

Phase: I/II

Title: STAR Ph1/2 BLU667 thy NSCLC Sol tum View

Description: A Phase 1/2 Study of the Highly-selective RET Inhibitor BLU-667 in Patients with Thyroid Cancer Non-Small Cell Lung Cancer (NSCLC) and Other Advanced Solid Tumors (BLU-667-1101)

Indication: Thyroid Cancer

Location: Texas Oncology-Grapevine

Phase: I/II

Title: STAR Ph1/2 MRTX849 Solids KRAS G12C View

Description: A Phase 1/2 Multiple Expansion Cohort Trial of MRTX849 in Patients with Advanced Solid Tumors with KRAS G12C Mutation (849-001)

Indication: Anal Cancer

Location: Texas Oncology-Grapevine

Phase: I/II

Title: STAR Ph1/2 MRTX849 Solids KRAS G12C View

Description: A Phase 1/2 Multiple Expansion Cohort Trial of MRTX849 in Patients with Advanced Solid Tumors with KRAS G12C Mutation (849-001)

Indication: Biliary Cancer

Location: Texas Oncology-Grapevine

Phase: I/II

Title: STAR Ph1/2 MRTX849 Solids KRAS G12C View

Description: A Phase 1/2 Multiple Expansion Cohort Trial of MRTX849 in Patients with Advanced Solid Tumors with KRAS G12C Mutation (849-001)

Indication: Bladder Cancer

Location: Texas Oncology-Grapevine

Phase: I/II

Title: STAR Ph1/2 MRTX849 Solids KRAS G12C View

Description: A Phase 1/2 Multiple Expansion Cohort Trial of MRTX849 in Patients with Advanced Solid Tumors with KRAS G12C Mutation (849-001)

Indication: Bone Mets

Location: Texas Oncology-Grapevine

Phase: I/II

Title: STAR Ph1/2 MRTX849 Solids KRAS G12C View

Description: A Phase 1/2 Multiple Expansion Cohort Trial of MRTX849 in Patients with Advanced Solid Tumors with KRAS G12C Mutation (849-001)

Indication: Brain Cancer

Location: Texas Oncology-Grapevine

Phase: I/II

Title: STAR Ph1/2 MRTX849 Solids KRAS G12C View

Description: A Phase 1/2 Multiple Expansion Cohort Trial of MRTX849 in Patients with Advanced Solid Tumors with KRAS G12C Mutation (849-001)

Indication: Breast Cancer

Location: Texas Oncology-Grapevine

Phase: I/II

Title: STAR Ph1/2 MRTX849 Solids KRAS G12C View

Description: A Phase 1/2 Multiple Expansion Cohort Trial of MRTX849 in Patients with Advanced Solid Tumors with KRAS G12C Mutation (849-001)

Indication: Urothelial Cancer

Location: Texas Oncology-Grapevine

Phase: I/II

Title: STAR Ph1/2 MRTX849 Solids KRAS G12C View

Description: A Phase 1/2 Multiple Expansion Cohort Trial of MRTX849 in Patients with Advanced Solid Tumors with KRAS G12C Mutation (849-001)

Indication: Uterine Cancer

Location: Texas Oncology-Grapevine

Phase: I/II

Title: STAR Ph1/2 MRTX849 Solids KRAS G12C View

Description: A Phase 1/2 Multiple Expansion Cohort Trial of MRTX849 in Patients with Advanced Solid Tumors with KRAS G12C Mutation (849-001)

Indication: Vaginal Cancer

Location: Texas Oncology-Grapevine

Phase: I/II

Title: STAR Ph1/2 MRTX849 Solids KRAS G12C View

Description: A Phase 1/2 Multiple Expansion Cohort Trial of MRTX849 in Patients with Advanced Solid Tumors with KRAS G12C Mutation (849-001)

Indication: Vulvar Cancer

Location: Texas Oncology-Grapevine

Phase: I/II

Title: STAR Ph1/2 MRTX849 Solids KRAS G12C View

Description: A Phase 1/2 Multiple Expansion Cohort Trial of MRTX849 in Patients with Advanced Solid Tumors with KRAS G12C Mutation (849-001)

Indication: Rectal Cancer

Location: Texas Oncology-Grapevine

Phase: I/II

Title: STAR Ph1/2 MRTX849 Solids KRAS G12C View

Description: A Phase 1/2 Multiple Expansion Cohort Trial of MRTX849 in Patients with Advanced Solid Tumors with KRAS G12C Mutation (849-001)

Indication: Renal Cancer

Location: Texas Oncology-Grapevine

Phase: I/II

Title: STAR Ph1/2 MRTX849 Solids KRAS G12C View

Description: A Phase 1/2 Multiple Expansion Cohort Trial of MRTX849 in Patients with Advanced Solid Tumors with KRAS G12C Mutation (849-001)

Indication: Sarcoma

Location: Texas Oncology-Grapevine

Phase: I/II

Title: STAR Ph1/2 MRTX849 Solids KRAS G12C View

Description: A Phase 1/2 Multiple Expansion Cohort Trial of MRTX849 in Patients with Advanced Solid Tumors with KRAS G12C Mutation (849-001)

Indication: Solid Tumors

Location: Texas Oncology-Grapevine

Phase: I/II

Title: STAR Ph1/2 MRTX849 Solids KRAS G12C View

Description: A Phase 1/2 Multiple Expansion Cohort Trial of MRTX849 in Patients with Advanced Solid Tumors with KRAS G12C Mutation (849-001)

Indication: Testicular Cancer

Location: Texas Oncology-Grapevine

Phase: I/II

Title: STAR Ph1/2 MRTX849 Solids KRAS G12C View

Description: A Phase 1/2 Multiple Expansion Cohort Trial of MRTX849 in Patients with Advanced Solid Tumors with KRAS G12C Mutation (849-001)

Indication: Thyroid Cancer

Location: Texas Oncology-Grapevine

Phase: I/II

Title: STAR Ph1/2 MRTX849 Solids KRAS G12C View

Description: A Phase 1/2 Multiple Expansion Cohort Trial of MRTX849 in Patients with Advanced Solid Tumors with KRAS G12C Mutation (849-001)

Indication: Malignant Adenoma

Location: Texas Oncology-Grapevine

Phase: I/II

Title: STAR Ph1/2 MRTX849 Solids KRAS G12C View

Description: A Phase 1/2 Multiple Expansion Cohort Trial of MRTX849 in Patients with Advanced Solid Tumors with KRAS G12C Mutation (849-001)

Indication: Ovarian Cancer

Location: Texas Oncology-Grapevine

Phase: I/II

Title: STAR Ph1/2 MRTX849 Solids KRAS G12C View

Description: A Phase 1/2 Multiple Expansion Cohort Trial of MRTX849 in Patients with Advanced Solid Tumors with KRAS G12C Mutation (849-001)

Indication: Pancreatic Cancer

Location: Texas Oncology-Grapevine

Phase: I/II

Title: STAR Ph1/2 MRTX849 Solids KRAS G12C View

Description: A Phase 1/2 Multiple Expansion Cohort Trial of MRTX849 in Patients with Advanced Solid Tumors with KRAS G12C Mutation (849-001)

Indication: Penile Cancer

Location: Texas Oncology-Grapevine

Phase: I/II

Title: STAR Ph1/2 MRTX849 Solids KRAS G12C View

Description: A Phase 1/2 Multiple Expansion Cohort Trial of MRTX849 in Patients with Advanced Solid Tumors with KRAS G12C Mutation (849-001)

Indication: Peritoneal Cancer

Location: Texas Oncology-Grapevine

Phase: I/II

Title: STAR Ph1/2 MRTX849 Solids KRAS G12C View

Description: A Phase 1/2 Multiple Expansion Cohort Trial of MRTX849 in Patients with Advanced Solid Tumors with KRAS G12C Mutation (849-001)

Indication: Prostate Cancer

Location: Texas Oncology-Grapevine

Phase: I/II

Title: STAR Ph1/2 MRTX849 Solids KRAS G12C View

Description: A Phase 1/2 Multiple Expansion Cohort Trial of MRTX849 in Patients with Advanced Solid Tumors with KRAS G12C Mutation (849-001)

Indication: Gastric Cancer

Location: Texas Oncology-Grapevine

Phase: I/II

Title: STAR Ph1/2 MRTX849 Solids KRAS G12C View

Description: A Phase 1/2 Multiple Expansion Cohort Trial of MRTX849 in Patients with Advanced Solid Tumors with KRAS G12C Mutation (849-001)

Indication: Head and Neck Cancer

Location: Texas Oncology-Grapevine

Phase: I/II

Title: STAR Ph1/2 MRTX849 Solids KRAS G12C View

Description: A Phase 1/2 Multiple Expansion Cohort Trial of MRTX849 in Patients with Advanced Solid Tumors with KRAS G12C Mutation (849-001)

Indication: Kaposi's Sarcoma

Location: Texas Oncology-Grapevine

Phase: I/II

Title: STAR Ph1/2 MRTX849 Solids KRAS G12C View

Description: A Phase 1/2 Multiple Expansion Cohort Trial of MRTX849 in Patients with Advanced Solid Tumors with KRAS G12C Mutation (849-001)

Indication: Kidney Cancer

Location: Texas Oncology-Grapevine

Phase: I/II

Title: STAR Ph1/2 MRTX849 Solids KRAS G12C View

Description: A Phase 1/2 Multiple Expansion Cohort Trial of MRTX849 in Patients with Advanced Solid Tumors with KRAS G12C Mutation (849-001)

Indication: Liver Cancer

Location: Texas Oncology-Grapevine

Phase: I/II

Title: STAR Ph1/2 MRTX849 Solids KRAS G12C View

Description: A Phase 1/2 Multiple Expansion Cohort Trial of MRTX849 in Patients with Advanced Solid Tumors with KRAS G12C Mutation (849-001)

Indication: Lung Cancer

Location: Texas Oncology-Grapevine

Phase: I/II

Title: STAR Ph1/2 MRTX849 Solids KRAS G12C View

Description: A Phase 1/2 Multiple Expansion Cohort Trial of MRTX849 in Patients with Advanced Solid Tumors with KRAS G12C Mutation (849-001)

Indication: Cervical Cancer

Location: Texas Oncology-Grapevine

Phase: I/II

Title: STAR Ph1/2 MRTX849 Solids KRAS G12C View

Description: A Phase 1/2 Multiple Expansion Cohort Trial of MRTX849 in Patients with Advanced Solid Tumors with KRAS G12C Mutation (849-001)

Indication: Colon Cancer

Location: Texas Oncology-Grapevine

Phase: I/II

Title: STAR Ph1/2 MRTX849 Solids KRAS G12C View

Description: A Phase 1/2 Multiple Expansion Cohort Trial of MRTX849 in Patients with Advanced Solid Tumors with KRAS G12C Mutation (849-001)

Indication: Endometrial Cancer

Location: Texas Oncology-Grapevine

Phase: I/II

Title: STAR Ph1/2 MRTX849 Solids KRAS G12C View

Description: A Phase 1/2 Multiple Expansion Cohort Trial of MRTX849 in Patients with Advanced Solid Tumors with KRAS G12C Mutation (849-001)

Indication: Esophageal Cancer

Location: Texas Oncology-Grapevine

Phase: I/II

Title: STAR Ph1/2 MRTX849 Solids KRAS G12C View

Description: A Phase 1/2 Multiple Expansion Cohort Trial of MRTX849 in Patients with Advanced Solid Tumors with KRAS G12C Mutation (849-001)

Indication: Fallopian Tube Cancer

Location: Texas Oncology-Grapevine

Phase: I/II

Title: STAR Ph1/2 MRTX849 Solids KRAS G12C View

Description: A Phase 1/2 Multiple Expansion Cohort Trial of MRTX849 in Patients with Advanced Solid Tumors with KRAS G12C Mutation (849-001)

Indication: Gall Bladder Cancer

Location: Texas Oncology-Grapevine

Phase: I/II

Phase II

Title: STAR Ph2 Seribantumab NRG1 Fusion+ ST View

Description: CRESTONE: A Phase 2 Study of Seribantumab in Adult Patients with Neuregulin-1 (NRG1) Fusion Positive Locally Advanced or Metastatic Solid Tumors (ELVCAP-001-01)

Indication: Solid Tumors

Location: Texas Oncology-Arlington Cancer Center North

Phase: II

Title: STAR Ph2 Seribantumab NRG1 Fusion+ ST View

Description: CRESTONE: A Phase 2 Study of Seribantumab in Adult Patients with Neuregulin-1 (NRG1) Fusion Positive Locally Advanced or Metastatic Solid Tumors (ELVCAP-001-01)

Indication: Solid Tumors

Location: Texas Oncology-Arlington South

Phase: II

Title: STAR Ph2 Basket Tucat+Tras ST HER2 Alt View

Description: A Phase 2 Basket Study of Tucatinib in Combination with Trastuzumab in Subjects with Previously Treated Locally-Advanced Unresectable or Metastatic Solid Tumors Driven by HER2 Alterations (SGNTUC-019)

Indication: Biliary Cancer

Location: Texas Oncology-Arlington Cancer Center North

Phase: II

Title: STAR Ph2 Basket Tucat+Tras ST HER2 Alt View

Description: A Phase 2 Basket Study of Tucatinib in Combination with Trastuzumab in Subjects with Previously Treated Locally-Advanced Unresectable or Metastatic Solid Tumors Driven by HER2 Alterations (SGNTUC-019)

Indication: Breast Cancer

Location: Texas Oncology-Arlington Cancer Center North

Phase: II

Title: STAR Ph2 Basket Tucat+Tras ST HER2 Alt View

Description: A Phase 2 Basket Study of Tucatinib in Combination with Trastuzumab in Subjects with Previously Treated Locally-Advanced Unresectable or Metastatic Solid Tumors Driven by HER2 Alterations (SGNTUC-019)

Indication: Cervical Cancer

Location: Texas Oncology-Arlington Cancer Center North

Phase: II

Title: STAR Ph2 Basket Tucat+Tras ST HER2 Alt View

Description: A Phase 2 Basket Study of Tucatinib in Combination with Trastuzumab in Subjects with Previously Treated Locally-Advanced Unresectable or Metastatic Solid Tumors Driven by HER2 Alterations (SGNTUC-019)

Indication: Gall Bladder Cancer

Location: Texas Oncology-Arlington Cancer Center North

Phase: II

Title: STAR Ph2 Basket Tucat+Tras ST HER2 Alt View

Description: A Phase 2 Basket Study of Tucatinib in Combination with Trastuzumab in Subjects with Previously Treated Locally-Advanced Unresectable or Metastatic Solid Tumors Driven by HER2 Alterations (SGNTUC-019)

Indication: Lung Cancer

Location: Texas Oncology-Arlington Cancer Center North

Phase: II

Title: STAR Ph2 Basket Tucat+Tras ST HER2 Alt View

Description: A Phase 2 Basket Study of Tucatinib in Combination with Trastuzumab in Subjects with Previously Treated Locally-Advanced Unresectable or Metastatic Solid Tumors Driven by HER2 Alterations (SGNTUC-019)

Indication: Solid Tumors

Location: Texas Oncology-Arlington Cancer Center North

Phase: II

Title: STAR Ph2 Basket Tucat+Tras ST HER2 Alt View

Description: A Phase 2 Basket Study of Tucatinib in Combination with Trastuzumab in Subjects with Previously Treated Locally-Advanced Unresectable or Metastatic Solid Tumors Driven by HER2 Alterations (SGNTUC-019)

Indication: Urothelial Cancer

Location: Texas Oncology-Arlington Cancer Center North

Phase: II

Title: STAR Ph2 Basket Tucat+Tras ST HER2 Alt View

Description: A Phase 2 Basket Study of Tucatinib in Combination with Trastuzumab in Subjects with Previously Treated Locally-Advanced Unresectable or Metastatic Solid Tumors Driven by HER2 Alterations (SGNTUC-019)

Indication: Uterine Cancer

Location: Texas Oncology-Arlington Cancer Center North

Phase: II

Title: STAR Ph2 Basket Tucat+Tras ST HER2 Alt View

Description: A Phase 2 Basket Study of Tucatinib in Combination with Trastuzumab in Subjects with Previously Treated Locally-Advanced Unresectable or Metastatic Solid Tumors Driven by HER2 Alterations (SGNTUC-019)

Indication: Biliary Cancer

Location: Texas Oncology-Arlington South

Phase: II

Title: STAR Ph2 Basket Tucat+Tras ST HER2 Alt View

Description: A Phase 2 Basket Study of Tucatinib in Combination with Trastuzumab in Subjects with Previously Treated Locally-Advanced Unresectable or Metastatic Solid Tumors Driven by HER2 Alterations (SGNTUC-019)

Indication: Breast Cancer

Location: Texas Oncology-Arlington South

Phase: II

Title: STAR Ph2 Basket Tucat+Tras ST HER2 Alt View

Description: A Phase 2 Basket Study of Tucatinib in Combination with Trastuzumab in Subjects with Previously Treated Locally-Advanced Unresectable or Metastatic Solid Tumors Driven by HER2 Alterations (SGNTUC-019)

Indication: Cervical Cancer

Location: Texas Oncology-Arlington South

Phase: II

Title: STAR Ph2 Basket Tucat+Tras ST HER2 Alt View

Description: A Phase 2 Basket Study of Tucatinib in Combination with Trastuzumab in Subjects with Previously Treated Locally-Advanced Unresectable or Metastatic Solid Tumors Driven by HER2 Alterations (SGNTUC-019)

Indication: Gall Bladder Cancer

Location: Texas Oncology-Arlington South

Phase: II

Title: STAR Ph2 Basket Tucat+Tras ST HER2 Alt View

Description: A Phase 2 Basket Study of Tucatinib in Combination with Trastuzumab in Subjects with Previously Treated Locally-Advanced Unresectable or Metastatic Solid Tumors Driven by HER2 Alterations (SGNTUC-019)

Indication: Lung Cancer

Location: Texas Oncology-Arlington South

Phase: II

Title: STAR Ph2 Basket Tucat+Tras ST HER2 Alt View

Description: A Phase 2 Basket Study of Tucatinib in Combination with Trastuzumab in Subjects with Previously Treated Locally-Advanced Unresectable or Metastatic Solid Tumors Driven by HER2 Alterations (SGNTUC-019)

Indication: Solid Tumors

Location: Texas Oncology-Arlington South

Phase: II

Title: STAR Ph2 Basket Tucat+Tras ST HER2 Alt View

Description: A Phase 2 Basket Study of Tucatinib in Combination with Trastuzumab in Subjects with Previously Treated Locally-Advanced Unresectable or Metastatic Solid Tumors Driven by HER2 Alterations (SGNTUC-019)

Indication: Urothelial Cancer

Location: Texas Oncology-Arlington South

Phase: II

Title: STAR Ph2 Basket Tucat+Tras ST HER2 Alt View

Description: A Phase 2 Basket Study of Tucatinib in Combination with Trastuzumab in Subjects with Previously Treated Locally-Advanced Unresectable or Metastatic Solid Tumors Driven by HER2 Alterations (SGNTUC-019)

Indication: Uterine Cancer

Location: Texas Oncology-Arlington South

Phase: II

Title: STAR Ph2 Ak104 Cervical Cancer View

Description: A Phase 2 multicenter single-arm open-label study to evaluate the efficacy and safety of AK104 in subjects with recurrent or metastatic cervical cancer (AK104-201-AU)

Indication: Cervical Cancer

Location: Texas Oncology-Arlington Cancer Center North

Phase: II

Title: STAR Ph2 Ak104 Cervical Cancer View

Description: A Phase 2 multicenter single-arm open-label study to evaluate the efficacy and safety of AK104 in subjects with recurrent or metastatic cervical cancer (AK104-201-AU)

Indication: Cervical Cancer

Location: Texas Oncology-Arlington South

Phase: II

Title: STAR PH2 Tuca+ Tras HER2+ CC View

Description: MOUNTAINEER: A Phase 2 Open Label Study of Tucatinib Combined with Trastuzumab in Patients with HER2+ Metastatic Colorectal Cancer (ACCRU-GI-1617 SGNTUC-017)

Indication: Colon Cancer

Location: Texas Oncology-Arlington Cancer Center North

Phase: II

Title: STAR PH2 Tuca+ Tras HER2+ CC View

Description: MOUNTAINEER: A Phase 2 Open Label Study of Tucatinib Combined with Trastuzumab in Patients with HER2+ Metastatic Colorectal Cancer (ACCRU-GI-1617 SGNTUC-017)

Indication: Rectal Cancer

Location: Texas Oncology-Arlington Cancer Center North

Phase: II

Title: STAR PH2 Tuca+ Tras HER2+ CC View

Description: MOUNTAINEER: A Phase 2 Open Label Study of Tucatinib Combined with Trastuzumab in Patients with HER2+ Metastatic Colorectal Cancer (ACCRU-GI-1617 SGNTUC-017)

Indication: Colon Cancer

Location: Texas Oncology-Arlington South

Phase: II

Title: STAR PH2 Tuca+ Tras HER2+ CC View

Description: MOUNTAINEER: A Phase 2 Open Label Study of Tucatinib Combined with Trastuzumab in Patients with HER2+ Metastatic Colorectal Cancer (ACCRU-GI-1617 SGNTUC-017)

Indication: Rectal Cancer

Location: Texas Oncology-Arlington South

Phase: II

Title: STAR KEAP1/NRF2 NSCLC View

Description: CX-839-014 "KEAPSAKE": A Phase 2 Randomized Multicenter Double-blind Study of the Glutaminase Inhibitor Telaglenastat with Pembrolizumab and Chemotherapy versus Placebo with Pembrolizumab and Chemotherapy in First-line Metastatic KEAP1/NRF2-mutated Nonsquamous Non-Small Cell Lung Cancer (NSCLC)

Indication: Lung Cancer

Location: Texas Oncology-Arlington South

Phase: II

Title: STAR Ph2 Erdafitinib FGFR Solid Tumors View

Description: A Phase 2 Study of Erdafitinib in Subjects With Advanced Solid Tumors and FGFR Gene Alterations (42756493CAN2002)

Indication: Solid Tumors

Location: Texas Oncology-Arlington South

Phase: II

Title: STAR Ph2 Pemigatinib Solids FGFR View

Description: (INCB 54828-207) A Phase 2 Open-Label Single-Arm Multicenter Study to Evaluate the Efficacy and Safety of Pemigatinib in Participants With Previously Treated Locally Advanced/Metastatic or Surgically Unresectable Solid Tumor Malignancies Harboring Activating FGFR Mutations or Translocations (FIGHT-207)

Indication: Solid Tumors

Location: Texas Oncology-Arlington South

Phase: II

Title: STAR Sitra+Nivo/Pembro+Enfor Adv/Met Uro View

Description: A Phase 2 Study of Sitravatinib in Combination with PD-(L)1 Checkpoint Inhibitor Regimens in Patients With Advanced or Metastatic Urothelial Carcinoma (516-003)

Indication: Bladder Cancer

Location: Texas Oncology-Arlington Cancer Center North

Phase: II

Title: STAR Sitra+Nivo/Pembro+Enfor Adv/Met Uro View

Description: A Phase 2 Study of Sitravatinib in Combination with PD-(L)1 Checkpoint Inhibitor Regimens in Patients With Advanced or Metastatic Urothelial Carcinoma (516-003)

Indication: Urothelial Cancer

Location: Texas Oncology-Arlington Cancer Center North

Phase: II

Title: STAR Sitra+Nivo/Pembro+Enfor Adv/Met Uro View

Description: A Phase 2 Study of Sitravatinib in Combination with PD-(L)1 Checkpoint Inhibitor Regimens in Patients With Advanced or Metastatic Urothelial Carcinoma (516-003)

Indication: Bladder Cancer

Location: Texas Oncology-Arlington South

Phase: II

Title: STAR Sitra+Nivo/Pembro+Enfor Adv/Met Uro View

Description: A Phase 2 Study of Sitravatinib in Combination with PD-(L)1 Checkpoint Inhibitor Regimens in Patients With Advanced or Metastatic Urothelial Carcinoma (516-003)

Indication: Urothelial Cancer

Location: Texas Oncology-Arlington South

Phase: II

Title: STAR BV in pts w/1L cHL or PTCL View

Description: (SGN35-015) A phase 2 open-label study of brentuximab vedotin in front-line therapy of Hodgkin lymphoma (HL) and CD30-expressing peripheral T-cell lymphoma (PTCL) in older patients or patients with significant comorbidities ineligible for standard chemotherapy

Indication: Lymphomas

Location: Texas Oncology-Arlington Cancer Center North

Phase: II

Title: STAR BV in pts w/1L cHL or PTCL View

Description: (SGN35-015) A phase 2 open-label study of brentuximab vedotin in front-line therapy of Hodgkin lymphoma (HL) and CD30-expressing peripheral T-cell lymphoma (PTCL) in older patients or patients with significant comorbidities ineligible for standard chemotherapy

Indication: Lymphomas

Location: Texas Oncology-Arlington South

Phase: II

Title: STAR BV in pts w/1L cHL or PTCL View

Description: (SGN35-015) A phase 2 open-label study of brentuximab vedotin in front-line therapy of Hodgkin lymphoma (HL) and CD30-expressing peripheral T-cell lymphoma (PTCL) in older patients or patients with significant comorbidities ineligible for standard chemotherapy

Indication: Lymphomas

Location: Texas Oncology-Bedford

Phase: II

Title: STAR Ublituximab+TGR-1202 Cross-over View

Description: (UTX-TGR-204) A Multi-Center Open-Label Compassionate Use Extension Study of Ublituximab (TG-1101) in Combination with Umbralisib (TGR-1202) for Patients Previously Enrolled in Protocol UTX-TGR-304

Indication: Leukemia

Location: Texas Oncology-Bedford

Phase: II

Title: STAR Sitra+Nivo/Pembro+Enfor Adv/Met Uro View

Description: A Phase 2 Study of Sitravatinib in Combination with PD-(L)1 Checkpoint Inhibitor Regimens in Patients With Advanced or Metastatic Urothelial Carcinoma (516-003)

Indication: Bladder Cancer

Location: Texas Oncology-Bedford

Phase: II

Title: STAR Sitra+Nivo/Pembro+Enfor Adv/Met Uro View

Description: A Phase 2 Study of Sitravatinib in Combination with PD-(L)1 Checkpoint Inhibitor Regimens in Patients With Advanced or Metastatic Urothelial Carcinoma (516-003)

Indication: Urothelial Cancer

Location: Texas Oncology-Bedford

Phase: II

Title: Ph2 Cervical 2L (RaPiDS) View

Description: A Two-arm Randomized Non-comparative Phase 2 Trial of AGEN2034(anti-PD-1) as a Monotherapy or Combination Therapy with AGEN1884(anti-CTLA4) or with Placebo in Women with Recurrent Cervical Cancer(Second Line) - RaPiDS (C-750-01/GOG-3028)

Indication: Cervical Cancer

Location: Texas Oncology-Bedford

Phase: II

Title: STAR Ph2 Pemigatinib Solids FGFR View

Description: (INCB 54828-207) A Phase 2 Open-Label Single-Arm Multicenter Study to Evaluate the Efficacy and Safety of Pemigatinib in Participants With Previously Treated Locally Advanced/Metastatic or Surgically Unresectable Solid Tumor Malignancies Harboring Activating FGFR Mutations or Translocations (FIGHT-207)

Indication: Solid Tumors

Location: Texas Oncology-Bedford

Phase: II

Title: STAR Ph2 Erdafitinib FGFR Solid Tumors View

Description: A Phase 2 Study of Erdafitinib in Subjects With Advanced Solid Tumors and FGFR Gene Alterations (42756493CAN2002)

Indication: Solid Tumors

Location: Texas Oncology-Bedford

Phase: II

Title: STAR KEAP1/NRF2 NSCLC View

Description: CX-839-014 "KEAPSAKE": A Phase 2 Randomized Multicenter Double-blind Study of the Glutaminase Inhibitor Telaglenastat with Pembrolizumab and Chemotherapy versus Placebo with Pembrolizumab and Chemotherapy in First-line Metastatic KEAP1/NRF2-mutated Nonsquamous Non-Small Cell Lung Cancer (NSCLC)

Indication: Lung Cancer

Location: Texas Oncology-Bedford

Phase: II

Title: STAR PH2 Tuca+ Tras HER2+ CC View

Description: MOUNTAINEER: A Phase 2 Open Label Study of Tucatinib Combined with Trastuzumab in Patients with HER2+ Metastatic Colorectal Cancer (ACCRU-GI-1617 SGNTUC-017)

Indication: Colon Cancer

Location: Texas Oncology-Bedford

Phase: II

Title: STAR PH2 Tuca+ Tras HER2+ CC View

Description: MOUNTAINEER: A Phase 2 Open Label Study of Tucatinib Combined with Trastuzumab in Patients with HER2+ Metastatic Colorectal Cancer (ACCRU-GI-1617 SGNTUC-017)

Indication: Rectal Cancer

Location: Texas Oncology-Bedford

Phase: II

Title: STAR Ph2 Seribantumab NRG1 Fusion+ ST View

Description: CRESTONE: A Phase 2 Study of Seribantumab in Adult Patients with Neuregulin-1 (NRG1) Fusion Positive Locally Advanced or Metastatic Solid Tumors (ELVCAP-001-01)

Indication: Solid Tumors

Location: Texas Oncology-Bedford

Phase: II

Title: STAR Ph2 Basket Tucat+Tras ST HER2 Alt View

Description: A Phase 2 Basket Study of Tucatinib in Combination with Trastuzumab in Subjects with Previously Treated Locally-Advanced Unresectable or Metastatic Solid Tumors Driven by HER2 Alterations (SGNTUC-019)

Indication: Biliary Cancer

Location: Texas Oncology-Bedford

Phase: II

Title: STAR Ph2 Basket Tucat+Tras ST HER2 Alt View

Description: A Phase 2 Basket Study of Tucatinib in Combination with Trastuzumab in Subjects with Previously Treated Locally-Advanced Unresectable or Metastatic Solid Tumors Driven by HER2 Alterations (SGNTUC-019)

Indication: Breast Cancer

Location: Texas Oncology-Bedford

Phase: II

Title: STAR Ph2 Basket Tucat+Tras ST HER2 Alt View

Description: A Phase 2 Basket Study of Tucatinib in Combination with Trastuzumab in Subjects with Previously Treated Locally-Advanced Unresectable or Metastatic Solid Tumors Driven by HER2 Alterations (SGNTUC-019)

Indication: Cervical Cancer

Location: Texas Oncology-Bedford

Phase: II

Title: STAR Ph2 Basket Tucat+Tras ST HER2 Alt View

Description: A Phase 2 Basket Study of Tucatinib in Combination with Trastuzumab in Subjects with Previously Treated Locally-Advanced Unresectable or Metastatic Solid Tumors Driven by HER2 Alterations (SGNTUC-019)

Indication: Gall Bladder Cancer

Location: Texas Oncology-Bedford

Phase: II

Title: STAR Ph2 Basket Tucat+Tras ST HER2 Alt View

Description: A Phase 2 Basket Study of Tucatinib in Combination with Trastuzumab in Subjects with Previously Treated Locally-Advanced Unresectable or Metastatic Solid Tumors Driven by HER2 Alterations (SGNTUC-019)

Indication: Lung Cancer

Location: Texas Oncology-Bedford

Phase: II

Title: STAR Ph2 Basket Tucat+Tras ST HER2 Alt View

Description: A Phase 2 Basket Study of Tucatinib in Combination with Trastuzumab in Subjects with Previously Treated Locally-Advanced Unresectable or Metastatic Solid Tumors Driven by HER2 Alterations (SGNTUC-019)

Indication: Solid Tumors

Location: Texas Oncology-Bedford

Phase: II

Title: STAR Ph2 Basket Tucat+Tras ST HER2 Alt View

Description: A Phase 2 Basket Study of Tucatinib in Combination with Trastuzumab in Subjects with Previously Treated Locally-Advanced Unresectable or Metastatic Solid Tumors Driven by HER2 Alterations (SGNTUC-019)

Indication: Urothelial Cancer

Location: Texas Oncology-Bedford

Phase: II

Title: STAR Ph2 Basket Tucat+Tras ST HER2 Alt View

Description: A Phase 2 Basket Study of Tucatinib in Combination with Trastuzumab in Subjects with Previously Treated Locally-Advanced Unresectable or Metastatic Solid Tumors Driven by HER2 Alterations (SGNTUC-019)

Indication: Uterine Cancer

Location: Texas Oncology-Bedford

Phase: II

Title: STAR Ph2 Basket Tucat+Tras ST HER2 Alt View

Description: A Phase 2 Basket Study of Tucatinib in Combination with Trastuzumab in Subjects with Previously Treated Locally-Advanced Unresectable or Metastatic Solid Tumors Driven by HER2 Alterations (SGNTUC-019)

Indication: Biliary Cancer

Location: Texas Oncology-Fort Worth Cancer Center

Phase: II

Title: STAR Ph2 Basket Tucat+Tras ST HER2 Alt View

Description: A Phase 2 Basket Study of Tucatinib in Combination with Trastuzumab in Subjects with Previously Treated Locally-Advanced Unresectable or Metastatic Solid Tumors Driven by HER2 Alterations (SGNTUC-019)

Indication: Breast Cancer

Location: Texas Oncology-Fort Worth Cancer Center

Phase: II

Title: STAR Ph2 Basket Tucat+Tras ST HER2 Alt View

Description: A Phase 2 Basket Study of Tucatinib in Combination with Trastuzumab in Subjects with Previously Treated Locally-Advanced Unresectable or Metastatic Solid Tumors Driven by HER2 Alterations (SGNTUC-019)

Indication: Cervical Cancer

Location: Texas Oncology-Fort Worth Cancer Center

Phase: II

Title: STAR Ph2 Basket Tucat+Tras ST HER2 Alt View

Description: A Phase 2 Basket Study of Tucatinib in Combination with Trastuzumab in Subjects with Previously Treated Locally-Advanced Unresectable or Metastatic Solid Tumors Driven by HER2 Alterations (SGNTUC-019)

Indication: Gall Bladder Cancer

Location: Texas Oncology-Fort Worth Cancer Center

Phase: II

Title: STAR Ph2 Basket Tucat+Tras ST HER2 Alt View

Description: A Phase 2 Basket Study of Tucatinib in Combination with Trastuzumab in Subjects with Previously Treated Locally-Advanced Unresectable or Metastatic Solid Tumors Driven by HER2 Alterations (SGNTUC-019)

Indication: Lung Cancer

Location: Texas Oncology-Fort Worth Cancer Center

Phase: II

Title: STAR Ph2 Basket Tucat+Tras ST HER2 Alt View

Description: A Phase 2 Basket Study of Tucatinib in Combination with Trastuzumab in Subjects with Previously Treated Locally-Advanced Unresectable or Metastatic Solid Tumors Driven by HER2 Alterations (SGNTUC-019)

Indication: Solid Tumors

Location: Texas Oncology-Fort Worth Cancer Center

Phase: II

Title: STAR Ph2 Basket Tucat+Tras ST HER2 Alt View

Description: A Phase 2 Basket Study of Tucatinib in Combination with Trastuzumab in Subjects with Previously Treated Locally-Advanced Unresectable or Metastatic Solid Tumors Driven by HER2 Alterations (SGNTUC-019)

Indication: Urothelial Cancer

Location: Texas Oncology-Fort Worth Cancer Center

Phase: II

Title: STAR Ph2 Basket Tucat+Tras ST HER2 Alt View

Description: A Phase 2 Basket Study of Tucatinib in Combination with Trastuzumab in Subjects with Previously Treated Locally-Advanced Unresectable or Metastatic Solid Tumors Driven by HER2 Alterations (SGNTUC-019)

Indication: Uterine Cancer

Location: Texas Oncology-Fort Worth Cancer Center

Phase: II

Title: Ph2 Bren Vedo + Pembro ST prior PD-1 View

Description: A phase 2 study of brentuximab vedotin in combination with pembrolizumab in subjects with metastatic solid malignancies after progression on prior PD-1 inhibitor treatment (SGN35-033)

Indication: Lung Cancer

Location: Texas Oncology-Fort Worth Cancer Center

Phase: II

Title: Ph2 Bren Vedo + Pembro ST prior PD-1 View

Description: A phase 2 study of brentuximab vedotin in combination with pembrolizumab in subjects with metastatic solid malignancies after progression on prior PD-1 inhibitor treatment (SGN35-033)

Indication: Melanoma

Location: Texas Oncology-Fort Worth Cancer Center

Phase: II

Title: Ph2 Bren Vedo + Pembro ST prior PD-1 View

Description: A phase 2 study of brentuximab vedotin in combination with pembrolizumab in subjects with metastatic solid malignancies after progression on prior PD-1 inhibitor treatment (SGN35-033)

Indication: Solid Tumors

Location: Texas Oncology-Fort Worth Cancer Center

Phase: II

Title: STAR Ph2 Seribantumab NRG1 Fusion+ ST View

Description: CRESTONE: A Phase 2 Study of Seribantumab in Adult Patients with Neuregulin-1 (NRG1) Fusion Positive Locally Advanced or Metastatic Solid Tumors (ELVCAP-001-01)

Indication: Solid Tumors

Location: Texas Oncology-Fort Worth Cancer Center

Phase: II

Title: STAR Ph2 Ak104 Cervical Cancer View

Description: A Phase 2 multicenter single-arm open-label study to evaluate the efficacy and safety of AK104 in subjects with recurrent or metastatic cervical cancer (AK104-201-AU)

Indication: Cervical Cancer

Location: Texas Oncology-Fort Worth Cancer Center

Phase: II

Title: STAR PH2 Tuca+ Tras HER2+ CC View

Description: MOUNTAINEER: A Phase 2 Open Label Study of Tucatinib Combined with Trastuzumab in Patients with HER2+ Metastatic Colorectal Cancer (ACCRU-GI-1617 SGNTUC-017)

Indication: Colon Cancer

Location: Texas Oncology-Fort Worth Cancer Center

Phase: II

Title: STAR PH2 Tuca+ Tras HER2+ CC View

Description: MOUNTAINEER: A Phase 2 Open Label Study of Tucatinib Combined with Trastuzumab in Patients with HER2+ Metastatic Colorectal Cancer (ACCRU-GI-1617 SGNTUC-017)

Indication: Rectal Cancer

Location: Texas Oncology-Fort Worth Cancer Center

Phase: II

Title: PH2 Brentux+CHP In Tx Naive PTCL View

Description: A dual-cohort open-label phase 2 study of brentuximab vedotin and CHP (A+CHP) in the frontline treatment of subjects with peripheral T-cell lymphoma (PTCL) with less than 10% CD30 expression (SGN35-032)

Indication: Hematologic

Location: Texas Oncology-Fort Worth Cancer Center

Phase: II

Title: PH2 Brentux+CHP In Tx Naive PTCL View

Description: A dual-cohort open-label phase 2 study of brentuximab vedotin and CHP (A+CHP) in the frontline treatment of subjects with peripheral T-cell lymphoma (PTCL) with less than 10% CD30 expression (SGN35-032)

Indication: Leukemia

Location: Texas Oncology-Fort Worth Cancer Center

Phase: II

Title: PH2 Brentux+CHP In Tx Naive PTCL View

Description: A dual-cohort open-label phase 2 study of brentuximab vedotin and CHP (A+CHP) in the frontline treatment of subjects with peripheral T-cell lymphoma (PTCL) with less than 10% CD30 expression (SGN35-032)

Indication: Lymphomas

Location: Texas Oncology-Fort Worth Cancer Center

Phase: II

Title: STAR KEAP1/NRF2 NSCLC View

Description: CX-839-014 "KEAPSAKE": A Phase 2 Randomized Multicenter Double-blind Study of the Glutaminase Inhibitor Telaglenastat with Pembrolizumab and Chemotherapy versus Placebo with Pembrolizumab and Chemotherapy in First-line Metastatic KEAP1/NRF2-mutated Nonsquamous Non-Small Cell Lung Cancer (NSCLC)

Indication: Lung Cancer

Location: Texas Oncology-Fort Worth Cancer Center

Phase: II

Title: INCMGA00012 Endo Cancer View

Description: An Umbrella Study of INCMGA00012 Alone and in Combination With Other Therapies in Participants With Advanced or Metastatic Endometrial Cancer Who Have Progressed on or After Platinum-Based Chemotherapy (INCMGA 0012-204/ POD1UM-204)

Indication: Endometrial Cancer

Location: Texas Oncology-Fort Worth Cancer Center

Phase: II

Title: PH2 MM Carf Poma & dexa (KPd) View

Description: An Open-label Phase 2 Study Treating Subjects With First or Second Relapse of Multiple Myeloma with Carfilzomib Pomalidomide and Dexamethasone (KPd) (20180117)

Indication: Myelomas

Location: Texas Oncology-Fort Worth Cancer Center

Phase: II

Title: STAR Ph2 Erdafitinib FGFR Solid Tumors View

Description: A Phase 2 Study of Erdafitinib in Subjects With Advanced Solid Tumors and FGFR Gene Alterations (42756493CAN2002)

Indication: Solid Tumors

Location: Texas Oncology-Fort Worth Cancer Center

Phase: II

Title: STAR Ph2 Pemigatinib Solids FGFR View

Description: (INCB 54828-207) A Phase 2 Open-Label Single-Arm Multicenter Study to Evaluate the Efficacy and Safety of Pemigatinib in Participants With Previously Treated Locally Advanced/Metastatic or Surgically Unresectable Solid Tumor Malignancies Harboring Activating FGFR Mutations or Translocations (FIGHT-207)

Indication: Solid Tumors

Location: Texas Oncology-Fort Worth Cancer Center

Phase: II

Title: Ph2 Cervical 2L (RaPiDS) View

Description: A Two-arm Randomized Non-comparative Phase 2 Trial of AGEN2034(anti-PD-1) as a Monotherapy or Combination Therapy with AGEN1884(anti-CTLA4) or with Placebo in Women with Recurrent Cervical Cancer(Second Line) - RaPiDS (C-750-01/GOG-3028)

Indication: Cervical Cancer

Location: Texas Oncology-Fort Worth Cancer Center

Phase: II

Title: STAR Sitra+Nivo/Pembro+Enfor Adv/Met Uro View

Description: A Phase 2 Study of Sitravatinib in Combination with PD-(L)1 Checkpoint Inhibitor Regimens in Patients With Advanced or Metastatic Urothelial Carcinoma (516-003)

Indication: Bladder Cancer

Location: Texas Oncology-Fort Worth Cancer Center

Phase: II

Title: STAR Sitra+Nivo/Pembro+Enfor Adv/Met Uro View

Description: A Phase 2 Study of Sitravatinib in Combination with PD-(L)1 Checkpoint Inhibitor Regimens in Patients With Advanced or Metastatic Urothelial Carcinoma (516-003)

Indication: Urothelial Cancer

Location: Texas Oncology-Fort Worth Cancer Center

Phase: II

Title: STAR BV in pts w/1L cHL or PTCL View

Description: (SGN35-015) A phase 2 open-label study of brentuximab vedotin in front-line therapy of Hodgkin lymphoma (HL) and CD30-expressing peripheral T-cell lymphoma (PTCL) in older patients or patients with significant comorbidities ineligible for standard chemotherapy

Indication: Lymphomas

Location: Texas Oncology-Fort Worth Cancer Center

Phase: II

Title: STAR Ph2 A+AVD +G-CSF or AOAD in CHL View

Description: SGN35-027: Multiple Part Clinical Trial of Brentuximab Vedotin in Classical Hodgkin Lymphoma Subjects

Indication: Lymphomas

Location: Texas Oncology-Fort Worth Cancer Center

Phase: II

Title: STAR Ph2 Seribantumab NRG1 Fusion+ ST View

Description: CRESTONE: A Phase 2 Study of Seribantumab in Adult Patients with Neuregulin-1 (NRG1) Fusion Positive Locally Advanced or Metastatic Solid Tumors (ELVCAP-001-01)

Indication: Solid Tumors

Location: Texas Oncology-Grapevine

Phase: II

Title: STAR PH2 Tuca+ Tras HER2+ CC View

Description: MOUNTAINEER: A Phase 2 Open Label Study of Tucatinib Combined with Trastuzumab in Patients with HER2+ Metastatic Colorectal Cancer (ACCRU-GI-1617 SGNTUC-017)

Indication: Colon Cancer

Location: Texas Oncology-Grapevine

Phase: II

Title: STAR PH2 Tuca+ Tras HER2+ CC View

Description: MOUNTAINEER: A Phase 2 Open Label Study of Tucatinib Combined with Trastuzumab in Patients with HER2+ Metastatic Colorectal Cancer (ACCRU-GI-1617 SGNTUC-017)

Indication: Rectal Cancer

Location: Texas Oncology-Grapevine

Phase: II

Title: STAR Ph2 Erdafitinib FGFR Solid Tumors View

Description: A Phase 2 Study of Erdafitinib in Subjects With Advanced Solid Tumors and FGFR Gene Alterations (42756493CAN2002)

Indication: Solid Tumors

Location: Texas Oncology-Grapevine

Phase: II

Title: STAR KEAP1/NRF2 NSCLC View

Description: CX-839-014 "KEAPSAKE": A Phase 2 Randomized Multicenter Double-blind Study of the Glutaminase Inhibitor Telaglenastat with Pembrolizumab and Chemotherapy versus Placebo with Pembrolizumab and Chemotherapy in First-line Metastatic KEAP1/NRF2-mutated Nonsquamous Non-Small Cell Lung Cancer (NSCLC)

Indication: Lung Cancer

Location: Texas Oncology-Grapevine

Phase: II

Title: STAR Ph2 Basket Tucat+Tras ST HER2 Alt View

Description: A Phase 2 Basket Study of Tucatinib in Combination with Trastuzumab in Subjects with Previously Treated Locally-Advanced Unresectable or Metastatic Solid Tumors Driven by HER2 Alterations (SGNTUC-019)

Indication: Biliary Cancer

Location: Texas Oncology-Grapevine

Phase: II

Title: STAR Ph2 Basket Tucat+Tras ST HER2 Alt View

Description: A Phase 2 Basket Study of Tucatinib in Combination with Trastuzumab in Subjects with Previously Treated Locally-Advanced Unresectable or Metastatic Solid Tumors Driven by HER2 Alterations (SGNTUC-019)

Indication: Breast Cancer

Location: Texas Oncology-Grapevine

Phase: II

Title: STAR Ph2 Basket Tucat+Tras ST HER2 Alt View

Description: A Phase 2 Basket Study of Tucatinib in Combination with Trastuzumab in Subjects with Previously Treated Locally-Advanced Unresectable or Metastatic Solid Tumors Driven by HER2 Alterations (SGNTUC-019)

Indication: Cervical Cancer

Location: Texas Oncology-Grapevine

Phase: II

Title: STAR Ph2 Basket Tucat+Tras ST HER2 Alt View

Description: A Phase 2 Basket Study of Tucatinib in Combination with Trastuzumab in Subjects with Previously Treated Locally-Advanced Unresectable or Metastatic Solid Tumors Driven by HER2 Alterations (SGNTUC-019)

Indication: Gall Bladder Cancer

Location: Texas Oncology-Grapevine

Phase: II

Title: STAR Ph2 Basket Tucat+Tras ST HER2 Alt View

Description: A Phase 2 Basket Study of Tucatinib in Combination with Trastuzumab in Subjects with Previously Treated Locally-Advanced Unresectable or Metastatic Solid Tumors Driven by HER2 Alterations (SGNTUC-019)

Indication: Lung Cancer

Location: Texas Oncology-Grapevine

Phase: II

Title: STAR Ph2 Basket Tucat+Tras ST HER2 Alt View

Description: A Phase 2 Basket Study of Tucatinib in Combination with Trastuzumab in Subjects with Previously Treated Locally-Advanced Unresectable or Metastatic Solid Tumors Driven by HER2 Alterations (SGNTUC-019)

Indication: Solid Tumors

Location: Texas Oncology-Grapevine

Phase: II

Title: STAR Ph2 Basket Tucat+Tras ST HER2 Alt View

Description: A Phase 2 Basket Study of Tucatinib in Combination with Trastuzumab in Subjects with Previously Treated Locally-Advanced Unresectable or Metastatic Solid Tumors Driven by HER2 Alterations (SGNTUC-019)

Indication: Urothelial Cancer

Location: Texas Oncology-Grapevine

Phase: II

Title: STAR Ph2 Basket Tucat+Tras ST HER2 Alt View

Description: A Phase 2 Basket Study of Tucatinib in Combination with Trastuzumab in Subjects with Previously Treated Locally-Advanced Unresectable or Metastatic Solid Tumors Driven by HER2 Alterations (SGNTUC-019)

Indication: Uterine Cancer

Location: Texas Oncology-Grapevine

Phase: II

Title: STAR BV in pts w/1L cHL or PTCL View

Description: (SGN35-015) A phase 2 open-label study of brentuximab vedotin in front-line therapy of Hodgkin lymphoma (HL) and CD30-expressing peripheral T-cell lymphoma (PTCL) in older patients or patients with significant comorbidities ineligible for standard chemotherapy

Indication: Lymphomas

Location: Texas Oncology-Grapevine

Phase: II

Title: STAR Ublituximab+TGR-1202 Cross-over View

Description: (UTX-TGR-204) A Multi-Center Open-Label Compassionate Use Extension Study of Ublituximab (TG-1101) in Combination with Umbralisib (TGR-1202) for Patients Previously Enrolled in Protocol UTX-TGR-304

Indication: Leukemia

Location: Texas Oncology-Grapevine

Phase: II

Title: STAR Sitra+Nivo/Pembro+Enfor Adv/Met Uro View

Description: A Phase 2 Study of Sitravatinib in Combination with PD-(L)1 Checkpoint Inhibitor Regimens in Patients With Advanced or Metastatic Urothelial Carcinoma (516-003)

Indication: Bladder Cancer

Location: Texas Oncology-Grapevine

Phase: II

Title: STAR Sitra+Nivo/Pembro+Enfor Adv/Met Uro View

Description: A Phase 2 Study of Sitravatinib in Combination with PD-(L)1 Checkpoint Inhibitor Regimens in Patients With Advanced or Metastatic Urothelial Carcinoma (516-003)

Indication: Urothelial Cancer

Location: Texas Oncology-Grapevine

Phase: II

Title: Ph2 Cervical 2L (RaPiDS) View

Description: A Two-arm Randomized Non-comparative Phase 2 Trial of AGEN2034(anti-PD-1) as a Monotherapy or Combination Therapy with AGEN1884(anti-CTLA4) or with Placebo in Women with Recurrent Cervical Cancer(Second Line) - RaPiDS (C-750-01/GOG-3028)

Indication: Cervical Cancer

Location: Texas Oncology-Grapevine

Phase: II

Title: STAR Ph2 Pemigatinib Solids FGFR View

Description: (INCB 54828-207) A Phase 2 Open-Label Single-Arm Multicenter Study to Evaluate the Efficacy and Safety of Pemigatinib in Participants With Previously Treated Locally Advanced/Metastatic or Surgically Unresectable Solid Tumor Malignancies Harboring Activating FGFR Mutations or Translocations (FIGHT-207)

Indication: Solid Tumors

Location: Texas Oncology-Grapevine

Phase: II

Title: A phase 2, multicenter, single-arm study of retreatment with brentuximab vedotin in subjects with relapsed or refractory classical Hodgkin lymphoma (cHL) or CD30-expressing peripheral T cell lymphoma (PTCL) View

Indication: Lymphomas

Location: Texas Oncology-Fort Worth Cancer Center

Phase: II

Phase II/III

Title: A Phase 2/3, Multicenter, Randomized, Study of Rituximab-Gemcitabine-Dexamethasone-Platinum (R_GDP) With or Without Selinexor in Patients with Relapsed/Refractory Diffuse Large B-Cell Lymphoma (DLBCL) View

Indication: Lymphomas

Location: Texas Oncology-Fort Worth Cancer Center

Phase: II/III

Phase III

Title: STAR Ph3 61186372 Osim Lazert EGFR NSCLC View

Description: A Phase 3 Randomized Study of Amivantamab and Lazertinib Combination Therapy Versus Osimertinib Versus Lazertinib as First-Line Treatment in Patients with EGFR-Mutated Locally Advanced or Metastatic Non-Small Cell Lung Cancer (73841937NSC3003)MARIPOSA

Indication: Lung Cancer

Location: Texas Oncology-Arlington Cancer Center North

Phase: III

Title: STAR Ph3 61186372 Osim Lazert EGFR NSCLC View

Description: A Phase 3 Randomized Study of Amivantamab and Lazertinib Combination Therapy Versus Osimertinib Versus Lazertinib as First-Line Treatment in Patients with EGFR-Mutated Locally Advanced or Metastatic Non-Small Cell Lung Cancer (73841937NSC3003)MARIPOSA

Indication: Lung Cancer

Location: Texas Oncology-Arlington South

Phase: III

Title: STAR PH3 JNJ-61186372 Peme EGFR NSCLC View

Description: A Randomized Open-label Phase 3 Study of Combination Amivantamab and Carboplatin-Pemetrexed Therapy Compared with Carboplatin-Pemetrexed in Patients with EGFR Exon 20ins Mutated Locally Advanced or Metastatic Non-Small Cell Lung Cancer (61186372NSC3001)

Indication: Lung Cancer

Location: Texas Oncology-Arlington Cancer Center North

Phase: III

Title: STAR PH3 JNJ-61186372 Peme EGFR NSCLC View

Description: A Randomized Open-label Phase 3 Study of Combination Amivantamab and Carboplatin-Pemetrexed Therapy Compared with Carboplatin-Pemetrexed in Patients with EGFR Exon 20ins Mutated Locally Advanced or Metastatic Non-Small Cell Lung Cancer (61186372NSC3001)

Indication: Lung Cancer

Location: Texas Oncology-Arlington South

Phase: III

Title: STAR PH3 Nirap Abira HRR mCSPC View

Description: A Phase 3 Randomized Placebo-controlled Double-blind Study of Niraparib in Combination with Abiraterone Acetate and Prednisone Versus Abiraterone Acetate and Prednisone for the Treatment of Participants with Deleterious Germline or Somatic Homologous Recombination Repair (HRR) Gene-Mutated Metastatic Castration-Sensitive Prostate Cancer (mCSPC)(67652000PCR3002)

Indication: Prostate Cancer

Location: Texas Oncology-Arlington Cancer Center North

Phase: III

Title: STAR PH3 Nirap Abira HRR mCSPC View

Description: A Phase 3 Randomized Placebo-controlled Double-blind Study of Niraparib in Combination with Abiraterone Acetate and Prednisone Versus Abiraterone Acetate and Prednisone for the Treatment of Participants with Deleterious Germline or Somatic Homologous Recombination Repair (HRR) Gene-Mutated Metastatic Castration-Sensitive Prostate Cancer (mCSPC)(67652000PCR3002)

Indication: Prostate Cancer

Location: Texas Oncology-Arlington South

Phase: III

Title: STAR Ph3 Carbo/Pac NCMGA00012 MSCC View

Description: A Phase 3 Global Multicenter Double-Blind Randomized Study of Carboplatin-Paclitaxel With INCMGA00012 or Placebo in Participants With Inoperable Locally Recurrent or Metastatic Squamous Cell Carcinoma of the Anal Canal Not Previously Treated With Systemic Chemotherapy (POD1UM-303/InterAACT 2) (INCMGA 0012-303)

Indication: Anal Cancer

Location: Texas Oncology-Arlington Cancer Center North

Phase: III

Title: STAR Ph3 Carbo/Pac NCMGA00012 MSCC View

Description: A Phase 3 Global Multicenter Double-Blind Randomized Study of Carboplatin-Paclitaxel With INCMGA00012 or Placebo in Participants With Inoperable Locally Recurrent or Metastatic Squamous Cell Carcinoma of the Anal Canal Not Previously Treated With Systemic Chemotherapy (POD1UM-303/InterAACT 2) (INCMGA 0012-303)

Indication: Carcinoid

Location: Texas Oncology-Arlington Cancer Center North

Phase: III

Title: STAR Ph3 Carbo/Pac NCMGA00012 MSCC